The German sickle cell disease registry reveals a surprising risk of acute splenic sequestration and an increased transfusion requirement in patients with compound heterozygous sickle cell disease HbS/β-thalassaemia and no or low HbA expression

EUR J HAEMATOL. 2024;113(4):501-509.

Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective
Ahmadi P, Ghandili S, Jakobs F, Konnopka C, Morgner-Miehlke A, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2024;59(4):572-574.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
Bastian L, Beder T, Barz M, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen B, Hartmann A, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller F, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus C
BLOOD. 2024;143(14):1391-1398.

Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
Beckmann L, Faizy T, Flottmann F, Fiehler J, Bokemeyer C, Well L, Beitzen-Heineke A, Langer F
HAMOSTASEOLOGIE. 2024.

Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations
Beitzen-Heineke A, Rolling C, Seidel C, Erley J, Molwitz I, Muellerleile K, Saering D, Senftinger J, Börschel N, Engel N, Bokemeyer C, Adam G, Tahir E, Chen H
EUR RADIOL. 2024;34(6):4102-4112.

Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany
Bidlingmaier C, Heller C, Langer F, Miesbach W, Scholz U, Oldenburg J, Nüesch E, Palmborg H, Santagostino E, Tiede A
RES PRACT THROMB HAE. 2024;8(5):102482.

S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2024;62(1):e67-e161.

Cetuximab every 2 weeks versus standard weekly dosing administration schedule
Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J
FUTURE ONCOL. 2024;20(7):393-407.

Alcohol consumption in cancer patients receiving psycho-oncologic care analysis of socio-demographic, health-related and cancer-related factors
Bokemeyer F, Gali K, Kiefer P, Bleich C, Freitag J, Bokemeyer C, Abel B, Schulz H, Lebherz L
J CANCER SURVIV. 2024.

Smoking patterns and the intention to quit in German cancer patients: a cross-sectional study
Bokemeyer F, Lebherz L, Bokemeyer C, Gali K, Schulz H, Bleich C
BMC CANCER. 2024;24(1):693.

Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology
Bonifay A, Mackman N, Hisada Y, Sachetto A, Hau C, Gray E, Hogwood J, Aharon A, Badimon L, Barile L, Baudar J, Beckmann L, Benedikter B, Bolis S, Bouriche T, Brambilla M, Burrello J, Camera M, Campello E, Ettelaie C, Faille D, Featherby S, Franco C, Guldenpfennig M, Hansen J, Judicone C, Kim Y, Kristensen S, Laakmann K, Langer F, Latysheva N, Lucien F, de Menezes E, Mullier F, Norris P, Nybo J, Orbe J, Osterud B, Paramo J, Radu C, Roncal C, Samadi N, Snir O, Suades R, Wahlund C, Chareyre C, Abdili E, Martinod K, Thaler J, Dignat-George F, Nieuwland R, Lacroix R
J THROMB HAEMOST. 2024;22(10):2910-2921.

Expression profiling by high-throughput sequencing reveals GADD45, SMAD7, EGR-1 and HOXA3 activation in Myostatin (MSTN) and GDF11 treated myoblasts
Braun P, Alawi M, Saygi C, Pantel K, Wagers A
GENET MOL BIOL. 2024;47(2):e20230304.

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium
Bührer E, D'Haese D, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema J, De Giorgi U, Cafferty F, Hansen A, Tandstad T, Huddart R, Necchi A, Sweeney C, Garcia-Del-Muro X, Heng D, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman D, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn D, Sternberg C, Heidenreich A, Collette L, Gillessen S, Beyer J
EUR J CANCER. 2024;202:114042.

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Celsa C, Cabibbo G, Am Fulgenzi C, Scheiner B, Antonio d'Alessio , Manfredi G, Nishida N, Ang C, Marron T, Saeed A, Wietharn B, Pinter M, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini P, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro F, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato D
J HEPATOL. 2024;80(3):431-442.

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi G, Stefanini B, Nishida N, Galle P, Schulze K, Wege H, Ciccia R, Hsu W, Vivaldi C, Wietharn B, Lin R, Pirozzi A, Pressiani T, Dalbeni A, Natola L, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang Y, Lee P, Ang C, Marron T, Pinter M, Cheon J, Phen S, Singal A, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin C, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon H, Cammà C, Pinato D
HEPATOLOGY. 2024 [Epub ahead of print].

Through the patients' eyes: psychometric evaluation of the 64-item version of the Experienced Patient-Centeredness Questionnaire (EPAT-64)
Christalle E, Zeh S, Führes H, Hahlweg P, Zill J, Härter M, Bokemeyer C, Gallinat J, Gebhardt C, Magnussen C, Müller V, Schmalstieg-Bahr K, Strahl A, Kriston L, Scholl I
BMJ QUAL SAF. 2024 [Epub ahead of print].

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Cirrincione A, Poos A, Ziccheddu B, Kaddoura M, Baertsch M, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin A, Davies F, Goldschmidt H, Fenk R, Weisel K, Mai E, Korde N, Morgan G, Usmani S, Landgren O, Raab M, Weinhold N, Maura F
BLOOD. 2024;144(7):771-783.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg J, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt C, Arnold D, Hurwitz H, Douillard J, Venook A, Saltz L, Maughan T, Kabbinavar F, Bokemeyer C, Grothey A, Mayer R, Kaplan R, Tebbutt N, Randolph Hecht J, Giantonio B, Díaz-Rubio E, Sobrero A, Peeters M, Koopman M, Goldberg R, Andre T, de Gramont A
EUR J CANCER. 2024;207:114160.

BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia
Czogalla J, Schliffke S, Lu S, Schwerk M, Petereit H, Zhang T, Liu S, Dumoulin B, Gies S, Wu G, Hänzelmann S, Bode M, Grahammer F, Gödel M, Voigtländer M, Butt L, Bokemeyer C, Bergmann C, Benzing T, Wiech T, Puelles V, Huber T
KIDNEY INT. 2024;105(4):877-881.

Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: A COMPERA analysis
Distler O, Ofner C, Huscher D, Jordan S, Ulrich S, Stähler G, Grünig E, Held M, Ghofrani H, Claussen M, Lange T, Klose H, Rosenkranz S, Vonk-Noordegraaf A, Vizza C, Delcroix M, Opitz C, Pausch C, Scelsi L, Neurohr C, Olsson K, Coghlan J, Halank M, Skowasch D, Behr J, Milger K, Remppis B, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Wilkens H, Pittrow D, Hoeper M, Ewert R
RHEUMATOLOGY. 2024;63(4):1139-1146.

Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins
Dyshlovoy S, Mansour W, Ramm N, Hauschild J, Zhidkov M, Kriegs M, Zielinski A, Hoffer K, Busenbender T, Glumakova K, Spirin P, Prassolov V, Tilki D, Graefen M, Bokemeyer C, von Amsberg G
SCI REP-UK. 2024;14(1):11788.

Applications of Nanopore sequencing in precision cancer medicine
Dyshlovoy S, Paigin S, Afflerbach A, Lobermeyer A, Werner S, Schüller U, Bokemeyer C, Schuh A, Bergmann L, von Amsberg G, Joosse S
INT J CANCER. 2024;155(12):2129-2140.

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk N, Ocio E, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos M
ADV THER. 2024;41(4):1576-1593.

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
El-Ashwah S, Salmanton-García J, Bilgin Y, Itri F, Žák P, Weinbergerová B, Verga L, Omrani A, Silva M, Szotkowski T, Marchetti M, Buquicchio C, Nucci M, Schönlein M, Farina F, Besson C, Prezioso L, Nizamuddin S, Dávila-Valls J, Martín-Pérez S, Bonuomo V, Van Doesum J, Tisi M, Passamonti F, Méndez G, Meers S, Maertens J, López-García A, Glenthøj A, Bonnani M, Rinaldi I, Ormazabal-Vélez I, Labrador J, Kulasekararaj A, Espigado I, Demirkan F, De Jonge N, Collins G, Calbacho M, Blennow O, Al-Khabori M, Adžić-Vukičević T, Arellano E, Mišković B, Mladenović M, Nordlander A, Ráčil Z, Ammatuna E, Cordoba R, Hersby D, Gräfe S, Emarah Z, Hanakova M, Sacchi M, Ijaz M, Rahimli L, Nunes Rodrigues R, Zambrotta G, Marchesi F, Cornely O, Pagano L
LEUKEMIA LYMPHOMA. 2024;65(2):199-208.

Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review
Favero D, Oing C, Seidel C, Rescigno P, Catalano F, Cremante M, Rebuzzi S, Gatto F, Rosti G, Ferone D, Fornarini G, Cocchiara F
FRONT ONCOL. 2024;14:.

Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
Fiedler W
BRIT J HAEMATOL. 2024;204(4):1135-1136.

Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen L, Wienken K, Wagner L, Kurtyka M, Vogel K, Körbelin J, Weggen S, Fricker G, Pietrzik C
FLUIDS BARRIERS CNS. 2024;21(1):74.

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Fulgenzi C, Scheiner B, D'Alessio A, Mehan A, Manfredi G, Celsa C, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Pirisi M, Park J, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini E, Cortellini A, Pinato D
JAMA ONCOL. 2024;10(9):1253-1258.

Standardized diagnosis of gastrointestinal tumors: an update regarding the situation in Germany
Gerwing M, Ristow I, Afat S, Juchems M, Wessling J, Schreyer A, Ringe K, Othman A, Paul R, Persigehl T, Eisenblätter M
ROFO-FORTSCHR RONTG. 2024 [Epub ahead of print].

A German perspective on the impact of socioeconomic status in diffuse large B-cell lymphoma
Ghandili S, Dierlamm J, Bokemeyer C, Kusche H, Peters F
BLOOD CANCER J. 2024;14(1):174.

The changing influence of neighborhood socioeconomic status on long-term survival in diffuse large B-cell lymphoma patients: A German metropolitan case-control study spanning over three decades
Ghandili S, Dierlamm J, Bokemeyer C, Kusche H, Peters F
HEMASPHERE. 2024;8(10):e70011.

New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets
Giannelli S, Luoni M, Iannielli A, Middeldorp J, Philippens I, Bido S, Körbelin J, Broccoli V
ISCIENCE. 2024;27(5):109777.

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
Gorantla S, Mueller T, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J
MOL ONCOL. 2024;18(2):415-430.

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies
Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Brümmendorf T, Loosen S, Luedde T
BRIT J CANCER. 2024;130(6):1013-1022.

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Gorgulho J, Schulze K, Sinn M, Bokemeyer C, von Felden J
J EXP CLIN CANC RES. 2024;43(1):298.

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients
Gorgulho J, von Felden J
ALIMENT PHARM THER. 2024;60(10):1467-1468.

S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2024;62(1):73-109.

Sex-specific Genetic Determinants of Right Ventricular Structure and Function
Harbaum L, Hennigs J, Pott J, Ostermann J, Sinning C, Sau A, Sieliwonczyk E, Ng F, Rhodes C, Tello K, Klose H, Gräf S, Wilkins M
AM J RESP CRIT CARE. 2024 [Epub ahead of print].

Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick
Harenberg J, Gosselin R, Cuker A, Becattini C, Pabinger I, Poli S, Weitz J, Ageno W, Bauersachs R, Ćelap I, Choi P, Douketis J, Douxfils J, Elalamy I, Fareed J, Falanga A, Favalor E, Gerotziafas G, Herkner H, Hetjens S, Klamroth R, Heubner L, Langer F, Lip G, Mac Grory B, Margetić S, Merrelaar A, Pikta M, Renne' T, Schwameis M, Schulman S, Strbian D, Tafur A, Violi F, Vassart J, Walenga J, Weiss C
THROMB HAEMOSTASIS. 2024;124(8):770-777.

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence
Hartley-Brown M, Weisel K, Bitetti J, Carter J, McNamara S, Purser M, Palumbo A, Richardson P
BRIT J HAEMATOL. 2024;205(3):780-797.

Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-A systematic review and meta-analysis
Heesen C, Röver C, Salem S, Heinz J, Chard D, Rio J, Fittipaldo A, Lehnert T, Köpke S, Solari A, Sormani M, Friede T, Rahn A
MULT SCLER J-EXP TRA. 2024;10(4):20552173241274618.

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample
Kamili A, Ahmadi P, Leypoldt L, Marquard F, Schaefers C, Kosch R, Peters F, Kusche H, Zamrik T, Hanoun C, Seib M, Shumilov E, Leitner T, Khandanpour C, Bokemeyer C, Weisel K, Ghandili S
HAEMATOLOGICA. 2024;109(11):3795-3799.

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
Karapetis C, Liu H, Sorich M, Pederson L, Van Cutsem E, Maughan T, Douillard J, O'Callaghan C, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, Yoshino T, de Gramont A, Shi Q
BRIT J CANCER. 2024;130(8):1269-1278.

Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke D, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel H, Sebastian M, Gattenlöhner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Büttner R, Wolf J, Hoffmann W
LANCET REG HEALTH-EU. 2024;36:.

Das fortgeschrittene Nierenzellkarzinom – Aktuelle Systemtherapie im Überblick
Kaune M, Bokemeyer C, von Amsberg G
DEUT MED WOCHENSCHR. 2024;149(4):180-190.

Health Experts’ Perspectives on Barriers, Facilitators, and Needs for Improvement of Hospital Care in the Dying Phase
Kaur S, Boström K, Ullrich A, Oubaid N, Oechsle K, Schulz H, Voltz R, Kremeike K
INT J CLIN PRACT. 2024;2024:1012971.

Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review
Klemm J, von Deimling M, Fisch M, Kramer G, Tilki D, Steuber T, von Amsberg G, Hengstenberg C, Shariat S
UROLOGE. 2024;63(3):262-268.

Gene therapy targeting the blood-brain barrier
Körbelin J, Arrulo A, Schwaninger M
VITAM HORM. 2024;126:191-217.

Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma
Körner M, Spohn M, Schüller U, Bockmayr M
ONCOIMMUNOLOGY. 2024;13(1):2386789.

CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann K, Ton G, Awwad M, Benner A, Bertsch U, Besemer B, Hänel M, Fenk R, Munder M, Dürig J, Blau I, Huhn S, Hose D, Jauch A, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens U, Kunz C, Hensel M, Seidel-Glätzer A, Weisel K, Salwender H, Müller-Tidow C, Raab M, Goldschmidt H, Mai E, Hundemer M
LEUKEMIA. 2024;38(7):1621-1625.

Murine Regulatory CD4+ T Cells Are Increased in Leukemic Spleens and Show High Co-Expression of Co-Regulatory Molecules CD39, CD73, PD1, and TIGIT
Krüger J, Wellbrock J, Witt M, Kruppa N, Muschhammer J, Bokemeyer C, Modemann F, Fiedler W, Behrmann L, Brauneck F
INT J MOL SCI. 2024;25(21):.

Daratumumab as rescue therapy in life-threatening granulomatosis with polyangiitis
Krusche M, Oqueka T, Wichmann D, Kluge S, Huber T, Kötter I, Schmidt-Lauber C
RHEUMATOLOGY. 2024;63(3):e94-e95.

International consensus statement on allergy and rhinology: Sinonasal tumors
Kuan E, Wang E, Adappa N, Beswick D, London N, Su S, Wang M, Abuzeid W, Alexiev B, Alt J, Antognoni P, Alonso-Basanta M, Batra P, Bhayani M, Bell D, Bernal-Sprekelsen M, Betz C, Blay J, Bleier B, Bonilla-Velez J, Callejas C, Carrau R, Casiano R, Castelnuovo P, Chandra R, Chatzinakis V, Chen S, Chiu A, Choby G, Chowdhury N, Citardi M, Cohen M, Dagan R, Dalfino G, Dallan I, Dassi C, de Almeida J, Tos A, DelGaudio J, Ebert C, El-Sayed I, Eloy J, Evans J, Fang C, Farrell N, Ferrari M, Fischbein N, Folbe A, Fokkens W, Fox M, Lund V, Gallia G, Gardner P, Geltzeiler M, Georgalas C, Getz A, Govindaraj S, Gray S, Grayson J, Gross B, Grube J, Guo R, Ha P, Halderman A, Hanna E, Harvey R, Hernandez S, Holtzman A, Hopkins C, Huang Z, Huang Z, Humphreys I, Hwang P, Iloreta A, Ishii M, Ivan M, Jafari A, Kennedy D, Khan M, Kimple A, Kingdom T, Knisely A, Kuo Y, Lal D, Lamarre E, Lan M, Le H, Lechner M, Lee N, Lee J, Lee V, Levine C, Lin J, Lin D, Lobo B, Locke T, Luong A, Magliocca K, Markovic S, Matnjani G, McKean E, Meço C, Mendenhall W, Michel L, Na'ara S, Nicolai P, Nuss D, Nyquist G, Oakley G, Omura K, Orlandi R, Otori N, Papagiannopoulos P, Patel Z, Pfister D, Phan J, Psaltis A, Rabinowitz M, Ramanathan M, Rimmer R, Rosen M, Sanusi O, Sargi Z, Schafhausen P, Schlosser R, Sedaghat A, Senior B, Shrivastava R, Sindwani R, Smith T, Smith K, Snyderman C, Solares C, Sreenath S, Stamm A, Stölzel K, Sumer B, Surda P, Tajudeen B, Thompson L, Thorp B, Tong C, Tsang R, Turner J, Turri-Zanoni M, Udager A, van Zele T, VanKoevering K, Welch K, Wise S, Witterick I, Won T, Wong S, Woodworth B, Wormald P, Yao W, Yeh C, Zhou B, Palmer J
INT FORUM ALLERGY RH. 2024;14(2):149-608.

Lectins CGL and MTL, representatives of mytilectin family, exhibit different antiproliferative activity in Burkitt's lymphoma cells
Kuzmich A, Filshtein A, Likhatskaya G, Gorpenchenko T, Chikalovets I, Mizgina T, Hua K, von Amsberg G, Dyshlovoy S, Chernikov O
IUBMB LIFE. 2024;76(12):1279-1294.

A Combined Cyto- and Histopathological Diagnostic Approach Reduces Time to Diagnosis and Time to Therapy in First Manifestation of Metastatic Spinal Disease: A Cohort Study
Leonhardt L, Heuer A, Stangenberg M, Schroeder M, Schmidt G, Welker L, von Amsberg G, Strahl A, Krüger L, Dreimann M, Bokemeyer C, Viezens L, Asemissen A
CANCERS. 2024;16(9):.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
J CLIN ONCOL. 2024;42(1):26-37.

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma
Leypoldt L, Tichy D, Besemer B, Hänel M, Raab M, Mann C, Munder M, Reinhardt H, Nogai A, Görner M, Ko Y, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel K
FUTURE ONCOL. 2024;1-15.

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Lin Y, Qiu L, Usmani S, Joo C, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho P, Kastritis E, Martinez-Lopez J, Mateos M, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk N, Weisel K, Zweegman S, Raje N, Otero P, Anderson L, Kumar S, Martin T
LANCET ONCOL. 2024;25(8):e374-e387.

Multidisciplinary survey on use of feeding tubes in head and neck cancer patients undergoing chemoradiotherapy in Germany-the SUFEETUBE project
Löser A, Fabian A, Rühle A, Thieme A, Baehr A, Käsmann L, Zwaan I, Kahle B, Soror T, Kunte A, Seyedi N, Kebenko M, Seidel C, Dierks F, Krause L, Bruchhage K, Rades D
STRAHLENTHER ONKOL. 2024;200(7):583-594.

Effect of factor XI inhibition on tumor cell-induced coagulation activation
Mäder J, Rolling C, Voigtländer M, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Beckmann L, Langer F
J THROMB HAEMOST. 2024;22(1):199-212.

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Mai E, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau I, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens U, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel K, Raab M, Salwender H
LANCET HAEMATOL. 2024;11(2):e101-e113.

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: results from the EPICOVIDEHA survey
Mai E, Hielscher T, Bertsch U, Salwender H, Zweegman S, Raab M, Munder M, Pantani L, Mancuso K, Brossart P, Beksac M, Blau I, Dürig J, Besemer B, Fenk R, Reimer P, van der Holt B, Hänel M, von Metzler I, Graeven U, Müller-Tidow C, Boccadoro M, Scheid C, Dimopoulos M, Hillengass J, Weisel K, Cavo M, Sonneveld P, Goldschmidt H
LEUKEMIA. 2024;38(3):640-647.

Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction
Marius W, Leticia O, Friedrich K, Stephan M, Louisa H, Tabea S, Elisa S, Pauline W, Yi D, Qi M, Barbara S, Carsten B, Walter F, Jasmin W, Franziska B
ONCOIMMUNOLOGY. 2024;13(1):2346359.

Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Mateos M, Weisel K, Diels J, Arribas A, Tamayo M, Schecter J, Roccia T, Haddad I, Pacaud L, Moreau P
CL LYMPH MYELOM LEUK. 2024;24(4):224-231.e2.

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Mateos M, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero P, Schjesvold F, Cavo M, Dimopoulos M
HAEMATOLOGICA. 2024;109(7):2337-2340.

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Maura F, Kaddoura M, Poos A, Baughn L, Ziccheddu B, Bärtsch M, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin A, Davies F, Goldschmidt H, Fenk R, Weisel K, Mai E, Korde N, Morgan G, Rajkumar S, Kumar S, Usmani S, Landgren O, Raab M, Weinhold N
bioRxiv. 2024 [Epub ahead of print].

Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura F, Rajanna A, Ziccheddu B, Poos A, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle E, Walker B, Hultcrantz M, Silva A, Hampton O, Teer J, Siegel E, Bolli N, Jackson G, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai E, Goldschmidt H, Weisel K, Fenk R, Raab M, Van Rhee F, Usmani S, Shain K, Weinhold N, Morgan G, Landgren O
J CLIN ONCOL. 2024;42(11):1229-1240.

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Messina C, Giunta E, Signori A, Rebuzzi S, Banna G, Maniam A, Buti S, Cattrini C, Fornarini G, Bauckneht M, Greystoke A, Plummer R, Oing C, Rescigno P
EUR UROL ONCOL. 2024;7(2):179-188.

Improving the dying situation on non-palliative care wards: Evaluation of the participants’ perspectives on a bottom-up approach
Milke V, Oubaid N, Schieferdecker A, Ullrich A, Schulz H, Kaur S, Meesters S, Kremeike K, Leminski C, Voltz R, Bokemeyer C, Oechsle K
2024. Oncology Research and Treatment. Büttner R (Hrsg.). (Suppl. 1). Aufl. Köln: Karger, 174-175.

SARS-CoV-2-associated T-cell infiltration in the central nervous system
Mohme M, Schultheiß C, Piffko A, Fitzek A, Paschold L, Thiele B, Püschel K, Glatzel M, Westphal M, Lamszus K, Matschke J, Binder M
CLIN TRANSL IMMUNOL. 2024;13(2):e1487.

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Moreau P, Mateos M, Gonzalez Garcia M, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk N, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K
ADV THER. 2024;41(2):696-715.

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif P, Brüggemann M, Gökbuget N, Baldus C
LEUKEMIA. 2024;38(6):1213-1222.

Prognostic importance of splicing-triggered aberrations of protein complex interfaces in cancer
Newaz K, Schaefers C, Weisel K, Baumbach J, Frishman D
NAR GENOM BIOINFORM. 2024;6(3):lqae133.

Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice;INSIGHTS-SVT study
Noppeney T, Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Pittrow D, Klotsche J, Gerlach H, Bauersachs R
J VASC SURG-VENOUS L. 2024;12(6):101917.

Angehörige - herausfordernd oder wertvolle Ressource?
Oechsle K
ONKOLOGIE-GER. 2024;30(Suppl 1):7–12.

Mitbetreuung der Angehörigen von Patient:innen mit einer nicht heilbaren Krebserkrankung im Erkrankungsverlauf
Oechsle K, Berendt J, Gebert T, Heckel M, Leopold H, Hornemann B, Jentschke E, Neukirchen M, van Oorschot B, Rechenmacher M, Schnabel A, Simon S, Stiel S, Ullrich A
ONKOLOGIE-GER. 2024;2024:1-8.

SOP - Mitbetreuung der Angehörigen von Patient:innen mit einer nicht heilbaren Krebserkrankung in der Sterbephase
Oechsle K, Berendt J, Gebert T, Heckel M, Leopold H, Hornemann B, Jentschke E, Neukirchen M, van Oorschot B, Rechenmacher M, Schnabel A, Simon S, Stiel S, Ullrich A
ONKOLOGIE-GER. 2024;2024:1-8.

74/m mit starken Schmerzen bei bekanntem metastasiertem Prostatakarzinom: Vorbereitung auf die Facharztprüfung. Fall 47
Oechsle K, Schieferdecker A, Coym A, Weidmann J
ONKOLOGIE-GER. 2024;30:329–334.

Mitbetreuung von Angehörigen in spezifischen Versorgungsformen und der Pandemie: Ein Überblick über neue Erkenntnisse aus der Forschung in Deutschland – Teil 2
Oechsle K, Strupp J, Doll A, Ullrich A, Stiel S
Z PALLIATMEDIZIN. 2024;25(5):224-228.

67/m mit dekompensierter häuslicher Versorgung unter Erstlinientherapie beim metastasiertem kleinzelligem Bronchialkarzinom: Vorbereitung auf die Facharztprüfung: Fall 49
Oechsle K, Stübig T, Coym A, Schieferdecker A, Weidmann J
ONKOLOGIE-GER. 2024;30:886–890.

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Oriol A, Dimopoulos M, Schjesvold F, Beksac M, Facon T, Dhanasiri S, Guo S, Mu Y, Hong K, Gentili C, Galli M, Yagci M, Larocca A, Richardson P, Weisel K
CL LYMPH MYELOM LEUK. 2024;24(3):165-176.e4.

Palliative-specific stressors for health care professionals on non-palliative care wards and comparison with palliative care wards
Oubaid N, Milke V, Schieferdecker A, Schulz H, Kaur S, Meesters S, Kremeike K, Leminski C, Voltz R, Bokemeyer C, Oechsle K
2024. Oncology Research and Treatment : 36. Deutscher Krebskongress Fortschritt gemeinsam gestalten. Köln: Karger, 173.

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)
Parmentier S, Koschmieder S, Henze L, Griesshammer M, Matzdorff A, Bakchoul T, Langer F, Alesci R, Duerschmied D, Thomalla G, Riess H
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
Pawlyn C, Schjesvold F, Cairns D, Wei L, Davies F, Nadeem O, Abdulhaq H, Mateos M, Laubach J, Weisel K, Ludwig H, Rajkumar S, Sonneveld P, Jackson G, Morgan G, Richardson P
BLOOD CANCER J. 2024;14(1):134.

ORPHYS – Behandlungsmanual für eine psychodynamische Kurzzeitpsychotherapie bei schwerer körperlicher Erkrankung
Philipp R, Walbaum C, Lindner R, Karger A, Maatouk I, Dinger U, Vehling S
PSYCHOTHER PSYCH MED. 2024;74(8):345-351.

Psychodynamic psychotherapy in serious physical illness: A systematic literature review of approaches and techniques for the treatment of existential distress and mental disorders
Philipp R, Walbaum C, Vehling S
DEATH STUD. 2024 [Epub ahead of print];1-22.

Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19
Pink I, Hennigs J, Ruhl L, Sauer A, Boblitz L, Huwe M, Fuge J, Falk C, Pietschmann T, de Zwaan M, Prasse A, Kluge S, Klose H, Hoeper M, Welte T
INFECTION. 2024;52(2):513-524.

Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management
Pose R, Knipper S, Ekrutt J, Kölker M, Tennstedt P, Heinzer H, Tilki D, Langer F, Graefen M
ASIAN J UROL. 2024;11(1):42-47.

Right ventricular strain to systolic pulmonary artery pressure ratio in response to treatment of pulmonary arterial hypertension
Pott J, Csengeri D, Ostermann J, Klose H, Sinning C, Harbaum L
ERJ OPEN RES. 2024;10(4):.

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Pratz K, Jonas B, Pullarkat V, Thirman M, Garcia J, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon S, Wolach O, Yeh S, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli R, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo C
AM J HEMATOL. 2024;99(4):615-624.

Effectiveness of high efficiency particulate (HEPA) air condition combined with the antifungal prophylaxis on incidence, morbidity and mortality of invasive fungal infections in patients with acute myeloid leukemia: a retrospective single-center study
Preyer L, Vettorazzi E, Fiedler W, Rohde H, Stemler J, Gönner S, Bokemeyer C, Khandanpour C, Wortmann F, Kebenko M
FRONT ONCOL. 2024;14:1429221.

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees M, D'Agostino M, Leypoldt L, Kumar S, Weisel K, Gay F
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2024;44(3):e433520.

Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis
Reis S, Faske A, Monsef I, Langer F, Müller O, Kranke P, Meybohm P, Weibel S
THROMB RES. 2024;238:141-150.

Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells
Rieckmann L, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, Krause J, O'Reilly R, Hille J, Velthaus-Rusik J, Beumer N, Günther A, Willnow L, Imbusch C, Iglauer P, Simon R, Franzenburg S, Winter H, Thomas M, Bokemeyer C, Gagliani N, Krebs C, Sprick M, Hardt O, Riethdorf S, Trumpp A, Stoecklein N, Peine S, Rosenstiel P, Pantel K, Loges S, Janning M
MOL CANCER. 2024;23(1):93.

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Rodriguez-Otero P, Usmani S, Cohen A, van de Donk N, Leleu X, Pérez-Larraya J, Manier S, Nooka A, Mateos M, Einsele H, Minnema M, Cavo M, Derman B, Puig N, Gay F, Ho P, Chng W, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje N, Zamagni E, Hájek R, Weinhold N, Yong K, Ye J, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman J
LANCET ONCOL. 2024;25(5):e205-e216.

Circulating Tumor Cells and Thromboembolic Events in Patients with Glioblastoma
Rolling C, Mohme M, Bokemeyer C, Westphal M, Riethdorf S, Lamszus K, Pantel K, Klingler F, Langer F
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin
Rücker F, Bullinger L, Cocciardi S, Skambraks S, Luck T, Weber D, Krzykalla J, Pozek E, Schneider I, Corbacioglu A, Gaidzik V, Meid A, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih H, Wulf G, Salwender H, Schroeder T, Götze K, Kühn M, Lübbert M, Schlenk R, Benner A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K
BLOOD ADV. 2024.

Hämophagozytische Lymphohistiozytose und Makrophagenaktivierungssyndrom: Eine multidisziplinäre Herausforderung
Ruffer N, Kosch R, Weisel K, Kötter I, Krusche M
Z RHEUMATOL. 2024;83(5):376-386.

German translation and cross-cultural adaptation of the Vestibular Schwannoma Quality of Life Index (VSQOL)
Rutenkröger M, Wandke S, Gempt J, Dührsen L, Scheer M, Strauss C, Führes H
J PATIENT-REP OUTCOM. 2024;8(1):95.

CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice
Saito S, Nakamura Y, Miyashita S, Sato T, Hoshina K, Okada M, Hasegawa H, Oishi M, Fujii Y, Körbelin J, Kubota Y, Tainaka K, Natsumeda M, Ueno M
JCI INSIGHT. 2024;9(22):.

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann H, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A
HEMATOLOGY. 2024;29(1):2320006.

Kopf-Hals-Tumoren
Schafhausen P
2024. Colloquium Onkologie 31. Ehninger G, F, Petrasch S (Hrsg.). 1.. Aufl. München: Lukon Verlagsgesellschaft mbH München, 177-200.

Diagnosing intravascular B-cell lymphoma using nanopore sequencing of cell-free DNA from cerebrospinal fluid
Schmidt B, Afflerbach A, Ludewig P, Dirksen P, Paulsen F, Magnus T, Alawi M, Schüller U, Weisel K, Bokemeyer C, Christopeit M
ESMO OPEN. 2024;9(11):103974.

Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?
Schmidt B, Leiderer M, Amin T, Viol F, Huber S, Henes F, Schrader J
ENDOCRINE. 2024;83(2):511-518.

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
Schmoll H, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, Goekkurt E, Kaiser U, Hoeffkes H, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Roll C, Bokemeyer C, Steighardt J, Cygon F, Ibach S, Stein A, Tintelnot J
BRIT J CANCER. 2024;130(2):233-241.

Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk F, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S
CANCERS. 2024.

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
Schorb E, Isbell L, Kerkhoff A, Mathas S, Braulke F, Egerer G, Röth A, Schliffke S, Borchmann P, Brunnberg U, Kroschinsky F, Möhle R, Rank A, Wellnitz D, Kasenda B, Pospiech L, Wendler J, Scherer F, Deckert M, Henkes E, von Gottberg P, Gmehlin D, Backenstraß M, Jensch A, Burger-Martin E, Grishina O, Fricker H, Malenica N, Orbán A, Duyster J, Ihorst G, Finke J, Illerhaus G
LANCET HAEMATOL. 2024;11(3):e196-e205.

Psycho-oncologists' experiences with video consultations during the Covid-19 pandemic and implications for the future-a multi-methods study
Schuster L, Führes H, Wandke S, Thomas M, Scholl I
PSYCHO-ONCOLOGY. 2024;33(1):e6257.

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Seckinger A, Salwender H, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde-Rajaratnam M, Beck S, Neben K, Dührig J, Lindemann W, Schmidt-Wolf I, Hänel M, Blau I, Weisel K, Weinhold N, Raab M, Goldschmidt H, Choon-Quinones M, Hose D
INT J MOL SCI. 2024;25(12):.

High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT
Secondino S, Badoglio M, Rosti G, Labopin M, Delaye M, Bokemeyer C, Seidel C, Kanfer E, Metafuni E, Finke J, Bouhris J, Kosmas C, Malard F, Pagani A, Kuball J, Koehl U, Ruggeri A, De Giorgi U, Pedrazzoli P
ESMO OPEN. 2024;9(9):103692.

Molecular and histopathological characterization of seminoma patients with highly elevated human chorionic gonadotropin levels in the serum
Seidel C, Paulsen F, Nestler T, Cathomas R, Hentrich M, Paffenholz P, Bokemeyer C, Heidenreich A, Nettersheim D, Bremmer F
VIRCHOWS ARCH. 2024;485(1):123-130.

Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis
Seidel C, Schaefers C, Connolly E, Weickhardt A, Grimison P, Wong V, De Giorgi U, Hentrich M, Zschäbitz S, Ochsenreither S, Vincenzi B, Oing C, Bokemeyer C, Engel N, Alsdorf W, Tran B
ESMO OPEN. 2024;9(5):103449.

A pathogenic role for IL-10 signalling in capillary stalling and cognitive impairment in type 1 diabetes
Sharma S, Cheema M, Reeson P, Narayana K, Boghozian R, Cota A, Brosschot T, FitzPatrick R, Körbelin J, Reynolds L, Brown C
NAT METAB. 2024;6(11):2082-2099.

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations
Shumilov E, Mazzeo P, Ghandili S, Künstner A, Weidemann S, Banz Y, Ströbel P, Pollak M, Kolloch L, Beltraminelli H, Kerkhoff A, Mikesch J, Schliemann C, Haase D, Wulf G, Legros M, Lenz G, Feldmeyer L, Pabst T, Witte H, Gebauer N, Bacher U
ANN HEMATOL. 2024;103(5):1587-1599.

Diet and immune response: how today's plate shapes tomorrow's health
Siracusa F, Tintelnot J, Cortesi F, Gagliani N
TRENDS IMMUNOL. 2024;45(1):4-10.

Daratumumab for patients with myeloma with early or late relapse after initial therapy: Subgroup Analysis of CASTOR and POLLUX
Spencer A, Moreau P, Mateos M, Goldschmidt H, Suzuki K, Levin M, Sonneveld P, Orlowski R, Yoon S, Usmani S, Weisel K, Reece D, Ahmadi T, Pei H, Garvin Mayo W, Gai X, Carey J, Bartlett J, Carson R, Dimopoulos M
BLOOD ADV. 2024;8(2):388-398.

Microglia targeting by adeno-associated viral vectors
Stamataki M, Rissiek B, Magnus T, Körbelin J
FRONT IMMUNOL. 2024;15:1425892.

Bedürfnisse, Probleme und Bedarfe von Angehörigen in der Palliativversorgung: Ein Überblick über neue Erkenntnisse aus der Forschung in Deutschland - Teil 1
Stiel S, Oechsle K, Doll A, Strupp J, Herbst F, Ullrich A
Z PALLIATMEDIZIN. 2024;25(4):172-175.

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, Voorhees P, Alonso A, Callander N, Mateos M, Reddy N, Hakim S, LaMacchia J, Patel N, Williams D, Jewell R, Zhou X, Gupta I, Opalinska J, Nooka A
CANCER-AM CANCER SOC. 2024;130(15):2629-2641.

Stonikacidin A, an Antimicrobial 4-Bromopyrrole Alkaloid Containing L-Idonic Acid Core from the Northwestern Pacific Marine Sponge Lissodendoryx papillosa
Tabakmakher K, Makarieva T, Sabutski Y, Kokoulin M, Menshov A, Popov R, Guzii A, Shubina L, Chingizova E, Chingizov A, Yurchenko E, Fedorov S, Grebnev B, von Amsberg G, Dyshlovoy S, Ivanchina N, Dmitrenok P
MAR DRUGS. 2024;22(9):.

"Being an informal caregiver - strengthening resources"
Theißen T, Ullrich A, Oechsle K, Wikert J, Bokemeyer C, Schieferdecker A
BMC PALLIAT CARE. 2024;23(1):95.

"Being an informal caregiver - strengthening resources": mixed methods evaluation of a psychoeducational intervention supporting informal caregivers in palliative care
Theißen T, Ullrich A, Oechsle K, Wikert J, Bokemeyer C, Schieferdecker A
BMC PALLIAT CARE. 2024;23(1):95.

Correction: "Being an informal caregiver - strengthening resources": mixed methods evaluation of a psychoeducational intervention supporting informal caregivers in palliative care
Theißen T, Ullrich A, Oechsle K, Wikert J, Bokemeyer C, Schieferdecker A
BMC PALLIAT CARE. 2024;23(1):113.

Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial
Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, Rüssel J, Schuch G, Wierecky J, Sinn M, Tintelnot J, Petersen C, Rothkamm K, Vettorazzi E, Binder M
CLIN COLORECTAL CANC. 2024 [Epub ahead of print].

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial
Thuss-Patience P, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, Stocker G, Reichardt P, Kullmann F, Pink D, Bartels P, Jarosch A, Hinke A, Schultheiß C, Paschold L, Stein A, Binder M
JAMA NETW OPEN. 2024;7(1):e2352830.

Proteomics of mouse brain endothelium uncovers dysregulation of vesicular transport pathways during aging
Todorov-Völgyi K, González-Gallego J, Müller S, Beaufort N, Malik R, Schifferer M, Todorov M, Crusius D, Robinson S, Schmidt A, Körbelin J, Bareyre F, Ertürk A, Haass C, Simons M, Paquet D, Lichtenthaler S, Dichgans M
NATURE AGING. 2024;4(4):595-612.

Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact
Toma K, Zhao M, Zhang S, Wang F, Graham H, Zou J, Modgil S, Shang W, Tsai N, Cai Z, Liu L, Hong G, Kriegstein A, Hu Y, Körbelin J, Zhang R, Liao Y, Kim T, Ye X, Duan X
CELL. 2024;187(11):2767-2784.e23.

The CAREPAL-8: a short screening tool for multidimensional family caregiver burden in palliative care
Ullrich A, Bergelt C, Marx-Rosenberg G, Daubmann A, Benze G, Heine J, Dickel L, Wowretzko F, Zhang Y, Bokemeyer C, Nauck F, Oechsle K
BMC PALLIAT CARE. 2024;23(1):195.

A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study
von Grundherr J, Elmers S, Koch B, Hail L, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann F, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen C, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer A, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J
JAMA NETW OPEN. 2024;7(3):e242375.

Death anxiety in patients with advanced cancer and their family caregivers
Walbaum C, Philipp R, Bokemeyer C, Härter M, Junghans J, Koch-Gromus U, Oechsle K, Schilling G, Vehling S
J PAIN SYMPTOM MANAG. 2024;68(6):622-631.

Existential distress among family caregivers of patients with advanced cancer: A systematic review and meta-analysis
Walbaum C, Philipp R, Oechsle K, Ullrich A, Vehling S
PSYCHO-ONCOLOGY. 2024;33(1):e6239.

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloman: indirect treatment comparisona
Weisel K, Dimopoulos M, Beksac M, Leleu X, Richter J, Heeg B, Patel S, Majer I, McFadden I, Mikhael J
LEUKEMIA LYMPHOMA. 2024;65(4):481-492.

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Welsh J, Goberdhan D, O'Driscoll L, Buzas E, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks T, Erdbrügger U, Falcon-Perez J, Fu Q, Hill A, Lenassi M, Lim S, Mahoney M, Mohanty S, Möller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas A, Zheng L, Zijlstra A, Abuelreich S, Bagabas R, Bergese P, Bridges E, Brucale M, Burger D, Carney R, Cocucci E, Crescitelli R, Hanser E, Harris A, Haughey N, Hendrix A, Ivanov A, Jovanovic-Talisman T, Kruh-Garcia N, Ku'ulei-Lyn Faustino V, Kyburz D, Lässer C, Lennon K, Lötvall J, Maddox A, Martens-Uzunova E, Mizenko R, Newman L, Ridolfi A, Rohde E, Rojalin T, Rowland A, Saftics A, Sandau U, Saugstad J, Shekari F, Swift S, Ter-Ovanesyan D, Tosar J, Useckaite Z, Valle F, Varga Z, van der Pol E, van Herwijnen M, Wauben M, Wehman A, Williams S, Zendrini A, Zimmerman A, Théry C, Witwer K
J EXTRACELL VESICLES. 2024;13(2):e12404.

Adeno-associated virus-based gene therapy treats inflammatory kidney disease in mice
Wu G, Liu S, Hagenstein J, Alawi M, Hengel F, Schaper M, Akyüz N, Liao Z, Wanner N, Tomas N, Failla A, Dierlamm J, Körbelin J, Lu S, Huber T
J CLIN INVEST. 2024;134(17):.

EBV and 1q Gains Affect Gene and miRNA Expression in Burkitt Lymphoma
Akyüz N, Janjetovic S, Ghandili S, Bokemeyer C, Dierlamm J
VIRUSES-BASEL. 2023;15(9):.

PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer
Ambrosini F, Koehler D, Ghadban T, Jacobsen F, Knipper S, von Amsberg G, Steuber T, Maurer T
CENT EUR J UROL. 2023;76(3):182-185.

Cancer associated fibroblasts induce proliferation and therapeutic resistance to everolimus in neuroendocrine tumors through STAT3 activation
Amin T, Viol F, Krause J, Fahl M, Eggers C, Awwad F, Schmidt B, Benten D, Ungefroren H, Fraune C, Clauditz T, Sauter G, Izbicki J, Lohse A, Huber S, Schrader J
NEUROENDOCRINOLOGY. 2023;113(5):501-518.

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts C, Brossart P, Brucker S, Brümmendorf T, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann U, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M
J CANCER RES CLIN. 2023;149(2):913-919.

Cytology-histology correlation, time to diagnosis and time to therapy when cytology is performed in addition to biopsies in malignant spinal lesions of previously unknown malignant disease.
Asemissen A, Köpke L, Heuer A, Welker L, Stangenberg M, Lübke A, Schröder M, Dreimann M, Bokemeyer C, Viezens L, Krüger L
J CLIN ONCOL. 2023;41(16):.

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, Puertas-Martinez B, Robak P, Crusoe E, Rodriguez-Lobato L, Gajewska M, Varga G, Delforge M, Cohen Y, Gozzetti A, Pena C, Shustik C, Mikala G, Zalac K, Alexander H, Barth P, Weisel K, Martínez-López J, Waszczuk-Gajda A, Krzystański M, Jurczyszyn A
CANCERS. 2023;15(17):.

Antigen recognition detains CD8+ T cells at the blood-brain barrier and contributes to its breakdown
Aydin S, Pareja J, Schallenberg V, Klopstein A, Gruber T, Page N, Bouillet E, Blanchard N, Liblau R, Körbelin J, Schwaninger M, Johnson A, Schenk M, Deutsch U, Merkler D, Engelhardt B
NAT COMMUN. 2023;14(1):.

The Clinical Significance of CD73 in Cancer
Bach N, Winzer R, Tolosa E, Fiedler W, Brauneck F
INT J MOL SCI. 2023;24(14):.

Expression and Release of Tumor Cell Tissue Factor Triggers Recurrent Thromboembolism in a Patient with Endometrial Cancer
Beckmann L, Lennartz M, Poch A, Holstein K, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2023;43(4):289-296.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy
Berger S, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk F
HAEMATOLOGICA. 2023;108(2):444-456.

The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospice
Biersching T, Schweda A, Oechsle K, Nauck F, Rosenbruch J, Schuler U, Hense J, Neukirchen M, Weber M, Junghanss C, Kramer T, Ostgathe C, Thuss-Patience P, van Oorschot B, Teufel M, Schuler M, Bausewein C, Tewes M
J CANCER RES CLIN. 2023;149(7):2929-2936.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome: Kurzversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):420-440.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):e92-e156.

Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model
Böckelmann L, Freytag V, Ahlers A, Maar H, Gosau T, Baranowsky A, Schmitz R, Pantel K, Schumacher U, Haider M, Lange T
BONE. 2023;171:116741.

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data
Bokemeyer C, Paracha N, Lassen U, Italiano A, Sullivan S, Marian M, Brega N, Garcia-Foncillas J
JCO PRECIS ONCOL. 2023;7:e2200436.

Practice patterns, experiences, and challenges of German oncology health care staff with smoking cessation in patients with cancer: a cross-sectional survey study
Bokemeyer F, Lebherz L, Bokemeyer C, Derksen J, Schulz H, Bleich C
J CANCER SURVIV. 2023 [Epub ahead of print].

Smoking patterns and the intention to quit in German patients with cancer: study protocol for a cross-sectional observational study
Bokemeyer F, Lebherz L, Schulz H, Bokemeyer C, Gali K, Bleich C
BMJ OPEN. 2023;13(4):.

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
Brauneck F, Schmalfeldt B, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J
FRONT IMMUNOL. 2023;14:1250258.

Positionspapier der Deutschen Gesellschaft für Rheumatologie e.V. (DGRh) zur Situation der Weiterbildung im Fach Rheumatologie in Deutschland
Braun J, Specker C, Schulze-Koops H, Haase I, Kötter I, Hoyer B, Aringer M, Krusche M, Voormann A, Wagner U, Krause A
Z RHEUMATOL. 2023;82(7):615-620.

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Busca A, Salmanton-García J, Marchesi F, Farina F, Seval G, Van Doesum J, De Jonge N, Bahr N, Maertens J, Meletiadis J, Fracchiolla N, Weinbergerová B, Verga L, Ráčil Z, Jiménez M, Glenthøj A, Blennow O, Tanase A, Schönlein M, Prezioso L, Khanna N, Duarte R, Žák P, Nucci M, Machado M, Kulasekararaj A, Espigado I, De Kort E, Ribera-Santa Susana J, Marchetti M, Magliano G, Falces-Romero I, Ilhan O, Ammatuna E, Zompi S, Tsirigotis P, Antoniadou A, Zambrotta G, Nordlander A, Karlsson L, Hanakova M, Dragonetti G, Cabirta A, Berg Venemyr C, Gräfe S, Van Praet J, Tragiannidis A, Petzer V, López-García A, Itri F, Groh A, Gavriilaki E, Dargenio M, Rahimli L, Cornely O, Pagano L
FRONT IMMUNOL. 2023;14:1125030.

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
Chauhan J, Grandits M, Palhares L, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth A, Sow H, Chiaruttini G, Gilbert A, Dodev T, Koers A, Pellizzari G, Ilieva K, Man F, Ali N, Hobbs C, Lombardi S, Lionarons D, Gould H, Beavil A, Geh J, MacKenzie Ross A, Healy C, Calonje E, Downward J, Nestle F, Tsoka S, Josephs D, Blower P, Karagiannis P, Lacy K, Spicer J, Karagiannis S, Bax H
NAT COMMUN. 2023;14(1):2192.

Left ventricular diastolic filling patterns in competitive triathletes with and without myocardial fibrosis by cardiac magnetic resonance time-volume analysis
Chen H, Jungesblut J, Saering D, Muellerleile K, Beitzen-Heineke A, Harms P, Erley J, Schoennagel B, Schneider J, Cavus E, Fischer R, Lund G, Adam G, Tahir E
EUR J RADIOL. 2023;158:.

SARS-CoV-2 Infection In Patients With Mastocytosis
Criscuolo M, Salmanton-García J, Fracchiolla N, Dragonetti G, Khanna N, Weinbergerová B, Schönlein M, Machado M, Labrador J, Kolditz M, Itri F, Gomes da Silva M, Bonuomo V, Sciumè M, Nunes Rodrigues R, Gräfe S, Marchesi F, Cornely O, Pagano L
J INVEST ALLERG CLIN. 2023;33(3):225-227.

Pulmonale Hypertonie bei Lungenerkrankungen und/oder Hypoxie: Pathophysiologie, Diagnose, Prognose und Behandlung
Daher A, Klose H
DEUT MED WOCHENSCHR. 2023;148(23):1507-1513.

Fallbericht einer jungen Frau mit symptomatischer Lungenvarikose
Dargahpour Barough M, Steurer S, Simon M, Bachmann K, Tahir E
ROFO-FORTSCHR RONTG. 2023;195(5):432-433.

A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
Davies F, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K
CL LYMPH MYELOM LEUK. 2023;23(11):829-837.e1.

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos M, Hungria V, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K
LANCET HAEMATOL. 2023;10(10):e801-e812.

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
Dimopoulos M, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison S, Kastritis E, Garderet L, Gozzetti A, van de Donk N, Weisel K, Badros A, Beksac M, Hillengass J, Mohty M, Ho P, Ntanasis-Stathopoulos I, Mateos M, Richardson P, Blade J, Moreau P, San-Miguel J, Munshi N, Rajkumar S, Durie B, Ludwig H, Terpos E
LANCET ONCOL. 2023;24(7):e293-e311.

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension
Dittrich A, Mienert J, Pott J, Engels L, Sinning C, Hennigs J, Klose H, Harbaum L
ERJ OPEN RES. 2023;9(2):.

Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Dyshlovoy S, Hauschild J, Venz S, Krisp C, Kolbe K, Zapf S, Heinemann S, Fita K, Shubina L, Makarieva T, Guzii A, Rohlfing T, Kaune M, Busenbender T, Mair T, Moritz M, Poverennaya E, Schlüter H, Serdyuk V, Stonik V, Dierlamm J, Bokemeyer C, Mohme M, Westphal M, Lamszus K, von Amsberg G, Maire C
MOL PHARMACEUT. 2023;20(10):4994-5005.

Marine Compounds from the Far Eastern Organisms
Dyshlovoy S, Malyarenko T, Zhuravleva O, Tomoda H, Zhidkov M
MAR DRUGS. 2023;21(2):116.

New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide
Dyshlovoy S, Zhuravleva O, Hauschild J, Busenbender T, Pelageev D, Yurchenko A, Khudyakova Y, Antonov A, Graefen M, Bokemeyer C, von Amsberg G
MAR DRUGS. 2023;21(1):.

Genetische Diagnostik und molekulare Ansätze bei pulmonalarterieller Hypertonie
Eichstaedt C, Bikou O, Sommer N, Schermuly R, Pullamsetti S, Weissmann N, Harbaum L, Tabeling C, Wißmüller M, Foris V, Kuebler W, Hinderhofer K, Olschewski A, Kwapiszewska G
PNEUMOLOGIE. 2023;77(11):862-870.

Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus
El Bannoudi H, Cornwell M, Luttrell-Williams E, Engel A, Rolling C, Barrett T, Izmirly P, Belmont H, Ruggles K, Clancy R, Buyon J, Berger J
ARTHRITIS RHEUMATOL. 2023;75(5):711-722.

Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Elsesy M, Oh-Hohenhorst S, Oing C, Eckhardt A, Burdak-Rothkamm S, Alawi M, Müller C, Schüller U, Maurer T, von Amsberg G, Petersen C, Rothkamm K, Mansour W
MOL ONCOL. 2023;17(6):1129-1147.

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab M, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D
FRONT IMMUNOL. 2023;14:1286700.

The Role of TAM Receptors in Bone
Engelmann J, Ragipoglu D, Ben Batalla I, Loges S
INT J MOL SCI. 2023;25(1):.

Psychological risk factors for Long COVID and their modification: study protocol of a three-arm, randomised controlled trial (SOMA.COV)
Engelmann P, Büchel C, Frommhold J, Klose H, Lohse A, Maehder K, Nestoriuc Y, Scherer M, Suling A, Toussaint A, Weigel A, Zapf A, Löwe B
BJPSYCH OPEN. 2023;9(6):e207.

Correction to: Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention study
Esser P, Sautier L, Sarkar S, Schilling G, Bokemeyer C, Koch U, Rose M, Friedrich M, Nolte S, Walter O, Mehnert-Theuerkauf A
J CANCER SURVIV. 2023;17(3):859.

Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh R, Uhlar C, Vermeulen J, Duran J, Borgsten F, Usmani S
FUTURE ONCOL. 2023;19(13):887-895.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K
ANN ONCOL. 2023;34(5):452-467.

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma
Fankhauser C, Jandari A, Collette L, Tandstad T, Jiang D, De Giorgi U, Sweeney C, Terbuch A, Chovanec M, Huddart R, Bokemeyer C, Beyer J, Gillessen S
EUR UROL OPEN SCI. 2023;56:25-28.

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
Gaidzik V, Paschka P, Schlenk R, Weber D, Fröhling S, Krämer A, Wäsch R, Westermann J, Mayer K, de Wit M, Fiedler W, Benner A, Heuser M, Thol F, Döhner K, Ganser A, Döhner H
HEMASPHERE. 2023;7(5):e877.

Precision oncology medicines and the need for real world evidence acceptance in health technology assessment: Importance of patient involvement in sustainable healthcare
Geissler J, Makaroff L, Söhlke B, Bokemeyer C
EUR J CANCER. 2023;193:.

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt L
ANN HEMATOL. 2023;102(1):117-124.

NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma
Ghandili S, Dierlamm J, Bokemeyer C, von Bargen C, Weidemann S
FRONT ONCOL. 2023;13:1146029.

IL-22BP controls the progression of liver metastasis in colorectal cancer
Giannou A, Kempski J, Zhang T, Lücke J, Shiri A, Zazara D, Belios I, Machicote A, Seeger P, Agalioti T, Tintelnot J, Sagebiel A, Tomczak M, Bauditz L, Bedke T, Kocheise L, Mercanoglu B, Fard-Aghaie M, Giorgakis E, Lykoudis P, Pikouli A, Grass J, Wahib R, Bardenhagen J, Brunswig B, Heumann A, Ghadban T, Duprée A, Tachezy M, Melling N, Arck P, Stringa P, Gentilini M, Gondolesi G, Nakano R, Thomson A, Perez D, Li J, Mann O, Izbicki J, Gagliani N, Maroulis I, Huber S
FRONT ONCOL. 2023;13:1170502.

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Giesen N, Chatterjee M, Scheid C, Poos A, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm K, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab M
BLOOD. 2023;141(14):1685-1690.

What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland
Giesler M, Busson-Spielberger M, Miemietz B, de Wit M, Weisel K, Lüftner D
J CANCER RES CLIN. 2023;149(8):5331-5344.

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
Goetze T, Hofheinz R, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, Angermeier S, Zander T, Kopp H, Pink D, Siegler G, Schenk M, de Vita F, Galizia G, Maiello E, Bechstein W, Elshafei M, Loose M, Sookthai D, Brulin T, Pauligk C, Homann N, Al-Batran S
INT J CANCER. 2023;153(1):153-163.

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Brümmendorf T, Luedde T, Loosen S
FRONT IMMUNOL. 2023;14:1206953.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Gotlib J, Castells M, Elberink H, Siebenhaar F, Hartmann K, Broesby-Olsen S, George T, Panse J, Alvarez-Twose I, Radia D, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward B, Schafhausen P, Vadas P, Bose P, DeAngelo D, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt N, Oh S, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall A, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti M, Bidollari I, Lin H, Sulllivan E, Mar B, Maurer M
NEJM Evidence. 2023;2023(2):.

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek M, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti C, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S
NAT BIOTECHNOL. 2023;41(11):1618-1632.

Rapid MRI Assessment of Long-Axis Strain to Indicate Systolic Dysfunction in Patients With Sickle Cell Disease
Grützediek K, Fischer R, Kurio G, Böckelmann L, Bleeke M, Hagar R, Tahir E, Grosse R, Weyhmiller M, Adam G, Bannas P, Schoennagel B
J MAGN RESON IMAGING. 2023;58(5):1499-1506.

Comparison of subthalamic unilateral and bilateral theta burst deep brain stimulation in Parkinson's disease
Gülke E, Horn M, Caffier J, Pinnschmidt H, Hamel W, Moll C, Gulberti A, Pötter-Nerger M
FRONT HUM NEUROSCI. 2023;17:1233565.

Major influencing factors on routine implementation of shared decision‑making in cancer care: qualitative process evaluation of a stepped‑wedge cluster randomized trial
Hahlweg P, Lindig A, Frerichs W, Zill J, Hanken H, Müller V, Peters M, Scholl I
BMC HEALTH SERV RES. 2023;23(1):840.

Therapie des nekrobiotischen Xanthogranuloms - Fallserie und aktuelle Literatur:
Hansen I, Ghandili S, Abeck F, Booken N, Schneider S
J DTSCH DERMATOL GES. 2023;21(11):1315-1319.

Therapy of necrobiotic xanthogranuloma - case series and review of the literature
Hansen I, Ghandili S, Abeck F, Booken N, Schneider S
J DTSCH DERMATOL GES. 2023;21(11):1315-1318.

Letaler Verlauf einer Kryoglobulinämie Typ I
Hansen I, Ghandili S, Abeck F, Kött J, Booken N, Schneider S
J DTSCH DERMATOL GES. 2023;21(Suppl 2):15-18.

Association between oncologists' death anxiety and their end-of-life communication with advanced cancer patients
Harnischfeger N, Rath H, Alt-Epping B, Brand H, Haller K, Letsch A, Rieder N, Thuss-Patience P, Bokemeyer C, Oechsle K, Bergelt C
PSYCHO-ONCOLOGY. 2023;32(6):923-932.

Wir sind Angehörige: die SORGEEINHEIT (care unit)
Heller A, Oechsle K
Praxis Palliative Care. 2023;(60):1.

Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis
Holzer M, Nies J, Oqueka T, Huber T, Kötter I, Krusche M
CHEST. 2023;163(1):e1-e5.

Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease
Huckhagel T, Atlihan G, Langer F, Flitsch J, Rotermund R
SCI REP-UK. 2023;13(1):3217.

The German Network for Personalized Medicine to enhance patient care and translational research
Illert A, Stenzinger A, Bitzer M, Horak P, Gaidzik V, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf C, Hallek M, Brümmendorf T, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts C, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann M, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer A, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek N
NAT MED. 2023;29(6):1298-1301.

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Isfort S, Manz K, Teichmann L, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert J, Illmer T, Schafhausen P, Al-Ali H, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke G, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf T
ANN HEMATOL. 2023;102(10):2741-2752.

Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension
Isobe S, Nair R, Kang H, Wang L, Moonen J, Shinohara T, Cao A, Taylor S, Otsuki S, Marciano D, Harper R, Adil M, Zhang C, Lago-Docampo M, Körbelin J, Engreitz J, Snyder M, Rabinovitch M
NAT COMMUN. 2023;14(1):.

Dupilumab (Dupixent®) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany
Jansen F, Becker B, Eden J, Breda P, Hot A, Oqueka T, Betz C, Hoffmann A
EUR ARCH OTO-RHINO-L. 2023;280(4):1741-1755.

SOP Akuter Verwirrtheitszustand und Delir in der Palliativmedizin
Jentschke E, Roch C, Reinholz U, Gahr S, Gärtner J, Lewerenz J, Mayer-Steinacker R, Oechsle K, Villalobos M
ONKOLOGIE-GER. 2023;2023(2):141-146.

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Joerg V, Scheiner B, D Alessio A, Fulgenzi C, Schönlein M, Kocheise L, Lohse A, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal Y, Chamseddine S, Phen S, Cheon J, Lee P, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang Y, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal A, Chon H, Pinato D, Schulze K, von Felden J
HEPATOL COMMUN. 2023;7(11):.

A20 regulates lymphocyte adhesion in murine neuroinflammation by restricting endothelial ICOSL expression in the CNS
Johann L, Soldati S, Müller K, Lampe J, Marini F, Klein M, Schramm E, Ries N, Schelmbauer C, Palagi I, Karram K, Assmann J, Khan M, Wenzel J, Schmidt M, Körbelin J, Schlüter D, van Loo G, Bopp T, Engelhardt B, Schwaninger M, Waisman A
J CLIN INVEST. 2023;133(24):.

A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Jonas B, Hou J, Roboz G, Alvares C, Jeyakumar D, Edwards J, Erba H, Kelly R, Röllig C, Fiedler W, Brackman D, Siddani S, Chyla B, Hilger-Rolfe J, Watts J
HEMATOL ONCOL. 2023;41(4):743-752.

Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A
FRONT IMMUNOL. 2023;14:1285406.

Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
Kirchner K, Seidel C, Paulsen F, Sievers B, Bokemeyer C, Lessel D
J CLIN MED. 2023;12(22):.

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
Klement P, Fiedler W, Gabdoulline R, Dallmann L, Wienecke C, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke A, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich A, Ganser A, Thol F, Heuser M
ANN HEMATOL. 2023;102(2):323-328.

Gezielte medikamentöse Therapie der pulmonalarteriellen Hypertonie bei Patient*innen ohne Komorbiditäten
Klose H, Harbaum L, Richter M, Lichtblau M, Marra A, Kabitz H, Harutyunova S, Milger-Kneidinger K, Lange T
PNEUMOLOGIE. 2023;77(11):890-900.

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Kocheise L, Schoenlein M, Behrends B, Joerg V, Casar C, Fründt T, Renné T, Heumann A, Li J, Huber S, Lohse A, Pantel K, Riethdorf S, Wege H, Schulze K, von Felden J
SCI REP-UK. 2023;13(1):20827.

Novel insights into the isolation of extracellular vesicles by anion exchange chromatography
Koch L, Best T, Wüstenhagen E, Adrian K, Rammo O, Saul M
FRONT BIOENG BIOTECH. 2023;11:1298892.

Does the COVID-19 personal protective equipment impair the surgeon’s performance?
Kolb J, Hättich A, Strahl A, Rolvien T, Hennigs J, Barg A, Frosch K, Hartel M, Schlickewei C
ARCH ORTHOP TRAUM SU. 2023;143(4):1989-1997.

Transcription factors in the pathogenesis of pulmonary arterial hypertension-Current knowledge and therapeutic potential
Körbelin J, Matuszcak C, Runge J, Harbaum L, Klose H, Hennigs J
FRONT CARDIOVASC MED. 2023;9:1036096.

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
Koschmieder S, Isfort S, Wolf D, Heidel F, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost P, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf T
ANN HEMATOL. 2023;102(2):349-358.

Grundlagen zur Anwendung von Andexanet
Koscielny J, Birschmann I, Bauersachs R, Trenk D, Langer F, Möhnle P, Beyer-Westendorf J
HAMOSTASEOLOGIE. 2023;43(6):398-409.

Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management
Krege S, Oing C, Bokemeyer C
DTSCH ARZTEBL INT. 2023;120(49):843-854.

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
Kreitman R, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet A, Wainberg Z, Stein A, Dietrich S, de Jonge M, Willenbacher W, De Grève J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah V
BLOOD. 2023;141(9):996-1006.

Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials
Laane E, Salek S, Oliva E, Bennink C, Clavreul S, Richardson P, Scheid C, Weisel K, Ionova T
CANCERS. 2023;15(24):.

Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
Langer F, Quick H, Beitzen-Heineke A, Janjetovic S, Mäder J, Lehr C, Bokemeyer C, Kuta P, Renné T, Fiedler W, Beckmann L, Klingler F, Rolling C
THROMB RES. 2023;229:155-163.

Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis
Lassen U, Bokemeyer C, Garcia-Foncillas J, Italiano A, Vassal G, Paracha N, Marian M, Chen Y, Linsell L, Abrams K
JCO PRECIS ONCOL. 2023;7:.

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
Lauritsen J, Sauvé N, Tryakin A, Jiang D, Huddart R, Heng D, Terbuch A, Winquist E, Chovanec M, Hentrich M, Fankhauser C, Shamash J, Del Muro X, Vaughn D, Heidenreich A, Sternberg C, Sweeney C, Necchi A, Bokemeyer C, Bandak M, Jandari A, Collette L, Gillessen S, Beyer J, Daugaard G
BRIT J CANCER. 2023;129(11):1759-1765.

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry
Lee H, Ramasamy K, Weisel K, Abonour R, Hardin J, Rifkin R, Ailawadhi S, Terebelo H, Durie B, Tang D, Joshi P, Liu L, Jou Y, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner L, Jagannath S
CL LYMPH MYELOM LEUK. 2023;23(2):112-122.

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
Leest P, Janning M, Rifaela N, Azpurua M, Kropidlowski J, Loges S, Lozano N, Sartori A, Irwin D, Lamy P, Hiltermann T, Groen H, Pantel K, Kempen L, Wikman H, Schuuring E
INT J MOL SCI. 2023;24(17):.

New Bioactive β-Resorcylic Acid Derivatives from the Alga-Derived Fungus Penicillium antarcticum KMM 4685
Leshchenko E, Antonov A, Borkunov G, Hauschild J, Zhuravleva O, Khudyakova Y, Menshov A, Popov R, Kim N, Graefen M, Bokemeyer C, von Amsberg G, Yurchenko A, Dyshlovoy S
MAR DRUGS. 2023;21(3):.

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Leypoldt L, Gavriatopoulou M, Besemer B, Salwender H, Raab M, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M, Martus P, Goldschmidt H, Bokemeyer C, Dimopoulos M, Weisel K
CANCERS. 2023;15(18):.

Young oncologists' perspective on the role and future of the clinician-scientist in oncology
Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Güven D, Kfoury M, Kocakavuk E, Mandó P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sánchez-Bayona R, Sobczuk P, Starzer A, Tečić Vuger A, Zhu H, Cruz-Ordinario M, Altuna S, Canário R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T
ESMO OPEN. 2023;8(5):101625.

Correction to: Role of prothrombin 19,911 A > G polymorphism, blood group and male gender in patients with venous thromboembolism: results of a german cohort study
Limperger V, Kenet G, Kiesau B, Köther M, Schmeiser M, Langer F, Juhl D, Shneyder M, Franke A, Klostermeier U, Mesters R, Rühle F, Stoll M, Steppat D, Kowalski D, Rocke A, Kuta P, Bajorat T, Torge A, Neuner B, Junker R, Nowak-Göttl U
J THROMB THROMBOLYS. 2023;56(1):212.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P
LANCET ONCOL. 2023;24(6):e255-e269.

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lüke F, Kutsch N, Müller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter A, Schulz-Eying C, Finlayson A, Flemmig C, Kühlcke K, Preußner L, Rengstl B, Türeci Ö, Şahin U
NAT MED. 2023;29(11):2844-2853.

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
Mai E, Huhn S, Miah K, Poos A, Scheid C, Weisel K, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau I, Hänel M, Salwender H, Benner A, Raab M, Goldschmidt H, Weinhold N
BLOOD CANCER J. 2023;13(1):1.

Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment
Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz H, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T
CANCER MED-US. 2023;12(16):16829-16836.

Synovitis and joint health in patients with haemophilia: Statements from a European e-Delphi consensus study
Mancuso M, Holstein K, O'Donnell J, Lobet S, Klamroth R
HAEMOPHILIA. 2023;29(2):619-628.

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
Manier S, Dimopoulos M, Hulin C, Leleu X, Delforge M, Weisel K, Mouro J, Costa B, Sturniolo M, Facon T
CL LYMPH MYELOM LEUK. 2023;23(9):e297-e306.e1.

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Marchesi F, Salmanton-García J, Buquicchio C, Itri F, Besson C, Dávila-Valls J, Martín-Pérez S, Fianchi L, Rahimli L, Tarantini G, Grifoni F, Sciume M, Labrador J, Cordoba R, López-García A, Fracchiolla N, Farina F, Ammatuna E, Cingolani A, García-Bordallo D, Gräfe S, Bilgin Y, Dargenio M, González-López T, Guidetti A, Lahmer T, Lavilla-Rubira E, Méndez G, Prezioso L, Schönlein M, Van Doesum J, Wolf D, Hersby D, Magyari F, Van Praet J, Petzer V, Tascini C, Falces-Romero I, Glenthøj A, Cornely O, Pagano L
J HEMATOL ONCOL. 2023;16(1):32.

COVID-19 in adult acute myeloid leukemia patients:a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Ráčil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux M, Verga L, Weinbergerová B, Szotkovski T, Da Silva M, Fracchiolla N, De Jonge N, Collins G, Marchetti M, Magliano G, García-Vidal C, Biernat M, Van Doesum J, Machado M, Demirkan F, Al-Khabori M, Žák P, Víšek B, Stoma I, Méndez G, Maertens J, Khanna N, Espigado I, Dragonetti G, Fianchi L, Del Principe M, Cabirta A, Ormazabal-Vélez I, Jaksic O, Buquicchio C, Bonuomo V, Batinić J, Omrani A, Lamure S, Finizio O, Fernández N, Falces-Romero I, Blennow O, Bergantim R, Ali N, Win S, Van Praet J, Tisi M, Shirinova A, Schönlein M, Prattes J, Piedimonte M, Petzer V, Navrátil M, Kulasekararaj A, Jindra P, Sramek J, Glenthøj A, Fazzi R, De Ramón-Sánchez C, Cattaneo C, Calbacho M, Bahr N, El-Ashwah S, Cordoba R, Hanakova M, Zambrotta G, Sciumè M, Booth S, Rodrigues R, Sacchi M, García-Poutón N, Martín-González J, Khostelidi S, Gräfe S, Rahimli L, Ammatuna E, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely O, Pagano L
HAEMATOLOGICA. 2023;108(1):22-33.

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
Marchetti M, Salmanton-García J, El-Ashwah S, Verga L, Itri F, Ráčil Z, Dávila-Valls J, Martín-Pérez S, Van Doesum J, Passamonti F, Abu-Zeinah G, Farina F, López-García A, Dragonetti G, Cattaneo C, Gomes Da Silva M, Bilgin Y, Žák P, Petzer V, Glenthøj A, Espigado I, Buquicchio C, Bonuomo V, Prezioso L, Meers S, Duarte R, Bergantim R, Jaksic O, Čolović N, Blennow O, Cernan M, Schönlein M, Samarkos M, Mitra M, Magliano G, Maertens J, Ledoux M, Jiménez M, Demirkan F, Collins G, Cabirta A, Gräfe S, Nordlander A, Wolf D, Arellano E, Cordoba R, Hanakova M, Zambrotta G, Nunes Rodrigues R, Limberti G, Marchesi F, Cornely O, Pagano L
THER ADV HEMATOL. 2023;14:.

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Mateos M, Chari A, Usmani S, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P
CL LYMPH MYELOM LEUK. 2023;23(5):385-393.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Mateos M, Weisel K, Martin T, Berdeja J, Jakubowiak A, Stewart A, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila N, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson C, Schecter J, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P
HAEMATOLOGICA. 2023;108(8):2192-2204.

Immunhistochemisches und molekulargenetisches Profil von Mantelzelllymphomen der Glandula lacrimalis: eine detaillierte Beschreibung einer seltenen Tumorentität der Tränendrüse
Mautone L, Dierlamm J, Heinrich M, Viehweger F, Schäfer H, Schüttauf F, Green S, Dulz S
KLIN MONATSBL AUGENH. 2023;240(1):33-38.

Anticancer Activity of the Marine Triterpene Glycoside Cucumarioside A2-2 in Human Prostate Cancer Cells
Menchinskaya E, Dyshlovoy S, Venz S, Jacobsen C, Hauschild J, Rohlfing T, Silchenko A, Avilov S, Balabanov S, Bokemeyer C, Aminin D, von Amsberg G, Honecker F
MAR DRUGS. 2023;22(1):.

"Wir sind alle Angehörige". Chancen und Risiken der Angehörigen-Perspektive
Menzel L, Oechsle K
Praxis Palliative Care. 2023;(60):24-25.

Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)
Miesbach W, Oldenburg J, Klamroth R, Eichler H, Koscielny J, Holzhauer S, Holstein K, Hovinga J, Alberio L, Olivieri M, Knöfler R, Male C, Tiede A
HAMOSTASEOLOGIE. 2023;43(3):196-207.

The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis
Modemann F, Ahmadi P, von Kroge P, Weidemann S, Bokemeyer C, Dierlamm J, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2023;64(11):1801-1810.

Rezidivierte/refraktäre AML – Herausforderungen in Diagnostik und Therapie
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Kompendium ... Hämatologie/Onkologie. 2023;2023(21-27):21-27.

Therapie der rezidivierten/refraktären akuten myeloischen Leukämie: Aktuelle Behandlungsoptionen bei einem Rezidiv
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Im Fokus Onkologie. 2023;26(2):18-23.

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A, Besemer B, Pawlyn C, Karlin L, Manier S, Leleu X, Weisel K, Ghilotti F, Diels J, Elsada A, Morano R, Strulev V, Pei L, Kobos R, Smit J, Slavcev M, Mateos M
ADV THER. 2023;40(5):2412-2425.

hGFAP-mediated GLI2 overexpression leads to early death and severe cerebellar malformations with rare tumor formation
Niesen J, Hermans-Borgmeyer I, Krüger C, Schoof M, Modemann F, Schüller U
ISCIENCE. 2023;26(9):107501.

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki J, Pantel K, Wikman H, Uzunoglu F
CLIN CHEM. 2023;69(3):295-307.

Angehörige in der Hospiz- und Palliativversorgung - Vernetzung von Forschung und Versorgungspraxis am Beispiel Hamburgs
Oechsle K
Die Hospiz-Zeitschrift: Fachforum für palliative Care. 2023;2023(3):11-15.

Angehörigen-Mitbetreuung: Wo stehen wir uns was brauchen wir?
Oechsle K
Praxis Palliative Care. 2023;2023(60):55-56.

Angehörige sterbenskranker Menschen in verschiedenen Versorgungsformen
Oechsle K
Public Health Forum. 2023;31(1):25-28.

Bedürfnisse und Betreuung von Angehörigen
Oechsle K
2023. Elsevier Essentials Palliativmedizin. Wedding U, Fuxius S (Hrsg.). 1. Aufl. München: Elsevier GmbH, 23-27.

Die Doppelrolle der Angehörigen. Erkenntnisse der Angehörigenforschung
Oechsle K
Praxis Palliative Care. 2023;(60):27-29.

Forschung mit und für Angehörige: Universitätsprofessur für Palliativmedizin mit Schwerpunkt Angehörigenforschung in Hamburg
Oechsle K
Praxis Palliative Care. 2023;(60):26.

Palliativmedizin
Oechsle K
2023. Taschenbuch Hämatologie und Onkologie. Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 21. Aufl. München: W. Zuckschwerdt Verlag, 302-307.

Schmerztherapie
Oechsle K
2023. Taschenbuch Hämatologie und Onkologie . Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 21. Aufl. München: W. Zuckschwerdt Verlag, 299-301.

Ungehört und „ungehörig“? Angehörige in der Hospiz- und Palliativversorgung
Oechsle K
Bundes-Hospiz-Anzeiger: Palliativversorgung am Lebensende im deutschen Gesundheitswesen. 2023;21(3):6-7.

Wenn Versorgende selbst Betroffene werden - Rollenkonflikte und deren Folgen: eine sehr persönliche Erfahrung und fachliche Einordnung
Oechsle K
Z PALLIATMEDIZIN. 2023;24(01):8-11.

Praxismaterial: Angehörigen-Mitbetreuung "aus der Distanz". Möglichkeiten und Erfahrungen.
Oechsle K, Theißen T, Gebert T, Schieferdecker A, Weidmann J, Ullrich A
Praxis Palliative Care. 2023;(60):1-11.

Bedürfnisse und Belastungsfaktoren pflegender Angehöriger
Oechsle K, Ullrich A
2023. Palliative Care. Kern M, Gaspar M, Hach M (Hrsg.). 1. Aufl. Stuttgart, New York: Thieme, 256-258.

Psychosoziale Belastungen und Unterstützungsbedürfnisse von Patient:innen in der Palliativversorgung
Oechsle K, Ullrich A
Onkologische Pflege. 2023;13(Sonderheft/2023):28-32.

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study
Oleshko O, Werwitzke S, Klingberg A, Witte T, Eichler H, Klamroth R, Holstein K, Hart C, Pfrepper C, Knöbl P, Greil R, Neumeister P, Reipert B, Tiede A
BLOOD ADV. 2023;7(1):122-130.

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension
Ostermann J, Pott J, Hennigs J, Roedl K, Sinning C, Harbaum L, Klose H
ERJ OPEN RES. 2023;9(3):.

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Ou F, Ahn D, Dixon J, Grothey A, Lou Y, Kasi P, Hubbard J, Van Cutsem E, Saltz L, Schmoll H, Goldberg R, Venook A, Hoff P, Douillard J, Hecht J, Hurwitz H, Punt C, Koopman M, Bokemeyer C, Fuchs C, Diaz-Rubio E, Tebbutt N, Cremolini C, Kabbinavar F, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams R, de Gramont A, Shi Q
CANCERS. 2023;15(16):4117.

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
Paschold L, Stein A, Thiele B, Tintelnot J, Henkes S, Coith C, Schultheiß C, Pantel K, Riethdorf S, Binder M
J IMMUNOTHER CANCER. 2023;11(6):.

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working G6roup
Pfrepper C, Klamroth R, Oldenburg J, Holstein K, Eichler H, Hart C, Moehnle P, Schilling K, Trautmann-Grill K, Alrifai M, Ay C, Miesbach W, Knoebl P, Tiede A
HAMOSTASEOLOGIE. 2023 [Epub ahead of print].

Chirurgie der Milz bei hämatologischen Erkrankungen: Indikationen und operative Technik
Preukschas A, Ghadban T, Hackert T, Block A, Nickel F
CHIRURGIE. 2023;94(12):987-993.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12-Month Results of the INSIGHTS-SVT Study
Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow D, Klotsche J, Gerlach H, Bauersachs R
EUR J VASC ENDOVASC. 2023;66(5):697-704.

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
Ramasamy K, Avet-Loiseau H, Hveding Blimark C, Delforge M, Gay F, Manier S, Martinez-Lopez J, Mateos M, Mohty M, van de Donk N, Weisel K
HEMASPHERE. 2023;7(9):e942.

A novel strategy for delivering Niemann-Pick type C2 proteins across the blood-brain barrier using the brain endothelial-specific AAV-BR1 virus
Rasmussen C, Hede E, Routhe L, Körbelin J, Helgudottir S, Thomsen L, Schwaninger M, Burkhart A, Moos T
J NEUROCHEM. 2023;164(1):6-28.

Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations
Ren J, Huang Y, Ren Y, Tu T, Qiu B, Ai D, Bi Z, Bai X, Li F, Li J, Chen X, Feng Z, Guo Z, Lei J, Tian A, Cui Z, Lindner V, Adams R, Wang Y, Zhao F, Körbelin J, Sun W, Wang Y, Zhang H, Hong T, Ge W
BRAIN. 2023;146(9):3634-3647.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Rha S, Oh D, Yañez P, Bai Y, Ryu M, Lee J, Rivera F, Alves G, Garrido M, Shiu K, Fernández M, Li J, Lowery M, Çil T, Cruz F, Qin S, Luo S, Pan H, Wainberg Z, Yin L, Bordia S, Bhagia P, Wyrwicz L
LANCET ONCOL. 2023;24(11):1181-1195.

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma
Rieke D, Schröder S, Schafhausen P, Blanc E, Zuljan E, von der Emde B, Beule D, Keller U, Keilholz U, Klinghammer K
FRONT ONCOL. 2023;13:1107134.

An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies F, Delforge M, Weisel K, Marshall T, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D
LEUKEMIA LYMPHOMA. 2023;64(11):1864-1869.

Platelet-monocyte aggregates: molecular mediators of thromboinflammation
Rolling C, Barrett T, Berger J
FRONT CARDIOVASC MED. 2023;10:960398.

Absence of Malaria-Associated Coagulopathy in Asymptomatic Plasmodium falciparum Infection: Results From a Cross-sectional Study in the Ashanti Region, Ghana
Rolling C, Phillips R, Abass K, Ken Adu Poku J, Osei-Mireku S, Osei-Wusu B, Thompson W, Vinnemeier C, Huebl L, Langer F, Francke P, Kuta P, Konrath S, Renné T, Tannich E, Rolling T, Heinemann M
OPEN FORUM INFECT DI. 2023;10(3):ofad074.

P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions
Rolling C, Sowa M, Wang T, Cornwell M, Myndzar K, Schwartz T, El Bannoudi H, Buyon J, Barrett T, Berger J
THROMB HAEMOSTASIS. 2023;123(2):231-244.

Effects of Exercise Training on Patient-Specific Outcomes in Pancreatic Cancer Patients: A Scoping Review
Rosebrock K, Sinn M, Uzunoglu F, Bokemeyer C, Jensen W, Salchow J
CANCERS. 2023;15(24):.

Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Rossi G, Salmanton-García J, Marchesi F, Dávila-Valls J, Martín-Pérez S, Itri F, López-García A, Glenthøj A, Gomes da Silva M, Besson C, Marchetti M, Weinbergerová B, Jaksic O, Jiménez M, Bilgin Y, Van Doesum J, Farina F, Žák P, Verga L, Collins G, Bonuomo V, Van Praet J, Nucci M, Meers S, Espigado I, Fracchiolla N, Valković T, Poulsen C, Čolović N, Dragonetti G, Ledoux M, Tascini C, Buquicchio C, Blennow O, Passamonti F, Machado M, Labrador J, Duarte R, Schönlein M, Prezioso L, Falces-Romero I, Kulasekararaj A, Garcia-Vidal C, Fernández N, Abu-Zeinah G, Ormazabal-Vélez I, Adžić-Vukičević T, Piukovics K, Stoma I, Cuccaro A, Magliano G, Szotkowski T, González-López T, El-Ashwah S, Bergantim R, Sili U, Maertens J, Demirkan F, De Ramón C, Petzer V, Del Principe M, Navrátil M, Dargenio M, Seval G, Samarkos M, Ráčil Z, Pinczés L, Lahmer T, Busca A, Méndez G, Vena A, Biernat M, Merelli M, Calbacho M, Barać A, Bavastro M, Limongelli A, Ilhan O, Wolf D, Çolak G, García-Sanz R, Emarah Z, Mišković B, Gräfe S, Mladenović M, Aiello T, Núñez-Martín-Buitrago L, Nordlander A, Arellano E, Zambrotta G, Ammatuna E, Cabirta A, Sacchi M, Nunes Rodrigues R, Hersby D, Hanakova M, Rahimli L, Cordoba R, Cornely O, Pagano L
INT J INFECT DIS. 2023;137:98-110.

Experimental in vitro, ex vivo and in vivo models in prostate cancer research
Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, Offermann A, Pantel K, Schuele R, Taubert H, Wach S, Perner S, Werner S, Aigner A
NAT REV UROL. 2023;20(3):158-178.

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Salmanton-García J, Marchesi F, Gomes da Silva M, Farina F, Dávila-Valls J, Bilgin Y, Glenthøj A, Falces-Romero I, Van Doesum J, Labrador J, Buquicchio C, El-Ashwah S, Petzer V, Van Praet J, Schönlein M, Dargenio M, Méndez G, Meers S, Itri F, Giordano A, Pinczés L, Espigado I, Stojanoski Z, López-García A, Prezioso L, Jaksic O, Vena A, Fracchiolla N, González-López T, Colović N, Delia M, Weinbergerová B, Marchetti M, Marques de Almeida J, Finizio O, Besson C, Biernat M, Valković T, Lahmer T, Cuccaro A, Ormazabal-Vélez I, Batinić J, Fernández N, De Jonge N, Tascini C, Anastasopoulou A, Duléry R, Del Principe M, Plantefeve G, Papa M, Nucci M, Jiménez M, Aujayeb A, Hernández-Rivas J, Merelli M, Cattaneo C, Blennow O, Nordlander A, Cabirta A, Varricchio G, Sacchi M, Cordoba R, Arellano E, Gräfe S, Wolf D, Emarah Z, Ammatuna E, Hersby D, Martín-Pérez S, Nunes Rodrigues R, Rahimli L, Pagano L, Cornely O
ECLINICALMEDICINE. 2023;58:101939.

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
Salmanton-García J, Marchesi F, Koehler P, Weinbergerová B, Čolović N, Falces-Romero I, Buquicchio C, Farina F, van Praet J, Biernat M, Itri F, Prezioso L, Tascini C, Vena A, Romano A, Delia M, Martín-Pérez S, Lavilla-Rubira E, Adžić-Vukičević T, García-Bordallo D, López-García A, Criscuolo M, Petzer V, Fracchiolla N, Espigado I, Sili U, Meers S, Erben N, Tragiannidis A, Gavriilaki E, Schönlein M, Mitrovic M, Pantic N, Merelli M, Labrador J, Hernández-Rivas J, Glenthøj A, Fouquet G, Del Principe M, Dargenio M, Calbacho M, Besson C, Kohn M, Gräfe S, Hersby D, Arellano E, Çolak G, Wolf D, Marchetti M, Nordlander A, Blennow O, Cordoba R, Mišković B, Mladenović M, Bavastro M, Limongelli A, Rahimli L, Pagano L, Cornely O
INT J ANTIMICROB AG. 2023;62(4):106952.

Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis
Schaefers C, Paulsen F, Frenzel C, Weisel K, Bokemeyer C, Seidel C
BRIT J HAEMATOL. 2023;201(2):222-226.

Nachweis einer hereditären hämorrhagischen Teleangiektasie (Morbus Osler) bei singulärer pulmonaler arteriovenöser Malformation
Schick-Bengardt X, Kachanov M, Bannas P, Galow S, Klose H, Woitschach R, Schönnagel B, Oqueka T
PNEUMOLOGIE. 2023;77(Suppl 01):S33.

IRF4 is required for migration of CD4+ T cells to the intestine but not for Th2 and Th17 cell maintenance
Schmidt C, Harberts A, Reimers D, Bertram T, Voß L, Schmid J, Lory N, Spohn M, Koch-Nolte F, Huber S, Raczkowski F, Breloer M, Mittrücker H
FRONT IMMUNOL. 2023;14:1182502.

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
Schmidt K, Milger K, Pausch C, Huscher D, Pittrow D, Grünig E, Staehler G, Gall H, Distler O, Skowasch D, Halank M, Wilkens H, Held M, Klose H, Hoeper M
EUR RESPIR J. 2023;61(4):.

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure
Schönborn L, Esteban O, Wesche J, Dobosz P, Broto M, Rovira Puig S, Fuhrmann J, Torres R, Serra J, Llevadot R, Palicio M, Wang J, Gordon T, Lindhoff-Last E, Hoffmann T, Alberio L, Langer F, Boehme C, Biguzzi E, Grosse L, Endres M, Liman T, Thiele T, Warkentin T, Greinacher A
BLOOD. 2023;142(26):2305-2314.

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
Schoof M, Godbole S, Albert T, Dottermusch M, Walter C, Ballast A, Qin N, Olivera M, Göbel C, Neyazi S, Holdhof D, Kresbach C, Peter L, Epplen G, Thaden V, Spohn M, Blattner-Johnson M, Modemann F, Mynarek M, Rutkowski S, Sill M, Varghese J, Afflerbach A, Eckhardt A, Münter D, Verma A, Struve N, Jones D, Remke M, Neumann J, Kerl K, Schüller U
NAT COMMUN. 2023;14(1):7717.

Evaluation of a short instrument for measuring health-related quality of life in oncological patients in routine care (HELP-6): an observational study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kroger N, Muller V, Krüll A, Schulz H, Bleich C
FRONT PSYCHOL. 2023;14:1158449.

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Shitara K, Di Bartolomeo M, Mandala M, Ryu M, Caglevic C, Olesinski T, Chung H, Muro K, Goekkurt E, McDermott R, Mansoor W, Wainberg Z, Shih C, Kobie J, Nebozhyn M, Cristescu R, Cao Z, Loboda A, Özgüroğlu M
J IMMUNOTHER CANCER. 2023;11(6):.

Screening versus multidimensional assessment of symptoms and psychosocial distress in cancer patients from the time of incurability
Solar S, Wieditz J, Lordick F, Mehnert-Theuerkauf A, Oechsle K, van Oorschot B, Thomas M, Asendorf T, Nauck F, Alt-Epping B
FRONT ONCOL. 2023;13:1002499.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Sonneveld P, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos M, Mark T, Levin M, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A
J CLIN ONCOL. 2023;41(8):1600-1609.

Effect of depression, anxiety, and distress screeners on the need, intention, and utilization of psychosocial support services among cancer patients
Springer F, Sautier L, Schilling G, Koch-Gromus U, Bokemeyer C, Friedrich M, Mehnert-Theuerkauf A, Esser P
SUPPORT CARE CANCER. 2023;31(2):117.

Symptom burden, psychosocial distress and palliative care needs in heart failure – A cross-sectional explorative pilot study
Strangl F, Ischanow E, Ullrich A, Oechsle K, Fluschnik N, Magnussen C, Knappe D, Grahn H, Blankenberg S, Bokemeyer C, Kirchhof P, Rybczynski M
CLIN RES CARDIOL. 2023;112(1):49-58.

Sarcoma Patients Admitted to the Intensive Care Unit (ICU): Predictive Relevance of Common Sepsis and Performance Parameters
Striefler J, Binder P, Brandes F, Rau D, Wittenberg S, Kaul D, Roohani S, Jarosch A, Schäfer F, Öllinger R, Märdian S, Bullinger L, Eckardt K, Kruse J, Flörcken A
CANCER MANAG RES. 2023;15:321-334.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A, Wen P, Dietrich S, de Jonge M, Blay J, Italiano A, Yonemori K, Cho D, de Vos F, Moreau P, Fernandez E, Schellens J, Zielinski C, Redhu S, Boran A, Passos V, Ilankumaran P, Bang Y
NAT MED. 2023;29(5):1103-1112.

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
Thompson M, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel K, Rifkin R, Usmani S, Hájek R, Cook G, Abonour R, Armour M, Morgan K, Yeh S, Costello C, Berdeja J, Davies F, Zonder J, Lee H, Omel J, Spencer A, Terpos E, Hungria V, Puig N, Fu C, Ferrari R, Ren K, Stull D, Chari A
CL LYMPH MYELOM LEUK. 2023;23(3):e171-e181.

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs U, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, Möhnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer F, Werwitzke S, Klamroth R
LANCET HAEMATOL. 2023;10(11):e913-e921.

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)
Tintelnot J, Stein A, Al-Batran S, Ettrich T, Götze T, Grün B, Haag G, Heuer V, Hofheinz R, Homann N, Bröring T, Cruz M, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E
FRONT ONCOL. 2023;13:1272175.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot J, Xu Y, Lesker T, Schönlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring T, Trajkovic-Arsic M, Siveke J, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu F, Güngör C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N
NATURE. 2023;615(7950):168-174.

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria
Tometten M, Kirschner M, Meyer R, Begemann M, Halfmeyer I, Vieri M, Kricheldorf K, Maurer A, Platzbecker U, Radsak M, Schafhausen P, Corbacioglu S, Höchsmann B, Matthias Wilk C, Hinze C, Chromik J, Heuser M, Kreuter M, Koschmieder S, Panse J, Isfort S, Kurth I, Brümmendorf T, Beier F
HEMASPHERE. 2023;7(5):e874.

A New Mild Method for Synthesis of Marine Alkaloid Fascaplysin and Its Therapeutically Promising Derivatives
Tryapkin O, Kantemirov A, Dyshlovoy S, Prassolov V, Spirin P, von Amsberg G, Sidorova M, Zhidkov M
MAR DRUGS. 2023;21(8):.

Forschung mit der Praxis für die Praxis
Ullrich A
Praxis Palliative Care. 2023;(60):32-33.

Evaluation of a Routine Psychosocial Screening for Patients Receiving Inpatient Specialist Palliative Care: Feasibility and Outcomes
Ullrich A, Bahloul S, Bokemeyer C, Oechsle K
J SOC WORK END-LIFE. 2023;19(1):33-52.

Specialist palliative care until the very end of life - reports of family caregivers and the multiprofessional team
Ullrich A, Goldbach S, Hollburg W, Wagener B, Rommel A, Müller M, Kirsch D, Kopplin-Foertsch K, Schulz H, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2023;22(1):.

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Usmani S, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, Weisel K, Shu X, Li C, Dimopoulos M
BLOOD ADV. 2023;7(14):3739-3748.

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
van Doesum J, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, Farina F, Besson C, Weinbergerová B, Van Praet J, Schönlein M, Lopez-Garcia A, Lamure S, Guidetti A, De Ramón-Sánchez C, Batinic J, Gavriilaki E, Tragiannidis A, Tisi M, Plantefeve G, Petzer V, Ormazabal-Velez I, Marques de Almeida J, Marchetti M, Maertens J, Machado M, Kulasekararaj A, Hernández-Rivas J, Gomes da Silva M, Fernández N, Espigado I, Drgona L, Dragonetti G, Metafuni E, Calbacho M, Blennow O, Wolf D, van Anrooij B, Nunes Rodrigues R, Nordlander A, Martín-González J, Lievin R, Jiménez M, Grafe S, Garcia-Sanz R, Córdoba R, Rahimli L, van Meerten T, Cornely O, Pagano L
BLOOD ADV. 2023;7(11):2645-2655.

Psychodynamische Psychotherapie bei existenzieller Belastung und schwerer Erkrankung
Vehling S, Walbaum C, Philipp R
PiD-Psychother Dialog. 2023;24(01):34-38.

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
HEPATOL INT. 2023;17(4):904-914.

Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
von Kroge P, Duprée A, Mann O, Izbicki J, Wagner J, Ahmadi P, Weidemann S, Adjallé R, Kröger N, Bokemeyer C, Fiedler W, Modemann F, Ghandili S
WORLD J EMERG SURG. 2023;18(1):12.

Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia
Wagner J, Al-Bazaz M, Forstreuter A, Hammada M, Hille J, Papingi D, Bokemeyer C, Fiedler W
BIOMEDICINES. 2023;12(1):.

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Weisel K, Dimopoulos M, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M
HEMASPHERE. 2023;7(3):e843.

CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis
Zhang T, Wahib R, Zazara D, Lücke J, Shiri A, Kempski J, Zhao L, Agalioti T, Machicote A, Giannou O, Belios I, Jia R, Zhang S, Tintelnot J, Seese H, Grass J, Mercanoglu B, Stern L, Scognamiglio P, Fard-Aghaie M, Seeger P, Wakker J, Kemper M, Brunswig B, Duprée A, Lykoudis P, Pikouli A, Giorgakis E, Stringa P, Lausada N, Gentilini M, Gondolesi G, Bachmann K, Busch P, Grotelüschen R, Maroulis I, Arck P, Nakano R, Thomson A, Ghadban T, Tachezy M, Melling N, Achilles E, Puelles V, Nickel F, Hackert T, Mann O, Izbicki J, Li J, Gagliani N, Huber S, Giannou A
ONCOIMMUNOLOGY. 2023;12(1):2269634.

SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review
Afshar Z, Barary M, Babazadeh A, Hosseinzadeh R, Alijanpour A, Miri S, Sio T, Sullman M, Carson-Chahhoud K, Langer F, Ebrahimpour S
REV MED VIROL. 2022;32(4):.

Haemostaseological pearls
Albisetti M, Langer F, Rühl H
HAMOSTASEOLOGIE. 2022;42(3):163-164.

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
Amsberg G, Zilles M, Mansour W, Gild P, Alsdorf W, Kaune M, Böckelmann L, Hauschild J, Krisp C, Rohlfing T, Saygi C, Alawi M, Zielinski A, Langebrake C, Su X, Perner S, Tilki D, Schluter H, Graefen M, Dyshlovoy S, Bokemeyer C
INT J MOL SCI. 2022;23(23):.

RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma
Andreassen C, Lorenzen M, Nielsen J, Kafai Yahyavi S, Toft B, Ingerslev L, Clemmensen C, Rasmussen L, Bokemeyer C, Juul A, Jørgensen A, Blomberg Jensen M
BRIT J CANCER. 2022;127(3):408-421.

Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVD-19-Pandemie
Arndt V, Doege D, Fröhling S, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts C, Brossart P, Brucker S, Brümmendorf T, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, Lordick F, Peters C, Schadendorf D, Stilgenbauer S, Braun D, Seufferlein T, Nettekoven G, Baumann M
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2022;37:372-376.

Rivaroxaban bei tumorassoziierter venöser Thromboembolie
Bauersachs R, Voigtländer M, Langer F
DEUT MED WOCHENSCHR. 2022;147(23):1545-1551.

National strategy for palliative care of severely ill and dying people and their relatives in pandemics (PallPan) in Germany - study protocol of a mixed-methods project
Bausewein C, Hodiamont F, Berges N, Ullrich A, Gerlach C, Oechsle K, Pauli B, Weber J, Stiel S, Schneider N, Krumm N, Rolke R, Jansky M, Nauck F, Wedding U, van Oorschot B, Roch C, Werner L, Fischer M, Schallenburger M, Reuters M, Schwartz J, Neukirchen M, Ates G, Maus K, Jaspers B, Radbruch L, Heckel M, Klinger I, Ostgathe C, Kriesen U, Junghanß C, Lehmann E, Gesell D, Gauder S, Boehlke C, Becker G, Pralong A, Strupp J, Leisse C, Schloesser K, Voltz R, Jung N, Simon S
BMC PALLIAT CARE. 2022;21(1):.

Purpura Fulminans Triggered by the Formation of Anti-Endothelial Autoantibodies in a Patient with Chronic Lymphocytic Leukemia
Beckmann L, Lennartz M, Beitzen-Heineke A, Voigtländer M, Rolling C, Holstein K, Bokemeyer C, Amirkhosravi A, Langer F
Ann Hematol Oncol. 2022;9(1):.

Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms
Beckmann L, Mäder J, Voigtlaender M, Klingler F, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Ruf W, Rolling C, Langer F
THROMB RES. 2022;220:48-59.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy
Beckmann M, Stübs F, Koch M, Mallmann P, Dannecker C, Dietl A, Sevnina A, Mergel F, Lotz L, Hack C, Ehret A, Gantert D, Martignoni F, Cieslik J, Menke J, Ortmann O, Stromberger C, Oechsle K, Hornemann B, Mumm F, Grimm C, Sturdza A, Wight E, Loessl K, Golatta M, Hagen V, Dauelsberg T, Diel I, Münstedt K, Merz E, Vordermark D, Lindel K, Wittekind C, Küppers V, Lellé R, Neis K, Griesser H, Pöschel B, Steiner M, Freitag U, Gilster T, Schmittel A, Friedrich M, Haase H, Gebhardt M, Kiesel L, Reinhardt M, Kreißl M, Kloke M, Horn L, Wiedemann R, Marnitz S, Letsch A, Zraik I, Mangold B, Möckel J, Alt C, Wimberger P, Hillemanns P, Paradies K, Mustea A, Denschlag D, Henscher U, Tholen R, Wesselmann S, Fehm T
GEBURTSH FRAUENHEILK. 2022;82(2):139-180.

Kardiale Nebenwirkungen antineoplastischer Substanzen
Beitzen-Heineke A, Bokemeyer C
2022. Kardio-Onkologie. Bokemeyer C, Lehmann L, Müller O (Hrsg.). 1. Aufl. De Gruyter, 179-196.

Kardiovaskuläre Langzeitüberwachung nach Krebstherapie
Beitzen-Heineke A, Bokemeyer C
2022. Kardio-Onkologie. Bokemeyer C, Lehmann L, Müller O (Hrsg.). 1. Aufl. De Gruyter, 219-228.

Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]
Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik V, Glimm H, Hacker U, Heinemann V, Illert A, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke J, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S
EUR J CANCER. 2022;162:245-246.

Langzeitüberleben bei Krebs: Definitionen, Konzepte und Gestaltungsprinzipien von Survivorship-Programmen
Bergelt C, Bokemeyer C, Hilgendorf I, Langer T, Rick O, Seifart U, Koch-Gromus U
BUNDESGESUNDHEITSBLA. 2022;65(4):406-411.

Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain
Berntorp E, LeBeau P, Ragni M, Borhany M, Abajas Y, Tarantino M, Holstein K, Croteau S, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton C, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss U, Kulkarni R, Witkop M, Lethagen S, Krouse R, Shapiro A, Astermark J
HAEMOPHILIA. 2022;28(3):453-461.

Sixth Åland Island Conference on von Willebrand disease
Berntorp E, Trakymienė S, Federici A, Holstein K, Corrales-Medina F, Pierce G, Srivastava A, Prondzinski M, Johnsen J, Zupan I, Halimeh S, Nummi V, Roberts J
HAEMOPHILIA. 2022;28(Suppl 5):3-15.

Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer
Besler K, Węglarz A, Keller L, von Amsberg G, Bednarz-Knoll N, Offermann A, Stoupiec S, Eltze E, Semjonow A, Boettcher L, Schneegans S, Perner S, Hauch S, Todenhöfer T, Peine S, Pantel K, Wikman H, Werner S
CLIN CHEM. 2022;68(7):973-983.

Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016
Biehl L, Higgins P, Stemler J, Gilles M, Peter S, Dörfel D, Vogel W, Kern W, Gölz H, Bertz H, Rohde H, Klupp E, Schafhausen P, Salmanton-García J, Stecher M, Wille J, Liss B, Xanthopoulou K, Zweigner J, Seifert H, Vehreschild M
EUROSURVEILLANCE. 2022;27(2):.

S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome: Langversion 2.0 – Juni 2021 – AWMF-Registernummer: 032-053OL
Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann R, Hofmann W, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2022;60(2):219-238.

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Blennow O, Salmanton-García J, Nowak P, Itri F, Van Doesum J, López-García A, Farina F, Jaksic O, Pinczés L, Bilgin Y, Falces-Romero I, Jiménez M, Ormazabal-Vélez I, Weinbergerová B, Duléry R, Stojanoski Z, Lahmer T, Fernández N, Hernández-Rivas J, Petzer V, De Jonge N, Glenthøj A, De Ramón C, Biernat M, Fracchiolla N, Aujayeb A, Van Praet J, Schönlein M, Méndez G, Cattaneo C, Guidetti A, Sciumè M, Ammatuna E, Cordoba R, García-Poutón N, Gräfe S, Cabirta A, Wolf D, Nordlander A, García-Sanz R, Delia M, Berg Venemyr C, Brones C, Di Blasi R, De Kort E, Meers S, Lamure S, Serrano L, Merelli M, Coppola N, Bergantim R, Besson C, Kohn M, Petiti J, Garcia-Vidal C, Dargenio M, Danion F, Machado M, Bailén-Almorox R, Hoenigl M, Dragonetti G, Chai L, Kho C, Bonanni M, Liévin R, Marchesi F, Cornely O, Pagano L
AM J HEMATOL. 2022;97(8):E312-E317.

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar P, Tsoka S, Bullinger L, Seubert E, Smit D, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W
J IMMUNOTHER CANCER. 2022;10(12):.

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study
Briggs A, Paracha N, Rosettie K, Upton A, Bokemeyer C, Lassen U, Sullivan S
ONCOLOGY-BASEL. 2022;100(2):124-130.

Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study
Briggs A, Wehler B, Gaultney J, Upton A, Italiano A, Bokemeyer C, Paracha N, Sullivan S
VALUE HEALTH. 2022;25(6):1002-1009.

Looking back: Identifying supportive care and unmet needs of parents of children receiving specialist paediatric palliative care from the bereavement perspective
Bronsema A, Theißen T, Oechsle K, Wikert J, Escherich G, Rutkowski S, Bokemeyer C, Ullrich A
BMC PALLIAT CARE. 2022;21(1):.

Cutaneous and Mediastinal Emphysema Following Dental Cleaning
Buescher G, Klose H, Schultze A
DTSCH ARZTEBL INT. 2022;119(7):112.

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Cattaneo C, Salmanton-García J, Marchesi F, El-Ashwah S, Itri F, Weinbergerová B, Gomes Da Silva M, Dargenio M, Dávila-Valls J, Martín-Pérez S, Farina F, Van Doesum J, Valković T, Besson C, Poulsen C, López-García A, Žák P, Schönlein M, Piukovics K, Jaksic O, Cabirta A, Ali N, Sili U, Fracchiolla N, Dragonetti G, Adžić-Vukičević T, Marchetti M, Machado M, Glenthøj A, Finizio O, Demirkan F, Blennow O, Tisi M, Omrani A, Navrátil M, Ráčil Z, Novák J, Magliano G, Jiménez M, Garcia-Vidal C, Erben N, Del Principe M, Buquicchio C, Bergantim R, Batinić J, Al-Khabori M, Verga L, Szotkowski T, Samarkos M, Ormazabal-Vélez I, Meers S, Maertens J, Pinczés L, Hoenigl M, Drgoňa Ľ, Cuccaro A, Bilgin Y, Aujayeb A, Rahimli L, Gräfe S, Sciumè M, Mladenović M, Çolak G, Sacchi M, Nordlander A, Berg Venemyr C, Hanáková M, García-Poutón N, Emarah Z, Zambrotta G, Nunes Rodrigues R, Cordoba R, Méndez G, Biernat M, Cornely O, Pagano L
CANCERS. 2022;14(22):.

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA
Cavo M, San-Miguel J, Usmani S, Weisel K, Dimopoulos M, Avet-Loiseau H, Paiva B, Bahlis N, Plesner T, Hungria V, Moreau P, Mateos M, Perrot A, Iida S, Facon T, Kumar S, van de Donk N, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N
BLOOD. 2022;139(6):835-844.

Acute impact of an endurance race on biventricular and biatrial myocardial strain in competitive male and female triathletes evaluated by feature-tracking CMR
Chen H, Warncke M, Muellerleile K, Saering D, Beitzen-Heineke A, Kisters A, Swiderska M, Cavus E, Jahnke C, Adam G, Lund G, Tahir E
EUR RADIOL. 2022;32(5):3423-3435.

Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Costa L, Hari P, Berdeja J, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos M, Moreau P, Usmani S, Olyslager Y, Schecter J, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo I, Lin Y, Diels J, Valluri S, Weisel K
CURR MED RES OPIN. 2022;38(10):1759-1767.

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard V, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D
HEPATOLOGY. 2022;76(4):1000-1012.

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies F, Pawlyn C, Usmani S, San-Miguel J, Einsele H, Boyle E, Corre J, Auclair D, Cho H, Lonial S, Sonneveld P, Stewart A, Bergsagel P, Kaiser M, Weisel K, Keats J, Mikhael J, Morgan K, Ghobrial I, Orlowski R, Landgren C, Gay F, Caers J, Chng W, Chari A, Walker B, Kumar S, Costa L, Anderson K, Morgan G
BLOOD CANCER DISCOV. 2022;3(4):273-284.

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Dieckmann K, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C, Dienes T, Zschäbitz S, Paffenholz P, Gschliesser T, Pichler R, Mego M, Bader P, Zengerling F, Heinzelbecker J, Krausewitz P, Krege S, Aurilio G, Aksoy C, Hentrich M, Seidel C, Törzsök P, Nestler T, Majewski M, Hiester A, Buchler T, Vallet S, Studentova H, Schönburg S, Niedersüß-Beke D, Ring J, Trenti E, Heidenreich A, Wülfing C, Isbarn H, Pichlmeier U, Pichler M
THER ADV MED ONCOL. 2022;14:17588359221086813.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K
LANCET HAEMATOL. 2022;9(6):e403-e414.

Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn M, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler H, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik V, Theis F, Thol F, Heuser M, Schlenk R, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A
BLOOD ADV. 2022;6(18):5345-5355.

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza A, Shah N, Rodriguez C, Voorhees P, Weisel K, Bueno O, Pothacamury R, Freise K, Yue S, Ross J, Polepally A, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S
J CLIN ONCOL. 2022;40(31):3576-3586.

Neoehrlichiose als Ursache eines Fiebers unklarer Genese
Dumoulin B, Schriefer T, Henes F, Frenzel C, Schnoor U, Iking-Konert C
Z RHEUMATOL. 2022;81(5):427-429.

Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer Cells
Dyshlovoy S, Busenbender T, Hauschild J, Girich E, Kriegs M, Hoffer K, Graefen M, Yurchenko A, Bokemeyer C, Amsberg G
MAR DRUGS. 2022;20(10):.

1-O-Alkylglycerol Ethers from the Marine Sponge Guitarra abbotti and Their Cytotoxic Activity
Dyshlovoy S, Fedorov S, Svetashev V, Makarieva T, Kalinovsky A, Moiseenko O, Krasokhin V, Shubina L, Guzii A, von Amsberg G, Stonik V
MAR DRUGS. 2022;20(7):.

Marine Compounds and Cancer: Updates 2022
Dyshlovoy S, Honecker F
MAR DRUGS. 2022;20(12):.

New Guanidine Alkaloids Batzelladines O and P from the Marine Sponge Monanchora pulchra Induce Apoptosis and Autophagy in Prostate Cancer Cells
Dyshlovoy S, Shubina L, Makarieva T, Guzii A, Hauschild J, Strewinsky N, Berdyshev D, Kudryashova E, Menshov A, Popov R, Dmitrenok P, Graefen M, Bokemeyer C, Amsberg G
MAR DRUGS. 2022;20(12):.

New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein
Dyshlovoy S, Shubina L, Makarieva T, Hauschild J, Strewinsky N, Guzii A, Menshov A, Popov R, Grebnev B, Busenbender T, Oh-Hohenhorst S, Maurer T, Tilki D, Graefen M, Bokemeyer C, Stonik V, von Amsberg G
SCI REP-UK. 2022;12(1):.

Arrested in Glass: Actin within Sophisticated Architectures of Biosilica in Sponges
Ehrlich H, Luczak M, Ziganshin R, Mikšík I, Wysokowski M, Simon P, Baranowska-Bosiacka I, Kupnicka P, Ereskovsky A, Galli R, Dyshlovoy S, Fischer J, Tabachnick K, Petrenko I, Jesionowski T, Lubkowska A, Figlerowicz M, Ivanenko V, Summers A
ADV SCI. 2022;9(11):e2105059.

Regulation of bone homeostasis by MERTK and TYRO3
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu T, Beitzen-Heineke A, Vargas-Delgado M, Pantel K, Bokemeyer C, Bhamidipati S, Darwish I, Masuda E, Burstyn-Cohen T, Alberto E, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben Batalla I, Loges S
NAT COMMUN. 2022;13(1):.

Kardioonkologie – was leistet die MRT? : Inflammation, Fibrose, Outcome
Erley J, Beitzen-Heineke A, Tahir E
RADIOLOGIE. 2022;62(11):941-946.

Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention study
Esser P, Sautier L, Sarkar S, Schilling G, Bokemeyer C, Koch U, Rose M, Friedrich M, Nolte S, Walter O, Mehnert-Theuerkauf A
J CANCER SURVIV. 2022;16(6):1401-1413.

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon T, Cook G, Usmani S, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis N, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner C, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rampelbergh R, Uhlar C, Kobos R, Zweegman S
LEUKEMIA. 2022;36(4):1066-1077.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities
Fehm T, Stübs F, Koch M, Mallmann P, Dannecker C, Dietl A, Sevnina A, Mergel F, Lotz L, Hack C, Ehret A, Gantert D, Martignoni F, Cieslik J, Menke J, Ortmann O, Stromberger C, Oechsle K, Hornemann B, Mumm F, Grimm C, Sturdza A, Wight E, Loessl K, Golatta M, Hagen V, Dauelsberg T, Diel I, Münstedt K, Merz E, Vordermark D, Lindel K, Wittekind C, Küppers V, Lellé R, Neis K, Griesser H, Pöschel B, Steiner M, Freitag U, Gilster T, Schmittel A, Friedrich M, Haase H, Gebhardt M, Kiesel L, Reinhardt M, Kreißl M, Kloke M, Horn L, Wiedemann R, Marnitz S, Letsch A, Zraik I, Mangold B, Möckel J, Alt C, Wimberger P, Hillemanns P, Paradies K, Mustea A, Denschlag D, Henscher U, Tholen R, Wesselmann S, Beckmann M
GEBURTSH FRAUENHEILK. 2022;82(2):181-205.

Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry
Fichtner A, Bohnenberger H, Elakad O, Richter A, Lenz C, Oing C, Ströbel P, Kueffer S, Nettersheim D, Bremmer F
WORLD J UROL. 2022;40(2):373-383.

Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach
Fichtner A, Richter A, Filmar S, Kircher S, Rosenwald A, Küffer S, Nettersheim D, Oing C, Marx A, Ströbel P, Bremmer F
HISTOPATHOLOGY. 2022;80(2):381-396.

Patientin mit therapieinduzierter sekundärer akuter myeloischer Leukämie (t-AML)
Fiedler W
2022.

Mebendazole's Conformational Space and Its Predicted Binding to Human Heat-Shock Protein 90
Fiedler W, Freisleben F, Wellbrock J, Kirschner K
J CHEM INF MODEL. 2022;62(15):3604-3617.

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz C, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W
HAEMATOLOGICA. 2022;107(12):2977-2982.

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database
Franko J, Yin J, Adams R, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg R, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, Yoshino T, de Gramont A, Shi Q
EUR J CANCER. 2022;174:142-152.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Fulgenzi C, Cheon J, D'Alessio A, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D
EUR J CANCER. 2022;175:204-213.

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U
CANCERS. 2022;14(7):.

The Impact of the SARS-CoV-2 Pandemic on the Needs of Non-Infected Patients and Their Families in Palliative Care—Interviews with Those Concerned
Gerlach C, Ullrich A, Berges N, Bausewein C, Oechsle K, Hodiamont F
J CLIN MED. 2022;11(13):.

Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation
Ghandili S, Kluger M, Leitner T, Grahammer F, Kirchner L, Modemann F, Achilles E, Kreipe H, Klein J, Steinemann D, Wolschke C, Fischer L, Bokemeyer C, Fiedler W, Huber T, Alsdorf W, Mahmud M
BRIT J HAEMATOL. 2022;198(1):199-202.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

Aktueller diagnostischer Standard und Risikostratifizierung der AML
Ghandili S, Modemann F, Oelrich J, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(7-8):10–15.

Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment
Ghandili S, von Kroge P, Simon M, Henes F, Rohde H, Hoffmann A, Lindeman N, Bokemeyer C, Fiedler W, Modemann F
CANCERS. 2022;14(11):.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Goldschmidt H, Mai E, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen A, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz S, Holderried T, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab M, Salwender H, Weisel K
LANCET HAEMATOL. 2022;9(11):e810-e821.

Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications
Götze J, Nitschke C, Uzunoglu F, Pantel K, Sinn M, Wikman H
FRONT CELL DEV BIOL. 2022;10:.

Short regulatory DNA sequences to target brain endothelial cells for gene therapy
Graßhoff H, Müller-Fielitz H, Dogbevia G, Körbelin J, Bannach J, Vahldieck C, Kusche-Vihrog K, Jöhren O, Müller O, Nogueiras R, Prevot V, Schwaninger M
J CEREBR BLOOD F MET. 2022;42(1):104-120.

Management of Esophageal Cancer-Associated Respiratory-Digestive Tract Fistulas
Grass J, Küsters N, von Döhren F, Melling N, Ghadban T, Rösch T, Simon M, Izbicki J, König A, Reeh M
CANCERS. 2022;14(5):.

Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin T
J THROMB HAEMOST. 2022;20(1):149-156.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al
Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin T
J THROMB HAEMOST. 2022;20(2):542-543.

Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy
Greinacher A, Langer F, Schonborn L, Thiele T, Haddad M, Renne T, Rollin J, Gruel Y, Warkentin T
HAEMATOLOGICA. 2022;107(5):1219-1221.

High-Flow-Sauerstofftherapie – Chancen und Risiken
Grensemann J, Simon M, Wachs C, Kluge S
PNEUMOLOGE. 2022;19(1):21-26.

Leishmania infantum reactivation with secondary IgA nephropathy
Grewe I, Brehm T, Kreuels B, Steinmetz O, Dumoulin B, Asemissen A, Tappe D, Ramharter M, Schmiedel S
J TRAVEL MED. 2022;29(7):.

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
Hambach J, Fumey W, Stähler T, Gebhardt A, Adam G, Weisel K, Koch-Nolte F, Bannas P
FRONT IMMUNOL. 2022;13:.

Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trial
Harnischfeger N, Rath H, Alt-Epping B, Brand H, Haller K, Letsch A, Rieder N, Thuss-Patience P, Bokemeyer C, Bergelt C, Oechsle K
ESMO OPEN. 2022;7(6):.

Addressing palliative care and end-of-life issues in patients with advanced cancer: a systematic review of communication interventions for physicians not specialised in palliative care
Harnischfeger N, Rath H, Oechsle K, Bergelt C
BMJ OPEN. 2022;12(6):.

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
Hartlapp I, Valta-Seufzer D, Siveke J, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich T, Held S, Keller R, Anger F, Germer C, Stang A, Kimmel B, Heinemann V, Kunzmann V
ESMO OPEN. 2022;7(4):100552.

Partizipation in der Palliativforschung
Heckel M, Gehrmann J, Burggraf L, Stark S, Ullrich A
Pflegezeitschrift. 2022;75:55-57.

Therapy of clinical stage IIA and IIB seminoma: a systematic review
Heinzelbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J, Dieing A, Hakenberg O, Krege S, Papachristofilou A, Pfister D, Ruf C, Schmelz H, Schmidberger H, Souchon R, Winter C, Zengerling F, Kliesch S, Albers P, Oing C
WORLD J UROL. 2022;40(12):2829-2841.

Respiratory muscle dysfunction in long-COVID patients
Hennigs J, Huwe M, Hennigs A, Oqueka T, Simon M, Harbaum L, Körbelin J, Schmiedel S, Schulze Zur Wiesch J, Addo M, Kluge S, Klose H
INFECTION. 2022;50(5):1391-1397.

Organbezogene Folgeerscheinungen von COVID‑19 bei Erwachsenen
Hennigs J, Oqueka T, Harbaum L, Klose H
BUNDESGESUNDHEITSBLA. 2022;65(4):462-470.

Shortening time to diagnosis in malignant spinal lesions using a novel diagnostic fast track - a multidisciplinary approach
Heuer A, Köpke L, Stangenberg M, Strahl A, Dreimann M, Welker L, Bokemeyer C, Viezens L, Asemissen A
ONCOL RES TREAT. 2022;2022(45):254.

Novel diagnostic fast track using aspiration cytology in malignant spinal lesions – a multidisciplinary approach
Heuer A, Köpke L, Strahl A, Stangenberg M, Dreimann M, Welker L, Bokemeyer C, Asemissen A, Viezens L
Ger Med Sci. 2022;2022:.

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
Hillengass J, Cohen A, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab M, Scheid C, Schecter J, de Braganca K, Varsos H, Yeh T, Mistry P, Roccia T, Corsale C, Akram M, Pacaud L, Nesheiwat T, Agha M, Cohen Y
CL LYMPH MYELOM LEUK. 2022;22(Suppl 2):.

Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510
Högner A, Al-Batran S, Siveke J, Lorenz M, Bartels P, Breithaupt K, Malfertheiner P, Homann N, Stein A, Gläser D, Tamm I, Hinke A, Vogel A, Thuss-Patience P
INT J CANCER. 2022;150(6):1007-1017.

Hämophilie im Alter: Herausforderungen der Therapie
Holstein K
Kompendium ... Hämatologie/Onkologie. 2022;2022:67-72.

Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
Holstein K, Le Quellec S, Klamroth R, Batorova A, Holme P, Jiménez-Yuste V, Astermark J
HAEMOPHILIA. 2022;28(2):215-222.

The Bone Microarchitecture Deficit in Patients with Hemophilia Is Influenced by Arthropathy, Hepatitis C Infection, and Physical Activity
Holstein K, Witt L, Matysiak A, Schmidt C, Barvencik F, Amling M, Rolvien T, Langer F
THROMB HAEMOSTASIS. 2022;122(5):692-702.

Keimzelltumoren
Honecker F, Bokemeyer C, Krege S, Classen J
2022. Taschenbuch Hämatologie und Onkologie. Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 21. Aufl. München: W. Zuckschwerdt Verlag, 121-127.

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination
Hosseinzadeh R, Barary M, Mehdinezhad H, Sio T, Langer F, Khosravi S
RES PRACT THROMB HAE. 2022;6(4):.

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Infante M, Salmanton-García J, Fernández-Cruz A, Marchesi F, Jaksic O, Weinbergerová B, Besson C, Duarte R, Itri F, Valković T, Szotkovski T, Busca A, Guidetti A, Glenthøj A, Collins G, Bonuomo V, Sili U, Seval G, Machado M, Cordoba R, Blennow O, Abu-Zeinah G, Lamure S, Kulasekararaj A, Falces-Romero I, Cattaneo C, Van Doesum J, Piukovics K, Omrani A, Magliano G, Ledoux M, de Ramon C, Cabirta A, Verga L, López-García A, Da Silva M, Stojanoski Z, Meers S, Lahmer T, Martín-Pérez S, Dávila-Vals J, Van Praet J, Samarkos M, Bilgin Y, Karlsson L, Batinić J, Nordlander A, Schönlein M, Hoenigl M, Ráčil Z, Mladenović M, Hanakova M, Zambrotta G, De Jonge N, Adžić-Vukičević T, Nunes-Rodrigues R, Prezioso L, Navrátil M, Marchetti M, Cuccaro A, Calbacho M, Giordano A, Cornely O, Hernández-Rivas J, Pagano L
FRONT ONCOL. 2022;12:.

AAV-BR1 targets endothelial cells in the retina to reveal their morphological diversity and to deliver Cx43
Ivanova E, Corona C, Eleftheriou C, Stout R, Körbelin J, Sagdullaev B
J COMP NEUROL. 2022;530(8):1302-1317.

Non-Random Pattern of Integration for Epstein-Barr Virus with Preference for Gene-Poor Genomic Chromosomal Regions into the Genome of Burkitt Lymphoma Cell Lines
Janjetovic S, Hinke J, Balachandran S, Akyüz N, Behrmann P, Bokemeyer C, Dierlamm J, Murga Penas E
VIRUSES-BASEL. 2022;14(1):.

Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia
Janjetovic S, Rolling C, Budde U, Schneppenhem S, Schafhausen P, Peters M, Bokemeyer C, Holstein K, Langer F
THROMB RES. 2022;218:35-43.

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel H, Wiesweg M, Schildhaus H, Stratmann J, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld F, Wermke M, Merkelbach-Bruse S, Hillmer A, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S
ANN ONCOL. 2022;33(6):602-615.

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
Jonas B, Wei A, Recher C, DiNardo C, Jang J, Pratz K, Panayiotidis P, Montesinos P, Yeh S, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y
AM J HEMATOL. 2022;97(8):E299-E303.

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients
Karagiannis P, Correa I, Chauhan J, Cheung A, Dominguez-Rodriguez D, Terranova Barberio M, Harris R, Crescioli S, Spicer J, Bokemeyer C, Lacy K, Karagiannis S
CLIN EXP IMMUNOL. 2022;207(1):84-94.

Multimodal survival prediction in advanced pancreatic cancer using machine learning
Keyl J, Kasper S, Wiesweg M, Götze J, Schönrock M, Sinn M, Berger A, Nasca E, Kostbade K, Schumacher B, Markus P, Albers D, Treckmann J, Schmid K, Schildhaus H, Siveke J, Schuler M, Kleesiek J
ESMO OPEN. 2022;7(5):.

Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study
Klamroth R, Sinn M, Pollich C, Bischoff S, Lohneis A, Orlovic A, Wislocka L, Habbel P, de Wit M, Späth-Schwalbe E, Scholz C, Riess H
ONCOL RES TREAT. 2022;45(4):178-185.

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
Klingler F, Alsdorf W, Ghandili S, Wolschke C, Brauneck F, Bokemeyer C, Fiedler W, Modemann F, Karagiannis P
LEUKEMIA LYMPHOMA. 2022;63(11):2645-2651.

Surgical Site Cytology to Diagnose Spinal Lesions
Koepke L, Heuer A, Stangenberg M, Dreimann M, Welker L, Bokemeyer C, Strahl A, Asemissen A, Viezens L
DIAGNOSTICS. 2022;12(2):.

17th German Spine Congress, Annual Meeting of the German Spine Society: Shortening the time to diagnosis and therapy in spinal lesions of unknown malignancy
Köpke L, Heuer A, Schmidt G, Strahl A, Stangenberg M, Dreimann M, Welker L, Bokemeyer C, Asemissen A, Viezens L
EUR SPINE J. 2022;31(11):3187-3187.

Gastrointestinale Stromatumoren (GIST)
Kopp H, Bokemeyer C, Hohenberger P
2022. Taschenbuch Hämatologie und Onkologie. Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 21. Aufl. 105-109.

Weichteilsarkome
Kopp H, Bokemeyer C, Hohenberger P, Müller A, Mosthaf F, Hentrich M
2022. Taschenbuch Hämatologie und Onkologie. Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 21. Aufl. München: W. Zuckschwerdt Verlag, 241-247.

Dying in hospital in Germany - optimising care in the dying phase:study protocol for a multi-centre bottom-up intervention on ward level
Kremeike K, Ullrich A, Schulz H, Rosendahl C, Boström K, Kaur S, Oubaid N, Plathe-Ignatz C, Leminski C, Hower K, Pfaff H, Hellmich M, Oechsle K, Voltz R
BMC PALLIAT CARE. 2022;21:.

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
Krohn S, Boje A, Gehlert C, Lutz S, Darzentas N, Knecht H, Herrmann D, Brüggemann M, Scheidig A, Weisel K, Gramatzki M, Peipp M, Klausz K
FRONT IMMUNOL. 2022;13:.

CDK7 is a prognostic biomarker for non-small cell lung cancer
Kuempers C, Jagomast T, Heidel C, Paulsen F, Bohnet S, Schierholz S, Dreyer E, Kirfel J, Perner S
FRONT ONCOL. 2022;12:.

EAU Guidelines on Testicular Cancer - 2022 edition
Laguna M, Albers P, Algaba F, Bokemeyer C, Boormans J, di Nardo D, Fischer S, Fizazi K, Gremmels H, Leao R, Nicol D, Nicolai N, Oldenburg J, Tandstad T
2022.

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim J, Shu N, Hu X, Li C, Usmani S
BRIT J HAEMATOL. 2022;198(6):988-993.

TEMPORARY REMOVAL OC-02: Outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
Langer F, Gerlach H, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R
THROMB RES. 2022;213 Suppl 2:S1-S2.

Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
Langer F, Gerlach H, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R
THROMB RES. 2022;220:145-152.

Use of Process Modelling for Optimization of Molecular Tumor Boards
Lauk K, Peters M, Velthaus J, Nürnberg S, Ueckert F
APPL SCI-BASEL. 2022;12(7):.

Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur R, Zhao T, Ramanathan M, Schartinger V, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel N, Stewart S, Brooks L, Pickles J, Jacques T, Fenton T, Williams L, Vaz F, O'Flynn P, Stimpson P, Wang S, Hannan S, Unadkat S, Hughes J, Dwivedi R, Forde C, Randhawa P, Gane S, Joseph J, Andrews P, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele C, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park K, Le Q, West R, Saade R, Manes R, Omay S, Vining E, Judson B, Yarbrough W, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez O, Magliocca K, Solares C, Wise S, Llorente J, Patel Z, Nayak J, Hwang P, Lacy P, Woods R, O'Neill J, Jay A, Carnell D, Forster M, Ishii M, London N, Bell D, Gallia G, Castelnuovo P, Severi S, Lund V, Hanna E
EUR J CANCER. 2022;162:221-236.

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min , Ocio E, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson P
ANN HEMATOL. 2022;101(10):2123-2137.

Meroantarctines A-C, Meroterpenoids with Rearranged Skeletons from the Alga-Derived Fungus Penicillium antarcticum KMM 4685 with Potent p-Glycoprotein Inhibitory Activity
Leshchenko E, Antonov A, Dyshlovoy S, Berdyshev D, Hauschild J, Zhuravleva O, Menshov A, Kirichuk N, Popov R, Gerasimenko A, Udovenko A, Graefen M, Bokemeyer C, von Amsberg G, Yurchenko A
J NAT PROD. 2022;85(12):2746-2752.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
Leypoldt L, Besemer B, Asemissen A, Hänel M, Blau I, Görner M, Ko Y, Reinhardt H, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel K
LEUKEMIA. 2022;36(3):885-888.

The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series
Lim K, Murali K, Thorne E, Punie K, Kamposioras K, Oing C, O'Connor M, Élez E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen C, Morgan G, Haanen J, Hardy C, Banerjee S
ESMO OPEN. 2022;7(1):.

Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism
Limperger V, Torge A, Kiesau B, Langer F, Kenet G, Mesters R, Juhl D, Stoll M, Shneyder M, Kowalski D, Bajorat T, Rocke A, Kuta P, Lasarow L, Spengler D, Junker R, Nowak-Göttl U
BLOOD CELL MOL DIS. 2022;94:.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson P, Facon T, Weisel K, Larsen J, Minnema M, Abdallah A, Badros A, Knop S, Stadtmauer E, Cheng Y, Amatangelo M, Chen M, Nguyen T, Amin A, Peluso T, van de Donk N
LANCET HAEMATOL. 2022;9(11):e822-e832.

Nutritional Status Impacts Quality of Life in Head and Neck Cancer Patients Undergoing (Chemo)Radiotherapy: Results from the Prospective HEADNUT Trial
Löser A, Avanesov M, Thieme A, Gargioni E, Baehr A, Hintelmann K, Tribius S, Krüll A, Petersen C
NUTR CANCER. 2022;74(8):2887-2895.

Impact of dosimetric factors on long-term percutaneous enteral gastrostomy (PEG) tube dependence in head and neck cancer patients after (chemo)radiotherapy-results from a prospective randomized trial
Löser A, Grohmann M, Finger A, Greinert F, Krause L, Molwitz I, Krüll A, Petersen C
STRAHLENTHER ONKOL. 2022;198(11):1016-1024.

Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients
Madanchi R, Engel N, Alsdorf W, Oing C, Frenzel C, Paulsen F, Bokemeyer C, Seidel C
BONE MARROW TRANSPL. 2022;57(5):729-733.

PO-31: The small-molecule FXIa inhibitor, BMS-26208, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression
Mäder J, Voigtländer M, Rolling C, Quick H, Schulenkorf A, Lehr C, Bokemeyer C, Beckmann L, Langer F
THROMB RES. 2022;213(Suppl 2):.

Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)
Malin J, Spinner C, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S
INFECTION. 2022;50(1):107-108.

Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)
Malin J, Spinner C, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S
INFECTION. 2022;50(1):93-106.

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
Martin T, Krishnan A, Yong K, Weisel K, Mehra M, Nair S, Qi K, Londhe A, Diels J, Crivera C, Jackson C, Olyslager Y, Vogel M, Schecter J, Banerjee A, Valluri S, Usmani S, Berdeja J, Jagannath S
EJHaem. 2022;3(1):97-108.

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk N, Ocio E, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter J, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P
LEUKEMIA. 2022;36(5):1371-1376.

Erstmalige interdiszipläre DKK-Programmplanung durch Zusammenschluss onkologischer Nachwuchsgruppen
Maurer M, Huber T, Sommer N, Mäurer I, Lazaridis L, Bodensohn R, Ziegler S, Fleischmann D, Käsmann L, Staudacher J, Kropf-Sanchen C, Scherg A, Wickert J, Pietzner K, Oing C, Beyer G, Hollenbach M, Nestler T, Siech C, Meyer R, Heinrich K, Stahler A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2022;2022(37):19-23.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
McCleary N, Harmsen W, Haakenstad E, Cleary J, Meyerhardt J, Zalcberg J, Adams R, Grothey A, Sobrero A, Van Cutsem E, Goldberg R, Peeters M, Tabernero J, Seymour M, Saltz L, Giantonio B, Arnold D, Rothenberg M, Koopman M, Schmoll H, Pitot H, Hoff P, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman S
JNCI CANCER SPECT. 2022;6(2):.

AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients
Mecklenbrauck R, Borchert N, Klement P, Funke C, Brandes M, Dallmann L, Fiedler W, Krauter J, Trummer A, Hertenstein B, Voβ A, Lübbert M, Gaidzik V, Döhner K, Döhner H, Ganser A, Thol F, Heuser M
CL LYMPH MYELOM LEUK. 2022;22(Suppl 2):S251-S252.

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J, Perner S, Pantel K, Werner S, von Amsberg G
J EXP CLIN CANC RES. 2022;41(1):.

Preventing adverse events of chemotherapy for gastrointestinal cancer by educating patients about the nocebo effect: a randomized-controlled trial
Michnevich T, Pan Y, Hendi A, Oechsle K, Stein A, Nestoriuc Y
BMC CANCER. 2022;22(1):.

Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH)
Miesbach W, Eichler H, Holstein K, Holzhauer S, Klamroth R, Knöfler R, Male C, Olivieri M, Oldenburg J, Tiede A
HAEMOPHILIA. 2022;28(2):264-269.

Erratum: Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)
Miesbach W, Oldenburg J, Klamroth R, Eichler H, Koscielny J, Holzhauer S, Holstein K, Hovinga J, Alberio L, Olivieri M, Knöfler R, Male C, Tiede A
HAMOSTASEOLOGIE. 2022.

Erstlinientherapie intensiv-therapierbarer AML Patient*innen
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(7-8):16-21.

Therapie der akuten Promyelozytenleukämie
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(12):16–21.

Überblick zur Diagnostik und Therapie neu diagnostizierter Patienten mit AML
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Onkologie heute. 2022;2022(09):22-29.

Aktuelle Therapieoptionen bei rezidivierter/refraktärer AML
Modemann F, Ghandili S, Oelrich J, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(10):18-23.

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
Modemann F, Ghandili S, Schmiedel S, Weisel K, Bokemeyer C, Fiedler W
CANCERS. 2022;14(15):.

Die akute Promyelozytenleukämie - ein hämatologischer Notfall
Modemann F, Ghandili S, Zhurba I, Langer F, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(12):10–15.

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia-A Single Center Analysis
Modemann F, Härterich S, Schulze Zur Wiesch J, Rohde H, Lindeman N, Bokemeyer C, Fiedler W, Ghandili S
ANTIBIOTICS-BASEL. 2022;11(2):.

COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies
Modemann F, Niederwieser C, Weisel K, Bokemeyer C, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2022;63(3):664-671.

Fat Quantification in Dual-Layer Detector Spectral Computed Tomography: Experimental Development and First In-Patient Validation
Molwitz I, Campbell G, Yamamura J, Knopp T, Toedter K, Fischer R, Wang Z, Busch A, Ozga A, Zhang S, Lindner T, Sevecke F, Grosser M, Adam G, Szwargulski P
INVEST RADIOL. 2022;57(7):463-469.

Multimodale Therapie des Hodentumors: wann Chemotherapie, Operation oder Strahlentherapie?
Nestler T, Schmelz H, Müller A, Seidel C
UROLOGE. 2022;61(12):1315-1323.

Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Konczalla L, Kropidlowski J, Pereira-Veiga T, Scognamiglio P, Schönrock M, Sinn M, Tölle M, Izbicki J, Pantel K, Uzunoglu F, Wikman H
BIOMEDICINES. 2022;10(11):.

Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients
Nitschke C, Markmann B, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Schlüter H, Kwiatkowski M, Sinn M, Izbicki J, Pantel K, Güngör C, Uzunoglu F, Wikman H
CANCERS. 2022;14(18):.

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
Novoyatleva T, Rai N, Kojonazarov B, Veeroju S, Ben-Batalla I, Caruso P, Shihan M, Presser N, Götz E, Lepper C, Herpel S, Manaud G, Perros F, Gall H, Ghofrani H, Weissmann N, Grimminger F, Wharton J, Wilkins M, Upton P, Loges S, Morrell N, Seeger W, Schermuly R
COMMUN BIOL. 2022;5(1):.

The HDL particle composition determines its antitumor activity in pancreatic cancer
Oberle R, Kührer K, Österreicher T, Weber F, Steinbauer S, Udonta F, Wroblewski M, Ben-Batalla I, Hassl I, Körbelin J, Unseld M, Jauhiainen M, Plochberger B, Röhrl C, Hengstschläger M, Loges S, Stangl H
LIFE SCI ALLIANCE. 2022;5(9):.

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
Ochsenreither S, Fiedler W, Conte G, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer K, Saavedra O, Baumeister H, Zurlo A, Garralda E
ESMO OPEN. 2022;7(2):.

Die „ungehörten“ und „ungehörigen“ sorgenden Angehörigen
Oechsle K
Die Hospiz-Zeitschrift: Fachforum für palliative Care. 2022;24(4):25-30.

Specialized Outpatient Palliative Care-an Interim Assessment
Oechsle K
DTSCH ARZTEBL INT. 2022;119(18):325-326.

Den letzten Weg gemeinsam gehen: Angehörige in verschiedenen Sterbesettings
Oechsle K, Ullrich A
2022. Kontext Sterben. Caduff C, Afzali M, Müller F, Soom E (Hrsg.). 1. Aufl. Zürich: Scheidegger & Spiess, 51-63.

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
Oldenburg J, Berney D, Bokemeyer C, Climent M, Daugaard G, Gietema J, De Giorgi U, Haugnes H, Huddart R, Leão R, Sohaib A, Gillessen S, Powles T
ANN ONCOL. 2022;33(4):362-375.

Sarkoidose als Paradebeispiel einer granulomatösen Erkrankung
Oqueka T, Galow S, Simon M, Weidmann A, Stübiger N, Zengin-Sahm E, Sinning C, Krusche M, Ruffer N, Steurer S, Schick-Bengardt X, Sebode M, Horst L, Steinmetz O, Melderis S, Rosenkranz S, Möller K, Jantke H, Klose H
Z RHEUMATOL. 2022;81(7):535-548.

Deutschsprachige Instrumente zur Bedarfserhebung bei Angehörigen: Eine narrative Übersicht über verfügbare Selbsteinschätzungsinstrumente zur Erfassung verschiedener Aspekte möglicher Angehörigenbedarfe
Oubaid N, Ullrich A, Schwenzitzki L, Berendt J, Heckel M, Hentschel L, Hornemann B, Jentschke E, Pauli B, Simon S, Stiel S, van Oorschot B, Oechsle K
ONKOLOGE. 2022;28:420-428.

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey
Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, van Doesum J, Bilgin Y, Lopez-Garcia A, Itri F, Nunes Rodrigues R, Weinbergerová B, Farina F, Dragonetti G, Berg Venemyr C, Van Praet J, Jaksic O, Valkovic T, Falces-Romero I, Martin-Perez S, Jiménez M, Davila-Valls J, Schonlein M, Ammatuna E, Meers S, Delia M, Stojanoski Z, Nordlander A, Lahmer T, Pinczés L, Buquicchio C, Piukovics K, Ormazabal-Velez I, Fracchiolla N, Samarkos M, Mendez G, Hernández-Rivas J, Espigado I, Cernan M, Petzer V, Lamure S, Di Blasi R, Marques de Almeida J, Dargenio M, Biernat M, Sciumè M, de Ramón C, De Jonge N, Batinic J, Aujayeb A, Marchetti M, Fouquet G, Fernández Escalada N, Zambrotta G, Sacchi M, Guidetti A, Demirken F, Prezioso L, Racil Z, Nucci M, Mladenovic M, Lievin R, Hanakova M, Grafe S, Sili U, Machado M, Cattaneo C, Adzic-Vukicevic T, Verga L, Labrador J, Rahimli L, Bonanni M, Passamonti F, Pagliuca A, Corradini P, Hoenigl M, Koehler P, Busca A, Cornely O
BLOOD. 2022;140(26):2773-2787.

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years
Papamichael D, Lopes G, Olswold C, Douillard J, Adams R, Maughan T, Van Cutsem E, Venook A, Lenz H, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q
EUR J CANCER. 2022;163:1-15.

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Pape L, Hambach J, Gebhardt A, Rissiek B, Stähler T, Tode N, Khan C, Weisel K, Adam G, Koch-Nolte F, Bannas P
FRONT IMMUNOL. 2022;13:.

Targeting Cyclin-Dependent Kinase 7 - Association between CDK7 and pMED1 Expression in Prostate Cancer Tissue
Paulsen F, Kang D, Becker F, Roth D, Jörg V, Dreyer E, Roesch M, Seidel C, Merseburger A, Kirfel J, Sailer V, Offermann A, Perner S
CARCINOGENESIS. 2022;43(8):779-786.

Editorial Comment to Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors
Paulsen F, Seidel C
INT J UROL. 2022;29(7):747.

First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment: A comprehensive review compiled by the German Testicular Cancer Study Group
Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzelbecker J, Ruf C, Winter C, Zengerling F, Kliesch S, Albers P, Oing C
WORLD J UROL. 2022;40(12):2853-2861.

Understanding avoidant attachment in a patient with terminal cancer: a psychoanalytic perspective
Philipp R, Krüger A, Lindner R, Mehnert-Theuerkauf A, Vehling S
PSYCHOANAL PSYCHOTHE. 2022;36(2):105-123.

Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C
DTSCH ARZTEBL INT. 2022;119(14):253-260.

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement
Pijnappel E, Suurmeijer J, Koerkamp B, Kos M, Siveke J, Salvia R, Ghaneh P, van Eijck C, van Etten-Jamaludin F, Abrams R, Brasiuniene B, Büchler M, Casadei R, van Laethem J, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos J, van Tienhoven G, Besselink M, Wilmink J, van Laarhoven H
JAMA ONCOL. 2022;8(6):929-937.

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Pollyea D, DiNardo C, Arellano M, Pigneux A, Fiedler W, Konopleva M, Rizzieri D, Smith B, Shinagawa A, Lemoli R, Dail M, Duan Y, Chyla B, Potluri J, Miller C, Kantarjian H
CLIN CANCER RES. 2022;28(13):2753-2761.

Management of Patients Receiving Direct Oral Anticoagulants Scheduled for Radical Prostatectomy: An Update of a Prospective Assessment
Pose R, Langer F, Tennstedt P, Graefen M, Isbarn H
EUR UROL FOCUS. 2022;8(1):128-133.

Das intimale Sarkom der Pulmonalarterie – Fallbericht einer seltenen Differenzialdiagnose der chronisch thromboembolischen pulmonalen Hypertonie
Pott J, Gräfin zu Reventlow P, Simon M, Steurer S, Harbaum L, Henes F, Klose H
PNEUMOLOGIE. 2022;76(9):633-638.

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Pratz K, Panayiotidis P, Recher C, Wei X, Jonas B, Montesinos P, Ivanov V, Schuh A, DiNardo C, Novak J, Pejsa V, Stevens D, Yeh S, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei A, Bui C, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W
BLOOD CANCER J. 2022;12(4):.

Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy - Addendum
Prondzynski M, Lemoine M, Zech A, Horváth A, Di Mauro V, Koivumäki J, Kresin N, Busch J, Krause T, Krämer E, Schlossarek S, Spohn M, Friedrich F, Münch J, Laufer S, Redwood C, Volk A, Hansen A, Mearini G, Catalucci D, Meyer C, Christ T, Patten M, Eschenhagen T, Carrier L
EMBO MOL MED. 2022;14(8):.

Adeno-Associated Virus-Mediated Gene Transfer of Inducible Nitric Oxide Synthase to an Animal Model of Pulmonary Hypertension
Remes A, Körbelin J, Arnold C, Rohwedder C, Heckmann M, Mairbauerl H, Frank D, Korff T, Frey N, Trepel M, Müller O
HUM GENE THER. 2022;33(17-18):959-967.

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Richardson P, Schjesvold F, Weisel K, Moreau P, Anderson L, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati A, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate A, Jiang R, Grote L, Peluso T, Dimopoulos M
EUR J HAEMATOL. 2022;108(1):73-83.

Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review
Ruf C, Schmidt S, Kliesch S, Oing C, Pfister D, Busch J, Heinzelbecker J, Winter C, Zengerling F, Albers P, Oechsle K, Krege S, Lackner J, Dieckmann K
WORLD J UROL. 2022;40(12):2889-2900.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):e56-e130.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):81-107.

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Salmanton-García J, Marchesi F, Glenthøj A, Bilgin Y, van Praet J, Dávila-Valls J, Martín-Pérez S, Labrador J, van Doesum J, Falces-Romero I, Farina F, Schönlein M, Chanut M, Petzer V, Espigado I, Dargenio M, Aujayeb A, Sili U, Serrano L, Pinczés L, de Jonge N, Soto-Silva A, Buquicchio C, Prezioso L, Marchetti M, Meers S, Busca A, Corradini P, Hoenigl M, Koehler P, Rahimli L, Çolak G, Arellano E, Wolf D, Gräfe S, Ammatuna E, Berg Venemyr C, Cornely O, Pagano L
HEMASPHERE. 2022;6(11):.

The prognostic impact of the smoking status of cancer patients receiving systemic treatment, radiation therapy, and surgery: A systematic review and meta-analysis
Schaefers C, Seidel C, Bokemeyer F, Bokemeyer C
EUR J CANCER. 2022;172:130-137.

Kopf-Hals-Tumoren
Schafhausen P
2022. Colloquium Onkologie 30. Petrasch S, Ehninger G (Hrsg.). Lukon Verlagsgesellschaft mbH München, 161-171.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

Comparison of four diagnostic criteria for invasive pulmonary aspergillosis - a diagnostic accuracy study in critically ill patients
Schroeder M, Giese M, Wijaya C, Winterland S, Nuechtern A, Grensemann J, Matthews H, Wichmann D, Stamm J, Rohde H, Christner M, Ozga A, Steurer S, Heinemann A, Simon M, Fischer M, Kluge S
MYCOSES. 2022;65(8):824-833.

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)
Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C
WORLD J UROL. 2022;40(2):355-361.

Identification of New AAV9 Engineered Capsids Targeting Mouse and Monkey Brains Through a Directed Evolution Approach in BALB/c Mice
Serena G, Luoni M, Bellinazzi B, Martin T, Körbelin J, Broccoli V
MOL THER. 2022;30(4):209-210.

S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich T, Grenacher L, Gress T, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W
Z GASTROENTEROL. 2022;60(6):991-1037.

S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich T, Grenacher L, Gress T, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W
Z GASTROENTEROL. 2022;60(11):e812-e909.

Akute Intoxikationen auf der Intensivstation: Eine 10-Jahres-Analyse
Siedler S, Trageser H, Grensemann J, Hilgarth H, Simon M, Kluge S
MED KLIN-INTENSIVMED. 2022;117(2):129-136.

Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation
Striefler J, Stieler J, Neumann C, Geisel D, Ghadjar P, Sinn M, Malinka T, Pratschke J, Stintzing S, Oettle H, Riess H, Pelzer U
J CLIN MED. 2022;11(16):.

MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F
BLOOD ADV. 2022;6(2):515-520.

Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma
Stüben B, Stuhlfelder J, Kemper M, Tachezy M, Ghadban T, Izbicki J, Bokemeyer C, Sinn M, Karstens K, Reeh M
CANCERS. 2022;14(4):.

Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency
Sundaram S, Arrulo Pereira A, Müller-Fielitz H, Köpke H, De Angelis M, Müller T, Heuer H, Körbelin J, Krohn M, Mittag J, Nogueiras R, Prevot V, Schwaninger M
BRAIN. 2022;145(12):4264-4274.

Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT
Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, Molwitz I, Muellerleile K, Stehning C, Schön G, Adam G, Petersen C, Müller V, Lund G
EUR RADIOL. 2022;32(3):1853-1865.

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
Terbuch A, Posch F, Bauernhofer T, Jost P, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli H, Dieckmann K, Gamulin M, Chovanec M, Fankhauser C, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S
INT J RADIAT ONCOL. 2022;113(4):825-832.

Safety of intramuscular COVID-19 vaccination in patients with haemophilia
Tiede A, Leise H, Horneff S, Oldenburg J, Halimeh S, Heller C, Königs C, Holstein K, Pfrepper C
HAEMOPHILIA. 2022;28(5):687-693.

Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors
Timmerman D, Eleveld T, Sriram S, Dorssers L, Gillis A, Schmidtova S, Kalavska K, van de Werken H, Oing C, Honecker F, Mego M, Looijenga L
J CLIN ONCOL. 2022;40(26):3077-3087.

Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Tintelnot J, Ristow I, Sauer M, Simnica D, Schultheiß C, Scholz R, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Dörfel S, Al-Batran S, Karthaus M, Pelzer U, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M, Stein A
FRONT ONCOL. 2022;12:.

What are the personal last wishes of people with a life-limiting illness?: Findings from a longitudinal observational study in specialist palliative care
Ullrich A, Hollburg W, Schulz H, Goldbach S, Rommel A, Müller M, Kirsch D, Kopplin-Foertsch K, Messerer J, König L, Schulz-Kindermann F, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2022;21(1):38.

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care - a Randomized Pilot Study
Ullrich A, Wilde S, Müller V, Sinn M, Gebhardt C, Velthaus J, Gerlach C, Bokemeyer C, Oechsle K
ONCOL RES TREAT. 2022;45(3):118-129.

The Alzheimer's risk factor CD2AP drives defects across the cerebrovascular network
Vandal M, Gunn C, Institoris A, Bourassa P, Korin B, Lee S, Mishra R, Peringod G, Hirai S, Jiang Y, Belzil C, Reveret L, Tremblay C, Hashem M, Nicola W, Körbelin J, Dunn J, Braun A, Bennett D, Shaw A, Gordon G, Calon F, Nguyen M
J CEREBR BLOOD F MET. 2022;42(1_SUPPL):286-287.

Prevalence of mental disorders in patients with cancer compared to matched controls - secondary analysis of two nationally representative surveys
Vehling S, Mehnert-Theuerkauf A, Philipp R, Härter M, Kraywinkel K, Kuhnert R, Koch U
ACTA ONCOL. 2022;61(1):7-13.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
LIVER INT. 2022;42(11):2538-2547.

Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors
Voigtlaender M, Edler C, Gerling M, Schädler J, Ondruschka B, Schröder A, Sperhake J, Ehrhardt S, Wang L, Haddad M, Kiencke V, Renné T, Roedl K, Kluge S, Wichmann D, Langer F
THROMB RES. 2022;218:171-176.

Management of Vascular Thrombosis in Patients with Thrombocytopenia
Voigtlaender M, Langer F
HAMOSTASEOLOGIE. 2022;42(1):19-28.

62/w mit rezidiviertem Ovarialkarzinom und Luftnot
Voigtländer M, Langer F
ONKOLOGE. 2022;2022(28):144-149.

Gerinnungsstörungen bei Tumorerkrankungen
Voigtländer M, Langer F
DERMATOLOGIE. 2022;73(10):809–819.

Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy S
INT J MOL SCI. 2022;23(5):.

Neue Follow-up-Daten zu Studien in der Uroonkologie
von Amsberg G, Bokemeyer C
Im Fokus Onkologie. 2022;25(4):40-41.

Primärprävention in der Onkologie- Ernährung und körperliche Aktivität
von Grundherr J, Reudelsterz C, Erickson N, Schmidt T
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2022;37(2):129-134.

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo C
BLOOD. 2022;140(25):2754-2756.

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
Weimer P, Wellbrock J, Sturmheit T, Ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Brauneck F
CELLS-BASEL. 2022;11(6):.

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Weisel K, Krishnan A, Schecter J, Vogel M, Jackson C, Deraedt W, Yeh T, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani S, Berdeja J, Jagannath S, Martin T
CL LYMPH MYELOM LEUK. 2022;22(9):690-701.

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schecter J, Banerjee A, Berdeja J, Nesheiwat T, Garrett A, Qi K, Valluri S, Usmani S, Yong K
CLIN DRUG INVEST. 2022;42(1):29-41.

Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Weisel K, Nooka A, Terpos E, Spencer A, Goldschmidt H, Dirnberger F, DeCosta L, Yusuf A, Kumar S
LEUKEMIA LYMPHOMA. 2022;63(8):1887-1896.

Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
Weisel K, Wadlund A, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, Rodriguez-Otero P
EUR J HAEMATOL. 2022;109(4):388-397.

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Wen P, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, von Bubnoff N, van Linde M, Lai A, Prager G, Campone M, Fasolo A, Lopez-Martin J, Kim T, Mason W, Hofheinz R, Blay J, Cho D, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V
LANCET ONCOL. 2022;23(1):53-64.

The SARS-CoV-2 main protease induces capillary cell death by cleaving NEMO in brain endothelial cells
Wenzel J, Lampe J, Muller-Fielitz H, Schuster R, Zille M, Körbelin J, Sauve F, Franz J, Stadelmann C, Trottein F, Glatzel M, Prevot V, Schwaninger M
J CEREBR BLOOD F MET. 2022;42(1_SUPPL):35.

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
Weskamm L, Fathi A, Raadsen M, Mykytyn A, Koch T, Spohn M, Friedrich M, , Haagmans B, Becker S, Sutter G, Dahlke C, Addo M
CELL REP MED. 2022;3(7):.

How does spirituality manifest in family caregivers of terminally ill cancer patients? A qualitative secondary analysis
Wikert J, Treutlein M, Theochari M, Bokemeyer C, Oechsle K, Ullrich A
PALLIAT SUPPORT CARE. 2022;20(1):45-54.

Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition
Wildner N, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze Zur Wiesch J
FRONT IMMUNOL. 2022;13:.

How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence
Winter C, Zengerling F, Busch J, Heinzelbecker J, Pfister D, Ruf C, Lackner J, Albers P, Kliesch S, Schmidt S, Bokemeyer C
WORLD J UROL. 2022;40(12):2863-2878.

Ethische Herausforderungen in der Onkologie
Woellert K, Hlawatsch C, Coym A, Wolters J
Pflegezeitschrift. 2022;75(3):13-15.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Wu Y, Fulgenzi C, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D, Ang C
CANCERS. 2022;14(23):.

Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters
Yogeswaran A, Tello K, Lund J, Klose H, Harbaum L, Sommer N, Oqueka T, Hennigs J, Grimminger F, Seeger W, Ghofrani H, Richter M, Gall H
J HEART LUNG TRANSPL. 2022;41(3):400-410.

Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents
Zhidkov M, Kaune M, Kantemirov A, Smirnova P, Spirin P, Sidorova M, Stadnik S, Shyrokova E, Kaluzhny D, Tryapkin O, Busenbender T, Hauschild J, Rohlfing T, Prassolov V, Bokemeyer C, Graefen M, von Amsberg G, Dyshlovoy S
MAR DRUGS. 2022;20(3):.

New Antibacterial Chloro-Containing Polyketides from the Alga-Derived Fungus Asteromyces cruciatus KMM 4696
Zhuravleva O, Oleinikova G, Antonov A, Kirichuk N, Pelageev D, Rasin A, Menshov A, Popov R, Kim N, Chingizova E, Chingizov A, Volchkova O, von Amsberg G, Dyshlovoy S, Yurchenko E, Guzhova I, Yurchenko A
J FUNGI. 2022;8(5):.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

AUTOPHAGY. 2021.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1

AUTOPHAGY. 2021;17(1):1-382.

Supportive care in patients with cancer during the COVID-19 pandemic
Aapro M, Lyman G, Bokemeyer C, Rapoport B, Mathieson N, Koptelova N, Cornes P, Anderson R, Gascón P, Kuderer N
ESMO OPEN. 2021;6(1):100038.

Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case
Akyüz N, Penas E, Janjetovic S, Loges S, Bokemeyer C, Dierlamm J
LEUKEMIA LYMPHOMA. 2021;62(14):3526-3530.

Hodentumore
Albers P, Bokemeyer C, Müller A, Schmidberger H
ONKOLOGE. 2021;2021(27):1-4.

Kardiale Toxizität antineoplastischer Substanzen
Alsdorf W, Beitzen-Heineke A, Schmid P, Suter T, Bokemeyer C
2021.

Renale Toxizität antineoplastischer Substanzen
Alsdorf W, Bokemeyer C, Lipp H
2021.

Standardized supportive care documentation improves safety of high-dose methotrexate treatment
Alsdorf W, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C
ONCOLOGIST. 2021;26(2):e327-e332.

Prävention der Harnsäurenephropathie
Alsdorf W, Sökler M, Bokemeyer C
2021.

Begleittherapie bei Methotrexat
Alsdorf W, Sökler M, Jaehde U, Bokemeyer C
2021.

Non-productive angiogenesis disassembles Aß plaque-associated blood vessels
Alvarez-Vergara M, Rosales-Nieves A, March-Diaz R, Rodriguez-Perinan G, Lara-Ureña N, Ortega-de San Luis C, Sanchez-Garcia M, Martin-Bornez M, Gómez-Gálvez P, Vicente-Munuera P, Fernandez-Gomez B, Marchena M, Bullones-Bolanos A, Davila J, Gonzalez-Martinez R, Trillo-Contreras J, Sanchez-Hidalgo A, Del Toro R, Scholl F, Herrera E, Trepel M, Körbelin J, Escudero L, Villadiego J, Echevarria M, de Castro F, Gutierrez A, Rabano A, Vitorica J, Pascual A
NAT COMMUN. 2021;12(1):.

The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B
Astermark J, Holstein K, Abajas Y, Kearney S, Croteau S, Liesner R, Funding E, Kempton C, Acharya S, Lethagen S, LeBeau P, Bowen J, Berntorp E, Shapiro A
HAEMOPHILIA. 2021;27(5):802-813.

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani S, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis N
J CLIN ONCOL. 2021;39(10):1139-1149.

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Awwad M, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, Raab M, Bertsch U, Munder M, Jauch A, Weisel K, Maier B, Weinhold N, Salwender H, Eckstein V, Hänel M, Fenk R, Dürig J, Brors B, Benner A, Müller-Tidow C, Goldschmidt H, Hundemer M
LEUKEMIA. 2021;35(9):2602-2615.

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kröger N, Fehse B
BLOOD ADV. 2021;5(11):2523-2527.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Baertsch M, Mai E, Hielscher T, Bertsch U, Salwender H, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab M, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann H, Bernhard H, Blau I, Scheid C, Besemer B, Weisel K, Hänel M, Dürig J, Goldschmidt H
BLOOD CANCER J. 2021;11(1):1.

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
Banerjee S, Lim K, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Devnani B, Lambertini M, Westphalen C, Garrido P, Amaral T, Morgan G, Haanen J, Hardy C
ESMO OPEN. 2021;6(2):.

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT)
Bauersachs R, Gerlach H, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E
EUR J VASC ENDOVASC. 2021;62(2):241-249.

Late Treatments Effects and Cancer Survivor Care in young adults
Beck J, Bokemeyer C, Langer T
2021.

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts
Beckmann L, Rolling C, Voigtländer M, Mäder J, Klingler F, Schulenkorf A, Lehr C, Bokemeyer C, Ruf W, Langer F
CANCERS. 2021;13(16):3941.

Monocyte activation and acquired autoimmune protein S deficiency promote disseminated intravascular coagulation in a patient with primary antiphospholipid syndrome
Beckmann L, Voigtländer M, Holstein K, Lennartz M, Schneider S, Haddad M, Renné T, Bokemeyer C, Rolling C, Langer F
RES PRACT THROMB HAE. 2021;5(5):.

Myeloperoxidase has no effect on the low procoagulant activity of silica-free DNA
Beckmann L, Voigtländer M, Rolling C, Schulenkorf A, Bokemeyer C, Langer F
THROMB RES. 2021;2021(203):36-45.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Päsler S, Gensch V, Udonta F, Vargas-Delgado M, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch C, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben Batalla I, Loges S
HEMASPHERE. 2021;5(9):.

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman D, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen A, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema J, Negaard H, Huddart R, Lorch A, Cafferty F, Heng D, Sweeney C, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg C, Vaughn D, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S
J CLIN ONCOL. 2021;39(14):1553-1562.

Long-Term Effects of Colorectal Carcinoma in Childhood and Adolescents
Block A, Brecht I
2021. Late Treatment Effects and Cancer Survivor Care in the Young. Beck J, Bokemeyer C, Langer T (Hrsg.). 1. Aufl. Cham: Springer Nature Switzerland, 365-373.

YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models
Böckelmann L, Felix T, Calabrò S, Schumacher U
CELL ONCOL. 2021;44(5):1183-1195.

Der Einfluss von subjektiven Krankheitstheorien auf Demoralisierung, Depression und Angst bei Patienten mit einer Krebserkrankung: eine Längsschnittstudie
Bockholt M, Mehnert-Theuerkauf A, Vehling S
PSYCHOTHER PSYCH MED. 2021;71(11):464-472.

Zielgerichtete Molekulardiagnostik umfasst Therapie, Prävention und Diagnosesicherung
Bokemeyer C
2021.

Dermatotoxizität antineoplastischer Substanzen
Bokemeyer C, Lipp H
2021.

Hepatotoxizität antineoplastischer Substanzen
Bokemeyer C, Lipp H
2021.

Cisplatinrefraktäre Keimzelltumoren – molekulare Grundlagen und klinische Konzepte
Bokemeyer C, Skowron M, Peters M, Nettersheim D, Oing C
ONKOLOGE. 2021;27(1):46-53.

Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors
Bokemeyer C, Vassal G, Italiano A, De La Cuesta E, Hiemeyer F, Fellous M, Marian M
JCO PRECIS ONCOL. 2021;5:1458-1465.

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp M, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth T, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra J, Moccia A, Kuhnert G, Bröckelmann P, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
LANCET ONCOL. 2021;22(2):223-234.

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders M, Pápai Z, Prager G, Stein A, André T, Argilés G, Cubillo A, Dahan L, Edeline J, Leger C, Cattan V, Fougeray R, Amellal N, Tabernero J
ESMO OPEN. 2021;6(5):.

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze Zur Wiesch J, Ackermann C, Fiedler W
ONCOIMMUNOLOGY. 2021;10(1):1930391.

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W
INT J MOL SCI. 2021;22(23):.

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W
FRONT MED-LAUSANNE. 2021;8:763773.

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
Brehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kröger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J CLIN MED. 2021;10(11):.

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
Brehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, Lütgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J
SCI REP-UK. 2021;11(1):.

Zytopenie-Mamgement akute myeloische Leukämie
Bullinger L, Fiedler W, Rieger C, Schliemann C
2021.

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
Chari A, Munder M, Weisel K, Jenner M, Bygrave C, Petrucci M, Boccadoro M, Cavo M, van de Donk N, Turgut M, Demirkan F, Karadogan I, Libby E, Kleiman R, Kuppens S, Bandekar R, Neff T, Heuck C, Qi M, Clemens P, Goldschmidt H
ADV THER. 2021;38(2):1328-1341.

Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin-dependent vascular remodeling
Chen D, Sun N, Chen X, Gong J, Yuan S, Hu Z, Lu N, Körbelin J, Fukunaga K, Liu Q, Lu Y, Han F
J CLIN INVEST. 2021;131(4):.

Late adverse effects and quality of life in survivors of testicular germ cell tumour
Chovanec M, Lauritsen J, Bandak M, Oing C, Kier G, Kreiberg M, Rosenvilde J, Wagner T, Bokemeyer C, Daugaard G
NAT REV UROL. 2021;18(4):227-245.

"Per aspera ad astra".. die Facharztreife
Christopeit M, Oing C, Höffken K
ONKOLOGE. 2021;2021(27, suppl issue 1):2-4.

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database
Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan T, Van Cutsem E, Venook A, Douillard J, Heinemann V, Punt C, Falcone A, Bokemeyer C, Kaplan R, Lenz H, Koopman M, Yoshino T, Zalcberg J, Grothey A, de Gramont A, Shi Q, André T
JNCI-J NATL CANCER I. 2021;113(10):1386-1395.

The Polycomb Protein Bmi1 is a Key Effector of the H3.3 K27m Oncohistone
Cui W, Xydous M, Haschke A, Korf K, Spohn M, Pohlmann D, Sweet S, Ip W, Wrzeszcz A, Indenbirken D, Ma H, Müller J, Kruchen A, Sternsdorf T
Social Science Research Network. 2021 [Epub ahead of print].

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull D, Huang H, Leleu X, Berdeja J, Lee H, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A
ANN HEMATOL. 2021;100(9):2325-2337.

Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study
Depping M, Uhlenbusch N, von Kodolitsch Y, Klose H, Mautner V, Löwe B
ORPHANET J RARE DIS. 2021;16(1):44.

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Dimopoulos M, Weisel K, Moreau P, Anderson L, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen T, Biyukov T, Peluso T, Richardson P
LEUKEMIA. 2021;35(6):1722-1731.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz M, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim H, Lee J, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst H, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo D, Naoe T, Sekeres M, Belsack V, Ge M, Taube T, Ottmann O
HEMASPHERE. 2021;5(8):e617.

Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells
Dyshlovoy S, Pelageev D, Jakob L, Borisova K, Hauschild J, Busenbender T, Kaune M, Khmelevskaya E, Graefen M, Bokemeyer C, Anufriev V, von Amsberg G
PHARMACEUTICALS-BASE. 2021;14(10):949.

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, Di Bona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk R, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla N, Bernardi M, Fazi P, Annibali O, Mayer K, Voso M, Vignetti M
BLOOD ADV. 2021;5(21):4370-4379.

Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow
Engel N, Reinert J, Borchert N, Panagiota V, Gabdoulline R, Thol F, Heuser M, Fiedler W
ANN HEMATOL. 2021;100(2):499-503.

Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation
Englert H, Rangaswamy C, Deppermann C, Sperhake J, Krisp C, Schreier D, Gordon E, Konrath S, Haddad M, Pula G, Mailer R, Schlüter H, Kluge S, Langer F, Püschel K, Panousis K, Stavrou E, Maas C, Renné T, Frye M
EBIOMEDICINE. 2021;67:.

Development and preliminary psychometric investigation of the German Satisfaction with Comprehensive Cancer Care (SCCC) Questionnaire
Esser P, Sautier L, Sarkar S, Schilling G, Bokemeyer C, Koch U, Friedrich M, Defossez G, Mehnert-Theuerkauf A
HEALTH QUAL LIFE OUT. 2021;19(1):147.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner C, Weisel K, Mace J, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar C, Tromp B, Delioukina M, Vermeulen J, Usmani S
LANCET ONCOL. 2021;22(11):1582-1596.

ASO Visual Abstract: Radical Hemiscrotectomy and En Bloc Orchidectomy-Surgical Technique, Perioperative and Oncologic Outcomes of a Supra-Regional UK Referral Centre
Fankhauser C, Issa A, Lee E, Oing C, Oliveira P, Parnham A, Oates J, Sangar V, Gulamhusein A, Clarke N
ANN SURG ONCOL. 2021;28(Suppl 3):563-564.

Radical Hemiscrotectomy and En Bloc Orchidectomy: Surgical Technique and Perioperative and Oncologic Outcomes of a Supra-Regional UK Referral Centre
Fankhauser C, Issa A, Lee E, Oing C, Oliveira P, Parnham A, Oates J, Sangar V, Gulamhusein A, Clarke N
ANN SURG ONCOL. 2021;28(13):9217-9222.

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser C, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans J, Fischer S, Fizazi K, Gremmels H, Mayor de Castro J, Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna M
EUR UROL. 2021;80(1):4-6.

The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction
Fichtner A, Richter A, Filmar S, Gaisa N, Schweyer S, Reis H, Nettersheim D, Oing C, Gayer F, Leha A, Küffer S, Ströbel P, Kaulfuß S, Bremmer F
HISTOPATHOLOGY. 2021;78(4):593-606.

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzschmar A, Köhne C, Grünwald V, Hofheinz R, Schütte K, Löffler H, Bokemeyer C, Krämer A
BRIT J CANCER. 2021;124(4):721-727.

Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia
Freisleben F, Modemann F, Muschhammer J, Stamm H, Brauneck F, Krispien A, Bokemeyer C, Kirschner K, Wellbrock J, Fiedler W
INT J MOL SCI. 2021;22(19):10670.

Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
Gaultney J, Bouvy J, Chapman R, Upton A, Kowal S, Bokemeyer C, Solà-Morales O, Wolf J, Briggs A
APPL HEALTH ECON HEA. 2021;19(5):625-634.

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili S, Schönlein M, Lütgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
CANCERS. 2021;13(15):.

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
J CLIN MED. 2021;10(23):.

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili S, Weisel K, Bokemeyer C, Leypoldt L
ONCOL RES TREAT. 2021;44(12):690-699.

Identification of New Adeno-Associated Virus 9 (AAV9) Capsid Variants Targeting the BALB/c Mouse Brain through Directed Evolution
Giannelli S, Luoni M, Conti E, Niro A, Trepel M, Körbelin J, Broccoli V
MOL THER. 2021;29(4):149-150.

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema J, De Giorgi U, Cafferty F, Hansen A, Tandstad T, Huddart R, Necchi A, Sweeney C, Garcia-Del-Muro X, Heng D, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman D, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn D, Sternberg C, Heidenreich A, Beyer J
J CLIN ONCOL. 2021;39(14):1563-1574.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Goldschmidt H, Baertsch M, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab M, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann H, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K
LEUKEMIA. 2021;35(4):1134-1144.

Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies
Gorgulho J, Roderburg C, Heymann F, Schulze-Hagen M, Beier F, Vucur M, Kather J, Laleh N, Tacke F, Brümmendorf T, Luedde T, Loosen S
INT J CANCER. 2021;149(5):1189-1198.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord J, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R
LANCET ONCOL. 2021;22(4):463-475.

Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma
Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja J, Boccadoro M, Brozova L, Spencer A, Rhee F, Vela-Ojeda J, Thompson M, Abonour R, Chari A, Cook G, Costello C, Davies F, Hungria V, Lee H, Leleu X, Puig N, Rifkin R, Terpos E, Usmani S, Weisel K, Zonder J, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull D, Ren K, Maisnar V
FUTURE ONCOL. 2021;17(19):2499-2512.

Genetic evidence for a causative effect of airflow obstruction on left ventricular filling: a Mendelian randomisation study
Harbaum L, Hennigs J, Simon M, Oqueka T, Watz H, Klose H
RESP RES. 2021;22(1):.

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Hecht A, Meyer J, Jann J, Sockel K, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Haferlach T, Schafhausen P, Bug G, Lübbert M, Thol F, Büsche G, Schuler E, Nowak V, Obländer J, Fey S, Müller N, Metzgeroth G, Hofmann W, Germing U, Nolte F, Reinwald M, Nowak D
ANN HEMATOL. 2021;100(6):1463-1471.

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension
Hennigs J, Cao A, Li C, Shi M, Mienert J, Miyagawa K, Körbelin J, Marciano D, Chen P, Roughley M, Elliott M, Harper R, Bill M, Chappell J, Moonen J, Diebold I, Wang L, Snyder M, Rabinovitch M
CIRC RES. 2021;128(3):401-418.

Vascular Endothelial Cells: Heterogeneity and Targeting Approaches
Hennigs J, Matuszcak C, Trepel M, Körbelin J
CELLS-BASEL. 2021;10(10):2712.

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Heuser M, Heida B, Büttner K, Wienecke C, Teich K, Funke C, Brandes M, Klement P, Liebich A, Wichmann M, Neziri B, Chaturvedi A, Kloos A, Mintzas K, Gaidzik V, Paschka P, Bullinger L, Fiedler W, Heim A, Puppe W, Krauter J, Döhner K, Döhner H, Ganser A, Stadler M, Hambach L, Gabdoulline R, Thol F
BLOOD ADV. 2021;5(9):2294-2304.

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Heuser M, Smith B, Fiedler W, Sekeres M, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón J, Hoang C, O'Brien T, Ma W, Zeremski M, O'Connell A, Chan G, Cortes J
ANN HEMATOL. 2021;100(5):1181-1194.

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Heuser M, Smith B, Fiedler W, Sekeres M, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón J, Hoang C, O'Brien T, Ma W, Zeremski M, O'Connell A, Chan G, Cortes J
ANN HEMATOL. 2021;100(7):1917-1918.

Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors
Hilgendorf I, Bergelt C, Bokemeyer C, Kaatsch P, Seifart U, Stein A, Langer T
ONCOL RES TREAT. 2021;44(4):184-189.

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
Hirt C, Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer von Weikersthal L, Ahmed A, Harich H, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M
HEMASPHERE. 2021;5(7):.

Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO® Registry
Honecker F, Huschens S, Angermund R, Kallischnigg G, Freier W, Friedrich C, Hartung G, Lutz A, Otremba B, Pientka L, Späth-Schwalbe E, Kolb G, Bokemeyer C, Wedding U
J CANCER RES CLIN. 2021;147(11):3183-3194.

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler J, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F
EBIOMEDICINE. 2021;66:.

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Hungria V, Beksac M, Weisel K, Nooka A, Masszi T, Spicka I, Munder M, Mateos M, Mark T, Qi M, Qin X, Fastenau J, Spencer A, Sonneveld P, Garvin W, Renaud T, Gries K
BRIT J HAEMATOL. 2021;193(3):561-569.

Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life
Jacobsen H, Walendy-Gnirß K, Tekin-Bubenheim N, Kouassi N, Ben-Batalla I, Berenbrok N, Wolff M, Dos Reis V, Zickler M, Scholl L, Gries A, Jania H, Kloetgen A, Düsedau A, Pilnitz-Stolze G, Jeridi A, Yildirim A, Fuchs H, Gailus-Durner V, Stoeger C, de Angelis M, Manuylova T, Klingel K, Culley F, Behrends J, Loges S, Schneider B, Krauss-Etschmann S, Openshaw P, Gabriel G
NAT COMMUN. 2021;12(1):4957.

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation
Janjetovic S, Beckmann L, Holstein K, Rolling C, Thiele B, Schafhausen P, Schön G, Bokemeyer C, Langer F, Voigtlaender M
THROMB RES. 2021;198:55-61.

Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias
Janjetovic S, Lohneis P, Nogai A, Balci D, Rasche L, Jähne D, Bokemeyer C, Schilling G, Blau I, Schmidt-Hieber M
BIOLOGY-BASEL. 2021;10(7):.

Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone
Karagiannis P, Alsdorf W, Tallarek A, Blohm M, Oelrich J, Waizenegger J, Wolschke C, Hecher K, Singer D, Bokemeyer C, Fiedler W
BRIT J HAEMATOL. 2021;192(2):e60-e63.

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial
Kfoury M, Oing C
2021.

Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO)
Kirschner M, do Ó Hartmann N, Parmentier S, Hart C, Henze L, Bisping G, Griesshammer M, Langer F, Pabinger-Fasching I, Matzdorff A, Riess H, Koschmieder S
CANCERS. 2021;13(12):2905.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Klein E, Tichy D, Salwender H, Mai E, Duerig J, Weisel K, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann H, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab M, Blau I, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
CANCERS. 2021;13(19):4856.

Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy
Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann K, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg O, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller A, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann D, Zillmann R, Albers P
UROL INT. 2021;105(3-4):181-191.

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages
Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann K, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg O, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller A, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann D, Zillmann R, Albers P
UROL INT. 2021;105(3-4):169-180.

S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19
Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Spinner C, Malin J, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Haase R, Marx G, Karagiannidis C
PNEUMOLOGIE. 2021;75(2):88-112.

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?
Knipper S, von Amsberg G, Stolzenbach F, Steuber T, Heck M, Eiber M, Berliner C, Maurer T
ASIAN J UROL. 2021;8(2):248-250.

16th German Spine Congress Annual Meeting of the German Spine Society 9th to 11th December 2021 Muenster, Germany: Aspiration cytology from malignant spinal lesions shortens time to diagnosis of previously unknown tumor disease
Köpke L, Heuer A, Stangenberg M, Dreimann M, Welker L, Bokemeyer C, Asemissen A, Viezens L
EUR SPINE J. 2021;30(11):3332-3333.

Inactivation of Adeno-Associated Viral Vectors by Oxidant-Based Disinfectants
Korte J, Mienert J, Hennigs J, Körbelin J
HUM GENE THER. 2021;32(13-14):771-781.

Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype
Kresbach C, Dorostkar M, Suwala A, Wefers A, Schweizer L, Engertsberger L, Bison B, Mynarek M, Kloth-Stachnau K, Spohn M, von Deimling A, Benesch M, Hagel C, Mautner V, Rutkowski S, Schüller U
ACTA NEUROPATHOL. 2021;141(6):971-974.

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
Kuempers C, Jagomast T, Krupar R, Paulsen F, Heidel C, Ribbat-Idel J, Idel C, Märkl B, Anlauf M, Berezowska S, Tiemann M, Bösmüller H, Fend F, Kalsdorf B, Bohnet S, Dreyer E, Sailer V, Kirfel J, Perner S
FRONT MED-LAUSANNE. 2021;8:.

Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
Kurreck A, Weckwerth J, Modest D, Striefler J, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M
EUR J CANCER. 2021;150:250-259.

Long-Term Follow-Up Guidelines and Organization of Long-Term Follow-Up Care for Children and Young Adult Cancer Survivers
Langer T, Beck J, Stein A, Bokemeyer C, Gebauer J
2021. Late Treatment Effects and Cancer Survivor Care in the Young. Beck J, Bokemeyer C, Langer T (Hrsg.). 1. Aufl. Cham: Springer Nature Switzerland, 435-439.

Virus-induced senescence is a driver and therapeutic target in COVID-19
Lee S, Yu Y, Trimpert J, Benthani F, Mairhofer M, Richter-Pechanska P, Wyler E, Belenki D, Kaltenbrunner S, Pammer M, Kausche L, Firsching T, Dietert K, Schotsaert M, Martínez-Romero C, Singh G, Kunz S, Niemeyer D, Ghanem R, Paar C, Mülleder M, Uccellini M, Michaelis E, Khan A, Lau A, Schönlein M, Habringer A, Tomasits J, Adler J, Kimeswenger S, Gruber A, Hoetzenecker W, Steinkellner H, Purfürst B, Motz R, Di Pierro F, Lamprecht B, Osterrieder N, Landthaler M, Drosten C, García-Sastre A, Langer R, Ralser M, Eils R, Reimann M, Fan D, Schmitt C
NATURE. 2021;599(7884):283-289.

56/m mit Rückenschmerzen und Konzentrationsstörungen
Leypoldt L, Weisel K
ONKOLOGE. 2021;2021(27 supplement issue 1):27-32.

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
Lim K, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen C, Morgan G, Haanen J, Hardy C, Banerjee S
ESMO OPEN. 2021;6(4):100199.

Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study
Limperger V, Kenet G, Kiesau B, Köther M, Schmeiser M, Langer F, Juhl D, Shneyder M, Franke A, Klostermeier U, Mesters R, Rühle F, Stoll M, Steppat D, Kowalski D, Rocke A, Kuta P, Bajorat T, Torge A, Neuner B, Junker R, Nowak-Göttl U
J THROMB THROMBOLYS. 2021;51(2):494-501.

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Lonial S, Lee H, Badros A, Trudel S, Nooka A, Chari A, Abdallah A, Callander N, Sborov D, Suvannasankha A, Weisel K, Voorhees P, Womersley L, Baron J, Piontek T, Lewis E, Opalinska J, Gupta I, Cohen A
CANCER-AM CANCER SOC. 2021;127(22):4198-4212.

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
Loosen S, Gorgulho J, Jördens M, Schulze-Hagen M, Beier F, Vucur M, Schneider A, Koppe C, Mertens A, Kather J, Tacke F, Keitel V, Brümmendorf T, Roderburg C, Luedde T
FRONT ONCOL. 2021;11:646883.

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
Loosen S, van den Bosch V, Gorgulho J, Schulze-Hagen M, Kandler J, Jördens M, Tacke F, Loberg C, Antoch G, Brümmendorf T, Neumann U, Kuhl C, Luedde T, Roderburg C
J CLIN MED. 2021;10(7):.

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse S, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider S, Belczacka I, Volkmer B, Greinert R, Yaspo M, Harter P, Pantel K, Wikman H
INT J MOL SCI. 2021;22(13):.

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos M, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P
LEUKEMIA. 2021;35(1):31-44.

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos M, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos M, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E
LANCET HAEMATOL. 2021;8(12):e934-e946.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Mai E, Miah K, Bertsch U, Dürig J, Scheid C, Weisel K, Kunz C, Munder M, Lindemann H, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab M, Blau I, Hänel M, Benner A, Salwender H, Goldschmidt H
LEUKEMIA. 2021;35(3):809-822.

Invasion of phagocytic Galectin 3 expressing macrophages in the diabetic brain disrupts vascular repair
Mehina E, Taylor S, Boghozian R, White E, Choi S, Cheema M, Korbelin J, Brown C
SCI ADV. 2021;7(34):.

The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors
Miranda-Gonçalves V, Lobo J, Guimarães-Teixeira C, Barros-Silva D, Guimarães R, Cantante M, Braga I, Maurício J, Oing C, Honecker F, Nettersheim D, Looijenga L, Henrique R, Jerónimo C
J EXP CLIN CANC RES. 2021;40(1):.

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2021;56(10):2617.

A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer
Moehler M, Michel M, Stein A, Trojan J, Marquardt J, Tintelnot J, Waidmann O, Weinmann A, Woerns M, Schroeder H, Maenz M, Foerster F
FUTURE ONCOL. 2021;17(25):3309-3319.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai E, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P
IMMUNOTHERAPY-UK. 2021;13(2):143-154.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Moreau P, Kumar S, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie B, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson S, Lentzsch S, Hajek R, Anderson K, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja J, Leal da Costa F, Maiolino A, Waage A, Vesole D, Ocio E, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel P, Hou J, Chng W, Mellqvist U, Dytfeld D, Harousseau J, Goldschmidt H, Laubach J, Munshi N, Gay F, Beksac M, Costa L, Kaiser M, Hari P, Boccadoro M, Usmani S, Zweegman S, Holstein S, Harrison S, Nahi H, Cook G, Mateos M, Rajkumar S, Dimopoulos M, Richardson P
LANCET ONCOL. 2021;22(3):e105-e118.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Munshi N, Anderson L, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn J, Kaiser S, Patel P, Huang L, Campbell T, Hege K, San-Miguel J
NEW ENGL J MED. 2021;384(8):705-716.

Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end-stage haemophilic arthropathy
Mussawy H, Kehrer M, Strahl A, Rolvien T, Hubert J, Beil F, Wirtz D, Oldenburg J, Holstein K, Strauss A
HAEMOPHILIA. 2021;27(6):e739-e746.

Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors
Nastały P, Honecker F, Pantel K, Riethdorf S
Methods Mol Biol. 2021;2195:245-261.

Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A
Nikolakopoulou A, Wang Y, Ma Q, Sagare A, Montagne A, Huuskonen M, Rege S, Kisler K, Dai Z, Körbelin J, Herz J, Zhao Z, Zlokovic B
J EXP MED. 2021;218(4):.

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka A, Weisel K, van de Donk N, Routledge D, Otero P, Song K, Quach H, Callander N, Minnema M, Trudel S, Jackson N, Ahlers C, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, de Oca R, Paul S, Holkova B, Gupta I, Kremer B, Richardson P
FUTURE ONCOL. 2021;17(16):1987-2003.

Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening
Nörz D, Mullins C, Smit D, Linnebacher M, Hagel G, Mirdogan A, Siekiera J, Ehm P, Izbicki J, Block A, Thastrup O, Jücker M
ANTICANCER RES. 2021;41(5):2257-2275.

Mitbetreuung und Einbeziehung von Angehörigen in Comprehensive Cancer Centern – eine Erhebung der AG Palliativmedizin der von der Deutschen Krebshilfe geförderten Onkologischen Spitzenzentren
Oechsle K, Theißen T, Heckel M, Schwenzitzki L, Ullrich A, Ostgathe C
DEUT MED WOCHENSCHR. 2021;146(18):e74-e80.

Editorial Comment to Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis
Oing C
INT J UROL. 2021;28(8):847-848.

28/m mit Rückenschmerzen und Vorwölbung der Bauchwand
Oing C, Bokemeyer C
ONKOLOGE. 2021;2021(27 supplement 1):5-11.

Aktuelle Therapiekonzepte bei keimzelltumoren des Mannes
Oing C, Bokemeyer C
ONKOLOGE. 2021;2021:1-13.

Erweiterung der Kombinationsmöglichkeiten in der Erstlinientherapie des metastasierten klarzelligen Nierenzellkarzinoms mit Nivolumab plus Cabozantinib: Ergebnisse der CheckMate-9ER-Studie
Oing C, Bokemeyer C
ONKOLOGE. 2021;27(2):168-171.

Primär mediastinale Keimzelltumoren – eine interdisziplinäre Herausforderung
Oing C, Schirren M, Sponholz S, Seidel C, Schirren J, Bokemeyer C
ONKOLOGE. 2021;27(1):36-45.

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf R, Pötzsch B, Greinacher A
HAMOSTASEOLOGIE. 2021;41(3):184-189.

Auswirkungen der COVID-19 Pandemie auf die medizinische Versorgung von Patienten mit angeborenen Blutungsneigungen
Olivieri M, Halimeh S, Wermes C, Hassenpflug W, Holstein K, von Mackensen S
GESUNDHEITSWESEN. 2021;83(4):282-290.

Granulomatosis with polyangiitis: mind the airway
Oqueka T, Klose H, Iking-Konert C, Schnoor U, Kluge S, Simon M
RESPIROL CASE REP. 2021;9(1):e00702.

Bevacizumab in Aggressive Pituitary Adenomas - Experience with 3 Patients
Osterhage K, Rotermund R, Droste M, Dierlamm J, Saeger W, Petersenn S, Aberle J, Flitsch J
EXP CLIN ENDOCR DIAB. 2021;129(3):178-185.

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins G, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux M, Čerňan M, Jakšić O, Duarte R, Magliano G, Omrani A, Fracchiolla N, Kulasekararaj A, Valković T, Poulsen C, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, Del Principe M, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat M, Tisi M, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez G, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval G, Bonuomo V, Mayer J, López-García A, Sacchi M, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson L, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak G, Nordlander A, Dragonetti G, Maraglino A, Rinaldi A, De Ramón-Sánchez C, Cornely O
J HEMATOL ONCOL. 2021;14(1):168.

Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice
Park E, Kim S, Huang S, Yoo J, Körbelin J, Lee T, Kaur B, Dash P, Chen P, Kim E
ANN NEUROL. 2021;89(5):926-941.

Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19)
Paulsen F, Schaefers C, Langer F, Frenzel C, Wenzel U, Hengel F, Bokemeyer C, Seidel C
BLOOD. 2021;138(11):996-999.

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot A, Facon T, Plesner T, Usmani S, Kumar S, Bahlis N, Hulin C, Orlowski R, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho K, Van Rampelbergh R, Uhlar C, Wang J, Kobos R, Gries K, Fastenau J, Weisel K
J CLIN ONCOL. 2021;39(3):227-237.

Thromoembolische Komplikationen und Thromboseprophylaye bei fortgeschrittenen testikularen Keimzelltumoren
Pfaffenholz P, Seidel C, Nestler T, Heidenreich A
ONKOLOGE. 2021;2021(27):13-20.

Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia
Pfrepper C, Holstein K, Königs C, Heller C, Krause M, Olivieri M, Bidlingmaier C, Sigl-Kraetzig M, Wendisch J, Halimeh S, Horneff S, Richter H, Wieland I, Klamroth R, Oldenburg J, Tiede A
HAMOSTASEOLOGIE. 2021;41(3):190-196.

Existential distress in patients with advanced cancer and their caregivers: study protocol of a longitudinal cohort study
Philipp R, Kalender A, Härter M, Bokemeyer C, Oechsle K, Koch-Gromus U, Vehling S
BMJ OPEN. 2021;11(4):.

The role of attachment avoidance: A longitudinal mediation model predicting existential distress in patients with advanced cancer
Philipp R, Mehnert-Theuerkauf A, Koranyi S, Härter M, Vehling S
PSYCHO-ONCOLOGY. 2021;30(7):1059-1067.

OmpF porin from Yersinia ruckeri as pathogenic factor: Surface antigenic sites and biological properties
Portnyagina O, Chistyulin D, Dyshlovoy S, Davidova V, Khomenko V, Shevchenko L, Novikova O
MICROB PATHOGENESIS. 2021;150:104694.

Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension
Qaderi V, Weimann J, Harbaum L, Schrage B, Knappe D, Hennigs J, Sinning C, Schnabel R, Blankenberg S, Kirchhof P, Klose H, Magnussen C
J CLIN MED. 2021;10(21):.

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Quach H, Nooka A, Samoylova O, Venner C, Kim K, Facon T, Spencer A, Usmani S, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos M
BRIT J HAEMATOL. 2021;194(4):784-788.

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Radocha J, van de Donk N, Weisel K
CANCERS. 2021;13(7):1551.

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos M, Richardson P
BLOOD REV. 2021;49:100808.

Prostate Cancer
Rebello R, Oing C, Knudsen K, Loeb S, Johnson D, Reiter R, Gillessen S, Van der Kwast T, Bristow R
NAT REV DIS PRIMERS. 2021;7(1):9.

Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
Reinert J, Beitzen-Heineke A, Wethmar K, Stelljes M, Fiedler W, Schwartz S
ANN HEMATOL. 2021;100(11):2727-2732.

PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren A, Snellings D, Su Y, Hong C, Castro M, Tang A, Detter M, Hobson N, Girard R, Romanos S, Lightle R, Moore T, Shenkar R, Benavides C, Beaman M, Mueller-Fielitz H, Chen M, Mericko P, Yang J, Sung D, Lawton M, Ruppert M, Schwaninger M, Körbelin J, Potente M, Awad I, Marchuk D, Kahn M
NATURE. 2021;594(7862):271-276.

Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
Rodriguez-Otero P, Ayers D, Cope S, Davies F, Delforge M, Mojebi A, Jansen J, Weisel K, Hege K, Dhanasiri S
LEUKEMIA LYMPHOMA. 2021;62(10):2482-2491.

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
Rolles B, Gorgulho J, Tometten M, Roderburg C, Vieri M, Abels A, Vucur M, Heymann F, Tacke F, Brümmendorf T, Luedde T, Beier F, Loosen S
FRONT ONCOL. 2021;11:729207.

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Rosiñol L, Beksac M, Zamagni E, Van de Donk N, Anderson K, Badros A, Caers J, Cavo M, Dimopoulos M, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle R, Leal da Costa F, Leleu X, Lentzsch S, Mateos M, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani S, Vanderkerken K, Vesole D, Waage A, Zweegman S, Richardson P, Bladé J
BRIT J HAEMATOL. 2021;194(3):496-507.

Das Zertifizierungssystem der Deutschen Krebsgesellschaft: Nutzen und Weiterentwicklung
Rückher J, Bokemeyer C, Fehm T, Graeven U, Wesselmann S
ONKOLOGE. 2021;2021(27.10):969-979.

Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trial
Salchow J, Koch B, Mann J, von Grundherr J, Elmers S, Dwinger S, Escherich G, Vettorazzi E, Reer R, Sinn M, Baumann F, Bokemeyer C, Stein A, Jensen W
CLIN REHABIL. 2021;35(8):1164-1174.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai E, Bertsch U, Blau I, Scheid C, Hose D, Seckinger A, Jauch A, Raab M, Luntz S, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann H, Weisel K, Duerig J, Goldschmidt H
LEUKEMIA. 2021;35(10):3007-3011.

Virtuelle Palliativversorgung: Pilotierung eines elektronischen Tools zur Prüfung kognitiver, psychomotorischer und affektiver palliativmedizinischer und schmerztherapeutischer Lerninhalte während der ärztlichen Ausbildung
Scherg A, Oechsle K, Coym A, Ilse B, Annweiler B, Alt-Epping B, Neukirchen M, Lemos M, Stummer T, Seibel J, Lenes A, Elsner F
SCHMERZ. 2021;35(4):242-250.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Schmalbrock L, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte T, Herzig J, Skambraks S, Rücker F, Gaidzik V, Paschka P, Fiedler W, Salih H, Wulf G, Schroeder T, Lübbert M, Schlenk R, Thol F, Heuser M, Larson R, Ganser A, Stunnenberg H, Minucci S, Stone R, Bloomfield C, Döhner H, Döhner K, Bullinger L
BLOOD. 2021;137(22):3093-3104.

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Schmoll H, Stein A, Van Cutsem E, Price T, Hofheinz R, Nordlinger B, Daisne J, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig C, Zalcberg J, Tebbutt N, Mauer M, Marreaud S, Lutz M, Haustermans K
J CLIN ONCOL. 2021;39(1):17-29.

Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial
Scholl I, Hahlweg P, Lindig A, Frerichs W, Zill J, Cords H, Bokemeyer C, Coym A, Schmalfeldt B, Smeets R, Vollkommer T, Witzel I, Härter M, Kriston L
IMPLEMENT SCI. 2021;16(1):.

71/m in reduziertem Allgemeinzustand mit Sklerenikterus
Schönrock M, Sinn M
ONKOLOGE. 2021;2021(27 supplement issue 1):109-113.

Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis
Schultheiß C, Germany D, Willscher E, Oberle A, Fanchi L, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse A, Binder M
HEPATOLOGY. 2021;73(4):1436-1448.

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)
Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann K, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C
WORLD J UROL. 2021;39(9):3407-3414.

Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
Shapiro A, Ragni M, Borhany M, Abajas Y, Tarantino M, Holstein K, Croteau S, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton C, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss U, Kulkarni R, Witkop M, Lethagen S, Donfield S, LeBeau P, Berntorp E, Astermark J
HAEMOPHILIA. 2021;27(1):49-59.

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X
LEUKEMIA LYMPHOMA. 2021;62(12):3002-3010.

The developmental origin of cancers defines basic principles of cisplatin resistance
Skowron M, Oing C, Bremmer F, Ströbel P, Murray M, Coleman N, Amatruda J, Honecker F, Bokemeyer C, Albers P, Nettersheim D
CANCER LETT. 2021;519:199-210.

Polyketides metabolites from the marine sediment-derived fungus Thermomyces lanuginosus Tsikl. KMM 4681
Sobolevskaya M, Berdyshev D, Zhuravleva O, Denisenko V, Dyshlovoy S, von Amsberg G, Khudyakova Y, Kirichuk N, Afiyatullov S
PHYTOCHEM LETT. 2021;41:114-118.

Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death
Spirin P, Shyrokova E, Lebedev T, Vagapova E, Smirnova P, Kantemirov A, Dyshlovoy S, Amsberg G, Zhidkov M, Prassolov V
MAR DRUGS. 2021;19(9):.

Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study
Springer A, Schleberger R, Oyen F, Hoffmann B, Willems S, Meyer C, Langer F, Schnabel R, Kirchhof P, Schneppenheim R, Lemoine M
CLIN APPL THROMB-HEM. 2021;27:10760296211021171.

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Dörfel S, Al-Batran S, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M
J IMMUNOTHER CANCER. 2021;9(7):.

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
Stenzinger A, van Tilburg C, Tabatabai G, Länger F, Graf N, Griesinger F, Heukamp L, Hummel M, Klingebiel T, Hettmer S, Vokuhl C, Merkelbach-Bruse S, Overkamp F, Reichardt P, Scheer M, Weichert W, Westphalen C, Bokemeyer C, Ivanyi P, Loges S, Schirmacher P, Wörmann B, Bielack S, Seufferlein T
PATHOLOGE. 2021;42(1):103-115.

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
Striefler J, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest D, Bahra M, Oettle H, Sinn M, Bläker H, Denkert C, Stintzing S, Sinn B, Pelzer U
FRONT ONCOL. 2021;11:.

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik V, Schlenk R, Paschka P, Weber D, Fiedler W, Kühn M, Schroeder T, Mayer K, Lübbert M, Ramachandran D, Benner A, Ganser A, Döhner H, Heuser M, Döhner K, Thol F
HAEMATOLOGICA. 2021;106(11):2986-2989.

High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells
Teo Hansen Selnø A, Schlichtner S, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Berger S, Klenova E, Gibbs B, Fasler-Kan E, Sumbayev V
FRONT IMMUNOL. 2021;12:.

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee H, Mateos M, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel K, Costello C, Elliott J, Palumbo A, Usmani S
BLOOD CANCER J. 2021;11(2):40.

Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation
Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel K, Bokemeyer C, Janjetovic S
ONCOL RES TREAT. 2021;44(7-8):375-381.

Gender-specific problems and needs of family caregivers during specialist inpatient palliative care: a qualitative study on experiences of family caregivers and healthcare professionals
Ullrich A, Eicken S, Coym A, Hlawatsch C, Bokemeyer C, Oechsle K
ANN PALLIAT MED. 2021;10(8):8571-8583.

Supportive care needs and service use during palliative care in family caregivers of patients with advanced cancer - a prospective longitudinal study
Ullrich A, Marx G, Bergelt C, Benze G, Zhang Y, Wowretzko F, Heine J, Dickel L, Nauck F, Bokemeyer C, Oechsle K
SUPPORT CARE CANCER. 2021;29(3):1303-1315.

Need for additional professional psychosocial and spiritual support in patients with advanced diseases in the course of specialist palliative care - a longitudinal observational study
Ullrich A, Schulz H, Goldbach S, Hollburg W, Rommel A, Müller M, Kirsch D, Kopplin-Förtsch K, Messerer J, König L, Schulz-Kindermann F, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2021;20(1):182.

Thoughts of death and suicidality among patients with cancer: examining subtypes and their association with mental disorders
Vehling S, Mehnert-Theuerkauf A, Glaesmer H, Bokemeyer C, Oechsle K, Härter M, Koch-Gromus U
PSYCHO-ONCOLOGY. 2021;30(12):2023-2031.

Perceived Positive and Negative Life Changes in Testicular Cancer Survivors
Vehling S, Oechsle K, Hartmann M, Bokemeyer C, Mehnert-Theuerkauf A
MEDICINA-LITHUANIA. 2021;57(9):993.

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report
Velthaus J, Iglauer P, Simon R, Bokemeyer C, Bannas P, Beumer N, Imbusch C, Goekkurt E, Loges S
ONCOL RES TREAT. 2021;44(9):495-502.

Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course
Vogt J, Beyer F, Sistermanns J, Kuon J, Kahl C, Alt-Epping B, Stevens S, Ahlborn M, George C, Heider A, Tienken M, Loquai C, Stahlhut K, Ruellan A, Kubin T, Dietz A, Oechsle K, Mehnert-Theuerkauf A, van Oorschot B, Thomas M, Ortmann O, Engel C, Lordick F
ONCOLOGIST. 2021;26(6):e1058-e1065.

Systemtherapie bei metastasierten Keimzelltumoren des Hodens
von Amsberg G, Bokemeyer C
2021. Medikamente in der Urologie. Merseberger A, Kramer M (Hrsg.). 1. Aufl. Springer, 475-494.

Diagnose und Therapie seltener Hodentumoren am Beispiel des malignen Mesothelioms der Tunica vaginalis testis und Sertoli-Zell-Tumoren
von Amsberg G, Sehovic M, Hartmann M, Bokemeyer C
UROLOGE. 2021;60(7):872-879.

Kardiovaskuläre Komplikationen unter Androgenentzugstherapie: Vorteil für Gonadotropin-Releasing-Hormon-Antagonisten? Ein Update
von Amsberg G, Thiele H, Merseburger A
UROLOGE. 2021;60(11):1450-1457.

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Wolters-Eisfeld G, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M
LEUKEMIA. 2021;35(4):1073-1086.

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens D, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo C
BLOOD CANCER J. 2021;11(10):163.

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens D, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo C
BLOOD CANCER J. 2021;11(10):171.

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
Weisel K, Mateos M, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P
LEUKEMIA. 2021;35(6):1732-1744.

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
Wellbrock J, Behrmann L, Muschhammer J, Modemann F, Khoury K, Brauneck F, Bokemeyer C, Campeau E, Fiedler W
ANN HEMATOL. 2021;100(12):2933-2941.

The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells
Wenzel J, Lampe J, Müller-Fielitz H, Schuster R, Zille M, Müller K, Krohn M, Körbelin J, Zhang L, Özorhan Ü, Neve V, Wagner J, Bojkova D, Shumliakivska M, Jiang Y, Fähnrich A, Ott F, Sencio V, Robil C, Pfefferle S, Sauve F, Coêlho C, Franz J, Spiecker F, Lembrich B, Binder S, Feller N, König P, Busch H, Collin L, Villaseñor R, Jöhren O, Altmeppen H, Pasparakis M, Dimmeler S, Cinatl J, Püschel K, Zelic M, Ofengeim D, Stadelmann C, Trottein F, Nogueiras R, Hilgenfeld R, Glatzel M, Prevot V, Schwaninger M
NAT NEUROSCI. 2021;24(11):1522-1533.

B cell analysis in SARS‐CoV‐2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID‐19
Wildner N, Ahmadi P, Schulte S, Brauneck F, Kohsar M, Lütgehetmann M, Beisel C, Addo M, Haag F, Schulze zur Wiesch J
J LEUKOCYTE BIOL. 2021;109(1):77-90.

Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies
Wirtz T, Loosen S, Schulze-Hagen M, Gorgulho J, Kandler J, Joerdens M, Demir M, Mohr R, Bruners P, Kuhl C, Trautwein C, Berres M, Tacke F, Luedde T, Roderburg C
CTS-CLIN TRANSL SCI. 2021;14(5):1853-1863.

Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
Woo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J
ISCIENCE. 2021;24(7):102752.

Kommunikationstraining für onkologisch tätige Ärtz*Innen in Deutschalnd
Wünsch A, Bergelt C, Götze H, Karger A, Oechsle K, Rüffer J, Speiser D, Vitinius F
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2021;2021(36):391-395.

Kommunikationstrainings für onkologisch tätige Ärzt*innen in Deutschland
Wünsch A, Bergelt C, Götze H, Karger A, Oechsle K, Rüffer J, Speiser D, Vitinius F
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2021;2021(5):.

Rätselhafte B-Symptomatik bei einem 61-Jährigen unter Therapie einer rheumatoiden Arthritis
Wüstenberg R, Christner M, Schmiedel S, Tariparast A, Wichmann D, Lennartz M, Klose H, Kluge S
INTERNIST. 2021;62(11):1231-1236.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan T, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt N, Seymour M, Bokemeyer C, Rubio E, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz H
JNCI-J NATL CANCER I. 2021;113(12):1705-1713.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll H, Goldberg R, Hoff P, Hecht J, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard J, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R
THER ADV MED ONCOL. 2021;13:17588359211020547.

Schwere sekundär sklerosierende Cholangitis als Manifestation einer sehr seltenen Grunderkrankung
Zecher B, Zenouzi R, Lang M, Karagiannis P, Clauditz T, Fischer L, Sterneck M, Schramm C, Lohse A, Sebode M
INTERNIST. 2021;62(12):1349-1353.

83/m mit Schwellung am Hals: Vorbereitung auf die Facharztprüfung: Fall 24
Zech H, Schafhausen P, Bußmann L
ONKOLOGE. 2021.

Efferocytosis fuels malignant pleural effusion through TIMP1
Zhao L, Giannou A, Xu Y, Shiri A, Liebold I, Steglich B, Bedke T, Zhang T, Lücke J, Scognamiglio P, Kempski J, Woestemeier A, Chen J, Agalioti T, Zazara D, Lindner D, Janning M, Hennigs J, Jagirdar R, Kotsiou O, Zarogiannis S, Kobayashi Y, Izbicki J, Ghosh S, Rothlin C, Bosurgi L, Huber S, Gagliani N
SCI ADV. 2021;7(33):.

New Deoxyisoaustamide Derivatives from the Coral-Derived Fungus Penicillium dimorphosporum KMM 4689
Zhuravleva O, Antonov A, Trang V, Pivkin M, Khudyakova Y, Denisenko V, Popov R, Kim N, Yurchenko E, Gerasimenko A, Udovenko A, Amsberg G, Dyshlovoy S, Afiyatullov S
MAR DRUGS. 2021;19(1):.

The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies
Behrmann L, Wellbrock J, Fiedler W
EXPERT OPIN THER TAR. 2020;24(5):451-462.

Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
Belloum Y, Janning M, Mohme M, Simon R, Kropidlowski J, Sartori A, Irwin D, Westphal M, Lamszus K, Loges S, Riethdorf S, Pantel K, Wikman H
CELLS-BASEL. 2020;9(11):.

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, Riethdorf S
ONCOIMMUNOLOGY. 2020;9(1):.

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih H, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert M, Rammensee H, Stevanović S, Walz J
BLOOD CANCER J. 2020;10(2):24.

Tipping point: When patients stop eating and drinking in the last phase of their life
Blum D, Jensen W, Ullrich A, Hlawatsch C, Bokemeyer C, Oechsle K
CLIN NUTR ESPEN. 2020;38:280-282.

Individual specialist physical activity assessment and intervention in advanced cancer patients on a palliative care ward; the 3STEPS-study
Blum D, Schuetz C, Jensen W, Wannke L, Ketels G, Bokemeyer C, Oechsle K
ANN PALLIAT MED. 2020;9(6):4315-4322.

Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells
Böckelmann L, Starzonek C, Niehoff A, Karst U, Thomale J, Schlüter H, Bokemeyer C, Aigner A, Schumacher U
HISTOCHEM CELL BIOL. 2020;153(5):367-377.

Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue
Canella C, Mikolasek M, Rostock M, Guckenberger M, Jenewein J, Linka E, Six C, Stoll S, Stupp R, Witt C
BMC CANCER. 2020;20(1):458.

Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset
Chari A, Samur M, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer E, Einsele H, Beksac M, Weisel K, Anderson K, Mateos M, Moreau P, San Miguel J, Munshi N, Avet-Loiseau H
BLOOD. 2020.

Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar A, Brückner L, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth F, Heussel C, El Shafie R, Schneider M, Muley T, Meister M, Faehling M, Fischer J, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M
LUNG CANCER. 2020;148:105-112.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih H, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso M, Ehninger G, Schlenk R, Lo-Coco F
LEUKEMIA. 2020;34(3):914-918.

Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos M, Weisel K, Jansen J
VALUE HEALTH. 2020;23(4):441-450.

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Cortes J, Heidel F, Fiedler W, Smith B, Robak T, Montesinos P, Candoni A, Leber B, Sekeres M, Pollyea D, Ferdinand R, Ma W, O'Brien T, O'Connell A, Chan G, Heuser M
J HEMATOL ONCOL. 2020;13(1):92.

Impact, challenges and limits of inpatient palliative care consultations - perspectives of requesting and conducting physicians
Coym A, Oechsle K, Kanitz A, Puls N, Blum D, Bokemeyer C, Ullrich A
BMC HEALTH SERV RES. 2020;20(1):86.

Systematic symptom and problem assessment at admission to the palliative care ward - perspectives and prognostic impacts
Coym A, Ullrich A, Hackspiel L, Ahrenholz M, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2020;19(1):75.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Dimopoulos M, Jakubowiak A, McCarthy P, Orlowski R, Attal M, Bladé J, Goldschmidt H, Weisel K, Ramasamy K, Zweegman S, Spencer A, Huang J, Lu J, Sunami K, Iida S, Chng W, Holstein S, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson K
BLOOD CANCER J. 2020;10(2):17.

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Dimopoulos M, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos M, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski R, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu K, Anderson K, Jou Y, Ganetsky A, Singhal A, Richardson P
BLOOD CANCER J. 2020;10(9):91.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Dimopoulos M, Niesvizky R, Weisel K, Siegel D, Hajek R, Mateos M, Cavo M, Huang M, Zahlten-Kumeli A, Moreau P
BLOOD CANCER J. 2020;10(3):35.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos M, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani S
LANCET. 2020;396(10245):186-197.

Marine Compounds and Cancer: Updates 2020
Dyshlovoy S, Honecker F
MAR DRUGS. 2020;18(12):.

Marine Drugs Acting as Autophagy Modulators
Dyshlovoy S, Honecker F
MAR DRUGS. 2020;18(1):.

Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells
Dyshlovoy S, Kaune M, Hauschild J, Kriegs M, Hoffer K, Busenbender T, Smirnova P, Zhidkov M, Poverennaya E, Oh-Hohenhorst S, Spirin P, Prassolov V, Tilki D, Bokemeyer C, Graefen M, von Amsberg G
MAR DRUGS. 2020;18(12):.

Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties
Dyshlovoy S, Kaune M, Kriegs M, Hauschild J, Busenbender T, Shubina L, Makarieva T, Hoffer K, Bokemeyer C, Graefen M, Stonik V, von Amsberg G
SCI REP-UK. 2020;10(1):13178.

Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting
Dyshlovoy S, Kudryashova E, Kaune M, Makarieva T, Shubina L, Busenbender T, Denisenko V, Popov R, Hauschild J, Fedorov S, Bokemeyer C, Graefen M, Stonik V, von Amsberg G
SCI REP-UK. 2020;10(1):9764.

Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer
Dyshlovoy S, Pelageev D, Hauschild J, Sabutskii Y, Khmelevskaya E, Krisp C, Kaune M, Venz S, Borisova K, Busenbender T, Denisenko V, Schlüter H, Bokemeyer C, Graefen M, Polonik S, Anufriev V, Amsberg G
MAR DRUGS. 2020;18(5):.

Polyphenolic Compounds from Lespedeza Bicolor Root Bark Inhibit Progression of Human Prostate Cancer Cells via Induction of Apoptosis and Cell Cycle Arrest
Dyshlovoy S, Tarbeeva D, Fedoreyev S, Busenbender T, Kaune M, Veselova M, Kalinovskiy A, Hauschild J, Grigorchuk V, Kim N, Bokemeyer C, Graefen M, Gorovoy P, von Amsberg G
BIOMOLECULES. 2020;10(3):.

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Elsesy M, Oh-Hohenhorst S, Löser A, Oing C, Mutiara S, Köcher S, Meien S, Zielinski A, Burdak-Rothkamm S, Tilki D, Huland H, Schwarz R, Petersen C, Bokemeyer C, Rothkamm K, Mansour W
CANCERS. 2020;12(9):.

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
Fankhauser C, Tran B, Pedregal M, Ruiz-Morales J, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan E, Cheng T, Castellano D, Del Muro X, Hamid A, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng D, Bedard P, Sweeney C, Connors J
EUR UROL FOCUS. 2020;7(5):1130-1136.

A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich A, Heuser M
BRIT J HAEMATOL. 2020;190(3):e169-e173.

Coagulation Disorders: Manifestations in the Gastrointestinal Tract
Fischbach W, Germer T, Langer F, Mössner J
VISC MED. 2020;36(4):288-291.

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, Gillessen S
Cancer treatment and research communications. 2020;25:100256.

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg C, Ståhl O, Fankhauser C, Hamid A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S
J CLIN ONCOL. 2020;38(12):1322-1331.

Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia
Freisleben F, Behrmann L, Thaden V, Muschhammer J, Bokemeyer C, Fiedler W, Wellbrock J
INT J MOL SCI. 2020;21(14):.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl D, Jakubowiak A, Dingli D, Cornell R, Hofmeister C, Siegel D, Berdeja J, Reece D, White D, Lentzsch S, Gasparetto C, Huff C, Jagannath S, Baz R, Nooka A, Richter J, Abonour R, Parker T, Yee A, Moreau P, Lonial S, Tuchman S, Weisel K, Mohty M, Choquet S, Unger T, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman M, Dimopoulos M
LEUKEMIA. 2020;34(9):2430-2440.

Guidelines for Long-Term Follow-Up after Childhood Cancer: Practical Implications for the Daily Work
Gebauer J, Baust K, Bardi E, Grabow D, Stein A, van der Pal H, Calaminus G, Langer T
ONCOL RES TREAT. 2020;43(3):61-69.

Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients
Ghandili S, Pfefferle S, Roedl K, Sonnemann P, Karagiannis P, Boenisch O, Kluge S, Schmiedel S, Ittrich H, Rohde H, Lütgehetmann M, Weisel K, Bokemeyer C, Wichmann D, Fiedler W, Jarczak D, Modemann F
BLOOD ADV. 2020;4(23):5936-5941.

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Goldschmidt H, Dimopoulos M, Rajkumar S, Weisel K, Moreau P, Chng W, Mikala G, Cavo M, Ramasamy K, Suryanarayan K, Teng Z, Labotka R, Mateos M
LEUKEMIA. 2020;34(11):3019-3027.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt H, Mai E, Dürig J, Scheid C, Weisel K, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann H, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab M, Blau I, Hänel M, Salwender H
LEUKEMIA. 2020;34(7):1853-1865.

Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol
Görlach M, Schrage T, Bokemeyer C, Kröger N, Müller V, Petersen C, Betz C, Krüll A, Schulz H, Bleich C
HEALTH QUAL LIFE OUT. 2020;18(1):3.

Simultaneous Magnetic Particle Imaging and Navigation of large superparamagnetic nanoparticles in bifurcation flow experiments
Griese F, Knopp T, Grüttner C, Thieben F, Müller K, Loges S, Ludewig P, Gdaniec N
J MAGN MAGN MATER. 2020;2020(498):.

Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Grünwald V, Karch A, Schuler M, Schöffski P, Kopp H, Bauer S, Kasper B, Lindner L, Chemnitz J, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Zimmermann S, Liu X, Kunitz A
J CLIN ONCOL. 2020;38(30):3555-3564.

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Haen S, Löffler M, Rammensee H, Brossart P
NAT REV CLIN ONCOL. 2020;17(10):595-610.

Upregulation of DDAH2 Limits Pulmonary Hypertension and Right Ventricular Hypertrophy During Chronic Hypoxia in Ddah1 Knockout Mice
Hannemann J, Glatzel A, Hillig J, Zummack J, Schumacher U, Lüneburg N, Harbaum L, Böger R
FRONT PHYSIOL. 2020;11:597559.

Blood carbon dioxide tension and risk in pulmonary arterial hypertension
Harbaum L, Fuge J, Kamp J, Hennigs J, Simon M, Sinning C, Oqueka T, Grimminger J, Olsson K, Hoeper M, Klose H
INT J CARDIOL. 2020;318:131-137.

Evaluation of a communication skills training to facilitate addressing palliative care related topics in advanced cancer patients: study protocol of a multicenter randomized controlled trial (PALLI-KOM)
Harnischfeger N, Rath H, Ullrich A, Alt-Epping B, Letsch A, Thuss-Patience P, Bokemeyer C, Oechsle K, Bergelt C
BMC PALLIAT CARE. 2020;19(1):67.

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Burchert A, Brümmendorf T, Hasford J, Hochhaus A, Saußele S, Baccarani M
LEUKEMIA. 2020;34(10):2823.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Burchert A, Brümmendorf T, Hasford J, Hochhaus A, Saußele S, Baccarani M
LEUKEMIA. 2020;34(8):2074-2086.

High prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018
Heinemann M, Phillips R, Vinnemeier C, Rolling C, Tannich E, Rolling T
MALARIA J. 2020;19(1):366.

Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer
Hennigs J, Minner S, Tennstedt P, Löser R, Huland H, Klose H, Graefen M, Schlomm T, Sauter G, Bokemeyer C, Honecker F
SCI REP-UK. 2020;10(1):3250.

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman L, Wang E, Fiedler W, Baldus C, Schwind S, Pardee T, Perl A, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A
LEUKEMIA. 2020;34(11):2903-2913.

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
Hoeper M, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, Pittrow D, Olsson K, Vizza C, Gall H, Benjamin N, Distler O, Opitz C, Gibbs J, Delcroix M, Ghofrani H, Rosenkranz S, Ewert R, Kaemmerer H, Lange T, Kabitz H, Skowasch D, Skride A, Jureviciene E, Paleviciute E, Miliauskas S, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Wirtz H, Pfeuffer-Jovic E, Harbaum L, Scholtz W, Dumitrescu D, Bruch L, Coghlan G, Neurohr C, Tsangaris I, Gorenflo M, Scelsi L, Vonk-Noordegraaf A, Ulrich S, Held M
J HEART LUNG TRANSPL. 2020;39(12):1435-1444.

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A
Holstein K, Albisetti M, Bidlingmaier C, Halimeh S, Heine S, Klamroth R, Königs C, Kurnik K, Male C, Oldenburg J, Streif W, Wermes C, Escuriola-Ettingshausen C
HAMOSTASEOLOGIE. 2020;40(5):561-571.

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study
Holstein K, Liu X, Smith A, Knöbl P, Klamroth R, Geisen U, Eichler H, Miesbach W, Tiede A
BLOOD. 2020;136(3):279-287.

LPS-induced expression and release of monocyte tissue factor in patients with haemophilia
Holstein K, Matysiak A, Witt L, Sievers B, Beckmann L, Haddad M, Renné T, Voigtländer M, Langer F
ANN HEMATOL. 2020;99(7):1531-1542.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Horne G, Stobo J, Kelly C, Mukhopadhyay A, Latif A, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf T, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark R, Milojkovic D, Helgason G, Foroni L, Nicolini F, Holyoake T, Copland M
LEUKEMIA. 2020;34(7):1775-1786.

Rationale and Design of the Hamburg City Health Study
Jagodzinski A, Johansen C, Koch-Gromus U, Aarabi G, Adam G, Anders S, Augustin M, der Kellen R, Beikler T, Behrendt C, Betz C, Bokemeyer C, Borof K, Briken P, Busch C, Büchel C, Brassen S, Debus E, Eggers L, Fiehler J, Gallinat J, Gellißen S, Gerloff C, Girdauskas E, Gosau M, Graefen M, Härter M, Harth V, Heidemann C, Heydecke G, Huber T, Hussein Y, Kampf M, von dem Knesebeck O, Konnopka A, König H, Kromer R, Kubisch C, Kühn S, Loges S, Löwe B, Lund G, Meyer C, Nagel L, Nienhaus A, Pantel K, Petersen E, Püschel K, Reichenspurner H, Sauter G, Scherer M, Scherschel K, Schiffner U, Schnabel R, Schulz H, Smeets R, Sokalskis V, Spitzer M, Terschüren C, Thederan I, Thoma T, Thomalla G, Waschki B, Wegscheider K, Wenzel J, Wiese S, Zyriax B, Zeller T, Blankenberg S
EUR J EPIDEMIOL. 2020;35(2):169-181.

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen D, Dreger P, Goldschmidt H, Brenner H
LEUKEMIA LYMPHOMA. 2020;61(10):2365-2374.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik V, Paschka P, Krönke J, Theis F, Rücker F, Teleanu M, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst H, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk R, Thol F, Heuser M, Ganser A, Döhner H, Döhner K
BLOOD. 2020;136(26):3041-3050.

Leptogorgins A-C, Humulane Sesquiterpenoids from the Vietnamese Gorgonian Leptogorgia sp
Kapustina I, Makarieva T, Guzii A, Kalinovsky A, Popov R, Dyshlovoy S, Grebnev B, Amsberg G, Stonik V
MAR DRUGS. 2020;18(6):.

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
Karagiannis P, Sänger L, Alsdorf W, Weisel K, Fiedler W, Kluge S, Wichmann D, Bokemeyer C, Fuhrmann V
CANCERS. 2020;12(6):.

IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
Kempski J, Giannou A, Riecken K, Zhao L, Steglich B, Lücke J, Garcia-Perez L, Karstens K, Wöstemeier A, Nawrocki M, Pelczar P, Witkowski M, Nilsson S, Konczalla L, Shiri A, Kempska J, Wahib R, Brockmann L, Huber P, Gnirck A, Turner J, Zazara D, Arck P, Stein A, Simon R, Daubmann A, Meiners J, Perez D, Strowig T, Koni P, Kruglov A, Sauter G, Izbicki J, Guse A, Roesch T, Lohse A, Flavell R, Gagliani N, Huber S
GASTROENTEROLOGY. 2020;159(4):1417-1430.e3.

Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 – 3. Version: S1-Leitlinie
Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Salzberger B, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Hoffmann F, Böttiger B, Marx G, Karagiannidis C
ANAESTHESIST. 2020;69(9):653-664.

Geriatrisches Assessment: Integration ins Tumorboard
Kolb G, Bokemeyer C, Wedding U
Deutsches Ärzteblatt. 2020;2020(27-28):1382-1384.

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta C, Awwad M, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel K, Blau I, Neubauer A, Müller-Tidow C, Raab M, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg
CANCERS. 2020;12(8):.

Successful Treatment of Delayed Methotrexate Clearance using Glucarpidase Dosed on Ideal Body Weight in Obese Patients
Krüger C, Engel N, Reinert J, Alsdorf W, Fiedler W, Dierlamm J, Bokemeyer C, Langebrake C
PHARMACOTHERAPY. 2020;40(5):479-483.

Sea Anemone Heteractis crispa Actinoporin Demonstrates In Vitro Anticancer Activities and Prevents HT-29 Colorectal Cancer Cell Migration
Kvetkina A, Malyarenko O, Pavlenko A, Dyshlovoy S, von Amsberg G, Ermakova S, Leychenko E
MOLECULES. 2020;25(24):.

Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis
Langer F, Kluge S, Klamroth R, Oldenburg J
HAMOSTASEOLOGIE. 2020;40(3):264-269.

64(th) Annual Congress of the Gesellschaft fur Thrombose- und Hamostaseforschung e.V. in Bremen: Novel Concepts for a Lifetime Challenge
Langer F, Renné T
HAMOSTASEOLOGIE. 2020;40(1):9-11.

64th Annual Congress of the Gesellschaft für Thrombose- und Hämostaseforschung e.V. in Bremen (Part II)
Langer F, Renné T
HAMOSTASEOLOGIE. 2020;40(2):143-144.

Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?
Lippi G, Langer F, Favaloro E
SEMIN THROMB HEMOST. 2020;46(4):457-464.

Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases
Llorens F, Villar-Piqué A, Schmitz M, Diaz-Lucena D, Wohlhage M, Hermann P, Goebel S, Schmidt I, Glatzel M, Hauw J, Sikorska B, Liberski P, Riggert J, Ferrer I, Zerr I
NEUROPATH APPL NEURO. 2020;46(3):240-254.

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
Lobo J, Guimarães-Teixeira C, Barros-Silva D, Miranda-Gonçalves V, Camilo V, Guimarães R, Cantante M, Braga I, Maurício J, Oing C, Honecker F, Nettersheim D, Looijenga L, Henrique R, Jerónimo C
CANCERS. 2020;12(10):.

Standard Operating Procedures (SOPs) for Palliative Care in German Comprehensive Cancer Centers - an evaluation of the implementation status
Lödel S, Ostgathe C, Heckel M, Oechsle K, Gahr S
BMC PALLIAT CARE. 2020;19(1):62.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial S, Lee H, Badros A, Trudel S, Nooka A, Chari A, Abdallah A, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm K, Rodríguez-Otero P, Usmani S, Hari P, Baz R, Quach H, Moreau P, Voorhees P, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell R, Dettman E, Popat R, Esposti S, Opalinska J, Richardson P, Cohen A
LANCET ONCOL. 2020;21(2):207-221.

Current status of immunotherapy in gastrointestinal malignancies
Lorenzen S, Lordick F, Loosen S, Tacke F, Trautwein C, Roderburg C, Ettrich T, Perkhofer L, Reinacher-Schick A, Stein A
Z GASTROENTEROL. 2020;58(6):542-555.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz K, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N
LEUKEMIA LYMPHOMA. 2020;61(2):377-386.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
Mateos M, Spencer A, Nooka A, Pour L, Weisel K, Cavo M, Laubach J, Cook G, Iida S, Benboubker L, Usmani S, Yoon S, Bahlis N, Chiu C, Ukropec J, Schecter J, Qin X, O' Rourke L, Dimopoulos M
HAEMATOLOGICA. 2020;105(2):468-477.

Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism
Matzdorff A, Langer F
HAMOSTASEOLOGIE. 2020;40(5):655-661.

An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial
Maurer T, von Grundherr J, Patra S, Jäger A, Becher H, Schmalfeld B, Zyriax B, Chang-Claude J
INT J GYNECOL CANCER. 2020;30(4):541-545.

Efficacy of the Managing Cancer and Living Meaningfully (CALM) individual psychotherapy for patients with advanced cancer: A single-blind randomized controlled trial
Mehnert A, Koranyi S, Philipp R, Scheffold K, Kriston L, Lehmann-Laue A, Engelmann D, Vehling S, Eisenecker C, Oechsle K, Schulz-Kindermann F, Rodin G, Härter M
PSYCHO-ONCOLOGY. 2020;29(11):1895-1904.

CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
Merseburger A, Bannowsky A, Becker K, Bokemeyer C, Eichenauer R, Lehmann J, Mickisch G, Steuber T, von Amsberg G, von Kügelgen T, Wülfing C
AKTUEL UROL. 2020;2020:.

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2020;55(12):2286-2293.

Local intracerebral immunomodulation using interleukin-expressing mesenchymal stem cells in glioblastoma
Mohme M, Maire C, Geumann U, Schliffke S, Dührsen L, Fita K, Akyüz N, Binder M, Westphal M, Guenther C, Lamszus K, Hermann F, Schmidt N
CLIN CANCER RES. 2020;26(11):2626-2639.

Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape
Mohme M, Maire C, Schliffke S, Joosse S, Alawi M, Matschke J, Schüller U, Dierlamm J, Martens T, Pantel K, Riethdorf S, Lamszus K, Westphal M
ACTA NEUROPATHOL COM. 2020;8(1):.

Management of germ cell tumors during the outbreak of the novel coronavirus disease-19 pandemic: a survey of international expertise centers
Nappi L, Ottaviano M, Rescigno P, Tortora M, Banna G, Baciarello G, Basso U, Canil C, Cavo A, Rocca M, Czaykowski P, De Giorgi U, Del Muro X, Di Napoli M, Fornarini G, Gietema J, Heng D, Hotte S, Kollmannsberger C, Maruzzo M, Messina C, Morelli F, Mulder S, Nichols C, Nolè F, Oing C, Sava T, Secondino S, Simone G, Soulieres D, Vincenzi B, Zucali P, De Placido S, Palmieri G
ONCOLOGIST. 2020;25(10):e1509-e1515.

Molecular characterization of histopathological ependymoma variants
Neumann J, Spohn M, Obrecht D, Mynarek M, Thomas C, Hasselblatt M, Dorostkar M, Wefers A, Frank S, Monoranu C, Koch A, Witt H, Kool M, Pajtler K, Rutkowski S, Glatzel M, Schüller U
ACTA NEUROPATHOL. 2020;139(2):305-318.

Case report: acute abdominal pain in a 37-year-old patient and the consequences for his family
Niemeyer E, Mofid H, Zornig C, Burandt E, Stein A, Block A, Volk A
BMC GASTROENTEROL. 2020;20(1):129.

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
Nilsson S, Stein A, Rolfo C, Kranich A, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C
CURR CANCER DRUG TAR. 2020;20(10):811-817.

Palliativmedizin
Oechsle K
2020. Taschenbuch Onkologie. Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 20. Aufl. München: W. Zuckschwerdt Verlag, 272-278.

Schmerztherapie
Oechsle K
2020. Taschenbuch Onkologie. . Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). 20. Aufl. München: 264-268.

Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer
Oechsle K, Ullrich A, Marx G, Benze G, Wowretzko F, Zhang Y, Dickel L, Heine J, Wendt K, Nauck F, Bokemeyer C, Bergelt C
AM J HOSP PALLIAT ME. 2020;37(3):201-213.

Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series
Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira R, Bokemeyer C, Seidel C
J CANCER RES CLIN. 2020;146(2):449-455.

Was der Onkologe vom Pathologen über Hodentumoren wissen muss
Oing C, Peters M, Bremmer F
PATHOLOGE. 2020;41(Suppl 2):111-117.

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
Oliveira-Ferrer L, Milde-Langosch K, Eylmann K, Rossberg M, Müller V, Schmalfeldt B, Witzel I, Wellbrock J, Fiedler W
INT J MOL SCI. 2020;21(2):.

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance
Orgaz J, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I, Monger J, Mele S, Georgouli M, Bridgeman V, Karagiannis P, Lee R, Pandya P, Boehme L, Wallberg F, Tape C, Karagiannis S, Malanchi I, Sanz-Moreno V
CANCER CELL. 2020;37(1):85-103.e9.

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
Pape U, Kasper S, Meiler J, Sinn M, Vogel A, Müller L, Burkhard O, Caca K, Heeg S, Büchner-Steudel P, Rodriguez-Laval V, Kühl A, Arsenic R, Jansen H, Treasure P, Utku N
CANCERS. 2020;12(11):.

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Raab M, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau I, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M
LANCET HAEMATOL. 2020;7(5):e381-e394.

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza V, Weisel K
LEUKEMIA LYMPHOMA. 2020;61(3):668-679.

Tumorvakzinierung – therapeutische Vakzinierung gegen Krebs
Rammensee H, Löffler M, Walz J, Bokemeyer C, Haen S, Gouttefangeas C
INTERNIST. 2020;61(7):690-698.

Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller O, Neudorf U, Pfister R, von Haehling S, Lehmann L, Bauersachs J
CLIN RES CARDIOL. 2020;109(10):1197-1222.

Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures
Rolling C, Tomada J, Frölich A, Holst B, Holstein K, Voigtländer M, Janjetovic S, Haddad M, Renné T, Fiehler J, Bokemeyer C, Rolling T, Langer F
CLIN CHEM LAB MED. 2020;59(2):383-392.

Die Misteltherapie in der Behandlung von Patienten mit einer Krebserkrankung
Rostock M
BUNDESGESUNDHEITSBLA. 2020;63(5):535-540.

Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays
Rothkamm K, Christiansen S, Rieckmann T, Horn M, Frenzel T, Brinker A, Schumacher U, Stein A, Petersen C, Burdak-Rothkamm S
CANCER LETT. 2020;493:179-188.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub L, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann J, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):16.

Endothelium-Macrophage Crosstalk Mediates Blood-Brain Barrier Dysfunction in Hypertension
Santisteban M, Ahn S, Lane D, Faraco G, Garcia-Bonilla L, Racchumi G, Poon C, Schaeffer S, Segarra S, Körbelin J, Anrather J, Iadecola C
HYPERTENSION. 2020;76(3):795-807.

Exome sequencing in 38 patients with intracranial aneurysms and subarachnoid hemorrhage
Sauvigny T, Alawi M, Krause L, Renner S, Spohn M, Busch A, Kolbe V, Altmüller J, Löscher B, Franke A, Brockmann C, Lieb W, Westphal M, Schmidt N, Regelsberger J, Rosenberger G
J NEUROL. 2020;267(9):2533-2545.

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma
Schieferdecker A, Hörber S, Ums M, Besemer B, Bokemeyer C, Peter A, Weisel K
BLOOD CANCER J. 2020;10(1):2.

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst H, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H
J CLIN ONCOL. 2020;38(6):623-632.

The Ambulatory Management of COVID-19 Via the German Department of Health
Schmidt B, Sivanathan V, Schmiedel S, Kohnen W, Hoffmann D
DTSCH ARZTEBL INT. 2020.

Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kröger N, Mueller V, Petersen C, Krüll A, Schulz H, Bleich C
JMIR RES PROTOC. 2020;9(7):e17854.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

Thioredoxin Interacting Protein (TXNIP) Is Differentially Expressed in Human Tumor Samples but Is Absent in Human Tumor Cell Line Xenografts: Implications for Its Use as an Immunosurveillance Marker
Schröder J, Schumacher U, Böckelmann L
CANCERS. 2020;12(10):.

Preclinical Quantification of Prostate Cancer-Associated Vascular Alterations in the Bone Microenvironment in vivo
Schroeder M, Viezens L, Sündermann J, Hettenhausen S, Hauenherm G, Wellbrock J, Mussawy H, Kossow K, Schaefer C
EUR SURG RES. 2020;61(6):188-200.

Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann K, Brito M, Ruf C, Oing C, Bokemeyer C
EUR J CANCER. 2020;132:127-135.

Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells
Selnø A, Schlichtner S, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Klenova E, Pavlova L, Gibbs B, Degen M, Schnyder I, Aliu N, Berger S, Fasler-Kan E, Sumbayev V
AGING-US. 2020;12(23):23478-23496.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K, Kudaba I, Garrido M, Chung H, Lee J, Castro H, Mansoor W, Braghiroli M, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko A, Wainberg Z, Kher U, Shah S, Kang S, Tabernero J
JAMA ONCOL. 2020;6(10):1571-1580.

Gracilosulfates A-G, Monosulfated Polyoxygenated Steroids from the Marine Sponge Haliclona gracilis
Shubina L, Makarieva T, Denisenko V, Popov R, Dyshlovoy S, Grebnev B, Dmitrenok P, von Amsberg G, Stonik V
MAR DRUGS. 2020;18(9):.

Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors
Simnica D, Ittrich H, Bockemeyer C, Stein A, Binder M
FRONT ONCOL. 2020;10:540030.

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler J, Pelzer U, Bischoff S, Bahra M, Oettle H
EUR J CANCER. 2020;138:172-181.

TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial
Sinn M, Sinn B, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler J, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C
CLIN CANCER RES. 2020;26(14):3732-3739.

Gallengangs- und Gallenblasenkarzinome: auf dem Weg zur personalisierten Therapie
Sinn M, Wege H, Stein A
DEUT MED WOCHENSCHR. 2020;145(7):442-446.

Assessing palliative care need in left ventricular assist device patients and heart transplant recipients
Strangl F, Ullrich A, Oechsle K, Bokemeyer C, Blankenberg S, Knappe-Wegner D, Reichenspurner H, Bernhardt A, Barten M, Rybczynski M
INTERACT CARDIOV TH. 2020;31(6):874-880.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager G, Greil R, Stein A, Fasolo A, Schellens J, Wen P, Viele K, Boran A, Gasal E, Burgess P, Ilankumaran P, Wainberg Z
LANCET ONCOL. 2020;21(9):1234-1243.

Strain Analysis Using Feature-Tracking CMR to Detect LV Systolic Dysfunction in Myocardial Iron Overload Disease
Tahir E, Fischer R, Grosse R, Yamamura J, Starekova J, Lund G, Bannas P, Graessner J, Radunski U, Muellerleile K, Adam G, Schoennagel B
JACC-CARDIOVASC IMAG. 2020;13(10):2267-2268.

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild J, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran S, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):503.

Crtap and p3h1 knock out zebrafish support defective collagen chaperoning as the cause of their osteogenesis imperfecta phenotype
Tonelli F, Cotti S, Leoni L, Besio R, Gioia R, Marchese L, Giorgetti S, Villani S, Gistelinck C, Wagener R, Kobbe B, Fiedler I, Larionova D, Busse B, Eyre D, Rossi A, Witten P, Forlino A
MATRIX BIOL. 2020;90:40-60.

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Tran B, Ruiz-Morales J, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan E, Cheng T, Castellano D, Garcia Del Muro X, Hamid A, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng D, Bedard P
CANCER MED-US. 2020;9(1):116-124.

Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study
Türkantoz H, Königs C, Knöbl P, Klamroth R, Holstein K, Huth-Kühne A, Heinz J, Eichler H, Tiede A
J THROMB HAEMOST. 2020;18(1):36-43.

Ethical challenges in family caregivers of patients with advanced cancer - a qualitative study
Ullrich A, Theochari M, Bergelt C, Marx G, Woellert K, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2020;19(1):70.

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Vij R, Nath R, Afar D, Mateos M, Berdeja J, Raab M, Guenther A, Martinez-Lopez J, Jakubowiak A, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan J, Reddy A, Paiva B, Singhal A, San-Miguel J, Moreau P
CLIN CANCER RES. 2020;26(10):2308-2317.

Effect of myeloperoxidase on the anticoagulant activity of low-molecular-weight heparin and rivaroxaban in an in-vitro tumor model
Voigtländer M, Beckmann L, Schulenkorf A, Sievers B, Rolling C, Bokemeyer C, Langer F
J THROMB HAEMOST. 2020;18(12):3267-3279.

Therapie und Prophylaxe der tumorassoziierten venösen Thromboembolie
Voigtländer M, Langer F
InFo Hämatologie + Onkologie. 2020;(06/2020):.

The Impact of Smoking Cessation and Continuation on Recurrence and Survival in Patients with Head and Neck Cancer: A Systematic Review of the Literature
von Kroge P, Bokemeyer F, Ghandili S, Bokemeyer C, Seidel C
ONCOL RES TREAT. 2020;43(10):549-558.

Impact of COVID-19 pandemic on mental health of patients with inherited bleeding disorders in Germany
von Mackensen S, Halimeh S, Siebert M, Wermes C, Hassenpflug W, Holstein K, Olivieri M
HAEMOPHILIA. 2020;26(6):e272-e281.

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Atanackovic D, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2020;34(9):2542.

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate A, Vural F, Cascavilla N, Basu S, Johnson P, Byeff P, Hus M, Rodríguez-Otero P, Muelduer E, Anttila P, Hayden P, Krauth M, Lucio P, Ben-Yehuda D, Mendeleeva L, Guo S, Yu X, Grote L, Biyukov T, Dhanasiri S, Richardson P
LEUKEMIA LYMPHOMA. 2020;61(8):1850-1859.

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Weisel K, Ludwig H, Rieth A, Lebioda A, Goldschmidt H
QUAL LIFE RES. 2020;29(1):69-79.

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, Dimopoulos M
LEUKEMIA LYMPHOMA. 2020;61(1):37-46.

Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg: Report of the University Cancer Center Hamburg
Weisel K, Morgner-Miehlke A, Petersen C, Fiedler W, Block A, Schafhausen P, Knobloch J, Bokemeyer C
ONCOL RES TREAT. 2020;43(6):307-313.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark T, Spicka I, Masszi T, Lauri B, Levin M, Bosi A, Hungria V, Cavo M, Lee J, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min C, Chanan-Khan A, Horvath N, Capra M, Beksac M, Ovilla R, Jo J, Shin H, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos M
J HEMATOL ONCOL. 2020;13(1):115.

Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'
Westphalen B, Bokemeyer C, Büttner R, Fröhling S, Gaidzik V, Glimm H, Hacker U, Heinemann V, Illert A, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke J, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S
EUR J CANCER. 2020;135:1-7.

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann D, Sperhake J, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder A, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen H, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo M, Aepfelbacher M, Püschel K, Kluge S
ANN INTERN MED. 2020;173(4):268-277.

Investigating the suitability of high-resolution mass spectrometry for newborn screening: identification of hemoglobinopathies and β-thalassemias in dried blood spots
Wiesinger T, Mechtler T, Schwarz M, Xie X, Grosse R, Nieves Cobos P, Kasper D, Lukacs Z
CLIN CHEM LAB MED. 2020;58(5):810-816.

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
Wörmann B, Bokemeyer C, Burmeister T, Köhne C, Schwab M, Arnold D, Blohmer J, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr C, Lorenzen S, Lüftner D, Moehler M, Nöthen M, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz R
ONCOL RES TREAT. 2020;43(11):628-636.

Extreme biomineralization: the case of the hypermineralized ear bone of gray whale (Eschrichtius robustus)
Wysokowski M, Petrenko I, Galli R, Schimpf C, Rafaja D, Hubalkova J, Aneziris C, Dyshlovoy S, von Amsberg G, Meissner H, Yakovlev Y, Tabachnick K, Stelling A, Ehrlich H
APPL PHYS A-MATER. 2020;126(9):.

Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Yan X, Xu X, Weisel K, Mateos M, Sonneveld P, Dimopoulos M, Usmani S, Bahlis N, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H
CTS-CLIN TRANSL SCI. 2020;13(6):1345-1354.

Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity
Yasinska I, Meyer N, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M, Fiedler W, Wellbrock J, Desmet C, Calzolai L, Varani L, Berger S, Raap U, Gibbs B, Fasler-Kan E, Sumbayev V
FRONT IMMUNOL. 2020;11:580557.

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
Yogeswaran A, Gall H, Tello K, Grünig E, Xanthouli P, Ewert R, Kamp J, Olsson K, Wißmüller M, Rosenkranz S, Klose H, Harbaum L, Lange T, Opitz C, Waelde A, Milger K, Sommer N, Seeger W, Ghofrani H, Richter M
PULM CIRC. 2020;10(3):2045894020941682.

Citriperazines A-D produced by a marine algae-derived fungus Penicillium sp. KMM 4672
Yurchenko A, Berdyshev D, Smetanina O, Ivanets E, Zhuravleva O, Rasin A, Khudyakova Y, Popov R, Dyshlovoy S, von Amsberg G, Afiyatullov S
NAT PROD RES. 2020;34(8):1118-1123.

Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma
Zech H, Moeckelmann N, Boettcher A, Muenscher A, Binder M, Vettorazzi E, Bokemeyer C, Schafhausen P, Betz C, Busch C
FUTURE ONCOL. 2020;16(36):3035-3043.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

NAT COMMUN. 2019;10(1):1741.

Piltunines A-F from the Marine-Derived Fungus Penicillium piltunense KMM 4668
Afiyatullov S, Zhuravleva O, Antonov A, Leshchenko E, Pivkin M, Khudyakova Y, Denisenko V, Pislyagin E, Kim N, Berdyshev D, Amsberg G, Dyshlovoy S
MAR DRUGS. 2019;17(11):.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, Kopp H, Mayer F, Haag G, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens U, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer D, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal L, Hartmann J, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu F, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein W, Schuler M, Schmalenberg H, Hofheinz R
LANCET. 2019;393(10184):1948-1957.

Current pharmacotherapy for testicular germ cell cancer
Alsdorf W, Seidel C, Bokemeyer C, Oing C
EXPERT OPIN PHARMACO. 2019;20(7):837-850.

Naphto-Γ-pyrones from the marine-derived fungus Aspergillus foetidus
Antonov A, Leshchenko E, Zhuravleva O, Dyshlovoy S, von Amsberg G, Popov R, Denisenko V, Kirichuk N, Afiyatullov S
NAT PROD RES. 2019;1-4.

Treatment of the antiphospholipid syndrome with direct oral anticoagulants Position statement of German societies
Bauersachs R, Langer F, Kalka C, Konstantinides S, Klamroth R, Oldenburg J, Schellong S, Scholz U, Stücker M, Lindhoff-Last E
VASA. 2019;48(6):483-486.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment
Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H
WORLD J UROL. 2019;37(12):2657-2662.

Sexual dimorphism in solid and hematological malignancies
Ben-Batalla I, Vargas-Delgado M, Meier L, Loges S
SEMIN IMMUNOPATHOL. 2019;41(2):251-263.

Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism
Beyer-Westendorf J, Klamroth R, Kreher S, Langer F, Matzdorff A, Riess H
DTSCH ARZTEBL INT. 2019;116(3):31-38.

Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients
Biehl L, Garzetti D, Farowski F, Ring D, Koeppel M, Rohde H, Schafhausen P, Stecher B, Vehreschild M
PLOS ONE. 2019;14(4):e0215428.

Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards
Biehl L, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp E, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild J, Seifert H, Vehreschild M
CLIN MICROBIOL INFEC. 2019;25(8):1013-1020.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
Bixby D, Noppeney R, Lin T, Cortes J, Krauter J, Yee K, Medeiros B, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons B, Riehl T, Colburn D
BRIT J HAEMATOL. 2019;185(3):595-598.

Sterbephase: Ernährung und Flüssigkeitsgabe in der Sterbephase
Blum D, Hlawatsch C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 150-152.

Symptomkontrolle: Kachexie, Anorexie und Ernährung
Blum D, Hlawatsch C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 98-102.

Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors?
Böckelmann L, Schumacher U
EXPERT OPIN THER TAR. 2019;23(12):1005-1014.

Psychische Aspekte: Künstlerische Therapien
Böhmer S, Weigle A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 198-204.

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells
Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M
LEUKEMIA LYMPHOMA. 2019;60(2):334-340.

Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines
Bremmer F, Bohnenberger H, Küffer S, Oellerich T, Serve H, Urlaub H, Strauss A, Maatoug Y, Behnes C, Oing C, Radzun H, Ströbel P, Balabanov S, Honecker F
DIS MARKERS. 2019;2019:8298524.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
Burzykowski T, Coart E, Saad E, Shi Q, Sommeijer D, Bokemeyer C, Díaz-Rubio E, Douillard J, Falcone A, Fuchs C, Goldberg R, Hecht J, Hoff P, Hurwitz H, Kabbinavar F, Koopman M, Maughan T, Punt C, Saltz L, Schmoll H, Seymour M, Tebbutt N, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg J, Buyse M
JAMA NETW OPEN. 2019;2(9):e1911750.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Chari A, Vogl D, Gavriatopoulou M, Nooka A, Yee A, Huff C, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart A, Richter J, Vij R, Tuchman S, Raab M, Weisel K, Delforge M, Cornell R, Kaminetzky D, Hoffman J, Costa L, Parker T, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo R, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman M, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin J, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson P, Jagannath S
NEW ENGL J MED. 2019;381(8):727-738.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes J, Heidel F, Hellmann A, Fiedler W, Smith B, Robak T, Montesinos P, Pollyea D, DesJardins P, Ottmann O, Ma W, Shaik M, Laird A, Zeremski M, O'Connell A, Chan G, Heuser M
LEUKEMIA. 2019;33(2):379-389.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Costello C, Davies F, Cook G, Vela-Ojeda J, Omel J, Rifkin R, Berdeja J, Puig N, Usmani S, Weisel K, Zonder J, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson M, Romanus D, Stull D, Hungria V
FUTURE ONCOL. 2019;15(13):1411-1428.

Symptomkontrolle: Schwäche und Immobilität, Fatigue, Schlafstörungen
Coym A, Hlawatsch C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 73-81.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Dieckmann K, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf C, Heinzelbecker J, Heidenreich A, Cremers J, Oing C, Hermanns T, Fankhauser C, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G
J CLIN ONCOL. 2019;37(16):1412-1423.

Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR)
Dimitriou V, Biehl L, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert T, Slickers P, Ehricht R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins P, Seifert H, Vehreschild M
J ANTIMICROB CHEMOTH. 2019;74(7):2065-2074.

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types
Dinkelborg P, Wang M, Gheorghiu L, Gurski J, Hong T, Benes C, Juric D, Jimenez R, Borgmann K, Willers H
BREAST CANCER RES TR. 2019;174(3):605-613.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer
Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas H, Kirkwood J, Vansteenkiste J, Sequist L, Atanackovic D, Goeman J, van Houwelingen H, Salceda S, Wang F, Therasse P, Debruyne C, Spiessens B, Brichard V, Louahed J, Ulloa-Montoya F
CLIN CANCER RES. 2019;26(7):1725-1735.

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk R, Krug U, Goeldner R, Hilbert J, Taube T, Ottmann O
BRIT J HAEMATOL. 2019;185(3):583-587.

Marine Compounds and Cancer: The First Two Decades of XXI Century
Dyshlovoy S, Honecker F
MAR DRUGS. 2019;18(1):.

Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones
Dyshlovoy S, Pelageev D, Hauschild J, Borisova K, Kaune M, Krisp C, Venz S, Sabutskii Y, Khmelevskaya E, Busenbender T, Denisenko V, Pokhilo N, Atopkina L, Graefen M, Schlüter H, Stonik V, Bokemeyer C, Anufriev V, von Amsberg G
CANCERS. 2019;11(11):.

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff A, Börner K, Albrecht B, Schäfer W, Baum N, Haag F, Körbelin J, Trepel M, Braren I, Grimm D, Adriouch S, Koch-Nolte F
MOL THER-METH CLIN D. 2019;15:211-220.

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren
Eichler H, Pedroni M, Halimeh S, Königs C, Langer F, Miesbach W, Oldenburg J, Scholz U, Streif W, Klamroth R
HAMOSTASEOLOGIE. 2019;39(4):311-321.

Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia
Engel N, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C, Lessel D
FRONT ONCOL. 2019;9:420.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner C, Weisel K, Mace J, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar C, Kobos R, Qi M, Usmani S
NEW ENGL J MED. 2019;380(22):2104-2115.

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp H, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2019;145(3):717-723.

Aspergillus Tracheobronchitis in Influenza B
Frings D, Simon M, Kluge S
DTSCH ARZTEBL INT. 2019;116(6):100.

Case Report: Apixaban - Behandlung venöser Thrombembolien und Rezidivprophylaxe
Galow S, Klose H
Case Report. 2019;11(Heft 11):6-7.

Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment
Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, Pandya P, Rodriguez-Hernandez I, Ilieva K, Cantelli G, Karagiannis P, Mele S, Lam H, Josephs D, Matias-Guiu X, Marti R, Nestle F, Orgaz J, Malanchi I, Fruhwirth G, Karagiannis S, Sanz-Moreno V
CELL. 2019;176(4):757-774.e23.

Specific challenges in end-of-life care for patients with hematological malignancies
Gerlach C, Alt-Epping B, Oechsle K
CURR OPIN SUPPORT PA. 2019;13(4):369-379.

Sterbephase: Palliative Sedierung
Goldbach S, Oechsle K
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 153-160.

Atemwegssicherung in der Intensiv- und Notfallmedizin: Was gibt es Neues?
Grensemann J, Simon M, Kluge S
MED KLIN-INTENSIVMED. 2019;114(4):334-341.

Roadmap 2019 für die Erforschung von Krebs- und Bluterkrankungen in Deutschlan
Hallek M, Bokemeyer C, Lüftner D, Weissinger F
2019.

Gene therapy to the blood-brain barrier with resulting protein secretion as a strategy for treatment of NPC2 disease
Hede E, Heegaard C, Körbelin J, Schwaninger M, Moos T, Burkhart A
HUM GENE THER. 2019;2019(30):.

Unklare Panzytopenie bei einem 52-jährigen Patienten
Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C
INTERNIST. 2019;60(8):867-870.

The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension
Hennigs J, Lüneburg N, Stage A, Schmitz M, Körbelin J, Harbaum L, Matuszcak C, Mienert J, Bokemeyer C, Böger R, Kiefmann R, Klose H
PURINERG SIGNAL. 2019;15(3):299-311.

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
Hille C, Gorges T, Riethdorf S, Mazel M, Steuber T, Amsberg G, König F, Peine S, Alix-Panabières C, Pantel K
CELLS-BASEL. 2019;8(9):.

Trauerbegleitung: Umgang mit Verstorbenen
Hlawatsch C, Scherg A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 161-164.

Niedermolekulare Heparine in der Onkologie: Überblick und Indikationen
Holstein K
Vasomed. 2019;2019(3):.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T
CSH MOL CASE STUD. 2019;5(2):.

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study
Hütter-Krönke M, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk R
HAEMATOLOGICA. 2019;104(2):E63-E64.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib
Janjetovic S, Asemissen A, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P
TUMORI J. 2019;105(6):NP8-NP11.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases
Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2019;39(3):294-297.

AML: Klinische Bedeutung von Spleißvarianten und Spleiß-assoziierten Genmutationen
Janning M, Fiedler W
J Onkol - Z Onkol Fortb. 2019;2019(6):42-45.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, Schatz S, Falk M, Berger L, Böttcher L, Päsler S, Gorges T, O'Flaherty L, Hille C, Joosse S, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S
CANCERS. 2019;11(6):.

Challenges Faced by Prehospital Emergency Physicians Providing Emergency Care to Patients with Advanced Incurable Diseases
Kamphausen A, Roese H, Oechsle K, Issleib M, Zöllner C, Bokemeyer C, Ullrich A
EMERG MED INT. 2019;2019:3456471.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
Lindsay C, Blackhall F, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen H, Hiltermann T, Krebs M, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria J, Farace F, Renehan A, Dive C, Besse B, Michiels S
EUR J CANCER. 2019;117:60-68.

A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
Löffler M, Nussbaum B, Jäger G, Jurmeister P, Budczies J, Pereira P, Clasen S, Kowalewski D, Mühlenbruch L, Königsrainer I, Beckert S, Ladurner R, Wagner S, Bullinger F, Gross T, Schroeder C, Sipos B, Königsrainer A, Stevanović S, Denkert C, Rammensee H, Gouttefangeas C, Haen S
FRONT IMMUNOL. 2019;10:2526.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study
Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K
FUTURE ONCOL. 2019;15(8):897-907.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study
Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2019;27(6):2301-2312.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz K, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N
BRIT J CANCER. 2019;121(9):751-757.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide
Mährle T, Akyüz N, Fuchs P, Bonzanni N, Simnica D, Germing U, Asemissen A, Jann J, Nolte F, Hofmann W, Nowak D, Binder M
HAEMATOLOGICA. 2019;104(7):1355-1364.

Bilaterale 4MRGN-Pseudomonas-aeruginosa-assoziierte choroidale Abszesse bei Mukoviszidose: Die bilaterale Enucleatio bulbi als Ultima Ratio bei vitaler Bedrohung
Mankichian B, Dulz S, Keserü M, Oqueka T, Schüttauf F, Wagenfeld L
OPHTHALMOLOGE. 2019;116(7):656-660.

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Mateos M, Sonneveld P, Hungria V, Nooka A, Estell J, Barreto W, Corradini P, Min C, Medvedova E, Weisel K, Chiu C, Schecter J, Amin H, Qin X, Ukropec J, Kobos R, Spencer A
CL LYMPH MYELOM LEUK. 2019.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
Merz M, Hielscher T, Mai E, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab M, Neben K, Salwender H, Blau I, Lindemann H, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J
BLOOD CANCER J. 2019;9(9):71.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause S, Kolb H, Hossfeld D, Nerl C, Baerlocher G, Heim D, Brümmendorf T, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler M, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne C, Lindemann H, Waller C, Spiekermann K, Berdel W, Müller L, Edinger M, Mayer J, Beelen D, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart M, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M
HAEMATOLOGICA. 2019;104(5):955-962.

Smart Medication ™, an Electronic Diary for Surveillance of Haemophilia Home Care and Optimization of Resource Distribution
Mondorf W, Eichler H, Fischer R, Holstein K, Klamroth R, Nimtz-Talaska A, Wermes C, Richter H, Severin K
HAMOSTASEOLOGIE. 2019;39(4):339-346.

Aktuelle Forschung pädiatrischer und adulter Keimzelltumoren: Ein Bericht vom ersten „Düsseldorfer Testis Cancer Day“
Nettersheim D, Oing C, Schönberger S, Skowron M, Vermeulen M, Müller M, Watolla M, Bremmer F, Pfister D, Calaminus G, Looijenga L, Lorch A, Albers P
UROLOGE. 2019;58(7):804-808.

Current Advances in Palliative & Hospice Care: Problems and Needs of Relatives and Family Caregivers During Palliative and Hospice Care-An Overview of Current Literature
Oechsle K
Medical sciences (Basel, Switzerland). 2019;7(3):.

Die Bedeutung der Lebensqualität für Therapieentscheidungen am Lebensende
Oechsle K
Gynäkologische Praxis. 2019;(44):1-6.

Forschung in der Palliativversorgung in Deutschland: aktuelle Situation, Perspektiven und Grenzen?
Oechsle K
Z PALLIATMEDIZIN. 2019;2019(20):79 -88.

Frühe Integration von Palliativversorgung - was wirklich diskutiert werden sollte
Oechsle K
Karger Kompass Onkologie. 2019;(6):94-95.

Grundlagen: Prinzipien der Palliativmedizin
Oechsle K
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 1-9.

Palliative Care in Patients with Hematological Malignancies
Oechsle K
ONCOL RES TREAT. 2019;42(1-2):25-30.

SOP - Akuter Verwirrtheitszustand
Oechsle K
ONKOLOGE. 2019;2018(24 (S1)):55 - 59.

Symptomkontrolle: Wunden und Blutungen
Oechsle K, Albert Y
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 118-122.

Soziale Aspekte: Mitbetreuung der Angehörigen
Oechsle K, Hlawatsch C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 253-256.

Grundlagen: Was ist ein "Palliativpatient"
Oechsle K, Scherg A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 18-23.

Grundlagen: Angehörige
Oechsle K, Ullrich A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 24-28.

Trauerbegleitung: Begleitung trauernder Angehöriger
Oechsle K, Ullrich A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 165-170.

Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care
Oechsle K, Ullrich A, Marx G, Benze G, Heine J, Dickel L, Zhang Y, Wowretzko F, Wendt K, Nauck F, Bokemeyer C, Bergelt C
BMC PALLIAT CARE. 2019;18(1):102.

Lokal-ablative Radiotherapie des oligometastasierten Prostatakarzinoms mit Überlebensvorteil
Oing C, Petersen C, Bokemeyer C
ONKOLOGE. 2019;25(9):827-828.

Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors-past, presentand future considerataions
Oing C, Skowron M, Bokemeyer C, Nettersheim D
ANDROLOGY-US. 2019;2019(4):487497.

Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations
Oing C, Skowron M, Bokemeyer C, Nettersheim D
ANDROLOGY-US. 2019;7(4):487-497.

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes H, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M
LANCET. 2019;394(10216):2271-2281.

Expression of miRN-371a-3p in seminal plasma and ejaculate is associated with sperm concentration
Radkte A, Diekmann K, Grobelny F, Salzbrunn A, Oing C, Schulze W, Belge G
ANDROLOGY-US. 2019;469-474.

Expression of miRNA-371a-3p in seminal plasma and ejaculate is associated with sperm concentration
Radtke A, Dieckmann K, Grobelny F, Salzbrunn A, Oing C, Schulze W, Belge G
ANDROLOGY-US. 2019;7(4):469-474.

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Rebello R, Oing C, Gillessen S, Bristow R
CLIN CANCER RES. 2019;25(6):1699-1701.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Retz M, Bedke J, Bögemann M, Grimm M, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend J
EUR J CANCER. 2019;107:37-45.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson P, Oriol A, Beksac M, Liberati A, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M
LANCET ONCOL. 2019;20(6):781-794.

Awareness of predatory journals and open access among medical oncologists: results of an online survey
Richtig G, Richtig E, Böhm A, Oing C, Bozorgmehr F, Kruger S, Kiesewetter B, Zielinski C, Berghoff A
ESMO OPEN. 2019;4(6):e000580.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M
J ONCOL. 2019;2019:8970645.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Rücker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst H, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk R, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K
BLOOD. 2019;134(19):1608-1618.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau I, Raab M, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann H, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H
BMC CANCER. 2019;19(1):504.

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2019;9(1):7406.

Ethische und rechtliche Aspekte: Sterbehilfe
Scherg A, Oechsle K
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 261-266.

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?
Schieferdecker A, Binder M, Weisel K, Bokemeyer C
DEUT MED WOCHENSCHR. 2019;144(14):982-989.

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze K, Horst H, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs H, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik V, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H
BLOOD. 2019;133(8):840-851.

T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model
Schliffke S, Carambia A, Akyüz N, Thiele B, Herkel J, Binder M
J NEUROIMMUNOL. 2019;332:49-56.

Positronenemissionstomographie bei Keimzelltumoren des Mannes: Einsatzmöglichkeiten und Grenzen
Schriefer P, Hartmann M, Oechsle K, Meyer C, Klutmann S, Fisch M, Bokemeyer C, Oing C
UROLOGE. 2019;58(4):418-423.

Symptomkontrolle: Obstipation, Passagestörung, Ileus
Schwartz J, Hlawatsch C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 82-87.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
Sebastian M, Schröder A, Scheel B, Hong H, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen K, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch S
CANCER IMMUNOL IMMUN. 2019;68(5):799-812.

The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3)
Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C
UROL ONCOL-SEMIN ORI. 2019;37(11):809.e19-809.e25.

T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors
Simnica D, Akyüz N, Schliffke S, Mohme M, V Wenserski L, Mährle T, Fanchi L, Lamszus K, Binder M
ONCOIMMUNOLOGY. 2019;8(11):e1644110.

High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias
Simnica D, Schliffke S, Schultheiß C, Bonzanni N, Fanchi L, Akyüz N, Gösch B, Casar C, Thiele B, Schlüter J, Lohse A, Binder M
FRONT IMMUNOL. 2019;10:1897.

Biologically Active Echinulin-Related Indolediketopiperazines from the Marine Sediment-Derived Fungus Aspergillus niveoglaucus
Smetanina O, Yurchenko A, Girich Ivanets E, Trinh P, Antonov A, Dyshlovoy S, von Amsberg G, Kim N, Chingizova E, Pislyagin E, Menchinskaya E, Yurchenko E, Van T, Afiyatullov S
MOLECULES. 2019;25(1):.

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Stamm H, Oliveira-Ferrer L, Grossjohann E, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J
ONCOIMMUNOLOGY. 2019;8(12):e1674605.

3D in vitro system for measuring treatment responses to immunotherapy in CRC patients
Sturmheit T, Stamm H, Sutus Temovski T, Konczalla L, Brauneck F, Stange I, Köllmann S, Li J, Perez D, thastrup J, Wellbrock J, Fiedler W, Kupper J, Block A
J CLIN ONCOL. 2019.

New Trisulfated Steroids from the Vietnamese Marine Sponge Halichondria vansoesti and Their PSA Expression and Glucose Uptake Inhibitory Activities
Tabakmakher K, Makarieva T, Denisenko V, Popov R, Dmitrenok P, Dyshlovoy S, Grebnev B, Bokemeyer C, von Amsberg G, Cuong N
MAR DRUGS. 2019;17(8):.

Endothelium-Derived Semaphorin 3G Regulates Hippocampal Synaptic Structure and Plasticity via Neuropilin-2/PlexinA4
Tan C, Lu N, Wang C, Chen D, Sun N, Lyu H, Körbelin J, Shi W, Fukunaga K, Lu Y, Han F
NEURON. 2019;101(5):920-937.e13.

Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
Tintelnot J, Baum N, Schultheiss C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schütze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M
MOL CANCER THER. 2019;18(4):823-833.

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M
FRONT ONCOL. 2019;9:1559.

Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot J, Stein A
WORLD J GASTROENTERO. 2019;25(29):3920-3928.

Kommunikation: Kommunikation mit Angehörigen
Ullrich A
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 287-292.

Psychische Aspekte: Umgang mit traumatisierten Menschen
Ullrich A, Eisenecker C
2019. FAQ Palliativmedizin. Oechsle K, Scherg A (Hrsg.). 1. Aufl. München: Urban & Fischer, 205-210.

Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit - the perspectives of patients and healthcare professionals
Ullrich A, Grube K, Hlawatsch C, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2019;18(1):59.

The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
Velthaus A, Cornils K, Hennigs J, Grüb S, Stamm H, Wicklein D, Bokemeyer C, Heuser M, Windhorst S, Fiedler W, Wellbrock J
CANCERS. 2019;11(11):.

Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2019;39(1):67-75.

Antikoagulatorische Therapie bei onkologischen Patienten
Voigtländer M, Lennartz M, Yamamura J, Langer F
J Onkol - Z Onkol Fortb. 2019;2019(1):62-70.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse A, Cornelissen J, de Man R, Mallet V
J HEPATOL. 2019;71(3):465-472.

Ernährungsberatung in der Onkologie
von Grundherr J, Buchholz D, Hübner J, Erickson N
J Onkol - Z Onkol Fortb. 2019;2019(12):22-29.

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial
von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J
CANCER MANAG RES. 2019;11:4493—4504.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Wei A, Strickland S, Hou J, Fiedler W, Lin T, Walter R, Enjeti A, Tiong I, Savona M, Lee S, Chyla B, Popovic R, Salem A, Agarwal S, Xu T, Fakouhi K, Humerickhouse R, Hong W, Hayslip J, Roboz G
J CLIN ONCOL. 2019;37(15):1277-1284.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
Weisel K, Scheid C, Zago M, Besemer B, Mai E, Haenel M, Duerig J, Munder M, Lindemann H, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H
BLOOD CANCER J. 2019;9(4):45.

Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1
Yousef H, Czupalla C, Lee D, Chen M, Burke A, Zera K, Zandstra J, Berber E, Lehallier B, Mathur V, Nair R, Bonanno L, Yang A, Peterson T, Hadeiba H, Merkel T, Körbelin J, Schwaninger M, Buckwalter M, Quake S, Butcher E, Wyss-Coray T
NAT MED. 2019;25(6):988-1000.

Auroglaucin-related neuroprotective compounds from Vietnamese marine sediment-derived fungus Aspergillus niveoglaucus
Yurchenko A, Smetanina O, Ivanets E, Phan T, Ngo N, Zhuravleva O, Rasin A, Dyshlovoy S, Menchinskaya E, Pislyagin E, von Amsberg G, Afiyatullov S, Yurchenko E
NAT PROD RES. 2019 [Epub ahead of print];1-6.

Biologically Active Metabolites from the Marine Sediment-Derived Fungus Aspergillus flocculosus
Yurchenko A, Trinh P, Girich Ivanets E, Smetanina O, Rasin A, Popov R, Dyshlovoy S, von Amsberg G, Menchinskaya E, Thanh Van T, Afiyatullov S
MAR DRUGS. 2019;17(10):.

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs: Highlights des ASCO-Meetings 2019
Zech H, Laban S, Schafhausen P, Bussmann L, Betz C, Busch C
HNO. 2019;67(12):898-904.

Total Syntheses and Preliminary Biological Evaluation of Brominated Fascaplysin and Reticulatine Alkaloids and Their Analogues
Zhidkov M, Smirnova P, Tryapkin O, Kantemirov A, Khudyakova Y, Malyarenko O, Ermakova S, Grigorchuk V, Kaune M, Amsberg G, Dyshlovoy S
MAR DRUGS. 2019;17(9):.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J
ANN ONCOL. 2018;29(Suppl 4):iv96-iv110.

Prenylated indole alkaloids from co-culture of marine-derived fungi Aspergillus sulphureus and Isaria felina
Afiyatullov S, Zhuravleva O, Antonov A, Berdyshev D, Pivkin M, Denisenko V, Popov R, Gerasimenko A, von Amsberg G, Dyshlovoy S, Leshchenko E, Yurchenko A
J ANTIBIOT. 2018;71(10):846-853.

Effect of the actin- and calcium-regulating activities of ITPKB on the metastatic potential of lung cancer cells
Bäder S, Glaubke E, Grüb S, Muhs S, Wellbrock J, Nalaskowski M, Lange T, Windhorst S
BIOCHEM J. 2018;475(12):2057-2071.

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner J, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S
CANCER RES. 2018;78(12):3220-3232.

Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor
Becher P, Hinrichs S, Fluschnik N, Hennigs J, Klingel K, Blankenberg S, Westermann D, Lindner D
PLOS ONE. 2018;13(3):e0193844.

Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look
Behrmann L, Wellbrock J, Fiedler W
FRONT ONCOL. 2018;8:444.

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
Bera T, Abe Y, Ise T, Oberle A, Gallardo D, Liu X, Nagata S, Binder M, Pastan I
LEUKEMIA. 2018;32(2):569-572.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Berger L, Janning M, Velthaus J, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S
J THORAC ONCOL. 2018;13(12):e243-e246.

Palliativmedizin
Blatt-Bodewig M, Oechsle K
2018. Taschenbuch Onkologie. Honnecker F, Claßen J, Preiß J, Dornhoff W (Hrsg.). 19. Aufl. München: W. Zuckschwerdt Verlag, 272-278.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis
Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B
ONCOL RES TREAT. 2018;41 Suppl 3:2-26.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Topp M, Hitz F, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A
LANCET. 2018;390(10114):2790-2802.

Novel Gene Therapy Approaches for Whole Brain Delivery of the Lysosomal Gcase Enzyme for Wide Protection from Alpha-Synuclein Toxic Aggregates
Broccoli V, Ordozza G, Bido S, Valtorta M, Morabito G, Körbelin J, Cacellieri C, Giannelli S
MOL THER. 2018;26(5 Suppl.):131-131.

DNA methylation-based reclassification of olfactory neuroblastoma
Capper D, Engel N, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers A, Jones D, Sill M, Weigert O, Ligon K, Olar A, Koch A, Forster M, Moran S, Tirado O, Sáinz-Japeado M, Mora J, Esteller M, Alonso J, Del Muro X, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu C, Lund V, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U
ACTA NEUROPATHOL. 2018;136(2):255-271.

Correction to: DNA methylation-based reclassification of olfactory neuroblastoma
Capper D, Engel N, Stichel D, Lechner M, Glöss S, Schmid S, Kölsche C, Schrimpf D, Niesen J, Wefers A, Jones D, Sill M, Weigert O, Ligon K, Olar A, Koch A, Forster M, Moran S, Tirado O, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro X, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu C, Lund V, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U
ACTA NEUROPATHOL. 2018;136(3):505.

DNA methylation-based classification of central nervous system tumours
Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss D, Kratz A, Wefers A, Huang K, Pajtler K, Schweizer L, Stichel D, Olar A, Engel N, Lindenberg K, Harter P, Braczynski A, Plate K, Dohmen H, Garvalov B, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez F, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford J, Kohlhof P, Kristensen B, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo N, Driever P, Kramm C, Müller H, Rutkowski S, von Hoff K, Frühwald M, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu C, Perry A, Jones C, Jacques T, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins V, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott P, Paulus W, Gajjar A, Robinson G, Taylor M, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis M, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison D, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister S
NATURE. 2018;555(7697):469-474.

RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
Carmeliet P, Li X, Treps L, Conradi L, Loges S
ANN ONCOL. 2018;29(3):527-529.

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes H, Hentrich M, Fankhauser C, Gillessen S, Beyer J
J CLIN ONCOL. 2018;JCO1800210.

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells
Correa I, Ilieva K, Crescioli S, Lombardi S, Figini M, Cheung A, Spicer J, Tutt A, Nestle F, Karagiannis P, Lacy K, Karagiannis S
FRONT IMMUNOL. 2018;9:493.

Dosisdichte neoadjuvante Chemotherapie beim Harnblasenkarzinom. Potenzial für die Zukunft?
Coym A
ONKOLOGE. 2018;24(10):.

Palliativmedizin
Distler L, Oechsle K
2018. Tachnbuch Onkologie. Honnecker , Claßen , Preiß , Dornhoff (Hrsg.). 19. Aufl. W. Zuckschwerdt Verlag, .

Schmerztherapie
Distler L, Oechsle K
2018. Taschenbuch Onkologie. Honnecker F, Claßen J, Preiß J, Dornhoff W (Hrsg.). 19. Aufl. München: W. Zuckschwerdt Verlag, 264-268.

Marine Compounds and Autophagy: Beginning of a New Era
Dyshlovoy S, Honecker F
MAR DRUGS. 2018;16(8):260.

Marine Compounds and Cancer: 2017 Updates
Dyshlovoy S, Honecker F
MAR DRUGS. 2018;16(2):41.

Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer
Dyshlovoy S, Otte K, Tabakmakher K, Hauschild J, Makarieva T, Shubina L, Fedorov S, Bokemeyer C, Stonik V, von Amsberg G
ONCOTARGET. 2018;9(24):16962-16973.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges T, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P
CLIN CHEM. 2018;64(3):536-546.

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L
ESMO OPEN. 2018;3(2):e000303.

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S
ESMO OPEN. 2018;3(4):e000381.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
Gaidzik V, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst H, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk R, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K
LEUKEMIA. 2018;32(1):30-37.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
Gambacorti-Passerini C, Cortes J, Lipton J, Kantarjian H, Kim D, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf T, Khoury H
HAEMATOLOGICA. 2018;103(8):1298-1307.

Spätfolgen einer Krebsbehandlung im Kindes-und Jugendalter: Eine Herausforderung für die Transtionsmedizin
Gebauer J, Lehnert H, Schmid H, Spix C, Stein A, Langer T
INTERNIST. 2018;2018(11):1157-1162.

Comparing fiberoptic bronchoscopy and a tracheal tube-mounted camera-guided percutaneous dilatational tracheostomy: authors reply
Grensemann J, Eichler L, Kähler S, Jarczak D, Simon M, Pinnschmidt H, Kluge S
CRIT CARE. 2018;22(1):84.

Endotracheal tube-mounted camera-assisted intubation versus conventional intubation in intensive care: a prospective, randomised trial (VivalTN)
Grensemann J, Eichler L, Wang N, Jarczak D, Simon M, Kluge S
CRIT CARE. 2018;22(1):235.

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
Grochtdreis T, König H, Dobruschkin A, von Amsberg G, Dams J
PLOS ONE. 2018;13(12):e0208063.

Pancreatic iron and fat, early indicators of impaired glucose metabolism?
Grosse R, Berliner C, Hainmann I, Weyhmiller M, Fung E, Schönnagel B, Yamamura J, Nielsen P, Fischer R
2018. ABSTRACT BOOK. .

Measuring the Psychosocial Dimensions of Quality of Life in Patients With Advanced Cancer
Grünke B, Philipp R, Vehling S, Scheffold K, Härter M, Oechsle K, Schulz-Kindermann F, Mehnert A, Lo C
J PAIN SYMPTOM MANAG. 2018;55(3):985-991.e1.

Vorwort
Hallek M, Bokemeyer C, Lüftner D, Weissinger F
ONCOL RES TREAT. 2018;41 Suppl 3:1.

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
Hanssen A, Riebensahm C, Mohme M, Joosse S, Velthaus J, Berger L, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H
CANCERS. 2018;10(12):E527.

Accuracy of Magnetic Resonance Imaging for Grading of Subglottic Stenosis in Patients with Granulomatosis with Polyangiitis: Correlation with Pulmonary Function Tests and Laryngoscopy
Henes F, Laudien M, Linsenhoff L, Bremer J, Oqueka T, Adam G, Schön G, Bannas P
ARTHRIT CARE RES. 2018;70(5):777-784.

Schistosomiasis bei Flüchtlingen und Migranten
Hennigs A, Hennigs J, Schmiedel S
FLUGMEDIZIN TROPENME. 2018;25(01):19-22.

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2018;38(3):150-157.

ESMO Consensus Conference on testicular germ cell cancer: past, present, and future considerations: diagnosis, treatment and follow-up
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann K, Fizazi K, Fosså S, Germa-Lluch J, Giannatempo P, Gietema J, Gillessen S, Haugnes H, Heidenreich A, Hemminki K, Huddart R, Jewett M, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A
ANN ONCOL. 2018;29(8):1658-1686.

Keimzelltumore
Honecker F, Bokemeyer C, Krege S, Classen J
2018. Taschenbuch Onkologie. Honecker F, Claßen J, Preiß J, Dornhoff W (Hrsg.). 19. Aufl. München: W. Zuckschwerdt Verlag, 116-121.

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial
Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran S, de Wit M
J GERIATR ONCOL. 2018;9(2):163-169.

Asperindoles A⁻D and a -Terphenyl Derivative from the Ascidian-Derived Fungus sp. KMM 4676
Ivanets E, Yurchenko A, Smetanina O, Rasin A, Zhuravleva O, Pivkin M, Popov R, von Amsberg G, Afiyatullov S, Dyshlovoy S
MAR DRUGS. 2018;16(7):232.

Anti-Angiogenics: Their Value in Lung Cancer Therapy
Janning M, Loges S
ONCOL RES TREAT. 2018;41(4):172-180.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
Hautnah Dermatologie. 2018;34(1):38-46.

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
Kebenko M, Goebeler M, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman J, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W
ONCOIMMUNOLOGY. 2018;7(8):e1450710.

Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase
Klinke A, Berghausen E, Friedrichs K, Molz S, Lau D, Remane L, Berlin M, Kaltwasser C, Adam M, Mehrkens D, Mollenhauer M, Manchanda K, Ravekes T, Heresi G, Aytekin M, Dweik R, Hennigs J, Kubala L, Michaëlsson E, Rosenkranz S, Rudolph T, Hazen S, Klose H, Schermuly R, Rudolph V, Baldus S
JCI INSIGHT. 2018;3(11):.

Gastointestinale Stromatumoren (GIST)
Kopp H, Bokemeyer C, Hohenberger P
2018. Taschenbuch Onkologie. Honecker F, Claßen J, Preiß J, Dornhoff W (Hrsg.). 19. Aufl. München: W. Zuckschwerdt Verlag, 95-97.

Weichteilsarkome
Kopp H, Bokemeyer C, Hohenberger P, Müller A
2018. Taschenbuch Onkologie. Honecker F, Claßen J, Preiß J, Dornhoff W (Hrsg.). 19. Aufl. München: W. Zuckschwerdt Verlag, 220-229.

Assessing the transduction profile of the brain-endothelial directed gene vector AAV-BR1
Körbelin J, Kleint M, Dogbevia G, Ohnmacht J, Trepel M, Schwaninger M
N-S ARCH PHARMACOL. 2018;(391):.

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)
Krauter J, Fiedler W, Schlenk R, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik V, Becker H, Greil C, Reimer P, Götze K, Döhner H, Ganser A, Heuser M
BRIT J HAEMATOL. 2018;183(2):235-241.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer
Lange T, Oh-Hohenhorst S, Joosse S, Pantel K, Hahn O, Gosau T, Dyshlovoy S, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U
SCI REP-UK. 2018;8:17535.

Personalisierte Krebstherapie 2018 - Fiktion oder Wirklichkeit?
Loges S, Bokemeyer C
InFo Onkologie. 2018;21 (S1):3-5.

Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
Mansour W, Tennstedt P, Volquardsen J, Oing C, Kluth M, Hube-Magg C, Borgmann K, Simon R, Petersen C, Dikomey E, Rothkamm K
SCI REP-UK. 2018;8(1):3947.

Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Mohme M, Schliffke S, Maire C, Rünger A, Glau L, Mende K, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt N, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K
CLIN CANCER RES. 2018;24(17):4187-4200.

The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo
Mussawy H, Viezens L, Schröder M, Hettenhausen S, Sündermann J, Wellbrock J, Kossow K, Schäfer C
BMC CANCER. 2018;18(1):979.

Kommentar II zum Fall: "Ethisch vertretbare Anwendung freiheitsentziehender Maßnahmen zur Durchführung einer Chemotherapie?
Oechsle K
ETHIK MED. 2018;2018(30):371 -373.

Palliativmedizin
Oechsle K
INTERNIST. 2018;59(9):921-933.

Palliativmedizinische Begleitung
Oechsle K
2018. Tumorerkrankungen der Vulva und Vagina. Schnürch H, Hampl M, Wölber L (Hrsg.). 1. Aufl. Springer, 315-328.

Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer
Oing C, Bokemeyer C
CURR OPIN UROL. 2018;28(5):479-484.

Palliative treatment of germ cell cancer
Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J
CANCER TREAT REV. 2018;71:102-107.

The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors
Oing C, Lorch A
ONCOL RES TREAT. 2018;41(6):365-369.

Therapeutic approaches for refractory germ cell cancer
Oing C, Seidel C, Bokemeyer C
EXPERT REV ANTICANC. 2018;18(4):389-397.

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy
Oing C, Tennstedt P, Simon R, Volquardsen J, Borgmann K, Bokemeyer C, Petersen C, Dikomey E, Rothkamm K, Mansour W
CANCER LETT. 2018;423:60-70.

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells
Oing C, Verem I, Mansour W, Bokemeyer C, Dyshlovoy S, Honecker F
INT J MOL SCI. 2018;20(1):21.

Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018
Olschewski A, Berghausen E, Eichstaedt C, Fleischmann B, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs J, Jonigk D, Kuebler W, Kwapiszewska G, Pullamsetti S, Stacher E, Weissmann N, Wenzel D, Schermuly R
INT J CARDIOL. 2018;272S(S1):4-10.

SOP - Umgang mit multiresistenten Erregern auf der Palliativstation
Ostgathe C, Stachura P, Hofmann S, van Oorschot B, Oechsle K, Bogdan C, Kunz B, Förtsch B, Klein C
ONKOLOGE. 2018;2018(24 (S1)):75 - 81.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Paschka P, Schlenk R, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik V, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst H, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih H, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H
LEUKEMIA. 2018;32(7):1621-1630.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy
Quidde J, Alsdorf W, von Amsberg G, Wilczak W, Bokemeyer C
ONCOL RES TREAT. 2018;41(1-2):58-60.

Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients
Quidde J, Pan Y, Salm M, Hendi A, Nilsson S, Oechsle K, Stein A, Nestoriuc Y
BMC CANCER. 2018;18(1):916.

Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression
Sakhnevych S, Yasinska I, Bratt A, Benlaouer O, Gonçalves Silva I, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Gibbs B, Ushkaryov Y, Sumbayev V
CELL MOL IMMUNOL. 2018;15(11):994-997.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
Salem M, Yin J, Weinberg B, Renfro L, Pederson L, Maughan T, Adams R, Van Cutsem E, Falcone A, Tebbutt N, Seymour M, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent D, Marshall J
EUR J CANCER. 2018;103:205-213.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Samsen A, von der Heyde S, Bokemeyer C, David K, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz C, Stang A, Stein A, Zornig C, Juhl H
ONCOTARGET. 2018;9(78):34794-34809.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
ANAESTHESIST. 2018;67(8):599-606.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
INTERNIST. 2018;59(7):744-752.

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M
BLOOD. 2018;131(15):1755-1758.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
Schliffke S, Sivina M, Kim E, Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger J, Binder M
ONCOIMMUNOLOGY. 2018;7(4):e1417720.

CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach
Schmalenberg H, Al-Batran S, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze T
J CANCER RES CLIN. 2018;144(3):559-569.

Psychoonkologische Aspekte beim Vulva- und Vaginalkarzinom
Schmitz K, Bergelt C
2018. Tumorerkrankungen der Vulva und Vagina. Schnürch H, Hampl M, Wölber L (Hrsg.). Berlin: Springer, 307-314.

Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial
Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Müller V, Smeets R, Witzel I, Kriston L, Härter M
IMPLEMENT SCI. 2018;13(1):51.

Psychoonkologische Versorgung in Deutschland: Bundesweite Bestandsaufnahme und Analyse: Wissenschaftliches Gutachten im Auftrag des Bundesministeriums für Gesundheit
Schulz H, Bleich C, Dabs M, Frerichs W, Sautier L, Bokemeyer C, Koch-Gromus U, Härter M
2018.

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors
Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C
EUR J CANCER. 2018;94:16-25.

Endoscopic lung volume reduction coil treatment in patients with very low FEV: an observational study
Simon M, Harbaum L, Oqueka T, Kluge S, Klose H
THER ADV RESPIR DIS. 2018;12:1-10.

Right Ventricular Index for Risk Stratification of Patients with Pulmonary Arterial Hypertension
Sinning C, Harbaum L, Schrage B, Rübsamen N, Magnussen C, Waschki B, Kleemann W, Baaske K, Kögler M, Ojeda F, Fischer C, Benjamin N, Westermann D, Zengin E, Schäfer U, Egenlauf B, Klose H, Blankenberg S, Grünig E
RESPIRATION. 2018;96(3):249-258.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Sjoquist K, Renfro L, Simes R, Tebbutt N, Clarke S, Seymour M, Adams R, Maughan T, Saltz L, Goldberg R, Schmoll H, Van Cutsem E, Douillard J, Hoff P, Hecht J, Tournigand C, Punt C, Koopman M, Hurwitz H, Heinemann V, Zalcberg J
JNCI-J NATL CANCER I. 2018;110(6):638-648.

2(S)-Acetamido-3-Phenylpropylacetate from Marine Isolate of the Fungus Penicillium thomii KMM 4675
Sobolevskaya M, Dyshlovoy S, Trinh P, Ly B, Nhut N, Afiyatullov S
CHEM NAT COMPD+. 2018;54(1):170-172.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark T, Spicka I, Masszi T, Lauri B, Levin M, Bosi A, Hungria V, Cavo M, Lee J, Nooka A, Quach H, Lee C, Barreto W, Corradini P, Min C, Scott E, Chanan-Khan A, Horvath N, Capra M, Beksac M, Ovilla R, Jo J, Shin H, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser A, Schecter J, Mateos M
HAEMATOLOGICA. 2018;103(12):2079-2087.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W
ONCOGENE. 2018;37(39):5269-5280.

Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
Stamm H, Wellbrock J, Fiedler W
MAMM GENOME. 2018;29(11-12):694-702.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik V, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk R, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M
BLOOD. 2018;132(16):1703-1713.

Joint disease in haemophilia: Pathophysiology, pain and imaging
van Vulpen L, Holstein K, Martinoli C
HAEMOPHILIA. 2018;24(SI 6):44-49.

The daily dynamics of loss orientation and life engagement in advanced cancer: A pilot study to characterise patterns of adaptation at the end of life
Vehling S, Gerstorf D, Schulz-Kindermann F, Oechsle K, Philipp R, Scheffold K, Härter M, Mehnert A, Lo C
EUR J CANCER CARE. 2018;27(4):e12842.

Existential distress and meaning-focused interventions in cancer survivorship
Vehling S, Philipp R
CURR OPIN SUPPORT PA. 2018;12(1):46-51.

Die medikamentöse onkologische Therapie im Wandel - Aufbau von Strukturen zur Patientenversorgung
Velthaus J, Bokemeyer C, Loges S
InFo Onkologie. 2018;21(S1):10-18.

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke J, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S
EUR J CANCER. 2018;92:11-19.

Management of cancer-associated venous thromboembolism - a case-based practical approach
Voigtlaender M, Langer F
VASA. 2018;47(2):77-89.

Lapatinib
Voigtländer M, Schneider-Merck T, Trepel M
Recent Results Cancer Res. 2018;211:19-44.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S
HAEMATOLOGICA. 2018;103(6):939-948.

Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates
Yasinska I, Ceccone G, Ojea-Jimenez I, Ponti J, Hussain R, Siligardi G, Berger S, Fasler-Kan E, Bardelli M, Varani L, Fiedler W, Wellbrock J, Raap U, Gibbs B, Calzolai L, Sumbayev V
NANOSCALE. 2018;10(13):5827-5833.

High mobility group box 1 (HMGB1) acts as an "alarmin" to promote acute myeloid leukaemia progression
Yasinska I, Gonçalves Silva I, Sakhnevych S, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Bardelli M, Varani L, Raap U, Berger S, Gibbs B, Fasler-Kan E, Sumbayev V
ONCOIMMUNOLOGY. 2018;7(6):e1438109.

Zosteropenillines: Polyketides from the Marine-Derived Fungus Penicillium thomii
Afiyatullov S, Leshchenko E, Berdyshev D, Sobolevskaya M, Antonov A, Denisenko V, Popov R, Pivkin M, Udovenko A, Pislyagin E, von Amsberg G, Dyshlovoy S, Kerr R
MAR DRUGS. 2017;15(2):46.

MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma
Akyüz N, Albert-Konetzny N, Pott C, Callet-Bauchu E, Bokemeyer C, Murga Penas E, Dierlamm J
LEUKEMIA LYMPHOMA. 2017;58(10):2480-2484.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

Testis cancer: some problems still remain unsolved
Albers P, Bokemeyer C
WORLD J UROL. 2017;35(8):1159-1160.

The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML
Asemissen A, Dierlamm J
BLOOD. 2017;130(10):1274.

Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis
Bauersachs R, Gerlach H, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E
J VASC SURG. 2017;5(4):553-560.e1.

Myeloperoxidase Is a Negative Regulator of Phospholipid-Dependent Coagulation
Beckmann L, Dicke C, Spath B, Lehr C, Sievers B, Klinke A, Baldus S, Rudolph V, Langer F
THROMB HAEMOSTASIS. 2017;117(12):2300-2311.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus J, Rankin S, Clark R, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf T, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason G, Holyoake T, Loges S
CLIN CANCER RES. 2017;23(9):2289-2300.

Lymph node retrieval in colorectal cancer: determining factors and prognostic significance
Betge J, Harbaum L, Pollheimer M, Lindtner R, Kornprat P, Ebert M, Langner C
INT J COLORECTAL DIS. 2017;32(7):991-998.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study
Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K
SUPPORT CARE CANCER. 2017;25(6):1819-1828.

Kapitel 11 - Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2017. Handbuch ONKOLOGIE 2017. 1. Aufl. Wiesbaden: med publico GmbH, 1 - 38.

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel
Boormans J, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes M, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P
EUR UROL. 2017.

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia
Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K
ANN HEMATOL. 2017;96(6):895-904.

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P, Bumm T, Böttcher S, Bargou R, Binder M
BLOOD. 2017;129(1):100-104.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann W, Giagounidis A, Götze K, Lübbert M, Schlenk R, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf T, Haas R, Trümper L, Shirneshan K, Haase D
ANN HEMATOL. 2017;96(6):887-894.

Induction chemotherapy followed by radiochemotherapy for locally advanced head and neck cancer as an individual treatment approach-Feasibility, safety and retrospective survival analysis in twenty-three patients
Busch C, Girke J, Tribius S, Bussmann L, Knecht R, Schafhausen P, Lörincz B, Münscher A
CLIN OTOLARYNGOL. 2017;42(6):1392-1396.

Proximity-Triggered Covalent Stabilization of Low-Affinity Protein Complexes In Vitro and In Vivo
Cigler M, Müller T, Horn-Ghetko D, von Wrisberg M, Fottner M, Goody R, Itzen A, Lang K
ANGEW CHEM INT EDIT. 2017;56(49):15737-15741.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
Cortes J, Gambacorti-Passerini C, Kim D, Kantarjian H, Lipton J, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf T, Khoury H
CL LYMPH MYELOM LEUK. 2017;17(10):684-695.e6.

Corrigendum re: "Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours" [Eur Urol 2017;71:213-20]
Dieckmann K, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G
EUR UROL. 2017;71(5):e161.

Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours
Dieckmann K, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G
EUR UROL. 2017;71(2):213-220.

Gene Therapy Decreases Seizures in a Model of Incontinentia Pigmenti
Dogbevia G, Töllner K, Körbelin J, Bröer S, Ridder D, Grasshoff H, Brandt C, Wenzel J, Straub B, Trepel M, Löscher W, Schwaninger M
ANN NEUROL. 2017;82(1):93-104.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

Marine Compounds As Modulators of Autophagy and Lysosomal Activity
Dyshlovoy S, Honecker F
2017.

The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells
Dyshlovoy S, Madanchi R, Hauschild J, Otte K, Alsdorf W, Schumacher U, Kalinin V, Silchenko A, Avilov S, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
BMC CANCER. 2017;17(1):93.

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin
Dyshlovoy S, Otte K, Venz S, Hauschild J, Junker H, Makarieva T, Balabanov S, Alsdorf W, Madanchi R, Honecker F, Bokemeyer C, Stonik V, von Amsberg G
PROTEOMICS. 2017;17(11):.

Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells
Dyshlovoy S, Rast S, Hauschild J, Otte K, Alsdorf W, Madanchi R, Kalinin V, Silchenko A, Avilov S, Dierlamm J, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
LEUKEMIA LYMPHOMA. 2017;58(12):2905-2915.

Trachealverletzung nach dilatativer Tracheotomie: Eine erfolgreiche konservative Behandlung
Eichler L, Simon M, Kluge S
MED KLIN-INTENSIVMED. 2017;112(7):629-631.

Structure-activity relationship studies of new marine anticancer agents and their synthetic analogues
Fedorov S, Stonik V, Honecker F, Dyshlovoy S
CURR MED CHEM. 2017;24(42):4779-4799.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Ferreri A, Cwynarski K, Pulczynski E, Fox C, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton K, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause S, Schmoll H, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi L, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G
LANCET HAEMATOL. 2017;4(11):e510-e523.

The role of B cell antigen receptors in mantle cell lymphoma
Fichtner M, Dreyling M, Binder M, Trepel M
J HEMATOL ONCOL. 2017;10(1):164.

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf H, Krause S, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G
LEUKEMIA. 2017;31(4):846-852.

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao Y, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F
SCI REP-UK. 2017;7(1):14289.

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
Gonçalves Silva I, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, Berger S, Ushkaryov Y, Gibbs B, Fasler-Kan E, Sumbayev V
EBIOMEDICINE. 2017;22:44-57.

Feasibility of an endotracheal tube-mounted camera for percutaneous dilatational tracheostomy
Grensemann J, Eichler L, Hopf S, Jarczak D, Simon M, Kluge S
ACTA ANAESTH SCAND. 2017;61(6):660-667.

Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study
Haag G, Stocker G, Quidde J, Jaeger D, Lordick F
BMC CANCER. 2017;17(1):509.

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension
Harbaum L, Baaske K, Simon M, Oqueka T, Sinning C, Glatzel A, Lüneburg N, Sydow K, Bokemeyer C, Klose H
BMC PULM MED. 2017;17(1):72.

Monitoring und Individualisierung von körperlichem Training bei Patienten mit pulmonaler Hypertonie
Harbaum L, Grimminger J, Galow S, Grünig E, Klose H, Hennigs J
PNEUMOLOGE. 2017;14(4):237-243.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Heim D, Brümmendorf T, Fabarius A, Haferlach C, Schlegelberger B, Müller M, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler M, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne C, Lindemann H, Waller C, Pfreundschuh M, Spiekermann K, Berdel W, Müller L, Edinger M, Mayer J, Beelen D, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart M, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J
LEUKEMIA. 2017;31(11):2398-2406.

Strong fascin expression promotes metastasis independent of its F-actin bundling activity
Heinz L, Muhs S, Schiewek J, Grüb S, Nalaskowski M, Lin Y, Wikman H, Oliveira-Ferrer L, Lange T, Wellbrock J, Konietzny A, Mikhaylova M, Windhorst S
ONCOTARGET. 2017;8(66):110077-110091.

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields
Ilieva K, Fazekas-Singer J, Achkova D, Dodev T, Mele S, Crescioli S, Bax H, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs D, Beavil A, Maher J, Spicer J, Jensen-Jarolim E, Tutt A, Karagiannis S
FRONT IMMUNOL. 2017;8:1112.

The Diagnosis and Treatment of Hemoptysis
Ittrich H, Bockhorn M, Klose H, Simon M
DTSCH ARZTEBL INT. 2017;114(21):371-381.

Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care
Iversen K, Oechsle K, Oing C, Bokemeyer C, Seidel C
ONCOL RES TREAT. 2017;40(10):609-614.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG)
Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik V, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne C, Horst H, Lübbert M, Ganser A, Schlenk R, Döhner H, Döhner K, Paschka P
LEUKEMIA. 2017;31(4):1012-1015.

Zielgerichtete Therapie und Immuntherapie bei der AML
Janning M, Fiedler W
J Onkol - Z Onkol Fortb. 2017;5(05):184-191.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
InFo Onkologie. 2017;20(S1):54-64.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih H, Held G, Köhne C, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst H, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk R
BLOOD CANCER J. 2017;7(5):e564.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G
LEUKEMIA. 2017;31(12):2623-2629.

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study
Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause S, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely O, Vehreschild M
INT J ANTIMICROB AG. 2017;49(2):218-223.

Brain Endothelial-Targeted Gene Therapy in a Mouse Model of Incontinentia Pigmenti
Körbelin J, Dogbevia G, Töllner K, Bröer S, Ridder D, Grasshoff H, Brandt C, Straub B, Trepel M, Löscher W, Schwaninger M
MOL THER. 2017;25(5):256-257.

Optimization of design and production strategies for novel adeno-associated viral display peptide libraries
Körbelin J, Hunger A, Alawi M, Sieber T, Binder M, Trepel M
GENE THER. 2017;24(8):470-481.

Viral vector for the targeted transfer of genes in the brain and spinal cord
Körbelin J, Michelfelder S, Trepel M
2017.

How to successfully screen random AAV display peptide libraries in vivo
Körbelin J, Trepel M
HUM GENE THER METHOD. 2017;28(3):109-123.

Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development
Kubuschok B, Trepel M
EXPERT OPIN DRUG DIS. 2017;12(7):733-745.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Latuske E, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J
ONCOTARGET. 2017;8(17):29187-29201.

The Inhibitory Activity of Luzonicosides from the Starfish Echinaster luzonicus against Human Melanoma Cells
Malyarenko O, Dyshlovoy S, Kicha A, Ivanchina N, Malyarenko T, Carsten B, Gunhild v, Stonik V, Ermakova S
MAR DRUGS. 2017;15(7):.

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)
Miesbach W, Reitter-Pfoertner S, Klamroth R, Langer F, Wolf H, Tiede A, Siegmund B, Scholz U, Müller P, Eichler H, Pabinger I
HAEMOPHILIA. 2017;23(5):721-727.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih H, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs H, Horst H, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik V, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk R
ANN HEMATOL. 2017;96(12):1993-2003.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Oberle A, Brandt A, Voigtländer M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyüz N, März M, Ford C, Krohn-Grimberghe A, Binder M
HAEMATOLOGICA. 2017;102(6):1105-1111.

Self-assessment and Screening for palliative care need in patients with chronic heart failure
Oechsle K, Ehlert J, Kodolitsch Y, Ullrich A, Bokemeyer C, Rybczynski M
J PALLIAT CARE. 2017;2017(7):304.

Nachsorge, Fertilität, Langzeittoxizität und Survivorship bei Keimzelltumoren
Oechsle K, Krege S, Honecker F
ONKOLOGE. 2017;23(2):129-135.

Platinum-refractory germ cell tumors: an update on current treatment options and developments
Oing C, Alsdorf W, von Amsberg G, Oechsle K, Bokemeyer C
WORLD J UROL. 2017;35(8):1167-1175.

Immuncheckpointinhibition beim Urothelkarzinom: Pembrolizumab als neuer Therapiestandard in der Zweitlinientherapie?
Oing C, Bokemeyer C
ONKOLOGE. 2017;23:678-680.

„Neue Substanzen in der Therapie des metastasierten Nierenzellkarzinoms – was, wann und für wen?“: Neuer Tyrosinkinaseinhibitor für die Zweitlinie
Oing C, Bokemeyer C
InFo Onkologie. 2017;03:12-14.

Neues zum Einsatz von Tumormarkern bei Hodentumoren: Inadäquater Markerabfall und miR-371a-3p
Oing C, Bokemeyer C
LEADING OPINIONS Hämatologie & Onkologie. 2017;13(7):14-15.

Monoubiquitination of histone H2B – a potential new target in treatment resistant germ cell tumors.
Oing C, Dyshlovoy S, Burandt E, Amsberg G, Honecker F, Bokemeyer C, Rothkamm K, Mansour W
ONCOL RES TREAT. 2017;40:95-96.

Impact of Primary Metastatic Bone Disease in Germ Cell Tumors: Results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Faré E, Bokemeyer C
ANN ONCOL. 2017;28(3):576-582.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Systemische Behandlung des Harnblasenkarzinoms: Klassische Chemotherapie und neue Optionen
Oing C, von Amsberg G, Bokemeyer C
Im Fokus Onkologie. 2017;20(9):50-56.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu A, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C
BRIT J HAEMATOL. 2017;179(3):410-420.

Attachment Insecurity in Advanced Cancer Patients: Psychometric Properties of the German Version of the Brief Experiences in Close Relationships Scale (ECR-M16-G)
Philipp R, Vehling S, Scheffold K, Grünke B, Härter M, Mehnert A, Oechsle K, Schulz-Kindermann F, Lo C
J PAIN SYMPTOM MANAG. 2017;54(4):555-562.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: A study of the AML study group (AMLSG)
Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih H, Wattad M, Lübbert M, Brandts C, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani E, Fozza C, D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk R, Lo-Coco F
J CLIN ONCOL. 2017;35(6):605-612.

Eremophilane-type glucosides from the leaves of Ligularia calthifolia Maxim:Critical Assessment of Small Molecules Identification 2016
Ponomarenko L, Ermolaeva S, Doudkin R, Dyshlovoy S, Gorovoy P
PHYTOCHEM LETT. 2017;21:264-268.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Personalizing Maintenance Therapy in Metastatic Colorectal Cancer
Quidde J, Stein A
CURR COLORECT CANC R. 2017;13(3):205-211.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro L, Goldberg R, Grothey A, Sobrero A, Adams R, Seymour M, Heinemann V, Schmoll H, Douillard J, Hurwitz H, Fuchs C, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff P, Kabbinavar F, Falcone A, Tebbutt N, Punt C, Hecht J, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent D
J CLIN ONCOL. 2017;35(17):1929-1937.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
Rossi A, Voigtländer M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M
BLOOD CANCER J. 2017;7(2):e537.

Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients
Rössler O, Betge J, Harbaum L, Mrak K, Tschmelitsch J, Langner C
MODERN PATHOL. 2017;30(6):897-904.

Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking
Rothmeier A, Marchese P, Langer F, Kamikubo Y, Schaffner F, Cantor J, Ginsberg M, Ruggeri Z, Ruf W
ARTERIOSCL THROM VAS. 2017;37(7):1323-1331.

Novel biomarkers in cancer: The whole is greater than the sum of its parts
Samatov T, Galatenko V, Block A, Shkurnikov M, Tonevitsky A, Schumacher U
SEMIN CANCER BIOL. 2017;45:50-57.

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
Schiffmann L, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns C, Hallek M, Kashkar H, Hacker U, Coutelle O
BRIT J CANCER. 2017;116(5):600-608.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Schlenk R, Frech P, Weber D, Brossart P, Horst H, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih H, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik V, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H
LEUKEMIA. 2017;31(5):1217-1220.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Schlenk R, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau I, Verbeek W, Heidel F, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K
LEUKEMIA. 2017;31(4):889-895.

Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
Schrader J, Henes F, Perez D, Burdak-Rothkamm S, Stein A, Izbicki J, Lohse A
ANN ONCOL. 2017;28(4):904-905.

Monanchoxymycalin C with anticancer properties, new analogue of crambescidin 800 from the marine sponge Monanchora pulchra
Shubina L, Makarieva T, von Amsberg G, Denisenko V, Popov R, Dyshlovoy S
NAT PROD RES. 2017;1-8.

High-Flow-Sauerstofftherapie in der Intensivmedizin
Simon M, Grensemann J, Kluge S
Intensivmed up2date. 2017;13(3):259-267.

Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study
Simon M, Harbaum L, Oqueka T, Kluge S, Klose H
THER ADV RESPIR DIS. 2017;11(1):9-19.

Unique prostate cancer-toxic polyketides from marine sediment-derived fungus Isaria felina
Smetanina O, Yurchenko A, Ivanets E, Kalinovsky A, Khudyakova Y, Dyshlovoy S, von Amsberg G, Yurchenko E, Afiyatullov S
J ANTIBIOT. 2017;70(7):856-858.

A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy
Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
INT J CANCER. 2017;140(2):381-389.

RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis
Speidel D, Wellbrock J, Abas M
CANCER RES. 2017;77(24):6818-6824.

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development
Subramaniam S, Jurk K, Hobohm L, Jäckel S, Saffarzadeh M, Schwierczek K, Wenzel P, Langer F, Reinhardt C, Ruf W
BLOOD. 2017;129(16):2291-2302.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M
GENE THER. 2017;24(11):749-753.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
Thoennissen G, Görlich D, Bacher U, Aufenberg T, Hüsken A, Hansmeier A, Evers G, Mikesch J, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters R, Krug U, Kropff M, Thoennissen N, Berdel W
ACTA HAEMATOL-BASEL. 2017;137(3):163-172.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik V, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M
LEUKEMIA. 2017;31(6):1286-1295.

The effects of music therapy in patients with high-dose chemotherapy and stem cell support: a randomized pilot study
Tuinmann G, Preissler P, Böhmer H, Suling A, Bokemeyer C
PSYCHO-ONCOLOGY. 2017;26(3):377-384.

Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients
Ullrich A, Ascherfeld L, Marx G, Bokemeyer C, Bergelt C, Oechsle K
BMC PALLIAT CARE. 2017;16(1):31.

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2017;37(4):241-255.

Tumorassoziierte venöse Thromboembolien
Voigtländer M, Langer F
Vasomed. 2017;29(3):127-134.

Neue Aspekte in der Therapie des metastasierten Prostatakarzinoms
von Amsberg G, Bokemeyer C
DEUT MED WOCHENSCHR. 2017;142(15):1106-1110.

Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia
Wellbrock J, Fiedler W
TRANSL CANCER RES. 2017;6(Suppl 2):286-291.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Metabolites of the Marine Fungus Aspergillus candidus KMM 4676 Associated with a Kuril Colonial Ascidian
Yurchenko A, Ivanets E, Smetanina O, Pivkin M, Dyshlovoi S, von Amsberg G, Afiyatullov S
CHEM NAT COMPD+. 2017;53(4):747-749.

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
Aapro M, Bokemeyer C, Ludwig H, Gascón P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I
J GERIATR ONCOL. 2016;8(2):86-95.

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
Aapro M, Ludwig H, Bokemeyer C, Gascón P, Boccadoro M, Denhaerynck K, Krendyukov A, Gorray M, MacDonald K, Abraham I
ANN ONCOL. 2016;27(11):2039-2045.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Al-Ali H, Griesshammer M, le Coutre P, Waller C, Liberati A, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco J, Ghosh J, Martino B, Vannucchi A
HAEMATOLOGICA. 2016;101(9):1065-73.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran S, Hofheinz R, Pauligk C, Kopp H, Haag G, Luley K, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens U, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer D, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein W, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze T, Sievert M, Jäger E, Mönig S, Tannapfel A
LANCET ONCOL. 2016;17(12):1697-1708.

EAU Guidelines on Testicular Cancer - 2016 edition
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
2016.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J ONCOL PHARM PRACT. 2016;22(3):523-7.

Genetic manipulation of brain endothelial cells in vivo
Assmann J, Körbelin J, Schwaninger M
BBA-MOL BASIS DIS. 2016;1862(3):381-94.

Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT
Bacher U, Binder M
J TRANSL MED. 2016;4(Suppl 1):S19.

Molekulargenetische Diagnostik - Was wissen die Maschinen?: Was wollen wir wissen?
Bauer P, Hummel M, von Kalle C, Schmutzler R, Block A, Stroth M, Woopen C, Engelke K
ONCOL RES TREAT. 2016;39 (Suppl 2):2-23.

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
Betge J, Schneider N, Harbaum L, Pollheimer M, Lindtner R, Kornprat P, Ebert M, Langner C
VIRCHOWS ARCH. 2016;469(3):255-65.

Triggered activity in atrial myocytes is influenced by Na+/Ca2+ exchanger activity in genetically altered mice
Bögeholz N, Pauls P, Kaese S, Schulte J, Lemoine M, Dechering D, Frommeyer G, Goldhaber J, Seidl M, Kirchhefer U, Eckardt L, Müller F, Pott C
J MOL CELL CARDIOL. 2016;101:106-115.

Lieferengpässe von Onkologika: Die gesicherte Versorgung ist ethische Verpflichtung
Bokemeyer C
Perspektiven der Onkologie. 2016;(2):28-29.

Sekundärneoplasien nach Primärtherapie als besondere Belastung von Krebspatienten
Bokemeyer C
2016. Handbuch Psychoonkologie. Mehnert A, Koch U (Hrsg.). 1. Aufl. Hogrefe, 77-86.

Vorwort
Bokemeyer C, Hallek M, Lüftner D, Weißinger F
ONCOL RES TREAT. 2016;39 Suppl 2(Suppl 2):1.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig F, Voigtländer M, Schieferdecker A, Busch C, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M
ONCOTARGET. 2016;7(28):42988-42995.

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Brümmendorf T, Cortes J, Khoury H, Kantarjian H, Kim D, Schafhausen P, Conlan M, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton J
BRIT J HAEMATOL. 2016;172(1):97-110.

Cyclin D1 gene amplification is highly homogeneous in breast cancer
Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W
BREAST CANCER-TOKYO. 2016;23(1):111-9.

Male Extragonadal Germ Cell Tumors of the Adult
Busch J, Seidel C, Zengerling F
ONCOL RES TREAT. 2016;39(3):140-4.

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer
Bussmann L, Busch C, Lörincz B, Rieckmann T, Block A, Knecht R
EUR ARCH OTO-RHINO-L. 2016;273(12):4073-4080.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48]
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;146:135.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;141:39-48.

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
Cortes J, Jean Khoury H, Kantarjian H, Brümmendorf T, Mauro M, Matczak E, Pavlov D, Aguiar J, Fly K, Dimitrov S, Leip E, Shapiro M, Lipton J, Durand J, Gambacorti-Passerini C
AM J HEMATOL. 2016;91(6):606-16.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Cortes J, Khoury H, Kantarjian H, Lipton J, Kim D, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf T, Gambacorti-Passerini C
AM J HEMATOL. 2016;91(12):1206-1214.

Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study
Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J
BMC PALLIAT CARE. 2016;15(1):25.

Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Degwert N, Latuske E, Vohwinkel G, Stamm H, Klokow M, Bokemeyer C, Fiedler W, Wellbrock J
EUR J HAEMATOL. 2016;97(3):239-44.

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias
Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F
ANN HEMATOL. 2016;95(6):945-57.

Topical Collection "Marine Compounds and Cancer": Topical Collection of Marine drugs journal "Marine Compounds and Cancer"
Dyshlovoy S, Honecker F
2016.

The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer
Dyshlovoy S, Menchinskaya E, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin V, Silchenko A, Avilov S, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin D, Fedorov S, Shubina L, Stonik V, Balabanov S, Honecker F, von Amsberg G
INT J CANCER. 2016;138(10):2450-65.

Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer
Dyshlovoy S, Otte K, Alsdorf W, Hauschild J, Lange T, Venz S, Bauer C, Bähring R, Amann K, Mandanchi R, Schumacher U, Schröder-Schwarz J, Makarieva T, Guzii A, Tabakmakher K, Fedorov S, Shubina L, Kasheverov I, Ehmke H, Steuber T, Stonik V, Bokemeyer C, Honecker F, von Amsberg G
ONCOTARGET. 2016;7(43):69703 - 69717.

Guanidine Alkaloids from the Marine Sponge Monanchora pulchra Show Cytotoxic Properties and Prevent EGF-Induced Neoplastic Transformation in Vitro
Dyshlovoy S, Tabakmakher K, Hauschild J, Shchekaleva R, Otte K, Guzii A, Makarieva T, Kudryashova E, Fedorov S, Shubina L, Bokemeyer C, Honecker F, Stonik V, von Amsberg G
MAR DRUGS. 2016;14(7):E133.

Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation
Dyshlovoy S, Venz S, Hauschild J, Tabakmakher K, Otte K, Madanchi R, Walther R, Guzii A, Makarieva T, Shubina L, Fedorov S, Stonik V, Bokemeyer C, Balabanov S, Honecker F, von Amsberg G
PROTEOMICS. 2016;16(10):1590-603.

Canonical Wnt Signaling Drives Tumor-Like Lesions from Sox2-Positive Precursors of the Murine Olfactory Epithelium
Engel N, Neumann J, Ahlfeld J, Wefers A, Merk D, Ohli J, Schüller U
PLOS ONE. 2016;11(11):e0166690.

A Comprehensive Multistate Model Analyzing Associations of Various Risk Factors With the Course of Breast Cancer in a Population-Based Cohort of Breast Cancer Cases
Eulenburg C, Schroeder J, Obi N, Heinz J, Seibold P, Rudolph A, Chang-Claude J, Flesch-Janys D
AM J EPIDEMIOL. 2016;183(4):325-334.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group
Feldman D, Lorch A, Kramar A, Albany C, Einhorn L, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart R, Bokemeyer C, Tryakin A, Sava T, Winquist E, De Giorgi U, Aparicio J, Sweeney C, Cohn Cedermark G, Beyer J, Powles T
J CLIN ONCOL. 2016;34(4):345-51.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Ferreri A, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L, Torri V, Fox C, Rosée P, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton K, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv J, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause S, Levis A, Schmoll H, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G
LANCET HAEMATOL. 2016;3(5):e217-27.

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M
HAEMATOLOGICA. 2016;101(9):e378-81.

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas
Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C
EUR J CANCER. 2016;63:55-63.

Akute Myeloische Leukämie.
Fiedler W, Janning M
Aktuelle Gesundheitsnachrichten . 2016.

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2016;24(2):911-25.

Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Gerwing M, Jacobsen C, Dyshlovoy S, Hauschild J, Rohlfing T, Oing C, Venz S, Oldenburg J, Oechsle K, Bokemeyer C, von Amsberg G, Honecker F
J CANCER RES CLIN. 2016;142(9):1979-94.

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group
Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M
LEUKEMIA LYMPHOMA. 2016;57(4):789-796.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®
Gorges T, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse S, Pantel K
PLOS ONE. 2016;11(5):e0155126.

COPD-associated pulmonary Hypertension: clinical implications and current methods for treatment
Grimminger J, Ghofrani H, Weissmann N, Klose H, Grimminger F
EXPERT REV RESP MED. 2016;10(7):755-66.

Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions
Gröbe A, Rybak L, Schön G, Smeets R, Tribius S, Schafhausen P, Clauditz T, Hanken H, Heiland M
J CANCER RES CLIN. 2016;142(2):505-20.

Melonoside A: An ω-Glycosylated Fatty Acid Amide from the Far Eastern Marine Sponge Melonanchora kobjakovae
Guzii A, Makarieva T, Denisenko V, Dmitrenok P, Kuzmich A, Dyshlovoy S, von Amsberg G, Krasokhin V, Stonik V
ORG LETT. 2016;18(14):3478-81.

Characterization of different CTC subpopulations in non-small cell lung cancer
Hanssen A, Wagner J, Gorges T, Tänzer A, Uzunoglu F, Driemel C, Stoecklein N, Knoefel W, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2016;6:28010.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
Harbaum L, Renk E, Yousef S, Glatzel A, Lüneburg N, Hennigs J, Oqueka T, Baumann H, Atanackovic D, Grünig E, Böger R, Bokemeyer C, Klose H
BMC PULM MED. 2016;16(1):145.

CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma
Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M
AIDS. 2016;30(5):753-60.

Lieferengpässe in der Onkologie: Frühzeitige und verpflichtende Meldung gefordert
Hofmann-Aßmus M, Bokemeyer C
Onkologie heute. 2016;15(8):46-47.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Hollestelle A, van der Baan F, Berchuck A, Johnatty S, Aben K, Agnarsson B, Aittomäki K, Alducci E, Andrulis I, Anton-Culver H, Antonenkova N, Antoniou A, Apicella C, Arndt V, Arnold N, Arun B, Arver B, Ashworth A, Baglietto L, Balleine R, Bandera E, Barrowdale D, Bean Y, Beckmann L, Beckmann M, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova N, Bojesen A, Bojesen S, Bolla M, Bonanni B, Brand J, Brauch H, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker C, Burwinkel B, Butzow R, Buys S, Caligo M, Campbell I, Carter J, Chang-Claude J, Chanock S, Claes K, Collée J, Cook L, Couch F, Cox A, Cramer D, Cross S, Cunningham J, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks E, Diez O, Doherty J, Domchek S, Dorfling C, Dörk T, Silva I, du Bois A, Dumont M, Dunning A, Duran M, Easton D, Eccles D, Edwards R, Ehrencrona H, Ejlertsen B, Ekici A, Ellis S, Engel C, Eriksson M, Fasching P, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley B, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther S, Gentry-Maharaj A, Gerdes A, Giles G, Glasspool R, Glendon G, Godwin A, Goodman M, Gore M, Greene M, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman S, Haeberle L, Haiman C, Hall P, Halverson S, Hamann U, Hansen T, Harter P, Hartikainen J, Healey S, Hein A, Heitz F, Henderson B, Herzog J, T Hildebrandt M, Høgdall C, Høgdall E, Hogervorst F, Hopper J, Humphreys K, Huzarski T, Imyanitov E, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen U, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan B, Kataja V, Kauff N, Kelemen L, Kerin M, Kiemeney L, Kjaer S, Knight J, Knol-Bout J, Konstantopoulou I, Kosma V, Krakstad C, Kristensen V, Kuchenbaecker K, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson M, Lasa A, Laurent-Puig P, Lazaro C, Le N, Le Marchand L, Leminen A, Lester J, Levine D, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu K, Lubinski J, Lundvall L, Lurie G, Mai P, Mannermaa A, Margolin S, Mariette F, Marme F, Martens J, Massuger L, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menéndez P, Menkiszak J, Menon U, Mensenkamp A, Miller N, Milne R, Modugno F, Montagna M, Moysich K, Müller H, Mulligan A, Muranen T, Narod S, Nathanson K, Ness R, Neuhausen S, Nevanlinna H, Neven P, Nielsen F, Nielsen S, Nordestgaard B, Nussbaum R, Odunsi K, Offit K, Olah E, Olopade O, Olson J, Olson S, Oosterwijk J, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce C, Pedersen I, Peissel B, Pejovic T, Pelttari L, Perkins J, Permuth-Wey J, Peterlongo P, Peto J, Phelan C, Phillips K, Piedmonte M, Pike M, Platte R, Plisiecka-Halasa J, Poole E, Poppe B, Pylkäs K, Radice P, Ramus S, Rebbeck T, Reed M, Rennert G, Risch H, Robson M, Rodriguez G, Romero A, Rossing M, Rothstein J, Rudolph A, Runnebaum I, Salani R, Salvesen H, Sawyer E, Schildkraut J, Schmidt M, Schmutzler R, Schneeweiss A, Schoemaker M, Schrauder M, Schumacher F, Schwaab I, Scuvera G, Sellers T, Severi G, Seynaeve C, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer C, Sinilnikova O, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey M, Stegmaier C, Stoppa-Lyonnet D, Sucheston L, Swerdlow A, Tangen I, Tea M, Teixeira M, Terry K, Terry M, Thomassen M, Thompson P, Tihomirova L, Tischkowitz M, Toland A, Tollenaar R, Tomlinson I, Torres D, Truong T, Tsimiklis H, Tung N, Tworoger S, Tyrer J, Vachon C, Van 't Veer L, van Altena A, Van Asperen C, van den Berg D, van den Ouweland A, van Doorn H, Van Nieuwenhuysen E, van Rensburg E, Vergote I, Verhoef S, Vierkant R, Vijai J, Vitonis A, von Wachenfeldt A, Walsh C, Wang Q, Wang-Gohrke S, Wappenschmidt B, Weischer M, Weitzel J, Weltens C, Wentzensen N, Whittemore A, Wilkens L, Winqvist R, Wu A, Wu X, Yang H, Zaffaroni D, Pilar Zamora M, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah P, Rookus M, Hooning M, Goode E
GYNECOL ONCOL. 2016;141(2):386-401.

Current view and outcome of ITI therapy - A change over time?
Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J
THROMB RES. 2016;148:38-44.

The impact of social factors on outcomes in patients with bleeding disorders
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(1):46-53.

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Hütter-Krönke M, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne C, Horst H, Schmidt-Wolf I, Rummel M, Götze K, Koller E, Petzer A, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff A, Ganser A, Döhner H, Schlenk R
HAEMATOLOGICA. 2016;101(7):839-45.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf H, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J
LANCET HAEMATOL. 2016;3(8):e388-97.

Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P, Koenig J, Trummer A, Busch J, Seidel C, Reuter C, Ganser A, Grünwald V
WORLD J UROL. 2016;34(7):909-15.

Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature
Janjetovic S, Bernd H, Bokemeyer C, Fiedler W
MOL CLIN ONCOL. 2016;4(3):390-392.

The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus
Kilic E, Tennstedt P, Högner A, Lebok P, Sauter G, Bokemeyer C, Izbicki J, Wilczak W
VIRCHOWS ARCH. 2016;468(4):483-92.

Aktuelle Evidenz bei pulmonal arterieller Hypertonie: Diagnose- und Therapieleitfaden
Klose H, Hennigs J, Harbaum L, Simon M, Oqueka T, Sydow K
2016. Aktuelle Evidenz bei pulmonal arterieller Hypertonie . Klose H (Hrsg.). 3. Aufl. 1-68.

A pull-down procedure for the identification of unknown GEFs for small GTPases
Koch D, Rai A, Ali I, Bleimling N, Friese T, Brockmeyer A, Janning P, Goud B, Itzen A, Goody R
Small GTPases. 2016;7(2):93-106.

A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases
Körbelin J, Dogbevia G, Michelfelder S, Ridder D, Hunger A, Wenzel J, Seismann H, Lampe M, Bannach J, Pasparakis M, Kleinschmidt J, Schwaninger M, Trepel M
EMBO MOL MED. 2016;8(6):609-25.

Vascular-targeted recombinant adeno-associated viral vectors for the treatment of rare diseases
Körbelin J, Schwaninger M, Trepel M
Rare Diseases. 2016;4(1):.

Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries
Körbelin J, Sieber T, Michelfelder S, Lunding L, Spies E, Hunger A, Alawi M, Rapti K, Indenbirken D, Müller O, Pasqualini R, Arap W, Kleinschmidt J, Trepel M
MOL THER. 2016;24(6):1050-61.

Prospective Study on Music Therapy in Terminally Ill Cancer Patients during Specialized Inpatient Palliative Care
Kordovan S, Preissler P, Kamphausen A, Bokemeyer C, Oechsle K
J PALLIAT MED. 2016;19(4):394-9.

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K
ONCOTARGET. 2016;7(29):45122-45133.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus S, Li Q, Delgado M, Lee J, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Arun B, Arver B, Bandera E, Barile M, Barkardottir R, Barrowdale D, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen S, Bolla M, Bonanni B, Børresen-Dale A, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari S, Burwinkel B, Butzow R, Buys S, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi J, Claes K, Cook L, Cox A, Cramer D, Cross S, Cybulski C, Czene K, Daly M, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty J, Domchek S, Dorfling C, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S, Engel C, Lee E, Evans D, Fasching P, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes W, Fridley B, Friedman E, Frost D, Gambino G, Ganz P, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles G, Glasspool R, Godwin A, Goldberg M, Goldgar D, González-Neira A, Goode E, Goodman M, Greene M, Gronwald J, Guénel P, Haiman C, Hall P, Hallberg E, Hamann U, Hansen T, Harrington P, Hartman M, Hassan N, Healey S, Heitz F, Herzog J, Høgdall E, Høgdall C, Hogervorst F, Hollestelle A, Hopper J, Hulick P, Huzarski T, Imyanitov E, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John E, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan B, Khan S, Kiemeney L, Kjaer S, Knight J, Konstantopoulou I, Kosma V, Kristensen V, Kupryjanczyk J, Kwong A, de La Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine D, Li J, Lindblom A, Long J, Lophatananon A, Loud J, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger L, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp A, Milne R, Montagna M, Moysich K, Muir K, Mulligan A, Nathanson K, Ness R, Neuhausen S, Nevanlinna H, Nord S, Nussbaum R, Odunsi K, Offit K, Olah E, Olopade O, Olson J, Olswold C, O'Malley D, Orlow I, Orr N, Osorio A, Park S, Pearce C, Pejovic T, Peterlongo P, Pfeiler G, Phelan C, Poole E, Pylkäs K, Radice P, Rantala J, Rashid M, Rennert G, Rhenius V, Rhiem K, Risch H, Rodriguez G, Rossing M, Rudolph A, Salvesen H, Sangrajrang S, Sawyer E, Schildkraut J, Schmidt M, Schmutzler R, Sellers T, Seynaeve C, Shah M, Shen C, Shu X, Sieh W, Singer C, Sinilnikova O, Slager S, Song H, Soucy P, Southey M, Stenmark-Askmalm M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira M, Teo S, Terry K, Terry M, Thomassen M, Tibiletti M, Tihomirova L, Tognazzo S, Toland A, Tomlinson I, Torres D, Truong T, Tseng C, Tung N, Tworoger S, Vachon C, Ouweland A, van Doorn H, van Rensburg E, Van't Veer L, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel J, Wentzensen N, Whittemore A, Wildiers H, Winqvist R, Wu A, Yannoukakos D, Yoon S, Yu J, Zheng W, Zheng Y, Khanna K, Simard J, Monteiro A, French J, Couch F, Freedman M, Easton D, Dunning A, Pharoah P, Edwards S, Chenevix-Trench G, Antoniou A, Gayther S
NAT COMMUN. 2016;7:12675.

Keimzelltumoren des Mannes
Lorch A, Albers P, Beyer J, Cathomas R, Oing C, Souchon R, Stöger H, Bokemeyer C
2016.

Long-Term Chronic Intermittent Hypobaric Hypoxia in Rats Causes an Imbalance in the Asymmetric Dimethylarginine/Nitric Oxide Pathway and ROS Activity: A Possible Synergistic Mechanism for Altitude Pulmonary Hypertension?
Lüneburg N, Siques P, Brito J, Arriaza K, Pena E, Klose H, Leon-Velarde F, Böger R
Pulmonary medicine. 2016;2016:6578578.

Tumour budding with and without admixed inflammation: two different sides of the same coin?
Max N, Harbaum L, Pollheimer M, Lindtner R, Kornprat P, Langner C
BRIT J CANCER. 2016;114(4):368-71.

High Ki67 expression is an independent good prognostic marker in colorectal cancer
Melling N, Kowitz C, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
J CLIN PATHOL. 2016;69(3):209-14.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Miranda M, Lauseker M, Kraus M, Proetel U, Hanfstein B, Fabarius A, Baerlocher G, Heim D, Hossfeld D, Kolb H, Krause S, Nerl C, Brümmendorf T, Verbeek W, Fauser A, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann W, Müller M, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S
LEUKEMIA. 2016;30(6):1255-62.

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
Mossner M, Jann J, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk R, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann W, Germing U, Nolte F
LEUKEMIA. 2016;30(9):1956-9.

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger L, Oechsle K, Schumacher K, Kanfer E, Bourhis J, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F
BONE MARROW TRANSPL. 2016;51(3):384-90.

The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies
Nickel K, Labberton L, Long A, Langer F, Fuchs T, Stavrou E, Butler L, Renné T
THROMB RES. 2016;141 Suppl 2:S4-7.

Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort
Obi N, Heinz J, Seibold P, Vrieling A, Rudolph A, Chang-Claude J, Berger J, Flesch-Janys D
INT J CANCER. 2016;138(9):2098-2108.

Palliativmedizinische Versorgung onkologischer Patienten
Oechsle K
2016. Handbuch Psychoonkologie. Mehnert A, Koch U (Hrsg.). 1. Aufl. Hogrefe Verlag GmbH and Co. KG, 94-102.

Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial
Oing C, Bokemeyer C, Lorch A
ONCOL RES TREAT. 2016;39(9):553-556.

Investigational targeted therapies for the treatment of testicular germ cell tumors
Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C
EXPERT OPIN INV DRUG. 2016;25(9):1033-43.

PARP-Inhibition - eine neue Therapieoption bei Prostatakarzinomen mit DNA-Reparaturdefizienz
Oing C, Mansour W, Bokemeyer C
InFo Onkologie. 2016;(02):2-3.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature
Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C
J UROLOGY. 2016;195(2):254-63.

Pharmacotherapeutic treatment of germ cell tumors - standard of care and recent developments
Oing C, Seidel C, von Amsberg G, Oechsle K, Bokemeyer C
EXPERT OPIN PHARMACO. 2016;17(4):545-60.

Pathobiologie, Pathologie und Genetik der pulmonalen Hypertonie: Empfehlungen der Kölner Konsensus-Konferenz 2016
Olschewski A, Berghausen E, Eichstaedt C, Fleischmann B, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs J, Jonigk D, Kübler W, Kwapiszewska G, Pullamsetti S, Stacher E, Weissmann N, Wenzel D, Schermuly R
DEUT MED WOCHENSCHR. 2016;141(S 01):S4-S9.

Detrimental social interactions predict loss of dignity among patients with cancer
Philipp R, Mehnert A, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Vehling S
SUPPORT CARE CANCER. 2016;24(6):2751-8.

Combined modified en bloc corpectomy with replacement of the aorta in curative interdisciplinary treatment of a large osteosarcoma infiltrating the aorta
Pilger A, Tsilimparis N, Bockhorn M, Trepel M, Dreimann M
EUR SPINE J. 2016;25 (Suppl 1):58-62.

Musiktherapie auf der Palliativstation: Ergebnisse einer Studie über ein musiktherapeutisches Angebot
Preißler P, Kordovan S, Bokemeyer C, Oechsle K
Musiktherapeutische Umschau. 2016;37(3):233-249.

Favored subjects and psychosocial needs in music therapy in terminally ill cancer patients: a content analysis
Preissler P, Kordovan S, Ullrich A, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2016;15:48.

Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature
Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A
THER ADV MED ONCOL. 2016;8(3):144-52.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller C, Killing B, Depenbusch R, Steffens C, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll H, Hinke A, Al-Batran S, Arnold D
ANN ONCOL. 2016;27(12):2203-2210.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

bMERB domains are bivalent Rab8 family effectors evolved by gene duplication
Rai A, Oprisko A, Campos J, Fu Y, Friese T, Itzen A, Goody R, Gazdag E
ELIFE. 2016;5:.

Testicular germ cell tumours
Rajpert-De Meyts E, McGlynn K, Okamoto K, Jewett M, Bokemeyer C
LANCET. 2016;387(10029):1762-74.

Tumor Protein (TP)-p53 members as regulators of autophagy in tumor cells upon marine drug exposure
Ratovitski E, Honecker F, Dyshlovoy S
MAR DRUGS. 2016;14(8):.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Renfro L, Loupakis F, Adams R, Seymour M, Heinemann V, Schmoll H, Douillard J, Hurwitz H, Fuchs C, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt N, Punt C, Hecht J, Bokemeyer C, Van Cutsem E, Goldberg R, Saltz L, de Gramont A, Sargent D, Lenz H
J CLIN ONCOL. 2016;34(2):144-150.

Inclusion of cytological features in tumor grading improves prognostic stratification of patients with colorectal cancer
Resch A, Harbaum L, Pollheimer M, Kornprat P, Lindtner R, Langner C
INT J COLORECTAL DIS. 2016;31(3):535-41.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
Schlenk R, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih H, Kündgen A, Horst H, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne C, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik V, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H
ANN HEMATOL. 2016;95(12):1931-1942.

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia
Schliffke S, Akyüz N, Ford C, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M
LEUKEMIA. 2016;30(11):2232-2234.

Peak Filling Rates Assessed by CMR Imaging Indicate Diastolic Dysfunction From Myocardial Iron Toxicity
Schoennagel B, Fischer R, Grosse R, Berliner C, Wehbe M, Kurio G, Lund G, Wang Z, Graessner J, Adam G, Yamamura J
JACC-CARDIOVASC IMAG. 2016;9(11):1353-1354.

Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? - A prospective observational study
Schroeder M, Simon M, Katchanov J, Wijaya C, Rohde H, Christner M, Laqmani A, Wichmann D, Fuhrmann V, Kluge S
CRIT CARE. 2016;20(1):139.

Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone
Schroeder M, Viezens L, Wellbrock J, Fiedler W, Ruether W, Algenstaedt P, Hansen-Algenstaedt N, Schäfer C
J SURG ONCOL. 2016;113(5):515-21.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk R, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U
LEUKEMIA. 2016;30(7):1580-2.

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-Registry data from an outcomes research project of the German Testicular Cancer Study Group
Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C
UROL ONCOL-SEMIN ORI. 2016;34(4):167.e21-8.

Absolute Configuration and Body Part Distribution of the Alkaloid 6-epi-Monanchorin from the Marine Polychaete Chaetopterus variopedatus
Shubina L, Makarieva T, Denisenko V, Dmitrenok P, Dyshlovoy S, von Amsberg G, Glazunov V, Silchenko A, Stonik V
NAT PROD COMMUN. 2016;11(9):1253-1257.

Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib
Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U
LEUKEMIA LYMPHOMA. 2016;1-5.

Wertigkeit der thorakalen Computertomografie in der Behandlung von Patienten mit ARDS
Simon M, Braune S, Quitzke A, Metschke M, Berliner C, Kalsow M, Klose H, Kluge S
PNEUMOLOGIE. 2016;70(S 01):P90.

Bleeding Complications After Endoscopic Lung Volume Reduction Coil Treatment: A Retrospective Observational Study
Simon M, Ittrich H, Harbaum L, Oqueka T, Kluge S, Klose H
ARCH BRONCONEUMOL. 2016;52(12):590-595.

Pallidopenillines: Polyketides from the Alga-Derived Fungus Penicillium thomii Maire KMM 4675
Sobolevskaya M, Leshchenko E, Hoai T, Denisenko V, Dyshlovoy S, Kirichuk N, Khudyakova Y, Kim N, Berdyshev D, Pislyagin E, Kuzmich A, Gerasimenko A, Popov R, von Amsberg G, Antonov A, Afiyatullov S
J NAT PROD. 2016;79(12):3031-3038.

Efficient transformation of primary human mesenchymal stromal cells by adenovirus early region 1 oncogenes
Speiseder T, Hofmann-Sieber H, Rodríguez E, Schellenberg A, Akyüz N, Dierlamm J, Spruss T, Lange C, Dobner T
J VIROL. 2016;91(1):e01782-16.

Multimodale Therapie des lokalisierten Magenkarzinoms
Stein A, Arnold D, Al-Batran S
ONKOLOGE. 2016;22(6):392-399.

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Stein A, Quidde J, Schröder J, Göhler T, Tschechne B, Valdix A, Höffkes H, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D
BMC CANCER. 2016;16(1):82.

Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
Stein A, Schwenke C, Folprecht G, Arnold D
CLIN COLORECTAL CANC. 2016;15(2):e29-39.

Activity of nintedanib in germ cell tumors
Steinemann G, Jacobsen C, Gerwing M, Hauschild J, Amsberg G, Höpfner M, Nitzsche B, Honecker F
ANTI-CANCER DRUG. 2016;27(2):89-98.

Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis
Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, Malleo G, Maggino L, Stein A, Izbicki J, Bockhorn M
SURGERY. 2016;160(1):136-44.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG)
Theis F, Corbacioglu A, Gaidzik V, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne C, Germing U, Brossart P, Horst H, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih H, Krauter J, Schlenk R, Döhner K
LEUKEMIA. 2016;30(11):2248-2250.

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study
Tiede A, Hofbauer C, Werwitzke S, Knöbl P, Gottstein S, Scharf R, Heinz J, Groß H, Holstein K, Dobbelstein C, Scheiflinger F, Koch A, Reipert B
BLOOD. 2016;127(19):2289-97.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske A, Baehner M, Brewster M, Walz A, Michielin F, Runza V, Meresse V, Recher C
ONCOTARGET. 2016;7(22):32532-42.

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
Voigtländer M, Holstein K, Spath B, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(6):e537-e544.

Fortschritte in der Therapie urogenitaler Tumoren
von Amsberg G, Bokemeyer C
Im Fokus Onkologie. 2016;19(7-8):64.

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study
Werwitzke S, Geisen U, Nowak-Göttl U, Eichler H, Stephan B, Scholz U, Holstein K, Klamroth R, Knöbl P, Huth-Kühne A, Bomke B, Tiede A
J THROMB HAEMOST. 2016;14(5):940-7.

Pretrichodermamides D-F from a Marine Algicolous Fungus Penicillium sp. KMM 4672
Yurchenko A, Smetanina O, Ivanets E, Kalinovsky A, Khudyakova Y, Kirichuk N, Popov R, Bokemeyer C, von Amsberg G, Chingizova E, Afiyatullov S, Dyshlovoy S
MAR DRUGS. 2016;14(7):E122.

Right heart failure in pregnant women with cyanotic congenital heart disease - The good, the bad and the ugly
Zengin E, Sinning C, Schrage B, Mueller G, Klose H, Sachweh J, Goepfert M, Hueneke B, Blankenberg S, Kozlik-Feldmann R
INT J CARDIOL. 2016;202:773-775.

Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature
Zielinski V, Laban S, Tribius S, Schafhausen P, Veldhoen S, Knecht R, Clauditz T, Muenscher A
ENT-EAR NOSE THROAT. 2016;95(1):23-8.

eau Guidelines on Testicular Cancer
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
2015. eau Guidelines on Testicular Cancer. 1-48.

Guidelines on Testicular Cancer: 2015 Update
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
EUR UROL. 2015;68(6):1054-68.

Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo
Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso J, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe D
LEUKEMIA. 2015;29(12):2307-16.

Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
Bakr A, Oing C, Köcher S, Borgmann K, Dornreiter I, Petersen C, Dikomey E, Mansour Khalfallah W
NUCLEIC ACIDS RES. 2015;43(6):3154-66.

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Bannas P, Lenz A, Kunick V, Fumey W, Rissiek B, Schmid J, Haag F, Leingärtner A, Trepel M, Adam G, Koch-Nolte F
JOVE-J VIS EXP. 2015;(98):52462.

Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection
Bannas P, Lenz A, Kunick V, Well L, Fumey W, Rissiek B, Haag F, Schmid J, Schütze K, Eichhoff A, Trepel M, Adam G, Ittrich H, Koch-Nolte F
CONTRAST MEDIA MOL I. 2015;10(5):367-378.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer C, Köhne C, Ciardiello F, Lenz H, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken J, Tejpar S
EUR J CANCER. 2015;51(10):1243-52.

Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2015. OnkoUpdate 2015. 1. Aufl. med publico GmbH, 1-55.

Metastatic Germ Cell Cancer: The Intermediate-Prognosis Risk Category
Bokemeyer C, Seidel C
2015. Diagnosis and Management of Testicular Cancer. Krege S (Hrsg.). 1. Aufl. Springer, 55-64.

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C
GASTRIC CANCER. 2015;18(4):833-842.

A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Borthakur G, Dombret H, Schafhausen P, Brummendorf T, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes J
HAEMATOLOGICA. 2015.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours
Bremmer F, Schallenberg S, Jarry H, Küffer S, Kaulfuss S, Burfeind P, Strauß A, Thelen P, Radzun H, Ströbel P, Honecker F, Behnes C
ONCOTARGET. 2015;6(32):33426-37.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial
Brümmendorf T, Cortes J, de Souza C, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis A, Gambacorti-Passerini C
BRIT J HAEMATOL. 2015;168(1):69-81.

The current role of systemic chemotherapy in the primary treatment of head and neck cancer
Busch C, Tribius S, Schafhausen P, Knecht R
CANCER TREAT REV. 2015;41(3):217-21.

TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination
Cantelli G, Orgaz J, Rodriguez-Hernandez I, Karagiannis P, Maiques O, Matias-Guiu X, Nestle F, Marti R, Karagiannis S, Sanz-Moreno V
CURR BIOL. 2015;25(22):2899-914.

PD-1 Blockade zeigt therapeutische Aktivität: Neuer Therapieansatz beim rezidiveren Hodgkin-Lymphom
Coym A, Dierlamm J, Bokemeyer C
InFo Onkologie. 2015;(6):34-36.

The Rare Occurrence of the Translocation t(8;14) in Chronic Lymphatic Leukemia: Case Report and Review of the Literature
Coym A, Janjetovic S, Bokemeyer C, Fiedler W
Ann Hematol Oncol. 2015;2(5):1039.

Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Day F, Ruth K, Thompson D, Lunetta K, Pervjakova N, Chasman D, Stolk L, Finucane H, Sulem P, Bulik-Sullivan B, Esko T, Johnson A, Elks C, Franceschini N, He C, Altmaier E, Brody J, Franke L, Huffman J, Keller M, McArdle P, Nutile T, Porcu E, Robino A, Rose L, Schick U, Smith J, Teumer A, Traglia M, Vuckovic D, Yao J, Zhao W, Albrecht E, Amin N, Corre T, Hottenga J, Mangino M, Smith A, Tanaka T, Abecasis G, Andrulis I, Anton-Culver H, Antoniou A, Arndt V, Arnold A, Barbieri C, Beckmann M, Beeghly-Fadiel A, Benitez J, Bernstein L, Bielinski S, Blomqvist C, Boerwinkle E, Bogdanova N, Bojesen S, Bolla M, Borresen-Dale A, Boutin T, Brauch H, Brenner H, Brüning T, Burwinkel B, Campbell A, Campbell H, Chanock S, Chapman J, Chen Y, Chenevix-Trench G, Couch F, Coviello A, Cox A, Czene K, Darabi H, De Vivo I, Demerath E, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning A, Eicher J, Fasching P, Faul J, Figueroa J, Flesch-Janys D, Gandin I, Garcia M, García-Closas M, Giles G, Girotto G, Goldberg M, González-Neira A, Goodarzi M, Grove M, Gudbjartsson D, Guénel P, Guo X, Haiman C, Hall P, Hamann U, Henderson B, Hocking L, Hofman A, Homuth G, Hooning M, Hopper J, Hu F, Huang J, Humphreys K, Hunter D, Jakubowska A, Jones S, Kabisch M, Karasik D, Knight J, Kolcic I, Kooperberg C, Kosma V, Kriebel J, Kristensen V, Lambrechts D, Langenberg C, Li J, Li X, Lindström S, Liu Y, Luan J, Lubinski J, Mägi R, Mannermaa A, Manz J, Margolin S, Marten J, Martin N, Masciullo C, Meindl A, Michailidou K, Mihailov E, Milani L, Milne R, Müller-Nurasyid M, Nalls M, Neale B, Nevanlinna H, Neven P, Newman A, Nordestgaard B, Olson J, Padmanabhan S, Peterlongo P, Peters U, Petersmann A, Peto J, Pharoah P, Pirastu N, Pirie A, Pistis G, Polasek O, Porteous D, Psaty B, Pylkäs K, Radice P, Raffel L, Rivadeneira F, Rudan I, Rudolph A, Ruggiero D, Sala C, Sanna S, Sawyer E, Schlessinger D, Schmidt M, Schmidt F, Schmutzler R, Schoemaker M, Scott R, Seynaeve C, Simard J, Sorice R, Southey M, Stöckl D, Strauch K, Swerdlow A, Taylor K, Thorsteinsdottir U, Toland A, Tomlinson I, Truong T, Tryggvadottir L, Turner S, Vozzi D, Wang Q, Wellons M, Willemsen G, Wilson J, Winqvist R, Wolffenbuttel B, Wright A, Yannoukakos D, Zemunik T, Zheng W, Zygmunt M, Bergmann S, Boomsma D, Buring J, Ferrucci L, Montgomery G, Gudnason V, Spector T, van Duijn C, Alizadeh B, Ciullo M, Crisponi L, Easton D, Gasparini P, Gieger C, Harris T, Hayward C, Kardia S, Kraft P, McKnight B, Metspalu A, Morrison A, Reiner A, Ridker P, Rotter J, Toniolo D, Uitterlinden A, Ulivi S, Völzke H, Wareham N, Weir D, Yerges-Armstrong L, Price A, Stefansson K, Visser J, Ong K, Chang-Claude J, Murabito J, Perry J, Murray A
NAT GENET. 2015;47(11):1294-303.

S2k-Leitlinie Qualitätsanforderungen in der gastrointestinalen Endoskopie, AWMF Register Nr. 021-022. Erstauflage 2015
Denzer U, Beilenhoff U, Eickhoff A, Faiss S, Hüttl P, In der Smitten S, Jakobs R, Jenssen C, Keuchel M, Langer F, Lerch M, Lynen Jansen P, May A, Menningen R, Moog G, Rösch T, Rosien U, Vowinkel T, Wehrmann T, Weickert U
Z GASTROENTEROL. 2015;53(12):E1-227.

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study
Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, Francis J, Bokemeyer C, Langer F
EXP HEMATOL ONCOL. 2015;4:22.

Atypical venous thromboses in myeloproliferative neoplasias
Dicke C, Frölich A, Holstein K, Bokemeyer C, Langer F
PHLEBOLOGIE. 2015;44(6):324–329.

Pathophysiology of Trousseau's syndrome
Dicke C, Langer F
HAMOSTASEOLOGIE. 2015;35(1):52-9.

Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization
Dyshlovoy S, Hauschild J, Amann K, Tabakmakher K, Venz S, Walther R, Guzii A, Makarieva T, Shubina L, Fedorov S, Stonik V, Bokemeyer C, Balabanov S, Honecker F, Amsberg G
ONCOTARGET. 2015;6(19):17328-41.

Marine Compounds and Cancer
Dyshlovoy S, Honecker F
2015.

Marine Compounds and Cancer: Where Do We Stand?
Dyshlovoy S, Honecker F
MAR DRUGS. 2015;13(9):5657-65.

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth H, Opitz C, Ulrich S, Egenlauf B, Grünig E
EUR HEART J. 2015;37(1):35-44.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Élez E, Kocáková I, Höhler T, Martens U, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J
ANN ONCOL. 2015;26(1):132-140.

Targeting the Gremlin-VEGFR2 axis - a promising strategy for multiple diseases?
Erdmann R, Ozden C, Weidmann J, Schultze A
J PATHOL. 2015;236(4):403-6.

Die Mitteilung schlechter Nachrichten durch den Arzt: Die deutsche Version des MPP- (Measure of Patients' Preferences) Fragebogens zu den kommunikativen Präferenzen von Krebspatienten
Ernst J, Friedrich M, Lehmann C, Vehling S, Oechsle K, Koch-Gromus U, Mehnert A
GESUNDHEITSWESEN. 2015.

Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2
Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner V
EUR ARCH OTO-RHINO-L. 2015;272(12):3857-60.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R
BRIT J HAEMATOL. 2015.

The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies: author's reply
Flammiger A, Binder M
LEUKEMIA LYMPHOMA. 2015;56(12):3455.

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Frost A, Barst R, Hoeper M, Chang H, Frantz R, Fukumoto Y, Galié N, Hassoun P, Klose H, Matsubara H, Morrell N, Peacock A, Pfeifer M, Simonneau G, Tapson V, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser J, Quinn D, Ghofrani H
J HEART LUNG TRANSPL. 2015;34(11):1366-75.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè N, Barberà J, Frost A, Ghofrani H, Hoeper M, McLaughlin V, Peacock A, Simonneau G, Vachiery J, Grünig E, Oudiz R, Vonk-Noordegraaf A, White R, Blair C, Gillies H, Miller K, Harris J, Langley J, Rubin L
NEW ENGL J MED. 2015;373(9):834-44.

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
Gambacorti-Passerini C, Kantarjian H, Kim D, Khoury H, Turkina A, Brümmendorf T, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes J
AM J HEMATOL. 2015;90(9):755-68.

Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2015;24(2):927.

Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation
Ghiaur G, Wroblewski M, Loges S
SEMIN HEMATOL. 2015;52(3):200-6.

Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1
Glubb D, Maranian M, Michailidou K, Pooley K, Meyer K, Kar S, Carlebur S, O'Reilly M, Betts J, Hillman K, Kaufmann S, Beesley J, Canisius S, Hopper J, Southey M, Tsimiklis H, Apicella C, Schmidt M, Broeks A, Hogervorst F, van der Schoot C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching P, Ruebner M, Ekici A, Beckmann M, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Pharoah P, Bolla M, Wang Q, Dennis J, Sawyer E, Tomlinson I, Kerin M, Miller N, Burwinkel B, Marme F, Yang R, Surowy H, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, González-Neira A, Benitez J, Zamora M, Arias Perez J, Anton-Culver H, Neuhausen S, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Meindl A, Schmutzler R, Brauch H, Ko Y, Brüning T, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Tanaka H, Dörk T, Bogdanova N, Helbig S, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Wu A, Tseng C, Van Den Berg D, Stram D, Lambrechts D, Zhao H, Weltens C, van Limbergen E, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Radice P, Peterlongo P, Barile M, Capra F, Couch F, Olson J, Hallberg E, Vachon C, Giles G, Milne R, McLean C, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Goldberg M, Labrèche F, Dumont M, Teo S, Yip C, See M, Cornes B, Cheng C, Ikram M, Kristensen V, Zheng W, Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis I, Knight J, Glendon G, Tchatchou S, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, García-Closas M, Figueroa J, Chanock S, Lissowska J, Czene K, Klevebring D, Darabi H, Eriksson M, Hooning M, Hollestelle A, Martens J, Collée J, Hall P, Li J, Humphreys K, Shu X, Lu W, Gao Y, Cai H, Cox A, Cross S, Reed M, Blot W, Signorello L, Cai Q, Shah M, Ghoussaini M, Kang D, Choi J, Park S, Noh D, Hartman M, Miao H, Lim W, Tang A, Hamann U, Torres D, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Olswold C, Slager S, Toland A, Yannoukakos D, Shen C, Wu P, Yu J, Hou M, Swerdlow A, Ashworth A, Orr N, Jones M, Pita G, Alonso M, Álvarez N, Herrero D, Tessier D, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Healey C, Brown M, Ponder B, Chenevix-Trench G, Thompson D, Edwards S, Easton D, Dunning A, French J
AM J HUM GENET. 2015;96(1):5-20.

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller M, Hehlmann R, Hofmann W, Fabarius A, Seifarth W
PLOS ONE. 2015;10(6):e0129648.

High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer
Hanke T, Melling N, Simon R, Sauter G, Bokemeyer C, Lebok P, Terracciano L, Izbicki J, Marx A
AM J CLIN PATHOL. 2015;8(7):8227-35.

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
Hanssen A, Loges S, Pantel K, Wikman-Kocher H
FRONT ONCOL. 2015;5:Art. 207.

Medikamentöse Therapie der pulmonal arteriellen Hypertonie
Harbaum L, Olschewski H, Klose H
PNEUMOLOGE. 2015;12(5):390-400.

Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?
Harbaum L, Oqueka T, Glatzel A, Hennigs J, Lüneburg N, Klose H
CHEST. 2015;148(4):e131-2.

Peritumoral eosinophils predict recurrence in colorectal cancer
Harbaum L, Pollheimer M, Kornprat P, Lindtner R, Bokemeyer C, Langner C
MODERN PATHOL. 2015;28(3):403-13.

Age-related variation and predictors of long-term quality of life in germ cell tumor survivors
Hartung T, Mehnert A, Friedrich M, Hartmann M, Vehling S, Bokemeyer C, Oechsle K
UROL ONCOL-SEMIN ORI. 2015.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Hegewisch-Becker S, Graeven U, Lerchenmüller C, Killing B, Depenbusch R, Steffens C, Al-Batran S, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll H, Arnold D
LANCET ONCOL. 2015;16(13):1355-69.

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
Hoeper M, Behr J, Held M, Grunig E, Vizza C, Vonk-Noordegraaf A, Lange T, Claussen M, Grohé C, Klose H, Olsson K, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs J
PLOS ONE. 2015;10(12):Art. e0141911.

Radiologic Management of Haemoptysis: Diagnostic and Interventional Bronchial Arterial Embolisation
Ittrich H, Klose H, Adam G
ROFO-FORTSCHR RONTG. 2015;187(4):248-259.

Cisplatin resistance in germ cell tumours: models and mechanisms
Jacobsen C, Honecker F
ANDROLOGY-US. 2015;3(1):111-21.

Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy
Jacobsen C, Oechsle K, Hauschild J, Steinemann G, Spath B, Bokemeyer C, Ruf W, Honecker F, Langer F
THROMB RES. 2015;136(3):673-81.

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M, Ben-Batalla I, Loges S
EXPERT REV HEMATOL. 2015;8(2):135-8.

Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT
Karagiannis P, Guth N, Thoennissen G, Bern C, Sperveslage J, Oschlies I, Bokemeyer C, Klapper W, Wardelmann E, Thoennissen N
Clin Sarcoma Res. 2015;5:24.

Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma
Karagiannis P, Villanova F, Josephs D, Correa I, Van Hemelrijck M, Hobbs C, Saul L, Egbuniwe I, Tosi I, Ilieva K, Kent E, Calonje E, Harries M, Fentiman I, Taylor-Papadimitriou J, Burchell J, Spicer J, Lacy K, Nestle F, Karagiannis S
ONCOIMMUNOLOGY. 2015;4(11):e1032492.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts
Kebenko M, Drenckhan A, Gros S, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki J, Bokemeyer C, Wellbrock J, Fiedler W
CELL SIGNAL. 2015;27(2):373-81.

Kommentar zu: Neue Hoffnung beim fortgeschrittenen Plattenepithelkarzinom der Lunge
Klein F, Loges S
Im Fokus Onkologie. 2015;(10):30-31.

Therapie der pulmonal arteriellen Hypertonie
Klose H, Harbaum L, Oqueka T, Simon M, Grünig E
PNEUMOLOGIE. 2015;69(8):483-93; quiz 494-5.

MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH
Kolditz M, Seyfarth H, Wilkens H, Ewert R, Bollmann T, Dinter C, Hertel S, Klose H, Opitz C, Grünig E, Höffken G, Halank M
LUNG. 2015;193(6):901-10.

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS)
Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe D
BLOOD. 2015;125(5):820-30.

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma
Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic D
BRIT J HAEMATOL. 2015;171(5):752-62.

Hämostaseologische Aspekte in der Onkologie
Langer F
HAMOSTASEOLOGIE. 2015;35(2):152-64; quiz 165.

Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Lin W, Camp N, Ghoussaini M, Beesley J, Michailidou K, Hopper J, Apicella C, Southey M, Stone J, Schmidt M, Broeks A, Van't Veer L, Th Rutgers E, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching P, Haeberle L, Ekici A, Beckmann M, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla M, Wang Q, Dennis J, Sawyer E, Cheng T, Tomlinson I, Kerin M, Miller N, Marmé F, Surowy H, Burwinkel B, Guénel P, Truong T, Menegaux F, Mulot C, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Benitez J, Zamora M, Arias Perez J, Menéndez P, González-Neira A, Pita G, Alonso M, Alvarez N, Herrero D, Anton-Culver H, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler R, Müller-Myhsok B, Brauch H, Brüning T, Ko Y, Tessier D, Vincent D, Bacot F, Nevanlinna H, Aittomäki K, Blomqvist C, Khan S, Matsuo K, Ito H, Iwata H, Horio A, Bogdanova N, Antonenkova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Wu A, Tseng C, Van Den Berg D, Stram D, Neven P, Wauters E, Wildiers H, Lambrechts D, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Manoukian S, Bonanni B, Couch F, Wang X, Vachon C, Purrington K, Giles G, Milne R, Mclean C, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Goldberg M, Labrèche F, Dumont M, Teo S, Yip C, Hassan N, Vithana E, Kristensen V, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis I, Knight J, Glendon G, Tchatchou S, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, García-Closas M, Figueroa J, Lissowska J, Brinton L, Czene K, Darabi H, Eriksson M, Brand J, Hooning M, Hollestelle A, Van Den Ouweland A, Jager A, Li J, Liu J, Humphreys K, Shu X, Lu W, Gao Y, Cai H, Cross S, Reed M, Blot W, Signorello L, Cai Q, Pharoah P, Perkins B, Shah M, Blows F, Kang D, Yoo K, Noh D, Hartman M, Miao H, Chia K, Putti T, Hamann U, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey C, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, Mckay J, Slager S, Toland A, Yannoukakos D, Shen C, Hsiung C, Wu P, Ding S, Ashworth A, Jones M, Orr N, Swerdlow A, Tsimiklis H, Makalic E, Schmidt D, Bui Q, Chanock S, Hunter D, Hein R, Dahmen N, Beckmann L, Aaltonen K, Muranen T, Heikkinen T, Irwanto A, Rahman N, Turnbull C, Waisfisz Q, Meijers-Heijboer H, Adank M, Van Der Luijt R, Hall P, Chenevix-Trench G, Dunning A, Easton D, Cox A
HUM MOL GENET. 2015;24(1):285-98.

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety
Lissitchkov T, Hampton K, von Depka M, Hay C, Rangarajan S, Tuddenham E, Holstein K, Huth-Kühne A, Pabinger I, Knaub S, Bichler J, Oldenburg J
HAEMOPHILIA. 2015.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1):an open-label, randomised phase 3 trial
Machiels J, Haddad R, Fayette J, Licitra L, Tahara M, Vermorken J, Clement P, Gauler T, Cupissol D, Grau J, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo J, Cong X, Ehrnrooth E, Cohen E
LANCET ONCOL. 2015;16(5):583-94.

Systemic treatment of vulvar cancer
Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Müller V, Jänicke F, Woelber L
EXPERT REV ANTICANC. 2015;15(6):629-37.

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
Mahner S, Woelber L, Müller V, Witzel I, Prieske K, Grimm D, von Amsberg G, Trillsch F
FRONT ONCOL. 2015;5:211.

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink A, Eichhorst B, Kreuzer K, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner C, Bergmann M, Fischer K
EUR J HAEMATOL. 2015.

Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers
Melling N, Grimm N, Simon R, Stahl P, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
PATHOL ONCOL RES. 2015;22(1):95-102.

Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer
Melling N, Muth J, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
DIAGN PATHOL. 2015;10:125.

Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization
Melling N, Simon R, Izbicki J, Terracciano L, Bokemeyer C, Sauter G, Marx A
AM J CLIN PATHOL. 2015;8(6):7009-15.

Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer
Melling N, Simon R, Mirlacher M, Izbicki J, Stahl P, Terracciano L, Bokemeyer C, Sauter G, Marx A
HISTOPATHOLOGY. 2015;68(2):191-8.

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush M, Maranian M, Bolla M, Wang Q, Shah M, Perkins B, Czene K, Eriksson M, Darabi H, Brand J, Bojesen S, Nordestgaard B, Flyger H, Nielsen S, Rahman N, Turnbull C, Fletcher O, Peto J, Gibson L, dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Khan S, Aaltonen K, Ahsan H, Kibriya M, Whittemore A, John E, Malone K, Gammon M, Santella R, Ursin G, Makalic E, Schmidt D, Casey G, Hunter D, Gapstur S, Gaudet M, Diver W, Haiman C, Schumacher F, Henderson B, Le Marchand L, Berg C, Chanock S, Figueroa J, Hoover R, Lambrechts D, Neven P, Wildiers H, van Limbergen E, Schmidt M, Broeks A, Verhoef S, Cornelissen S, Couch F, Olson J, Hallberg E, Vachon C, Waisfisz Q, Meijers-Heijboer H, Adank M, van der Luijt R, Li J, Liu J, Humphreys K, Kang D, Choi J, Park S, Yoo K, Matsuo K, Ito H, Iwata H, Tajima K, Guénel P, Truong T, Mulot C, Sanchez M, Burwinkel B, Marme F, Surowy H, Sohn C, Wu A, Tseng C, Van Den Berg D, Stram D, González-Neira A, Benitez J, Zamora M, Perez J, Shu X, Lu W, Gao Y, Cai H, Cox A, Cross S, Reed M, Andrulis I, Knight J, Glendon G, Mulligan A, Sawyer E, Tomlinson I, Kerin M, Miller N, Lindblom A, Margolin S, Teo S, Yip C, Taib N, Tan G, Hooning M, Hollestelle A, Martens J, Collée J, Blot W, Signorello L, Cai Q, Hopper J, Southey M, Tsimiklis H, Apicella C, Shen C, Hsiung C, Wu P, Hou M, Kristensen V, Nord S, Alnaes G, Giles G, Milne R, McLean C, Canzian F, Trichopoulos D, Peeters P, Lund E, Sund M, Khaw K, Gunter M, Palli D, Mortensen L, Dossus L, Huerta J, Meindl A, Schmutzler R, Sutter C, Yang R, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Chia K, Chan C, Fasching P, Hein A, Beckmann M, Haeberle L, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Ashworth A, Orr N, Schoemaker M, Swerdlow A, Brinton L, Garcia-Closas M, Zheng W, Halverson S, Shrubsole M, Long J, Goldberg M, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T, Radice P, Peterlongo P, Manoukian S, Bernard L, Bogdanova N, Dörk T, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, Jakubowska A, Lubinski J, Jaworska K, Huzarski T, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland A, Ambrosone C, Yannoukakos D, Kabisch M, Torres D, Neuhausen S, Anton-Culver H, Luccarini C, Baynes C, Ahmed S, Healey C, Tessier D, Vincent D, Bacot F, Pita G, Alonso M, Álvarez N, Herrero D, Simard J, Pharoah P, Kraft P, Dunning A, Chenevix-Trench G, Hall P, Easton D
NAT GENET. 2015;47(4):373-80.

The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Nickel K, Ronquist G, Langer F, Labberton L, Fuchs T, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou E, Ronquist G, Renné T
BLOOD. 2015;126(11):1379-89.

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann C, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P
ONCOLOGY-BASEL. 2015;89(2):70-8.

Symptom burden in long-term germ cell tumor survivors
Oechsle K, Hartmann M, Mehnert A, Oing C, Bokemeyer C, Vehling S
SUPPORT CARE CANCER. 2015.

First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database
Oing C, Lorch A, Bokemeyer C, Honecker F, Beyer J, Berger L, Oechsle K
J CANCER RES CLIN. 2015;141(5):923-31.

Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2
Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper J, Southey M, Apicella C, Stone J, Schmidt M, Broeks A, Van't Veer L, Hogervorst F, Fasching P, Haeberle L, Ekici A, Beckmann M, Gibson L, Aitken Z, Warren H, Sawyer E, Tomlinson I, Kerin M, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina-Duverger E, Sanchez M, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Benitez J, Zamora M, Arias Perez J, Menéndez P, Anton-Culver H, Neuhausen S, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Hamann U, Brauch H, Justenhoven C, Brüning T, Ko Y, Nevanlinna H, Aittomäki K, Blomqvist C, Khan S, Bogdanova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Chenevix-Trench G, Beesley J, Lambrechts D, Moisse M, Floris G, Beuselinck B, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Peissel B, Pensotti V, Couch F, Olson J, Slettedahl S, Vachon C, Giles G, Milne R, McLean C, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Goldberg M, Labrèche F, Dumont M, Kristensen V, Alnæs G, Nord S, Borresen-Dale A, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight J, Glendon G, Tchatchou S, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, Garcia-Closas M, Figueroa J, Chanock S, Lissowska J, Czene K, Darabi H, Eriksson M, Klevebring D, Hooning M, Hollestelle A, van Deurzen C, Kriege M, Hall P, Li J, Liu J, Humphreys K, Cox A, Cross S, Reed M, Pharoah P, Dunning A, Shah M, Perkins B, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Ashworth A, Swerdlow A, Jones M, Schoemaker M, Meindl A, Schmutzler R, Olswold C, Slager S, Toland A, Yannoukakos D, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Matsuo K, Ito H, Iwata H, Ishiguro J, Wu A, Tseng C, Van Den Berg D, Stram D, Teo S, Yip C, Kang P, Ikram M, Shu X, Lu W, Gao Y, Cai H, Kang D, Choi J, Park S, Noh D, Hartman M, Miao H, Lim W, Lee S, Sangrajrang S, Gaborieau V, Brennan P, Mckay J, Wu P, Hou M, Yu J, Shen C, Blot W, Cai Q, Signorello L, Luccarini C, Bayes C, Ahmed S, Maranian M, Healey C, González-Neira A, Pita G, Alonso M, Álvarez N, Herrero D, Tessier D, Vincent D, Bacot F, Hunter D, Lindstrom S, Dennis J, Michailidou K, Bolla M, Easton D, dos Santos Silva I, Fletcher O, Peto J
HUM MOL GENET. 2015;24(10):2966-84.

Biological Relevance and Therapeutic Potential of the Hypusine Modification System
Pallmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel C, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S
J BIOL CHEM. 2015;290(30):18343-18360.

Grading lymph node metastasis: a feasible approach for prognostication of patients with stage III colorectal cancer
Resch A, Harbaum L, Pollheimer M, Kornprat P, Lindtner R, Langner C
J CLIN PATHOL. 2015;68(9):742-5.

Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors
Rudolph A, Milne R, Truong T, Knight J, Seibold P, Flesch-Janys D, Behrens S, Eilber U, Bolla M, Wang Q, Dennis J, Dunning A, Shah M, Munday H, Darabi H, Eriksson M, Brand J, Olson J, Vachon C, Hallberg E, Castelao J, Carracedo A, Torres M, Li J, Humphreys K, Cordina-Duverger E, Menegaux F, Flyger H, Nordestgaard B, Nielsen S, Yesilyurt B, Floris G, Leunen K, Engelhardt E, Broeks A, Rutgers E, Glendon G, Mulligan A, Cross S, Reed M, Gonzalez-Neira A, Arias Perez J, Provenzano E, Apicella C, Southey M, Spurdle A, Häberle L, Beckmann M, Ekici A, Dieffenbach A, Arndt V, Stegmaier C, McLean C, Baglietto L, Chanock S, Lissowska J, Sherman M, Brüning T, Hamann U, Ko Y, Orr N, Schoemaker M, Ashworth A, Kosma V, Kataja V, Hartikainen J, Mannermaa A, Swerdlow A, Giles G, Brenner H, Fasching P, Chenevix-Trench G, Hopper J, Benítez J, Cox A, Andrulis I, Lambrechts D, Gago-Dominguez M, Couch F, Czene K, Bojesen S, Easton D, Schmidt M, Guénel P, Hall P, Pharoah P, Garcia-Closas M, Chang-Claude J
INT J CANCER. 2015;136(6):E685-96.

Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients
Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch-Gromus U, Mehnert A
J CANCER SURVIV. 2015;9(4):567-575.

Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial
Scheffold K, Philipp R, Engelmann D, Schulz-Kindermann F, Rosenberger C, Oechsle K, Härter M, Wegscheider K, Lordick F, Lo C, Hales S, Rodin G, Mehnert A
BMC CANCER. 2015;15:592.

Thrombin generation in a patient with an acquired high-titre factor V inhibitor
Schmidt D, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F
BLOOD COAGUL FIBRIN. 2015;26(1):81-87.

Determinants of long-term fatigue in breast cancer survivors: results of a prospective patient cohort study
Schmidt M, Chang-Claude J, Seibold P, Vrieling A, Heinz J, Flesch-Janys D, Steindorf K
PSYCHO-ONCOLOGY. 2015;24(1):40-6.

Integration von palliativmedizinischer Betreuung – Ist früher besser?
Schmitz M, Bokemeyer C, Oechsle K
ONKOLOGE. 2015;21(1):848-851.

Needs, symptoms, and outcome of patients with advanced head and neck cancer treated on a palliative care inpatient ward
Schmitz M, Wolfram M, Bokemeyer C, Oechsle K
2015. Gemeinsame Jahrestagung, Basel, Oktober 2015: Abstracts. .

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll H, Seymour M, Adams R, Saltz L, Goldberg R, Punt C, Douillard J, Hoff P, Hecht J, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt N, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar F, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent D
J CLIN ONCOL. 2015;33(1):22-8.

Biomathematical description of synthetic peptide libraries
Sieber T, Hare E, Hofmann H, Trepel M
PLOS ONE. 2015;10(6):e0129200.

Management of advanced bladder cancer in the era of targeted therapies
Soave A, Engel O, von Amsberg G, Becker A, Dahlem R, Shariat S, Fisch M, Rink M
MINERVA UROL NEFROL. 2015;67(2):103-15.

Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins"
Spies E, Fichtner M, Müller F, Krasemann S, Illerhaus G, Glatzel M, Binder M, Trepel M
J IMMUNOL. 2015;195(10):4549-50.

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki J, Bokemeyer C, Simon R, Sauter G, Marx A
BMC GASTROENTEROL. 2015;15(1):7.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen L, Klümpen H, Lohse A, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H
BMC CANCER. 2015;15:Art. 564.

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens C, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C
BRIT J CANCER. 2015;113(6):872-7.

Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study
Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes H, Valdix A, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D
ACTA ONCOL. 2015;54(2):171-8.

Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma
Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B
LEUKEMIA LYMPHOMA. 2015;56(2):368-76.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
Tiede A, Klamroth R, Scharf R, Trappe R, Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt J, Werwitzke S, Budde E, Koch A, Knöbl P
BLOOD. 2015;125(7):1091-7.

Erratum for "Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors"
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-847.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-7.

Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers
Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf T, Murthy P, Balabanov S
J PROTEOMICS. 2015;119:218-29.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
Vansteenkiste J, Barlesi F, Waller C, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K
ANN ONCOL. 2015;26(8):1734-40.

The Preference to Discuss Expected Survival Is Associated with Loss of Meaning and Purpose in Terminally Ill Cancer Patients
Vehling S, Kamphausen A, Oechsle K, Hroch S, Bokemeyer C, Mehnert A
J PALLIAT MED. 2015;18(11):970-976.

Anxiety and depression in long-term testicular germ cell tumor survivors
Vehling S, Mehnert A, Hartmann M, Oing C, Bokemeyer C, Oechsle K
GEN HOSP PSYCHIAT. 2015.

Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
Voigtländer M, Conradi L, Hinsch A, Langer F
THORAC CARD SURG REP. 2015;4(1):40-43.

Clinical Evidence that Coagulation Activation Drives Cancer Progression - a Report of 2 Cases
Voigtländer M, Holstein K, Leuenroth S, Mudter J, Bokemeyer C, Langer F
ONCOL RES TREAT. 2015;38(9):449-52.

Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type
Voigtländer M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M
ANN HEMATOL. 2015;94(9):1559-65.

Viele innovative Substanzen: Kastrationsresistentes fortgeschrittenes Prostatakarzinom
von Amsberg G, Steuber T, Bokemeyer C
Deutsches Ärzteblatt. 2015;112(20):8-10.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension
Wellbrock J, Harbaum L, Stamm H, Hennigs J, Schulz B, Klose H, Bokemeyer C, Fiedler W, Lüneburg N
LUNG. 2015.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Locking GTPases covalently in their functional states
Wiegandt D, Vieweg S, Hofmann F, Koch D, Li F, Wu Y, Itzen A, Goody R
NAT COMMUN. 2015;6:7773.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D
J TRANSL MED. 2015;13:197.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
Yousef S, Kovacsovics-Bankowski M, Salama M, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D
HUM VACC IMMUNOTHER. 2015;11(7):1606-11.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D
BLOOD CANCER J. 2015;5:e285.

Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Zhang B, Shu X, Delahanty R, Zeng C, Michailidou K, Bolla M, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning A, Chang-Claude J, Shah M, Perkins B, Czene K, Darabi H, Eriksson M, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Lambrechts D, Neven P, Wildiers H, Floris G, Schmidt M, Rookus M, van den Hurk K, de Kort W, Couch F, Olson J, Hallberg E, Vachon C, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Li J, Humphreys K, Brand J, Guénel P, Truong T, Cordina-Duverger E, Menegaux F, Burwinkel B, Marme F, Yang R, Surowy H, Benitez J, Zamora M, Perez J, Cox A, Cross S, Reed M, Andrulis I, Knight J, Glendon G, Tchatchou S, Sawyer E, Tomlinson I, Kerin M, Miller N, Chenevix-Trench G, Haiman C, Henderson B, Schumacher F, Marchand L, Lindblom A, Margolin S, Hooning M, Martens J, Tilanus-Linthorst M, Collée J, Hopper J, Southey M, Tsimiklis H, Apicella C, Slager S, Toland A, Ambrosone C, Yannoukakos D, Giles G, Milne R, McLean C, Fasching P, Haeberle L, Ekici A, Beckmann M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Garcia-Closas M, Brinton L, Lissowska J, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko Y, Peterlongo P, Manoukian S, Bonanni B, Radice P, Bogdanova N, Antonenkova N, Dörk T, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Devilee P, Seynaeve C, Van Asperen C, Jakubowska A, Lubiński J, Jaworska-Bieniek K, Durda K, Hamann U, Torres D, Schmutzler R, Neuhausen S, Anton-Culver H, Kristensen V, Grenaker Alnæs G, Pierce B, Kraft P, Peters U, Lindstrom S, Seminara D, Burgess S, Ahsan H, Whittemore A, John E, Gammon M, Malone K, Tessier D, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey C, González-Neira A, Pita G, Alonso M, Álvarez N, Herrero D, Pharoah P, Simard J, Hall P, Hunter D, Easton D, Zheng W
JNCI-J NATL CANCER I. 2015;107(11):djv219.

73-jährige leber- und nierentransplantierte Patientin mit dumpfen Oberbauchschmerzen und rezidivierendem Nasenbluten
Zinser M, Salzer H, Stein A, von Petersdorff-Campen M, Koops A, Holzhüter J
INTERNIST. 2015;56(5):566-72.

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno L, Alonso M, Dennis J, Wang Q, Bolla M, Meyer K, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Lindblom A, Margolin S, Swerdlow A, Ashworth A, Orr N, Jones M, Matsuo K, Ito H, Iwata H, Kondo N, Hartman M, Hui M, Lim W, Iau P, Sawyer E, Tomlinson I, Kerin M, Miller N, Kang D, Choi J, Park S, Noh D, Hopper J, Schmidt D, Makalic E, Southey M, Teo S, Yip C, Sivanandan K, Tay W, Brauch H, Brüning T, Hamann U, Dunning A, Shah M, Andrulis I, Knight J, Glendon G, Tchatchou S, Schmidt M, Broeks A, Rosenberg E, van't Veer L, Fasching P, Renner S, Ekici A, Beckmann M, Shen C, Hsiung C, Yu J, Hou M, Blot W, Cai Q, Wu A, Tseng C, Van Den Berg D, Stram D, Cox A, Brock I, Reed M, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Shu X, Lu W, Gao Y, Zhang B, Radice P, Peterlongo P, Manoukian S, Mariette F, Sangrajrang S, McKay J, Couch F, Toland A, Yannoukakos D, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Marme F, Burwinkel B, Guénel P, Truong T, Sanchez M, Mulot C, Bojesen S, Nordestgaard B, Flyer H, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Lambrechts D, Yesilyurt B, Floris G, Leunen K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson J, Vachon C, Purrington K, Giles G, Severi G, Baglietto L, Haiman C, Henderson B, Schumacher F, Marchand L, Simard J, Dumont M, Goldberg M, Labréche F, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Devilee P, Tollenaar R, Seynaeve C, García-Closas M, Chanock S, Lissowska J, Figueroa J, Czene K, Eriksson M, Humphreys K, Darabi H, Hooning M, Kriege M, Collée J, Tilanus-Linthorst M, Li J, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Bogdanova N, Dörk T, Hall P, Chenevix-Trench G, Easton D, Pharroah P, Arias-Perez J, Zamora P, Benítez J, Milne R
BRIT J CANCER. 2014;110(4):1088-100.

A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age
Ahsan H, Halpern J, Kibriya M, Pierce B, Tong L, Gamazon E, McGuire V, Felberg A, Shi J, Jasmine F, Roy S, Brutus R, Argos M, Melkonian S, Chang-Claude J, Andrulis I, Hopper J, John E, Malone K, Ursin G, Gammon M, Thomas D, Seminara D, Casey G, Knight J, Southey M, Giles G, Santella R, Lee E, Conti D, Duggan D, Gallinger S, Haile R, Jenkins M, Lindor N, Newcomb P, Michailidou K, Apicella C, Park D, Peto J, Fletcher O, dos Santos Silva I, Lathrop M, Hunter D, Chanock S, Meindl A, Schmutzler R, Müller-Myhsok B, Lochmann M, Beckmann L, Hein R, Makalic E, Schmidt D, Bui Q, Stone J, Flesch-Janys D, Dahmen N, Nevanlinna H, Aittomäki K, Blomqvist C, Hall P, Czene K, Irwanto A, Liu J, Rahman N, Turnbull C, Dunning A, Pharoah P, Waisfisz Q, Meijers-Heijboer H, Uitterlinden A, Rivadeneira F, Nicolae D, Easton D, Cox N, Whittemore A
CANCER EPIDEM BIOMAR. 2014;23(4):658-69.

Exploring adenylylation and phosphocholination as post-translational modifications
Albers M, Itzen A, Hedberg C
CHEMBIOCHEM. 2014;15(1):19-26.

Bosutinib
Amsberg G, Brümmendorf T
2014. Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML). Brümmendorf T, Koschmieder S (Hrsg.). 1. Aufl. Bremen-London-Boston: Uni-Med, 71-75.

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom
Amsberg G, Strölin P, Bokemeyer C, Steuber T
DEUT MED WOCHENSCHR. 2014;139(41):2086-90.

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic D, Luetkens T, Kröger N
LEUKEMIA. 2014;28(5):993-1000.

Insula and sensory insular cortex and somatosensory control in patients with insular stroke
Baier B, zu Eulenburg P, Geber C, Rohde F, Rolke R, Maihöfner C, Birklein F, Dieterich M
EUR J PAIN. 2014;18(10):1385-93.

In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies
Bannas P, Well L, Lenz A, Rissiek B, Haag F, Schmid J, Hochgräfe K, Trepel M, Adam G, Ittrich H, Nolte F
CONTRAST MEDIA MOL I. 2014;9(2):135-42.

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
Berdien B, Mock U, Atanackovic D, Fehse B
GENE THER. 2014;21:539–548.

First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
Berger L, Bokemeyer C, Lorch A, Hentrich M, Kopp H, Gauler T, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K
J CANCER RES CLIN. 2014;140(7):1211-1220.

Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance
Bettenworth D, Nowacki T, Ross M, Kyme P, Schwammbach D, Kerstiens L, Thoennissen G, Bokemeyer C, Hengst K, Berdel W, Heidemann J, Thoennissen N
MOL NUTR FOOD RES. 2014;58(7):1474-1490.

The role of CD81 for plasma cell dyscrasias
Binder M, Bacher U
LEUKEMIA RES. 2014;38(3):292-3.

ASCO – Highlights zum kolorektalen Karzinom
Block A
Onkologie heute. 2014;(6-2014):.

Editorial. Cancer Survivorship
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:157.

Editorial. Guten Appetit - Mythen und Fakten zur Ernährung bei Krebspatienten
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:361.

Editorial. Im stetigen Wandel
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:457.

Editorial. Innovation und Zukunft
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:261.

Editorial. Komplexes Wechselspiel
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:77.

Editorial. Schritt für Schritt
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29(1):1.

Nausea und Emesis bei urogenitalen Tumoren
Bokemeyer C
2014. Nausea und Emesis in der Onkologie. Lordick F, Lorenzen S (Hrsg.). 1. Aufl. Uni-Med, 86-96.

Studien sind Teil der Behandlung
Bokemeyer C
Hilfe! Zwischen Krankheit, Versorgung und Geschäft. Ein Magazin im Auftrag des BPI . 2014;20-21.

Prostatakarzinom
Bokemeyer C, Heidenreich A, Schaefer R
2014. Krebsfrüherkennung in Deutschland 2014. Freund M, Lüftner D, Wilhelm M (Hrsg.). 1. Aufl. 79-91.

Moderne Krebstherapie: aktueller Stand und zukünftige Entwicklung
Bokemeyer C, Hiddemann W
DEUT MED WOCHENSCHR. 2014;139(41):2067.

Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2014. OnkoUpdate 2014. 1. Aufl. med publico GmbH, 1-40.

Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?
Braga W, da Silva B, Alves V, Bortoluzo A, Atanackovic D, Colleoni G
IMMUNOTHERAPY-UK. 2014;6(5):569-75.

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells
Braga W, da Silva B, de Carvalho A, Maekawa Y, Bortoluzzo A, Rizzatti E, Atanackovic D, Colleoni G
CANCER IMMUNOL IMMUN. 2014;63(11):1189-97.

A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells
Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph K, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf T
LEUKEMIA. 2014;28(10):2028-39.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
Burandt E, Schreiber M, Stein A, Minner S, Clauditz T, Bokemeyer C, Jänicke F, Fisch M, Izbicki J, Knecht R, Sauter G, Stahl P
GENE CHROMOSOME CANC. 2014;53(3):228-39.

Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F, Magheli A, Miller K, Grünwald V, Weikert S
EUR J CANCER. 2014;50(3):563-9.

A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer
Campa D, Barrdahl M, Tsilidis K, Severi G, Diver W, Siddiq A, Chanock S, Hoover R, Ziegler R, Berg C, Buys S, Haiman C, Henderson B, Schumacher F, Le Marchand L, Flesch-Janys D, Lindström S, Hunter D, Hankinson S, Willett W, Kraft P, Cox D, Khaw K, Tjønneland A, Dossus L, Trichopoulos D, Panico S, van Gils C, Weiderpass E, Barricarte A, Sund M, Gaudet M, Giles G, Southey M, Baglietto L, Chang-Claude J, Kaaks R, Canzian F
PLOS ONE. 2014;9(2):e85955.

Test-retest reliability of an infectious disease questionnaire and evaluation of self-assessed vulnerability to infections: findings of Pretest 2 of the German National Cohort
Castell S, Akmatov M, Obi N, Flesh-Janys D, Nieters A, Kemmling Y, Pessler F, Krause G
BUNDESGESUNDHEITSBLA. 2014;57(11):1300-7.

Feasibility and acceptance of cervicovaginal self-sampling within the German National Cohort (Pretest 2)
Castell S, Krause G, Schmitt M, Pawlita M, Deleré Y, Obi N, Flesch-Janys D, Kemmling Y, Kaufmann A
BUNDESGESUNDHEITSBLA. 2014;57(11):1270-6.

Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Dicke C, Holstein K, Schneppenheim S, Dittmer R, Schneppenheim R, Bokemeyer C, Iking-Konert C, Budde U, Langer F
EXP HEMATOL ONCOL. 2014;3:21.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein J, Lepretre S, Reman O, Turlure P, Ottmann O, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk R, Voss F, Taube T, Fritsch H, Maertens J
BLOOD. 2014;124(9):1426-33.

Agent Orange in Vietnam. 1995
Dwyer J, Flesch-Janys D
AM J PUBLIC HEALTH. 2014;104(10):1857-60.

Aaptamines from the marine sponge Aaptos sp. display anticancer activities in human cancer cell lines and modulate AP-1-, NF-κB-, and p53-dependent transcriptional activity in mouse JB6 Cl41 cells
Dyshlovoy S, Fedorov S, Shubina L, Kuzmich A, Bokemeyer C, Amsberg G, Honecker F
BIOMED RES INT . 2014;2014:469309.

Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer
Dyshlovoy S, Venz S, Shubina L, Fedorov S, Walther R, Jacobsen C, Stonik V, Bokemeyer C, Balabanov S, Honecker F
J PROTEOMICS. 2014;96:223-39.

Economic evaluation of exercise training in patients with pulmonary hypertension
Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz C, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E
LUNG. 2014;192(3):359-66.

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
Erdmann R
2014. Hematology 2013. .

Akute myeloische Leukämie –bestmögliche Behandlung.
Fiedler W, Janning M, Kebenko M, Weidmann J, Janjetovic S, Bokemeyer C
Hamb Ärztebl. 2014;68:11-17.

Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance
Flammiger A, Bacher U, Christopeit M, Horn C, Rühlmann E, Kluge K, Vettorazzi E, Bokemeyer C, Binder M
LEUKEMIA LYMPHOMA. 2014;56(3):639-644.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
Gambacorti-Passerini C, Brümmendorf T, Kim D, Turkina A, Masszi T, Assouline S, Durrant S, Kantarjian H, Khoury H, Zaritskey A, Shen Z, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes J
AM J HEMATOL. 2014;89(7):732-42.

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Gambacorti-Passerini C, Cortes J, Lipton J, Dmoszynska A, Wong R, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian H, Brümmendorf T
AM J HEMATOL. 2014;89(10):947-53.

Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Ghoussaini M, Edwards S, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman K, Kaufmann S, Glubb D, Beesley J, Dennis J, Bolla M, Wang Q, Dicks E, Guo Q, Schmidt M, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer L, Th Rutgers E, Couch F, Olson J, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi J, Park S, Noh D, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu A, Tseng C, Van Den Berg D, Stram D, Benitez J, Zamora M, Perez J, Menéndez P, Shu X, Lu W, Gao Y, Cai Q, Cox A, Cross S, Reed M, Andrulis I, Knight J, Glendon G, Tchatchou S, Sawyer E, Tomlinson I, Kerin M, Miller N, Haiman C, Henderson B, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo S, Yip C, Lee D, Wong T, Hooning M, Martens J, Collée J, van Deurzen C, Hopper J, Southey M, Tsimiklis H, Kapuscinski M, Shen C, Wu P, Yu J, Chen S, Alnæs G, Borresen-Dale A, Giles G, Milne R, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari S, Teo Y, Fasching P, Haeberle L, Ekici A, Beckmann M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker M, García-Closas M, Figueroa J, Chanock S, Lissowska J, Simard J, Goldberg M, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto Y, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova N, Helbig S, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland A, Ambrosone C, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen S, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey C, González-Neira A, Pita G, Alonso M, Alvarez N, Herrero D, Tessier D, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown M, Lupien M, Kristensen V, Pharoah P, Chenevix-Trench G, French J, Easton D, Dunning A
NAT COMMUN. 2014;4:4999.

Clinical management of epithelial ovarian cancer during pregnancy
Grimm D, Woelber L, Trillsch F, Keller-v. Amsberg G, Mahner S
EUR J CANCER. 2014;50(5):963-971.

DACH-Konferenz zur pulmonalen Hypertonie 2014
Grünig E, Klose H
DEUT MED WOCHENSCHR. 2014;139(Suppl 4):S109-S110.

Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy
Harbaum L, Hennigs J, Baumann H, Bokemeyer C, Olschewski H, Klose H
EUR RESPIR J. 2014;43(5):1513-5.

N-terminal pro-brain natriuretic Peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency
Harbaum L, Hennigs J, Baumann H, Lüneburg N, Griesch E, Bokemeyer C, Grünig E, Klose H
PLOS ONE. 2014;9(4):e94263.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D
INT J HEMATOL. 2014;99(1):91-4.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Hehlmann R, Müller M, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller C, Spiekermann K, Baerlocher G, Ehninger G, Heim D, Heimpel H, Nerl C, Krause S, Hossfeld D, Kolb H, Hasford J, Saußele S, Hochhaus A
J CLIN ONCOL. 2014;32(5):415-23.

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
Heiss M, Ströhlein M, Bokemeyer C, Arnold D, Parsons S, Seimetz D, Lindhofer H, Schulze E, Hennig M
CLIN CANCER RES. 2014;20(12):3348-57.

Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension
Hennigs J, Baumann H, Lüneburg N, Quast G, Harbaum L, Heyckendorf J, Sydow K, Schulte-Hubbert B, Halank M, Klose H
SCI REP-UK. 2014;4:4808.

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse
Hennigs J, Müller J, Adam M, Spin J, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S
PLOS ONE. 2014;9(7):e100469.

Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller Hypertonie
Hoeper M, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange T, Grünig E, Seeger W, Ewert R, Borst M, Welte T, Rosenkranz S, Ghofrani H
DEUT MED WOCHENSCHR. 2014;139 Suppl 4:S151-4.

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results
Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes H, Valdix A, Schroeder J, Herrenberger J, Stein A, Hinke A, Arnold D
BMC CANCER. 2014;14:761.

Relationship between haemophilia and social status
Holstein K, Eifrig B, Langer F
THROMB RES. 2014.

Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2014;34 (4A):5-8.

Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines
Honecker F, Rohlfing T, Harder S, Braig M, Gillis A, Gläsener S, Barett C, Bokemeyer C, Buck F, Brümmendorf T, Looijenga L, Balabanov S
J PROTEOMICS. 2014;96:300-13.

Bosutinib: a novel second-generation tyrosine kinase inhibitor
Isfort S, Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf T
Recent Results Cancer Res. 2014;201:81-97.

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development
Janning M, Fiedler W
FUTURE ONCOL. 2014;10(7):1157-65.

Exercise training in patients with advanced gastrointestinal cancer undergoing palliative chemotherapy: a pilot study
Jensen W, Baumann F, Stein A, Bloch W, Bokemeyer C, de Wit M, Oechsle K
SUPPORT CARE CANCER. 2014;22(7):1797-806.

Physical exercise and therapy in terminally ill cancer patients: a retrospective feasibility analysis
Jensen W, Bialy L, Ketels G, Baumann F, Bokemeyer C, Oechsle K
SUPPORT CARE CANCER. 2014;22(5):1261-8.

Effects of exercise training programs on physical performance and quality of life in patients with metastatic lung cancer undergoing palliative chemotherapy--a study protocol
Jensen W, Oechsle K, Baumann H, Mehnert A, Klose H, Bloch W, Bokemeyer C, Baumann F
CONTEMP CLIN TRIALS. 2014;37(1):120-8.

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Johnson N, Dudbridge F, Orr N, Gibson L, Jones M, Schoemaker M, Folkerd E, Haynes B, Hopper J, Southey M, Dite G, Apicella C, Schmidt M, Broeks A, Van T Veer L, Atsma F, Muir K, Lophatananon A, Fasching P, Beckmann M, Ekici A, Renner S, Sawyer E, Tomlinson I, Kerin M, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina E, Menegaux F, Bojesen S, Nordestgaard B, Flyger H, Milne R, Zamora M, Arias Perez J, Benitez J, Bernstein L, Anton-Culver H, Ziogas A, Clarke Dur C, Brenner H, Müller H, Arndt V, Dieffenbach A, Meindl A, Heil J, Bartram C, Schmutzler R, Brauch H, Justenhoven C, Ko Y, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Matsuo K, Dörk T, Bogdanova N, Antonenkova N, Lindblom A, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Chenevix-Trench G, Beesley J, Wu A, Van den Berg D, Tseng C, Lambrechts D, Smeets D, Neven P, Wildiers H, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Pensotti V, Couch F, Olson J, Wang X, Fredericksen Z, Pankratz V, Giles G, Severi G, Baglietto L, Haiman C, Simard J, Goldberg M, Labrèche F, Dumont M, Soucy P, Teo S, Yip C, Phuah S, Cornes B, Kristensen V, Grenaker Alnæs G, Børresen-Dale A, Zheng W, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight J, Glendon G, Mulligan A, Devillee P, Figueroa J, Chanock S, Lissowska J, Sherman M, Hall P, Schoof N, Hooning M, Hollestelle A, Oldenburg R, Tilanus-Linthorst M, Liu J, Cox A, Brock I, Reed M, Cross S, Blot W, Signorello L, Pharoah P, Dunning A, Shah M, Kang D, Noh D, Park S, Choi J, Hartman M, Miao H, Lim W, Tang A, Hamann U, Försti A, Rüdiger T, Ulmer H, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland A, Vachon C, Yannoukakos D, Shen C, Yu J, Huang C, Hou M, González-Neira A, Tessier D, Vincent D, Bacot F, Luccarini C, Dennis J, Michailidou K, Bolla M, Wang J, Easton D, García-Closas M, Dowsett M, Ashworth A, Swerdlow A, Peto J, Dos Santos Silva I, Fletcher O
BREAST CANCER RES. 2014;16(3):R51.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller M, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller C, Spiekermann K, Krause S, Heim D, Nerl C, Hossfeld D, Kolb H, Hochhaus A, Hasford J, Hehlmann R
ANN HEMATOL. 2014;93(1):71-80.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Kantarjian H, Cortes J, Kim D, Khoury H, Brümmendorf T, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C
BLOOD. 2014;123(9):1309-18.

MicroRNA related polymorphisms and breast cancer risk
Khan S, Greco D, Michailidou K, Milne R, Muranen T, Heikkinen T, Aaltonen K, Dennis J, Bolla M, Liu J, Hall P, Irwanto A, Humphreys K, Li J, Czene K, Chang-Claude J, Hein R, Rudolph A, Seibold P, Flesch-Janys D, Fletcher O, Peto J, dos Santos Silva I, Johnson N, Gibson L, Aitken Z, Hopper J, Tsimiklis H, Bui M, Makalic E, Schmidt D, Southey M, Apicella C, Stone J, Waisfisz Q, Meijers-Heijboer H, Adank M, van der Luijt R, Meindl A, Schmutzler R, Müller-Myhsok B, Lichtner P, Turnbull C, Rahman N, Chanock S, Hunter D, Cox A, Cross S, Reed M, Schmidt M, Broeks A, Van't Veer L, Hogervorst F, Fasching P, Schrauder M, Ekici A, Beckmann M, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Benitez J, Zamora P, Perez J, Haiman C, Henderson B, Schumacher F, Le Marchand L, Pharoah P, Dunning A, Shah M, Luben R, Brown J, Couch F, Wang X, Vachon C, Olson J, Lambrechts D, Moisse M, Paridaens R, Christiaens M, Guénel P, Truong T, Laurent-Puig P, Mulot C, Marme F, Burwinkel B, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin M, Miller N, Andrulis I, Knight J, Tchatchou S, Mulligan A, Dörk T, Bogdanova N, Antonenkova N, Anton-Culver H, Darabi H, Eriksson M, Garcia-Closas M, Figueroa J, Lissowska J, Brinton L, Devilee P, Tollenaar R, Seynaeve C, van Asperen C, Kristensen V, Slager S, Toland A, Ambrosone C, Yannoukakos D, Lindblom A, Margolin S, Radice P, Peterlongo P, Barile M, Mariani P, Hooning M, Martens J, Collée J, Jager A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Giles G, McLean C, Brauch H, Brüning T, Ko Y, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Simard J, Goldberg M, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Kataja V, Kosma V, Hartikainen J, Mannermaa A, Hamann U, Chenevix-Trench G, Blomqvist C, Aittomäki K, Easton D, Nevanlinna H
PLOS ONE. 2014;9(11):e109973.

Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH)
Klose H, Opitz C, Bremer H, Ewert R, Bonderman D, Rosenkranz S, Seeger W, Schmeißer A, Harbaum L, Buerke M, Ghofrani H, Borst M, Leuchte H, Lange T, Behr J, Ulrich S, Lang I, Olschewski H, Gall H, Kabitz H, Kleber F, Held M, Hoeper M, Grünig E
DEUT MED WOCHENSCHR. 2014;139 Suppl 4:S142-50.

Therapie von Kopf-Hals-Karzinomen
Knecht R, Busch C, Lörincz B, Schafhausen P, Tribius S, Heiland M, Jenckel F, Münscher A, Petersen C, Bokemeyer C
Hamb Ärztebl. 2014;8:12-17.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation
Kröger N, Stübig T, Atanackovic D
BIOL BLOOD MARROW TR. 2014;20(2):168-72.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction
Kuehnle M, Attig S, Britten C, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O
CANCER IMMUNOL IMMUN. 2014;63(12):1273-84.

Epigenetik und Genetik der pulmonal arteriellen Hypertonie--neue Erkenntnisse der letzten Jahre
Kwapiszewska G, Viales R, Ehlken N, Eichstaedt C, Riemekasten G, Grünig G, Mäder I, Klose H, Hinderhofer K, Fischer C, Ulrich S, Grünig E, Olschewski A
DEUT MED WOCHENSCHR. 2014;139 Suppl 4:S111-5.

Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer
Laban S, Atanackovic D, Luetkens T, Knecht R, Busch C, Freytag M, Spagnoli G, Ritter G, Hoffmann T, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Münscher A, Clauditz T
INT J CANCER. 2014.

Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion
Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White J, Budde U, Bokemeyer C, Schneppenheim R
THROMB HAEMOSTASIS. 2014;111(4):777-779.

Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation
Langer F, Ruf W
THROMB HAEMOSTASIS. 2014;111(4):590-7.

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Li J, Lindström L, Foo J, Rafiq S, Schmidt M, Pharoah P, Michailidou K, Dennis J, Bolla M, Wang Q, Van 't Veer L, Cornelissen S, Rutgers E, Southey M, Apicella C, Dite G, Hopper J, Fasching P, Haeberle L, Ekici A, Beckmann M, Blomqvist C, Muranen T, Aittomäki K, Lindblom A, Margolin S, Mannermaa A, Kosma V, Hartikainen J, Kataja V, Chenevix-Trench G, Phillips K, McLachlan S, Lambrechts D, Thienpont B, Smeets A, Wildiers H, Chang-Claude J, Flesch-Janys D, Seibold P, Rudolph A, Giles G, Baglietto L, Severi G, Haiman C, Henderson B, Schumacher F, Le Marchand L, Kristensen V, Alnæs G, Borresen-Dale A, Nord S, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight J, Glendon G, Tchatchou S, Devilee P, Tollenaar R, Seynaeve C, Hooning M, Kriege M, Hollestelle A, van den Ouweland A, Li Y, Hamann U, Torres D, Ulmer H, Rüdiger T, Shen C, Hsiung C, Wu P, Chen S, Teo S, Taib N, Har Yip C, Fuang Ho G, Matsuo K, Ito H, Iwata H, Tajima K, Kang D, Choi J, Park S, Yoo K, Maishman T, Tapper W, Dunning A, Shah M, Luben R, Brown J, Khor C, Eccles D, Nevanlinna H, Easton D, Humphreys K, Liu J, Hall P, Czene K
NAT COMMUN. 2014;5:4051.

UCH-L1 induces podocyte hypertrophy in membranous nephropathy by protein accumulation
Lohmann F, Sachs M, Meyer T, Sievert H, Lindenmeyer M, Wiech T, Cohen C, Balabanov S, Stahl R, Meyer-Schwesinger C
BBA-MOL BASIS DIS. 2014;1842(7):945-58.

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood T, Osterborg A, Rzychon B, Mitchell D, Beguin Y
SUPPORT CARE CANCER. 2014.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels B, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
CANCER IMMUNOL IMMUN. 2014;63(11):1151-62.

The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases
Lüneburg N, Harbaum L, Hennigs J
BIOMED RES INT . 2014;2014:501612.

Das Handbuch gegen Krebs
Majorczyk S
2014. Das Handbuch gegen Krebs. 1. Aufl. ZS Verlag Zabert Sandmann GmbH, 1-400.

Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Milne R, Burwinkel B, Michailidou K, Arias-Perez J, Zamora M, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso M, Dennis J, Wang Q, Bolla M, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ko Y, Brauch H, Hamann U, Andrulis I, Knight J, Glendon G, Tchatchou S, Matsuo K, Ito H, Iwata H, Tajima K, Li J, Brand J, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Lambrechts D, Peuteman G, Christiaens M, Smeets A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Hartman M, Hui M, Yen Lim W, Wan Chan C, Marme F, Yang R, Bugert P, Lindblom A, Margolin S, García-Closas M, Chanock S, Lissowska J, Figueroa J, Bojesen S, Nordestgaard B, Flyger H, Hooning M, Kriege M, van den Ouweland A, Koppert L, Fletcher O, Johnson N, dos-Santos-Silva I, Peto J, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Cox A, Cross S, Reed M, Schmidt M, Broeks A, Cornelissen S, Braaf L, Kang D, Choi J, Park S, Noh D, Simard J, Dumont M, Goldberg M, Labrèche F, Fasching P, Hein A, Ekici A, Beckmann M, Radice P, Peterlongo P, Azzollini J, Barile M, Sawyer E, Tomlinson I, Kerin M, Miller N, Hopper J, Schmidt D, Makalic E, Southey M, Hwang Teo S, Har Yip C, Sivanandan K, Tay W, Shen C, Hsiung C, Yu J, Hou M, Guénel P, Truong T, Sanchez M, Mulot C, Blot W, Cai Q, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Wu A, Tseng C, Van Den Berg D, Stram D, Bogdanova N, Dörk T, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Shu X, Lu W, Gao Y, Zhang B, Couch F, Toland A, Yannoukakos D, Sangrajrang S, McKay J, Wang X, Olson J, Vachon C, Purrington K, Severi G, Baglietto L, Haiman C, Henderson B, Schumacher F, Le Marchand L, Devilee P, Tollenaar R, Seynaeve C, Czene K, Eriksson M, Humphreys K, Darabi H, Ahmed S, Shah M, Pharoah P, Hall P, Giles G, Benítez J, Dunning A, Chenevix-Trench G, Easton D
HUM MOL GENET. 2014;23(22):6096-111.

A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Milne R, Herranz J, Michailidou K, Dennis J, Tyrer J, Zamora M, Arias-Perez J, González-Neira A, Pita G, Alonso M, Wang Q, Bolla M, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Neuhausen S, Ziogas A, Clarke C, Hopper J, Dite G, Apicella C, Southey M, Chenevix-Trench G, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Andrulis I, Knight J, Glendon G, Mulligan A, Bojesen S, Nordestgaard B, Flyger H, Nevanlinna H, Muranen T, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson J, Vachon C, Purrington K, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Dunning A, Shah M, Guénel P, Truong T, Sanchez M, Mulot C, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Lindblom A, Margolin S, Hooning M, Hollestelle A, Collée J, Jager A, Cox A, Brock I, Reed M, Devilee P, Tollenaar R, Seynaeve C, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Dumont M, Soucy P, Dörk T, Bogdanova N, Hamann U, Försti A, Rüdiger T, Ulmer H, Fasching P, Häberle L, Ekici A, Beckmann M, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Radice P, Peterlongo P, Peissel B, Mariani P, Giles G, Severi G, Baglietto L, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Burwinkel B, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Lambrechts D, Yesilyurt B, Floris G, Leunen K, Alnæs G, Kristensen V, Børresen-Dale A, García-Closas M, Chanock S, Lissowska J, Figueroa J, Schmidt M, Broeks A, Verhoef S, Rutgers E, Brauch H, Brüning T, Ko Y, Couch F, Toland A, Yannoukakos D, Pharoah P, Hall P, Benítez J, Malats N, Easton D
HUM MOL GENET. 2014;23(7):1934-46.

Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples
Murga-Penas E, Schilling G, Behrmann P, Klokow M, Vettorazzi E, Bokemeyer C, Dierlamm J
GENE CHROMOSOME CANC. 2014;53(6):497-515.

Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription
Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang C, Grundhoff A, Johnsen S
CELL REP. 2014;8(2):459-468.

Circulating tumor cells in patients with testicular germ cell tumors
Nastały P, Ruf C, Becker P, Bednarz-Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Höppner D, Fisch M, Bokemeyer C, Ahyai S, Honecker F, Riethdorf S, Pantel K
CLIN CANCER RES. 2014;20(14):3830-41.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

Lapatinib
Nolting M, Schneider-Merck T, Trepel M
Recent Results Cancer Res. 2014;201:125-43.

Bridging: Perioperatives Vorgehen bei dauerhafter oraler Antikoagulation oder Plättchenfunktionshemmung
Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe R
DEUT MED WOCHENSCHR. 2014;139(24):1301-6.

Determinants of newly diagnosed comorbidities among breast cancer survivors
Obi N, Gornyk D, Heinz J, Vrieling A, Seibold P, Chang-Claude J, Flesch-Janys D
J CANCER SURVIV. 2014;8(3):384-93.

Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial
Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M
SUPPORT CARE CANCER. 2014;22(1):63-9.

Relationship Between Symptom Burden, Distress, and Sense of Dignity in Terminally Ill Cancer Patients
Oechsle K, Wais M, Vehling S, Bokemeyer C, Mehnert A
J PAIN SYMPTOM MANAG. 2014.

State of the Art: Hodentumore im klinischen Stadium I: Adjuvante Therapieoptionen nach inguinaler Orchiektomie
Oing C
Urologik. 2014;21(2):22-25.

Testicular Germ Cell Tumors
Oing C, Bokemeyer C, Oechsle K
2014. Nuclear Oncology. 1. Aufl. Philadelphia, PA 19103 USA: Wolters Kluwer, 241-250.

Nodal, pulmonary and pleural gliomatosis in a 42-year-old-male with non-seminomatous testicular germ cell cancer
Oing C, Wagner R, Bokemeyer C, Honecker F
HISTOPATHOLOGY. 2014;65(1):142-3.

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)
Olsson K, Delcroix M, Ghofrani H, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange T, Behr J, Klose H, Claussen M, Ewert R, Opitz C, Vizza C, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs J, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper M
CIRCULATION. 2014;129(1):57-65.

Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)"
Olsson K, Delcroix M, Ghofrani H, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange T, Behr J, Klose H, Claussen M, Ewert R, Opitz C, Vizza C, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs J, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper M
CIRCULATION. 2014;130(12):e110-2.

Quinone-carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: synthesis and determination of in vitro activity
Pelageev D, Dyshlovoy S, Pokhilo N, Denisenko V, Borisova K, Amsberg G, Bokemeyer C, Fedorov S, Honecker F, Anufriev V
EUR J MED CHEM. 2014;77:139-44.

Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche
Perry J, Day F, Elks C, Sulem P, Thompson D, Ferreira T, He C, Chasman D, Esko T, Thorleifsson G, Albrecht E, Ang W, Corre T, Cousminer D, Feenstra B, Franceschini N, Ganna A, Johnson A, Kjellqvist S, Lunetta K, McMahon G, Nolte I, Paternoster L, Porcu E, Smith A, Stolk L, Teumer A, Tšernikova N, Tikkanen E, Ulivi S, Wagner E, Amin N, Bierut L, Byrne E, Hottenga J, Koller D, Mangino M, Pers T, Yerges-Armstrong L, Hua Zhao J, Andrulis I, Anton-Culver H, Atsma F, Bandinelli S, Beckmann M, Benitez J, Blomqvist C, Bojesen S, Bolla M, Bonanni B, Brauch H, Brenner H, Buring J, Chang-Claude J, Chanock S, Chen J, Chenevix-Trench G, Collée J, Couch F, Couper D, Coviello A, Cox A, Czene K, D'adamo A, Davey Smith G, De Vivo I, Demerath E, Dennis J, Devilee P, Dieffenbach A, Dunning A, Eiriksdottir G, Eriksson J, Fasching P, Ferrucci L, Flesch-Janys D, Flyger H, Foroud T, Franke L, Garcia M, García-Closas M, Geller F, de Geus E, Giles G, Gudbjartsson D, Gudnason V, Guénel P, Guo S, Hall P, Hamann U, Haring R, Hartman C, Heath A, Hofman A, Hooning M, Hopper J, Hu F, Hunter D, Karasik D, Kiel D, Knight J, Kosma V, Kutalik Z, Lai S, Lambrechts D, Lindblom A, Mägi R, Magnusson P, Mannermaa A, Martin N, Masson G, McArdle P, McArdle W, Melbye M, Michailidou K, Mihailov E, Milani L, Milne R, Nevanlinna H, Neven P, Nohr E, Oldehinkel A, Oostra B, Palotie A, Peacock M, Pedersen N, Peterlongo P, Peto J, Pharoah P, Postma D, Pouta A, Pylkäs K, Radice P, Ring S, Rivadeneira F, Robino A, Rose L, Rudolph A, Salomaa V, Sanna S, Schlessinger D, Schmidt M, Southey M, Sovio U, Stampfer M, Stöckl D, Storniolo A, Timpson N, Tyrer J, Visser J, Vollenweider P, Völzke H, Waeber G, Waldenberger M, Wallaschofski H, Wang Q, Willemsen G, Winqvist R, Wolffenbuttel B, Wright M, Boomsma D, Econs M, Khaw K, Loos R, McCarthy M, Montgomery G, Rice J, Streeten E, Thorsteinsdottir U, van Duijn C, Alizadeh B, Bergmann S, Boerwinkle E, Boyd H, Crisponi L, Gasparini P, Gieger C, Harris T, Ingelsson E, Järvelin M, Kraft P, Lawlor D, Metspalu A, Pennell C, Ridker P, Snieder H, Sørensen T, Spector T, Strachan D, Uitterlinden A, Wareham N, Widen E, Zygmunt M, Murray A, Easton D, Stefansson K, Murabito J, Ong K
NATURE. 2014;514(7520):92-7.

DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies
Peters I, Dubrowinskaja N, Abbas M, Seidel C, Kogosov M, Scherer R, Gebauer K, Merseburger A, Kuczyk M, Grünwald V, Serth J
PLOS ONE. 2014;9(3):e91440.

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia
Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld D, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer H, Bunjes D, Ganser A, Beelen D, Baldomero H, Schanz U, Heimpel H, Kolb H, Hasford J, Gratwohl A, Hehlmann R
J CANCER RES CLIN. 2014;140(8):1367-81.

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules
Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W
NEURO-ONCOLOGY. 2014;86(1):46-52.

Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients
Porter J, Walter P, Neumayr L, Evans P, Bansal S, Garbowski M, Weyhmiller M, Harmatz P, Wood J, Miller J, Byrnes C, Weiss G, Seifert M, Grosse R, Grabowski D, Schmidt A, Fischer R, Nielsen P, Niemeyer C, Vichinsky E
BRIT J HAEMATOL. 2014;167(5):692-6.

Taschenbuch Onkologie 2014/15
Preiss J, Dornoff W, Schmieder A, Honecker F
2014.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Proetel U, Pletsch N, Lauseker M, Müller M, Hanfstein B, Krause S, Kalmanti L, Schreiber A, Heim D, Baerlocher G, Hofmann W, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S
ANN HEMATOL. 2014;93(7):1167-76.

Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Purrington K, Slettedahl S, Bolla M, Michailidou K, Czene K, Nevanlinna H, Bojesen S, Andrulis I, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman C, Fasching P, Mannermaa A, Winqvist R, Brenner H, Lindblom A, Chenevix-Trench G, Benitez J, Swerdlow A, Kristensen V, Guénel P, Meindl A, Darabi H, Eriksson M, Fagerholm R, Aittomäki K, Blomqvist C, Nordestgaard B, Nielsen S, Flyger H, Wang X, Olswold C, Olson J, Mulligan A, Knight J, Tchatchou S, Reed M, Cross S, Liu J, Li J, Humphreys K, Clarke C, Scott R, Fostira F, Fountzilas G, Konstantopoulou I, Henderson B, Schumacher F, Le Marchand L, Ekici A, Hartmann A, Beckmann M, Hartikainen J, Kosma V, Kataja V, Jukkola-Vuorinen A, Pylkäs K, Kauppila S, Dieffenbach A, Stegmaier C, Arndt V, Margolin S, Balleine R, Arias Perez J, Pilar Zamora M, Menéndez P, Ashworth A, Jones M, Orr N, Arveux P, Kerbrat P, Truong T, Bugert P, Toland A, Ambrosone C, Labrèche F, Goldberg M, Dumont M, Ziogas A, Lee E, Dite G, Apicella C, Southey M, Long J, Shrubsole M, Deming-Halverson S, Ficarazzi F, Barile M, Peterlongo P, Durda K, Jaworska-Bieniek K, Tollenaar R, Seynaeve C, Brüning T, Ko Y, Van Deurzen C, Martens J, Kriege M, Figueroa J, Chanock S, Lissowska J, Tomlinson I, Kerin M, Miller N, Schneeweiss A, Tapper W, Gerty S, Durcan L, Mclean C, Milne R, Baglietto L, dos Santos Silva I, Fletcher O, Johnson N, Van'T Veer L, Cornelissen S, Försti A, Torres D, Rüdiger T, Rudolph A, Flesch-Janys D, Nickels S, Weltens C, Floris G, Moisse M, Dennis J, Wang Q, Dunning A, Shah M, Brown J, Simard J, Anton-Culver H, Neuhausen S, Hopper J, Bogdanova N, Dörk T, Zheng W, Radice P, Jakubowska A, Lubinski J, Devillee P, Brauch H, Hooning M, García-Closas M, Sawyer E, Burwinkel B, Marmee F, Eccles D, Giles G, Peto J, Schmidt M, Broeks A, Hamann U, Chang-Claude J, Lambrechts D, Pharoah P, Easton D, Pankratz V, Slager S, Vachon C, Couch F
HUM MOL GENET. 2014;23(22):6034-46.

Alkoholerkrankung: Früherkennung, Gesprächsführung und Behandlung im primärärztlichen Bereich
Reimer J, Cimander K, Reimer C
DEUT MED WOCHENSCHR. 2014;139(18):943-954.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kröger N, Atanackovic D
BLOOD CANCER J. 2014;4:e212.

Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, Zirlik K, Trepel M, Tolosa E, Binder M
INT J CANCER. 2014;135(10):2370-2379.

Participation in patient support groups among cancer survivors: do psychosocial and medical factors have an impact?
Sautier L, Mehnert A, Höcker A, Schilling G
EUR J CANCER CARE. 2014;23(1):140-8.

Imatinib
Schafhausen P
2014. Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML). Brümmendorf T, Koschmieder S (Hrsg.). 1. Aufl. Bremen-London-Boston: Uni-Med, 52-59.

Kopf-Hals-Tumoren
Schafhausen P
2014. Colloquium Onkologie 18: Update Hämatologie / Onkologie 2014. Petrasch S, Ehninger G (Hrsg.). Lukon Verlagsgesellschaft mbH München, 233-244.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Überbringen schlechter Nachrichten - eine Herausforderung für jeden Arzt
Schilling G, Mehnert A
MED KLIN-INTENSIVMED. 2014;109(8):609-13.

Survivorship-Programme: Ziele und Inhalte einer strukturierten Betreuung
Schilling G, Stein A, Quidde J, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;3(29):202-205.

Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection
Schmoll H, Stein A
NAT REV CLIN ONCOL. 2014;11(2):79-80.

Quantification of prenatal liver and spleen iron in a sheep model and assessment of iron stores in a human neonate with neonatal hemochromatosis using R2* mapping
Schoennagel B, Remus C, Wedegärtner U, Salzmann I, Grabhorn E, Adam G, Fischer R, Harmatz P, Kooijman H, Yamamura J
MAGN RESON MED. 2014;13(3):167-173.

Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions
Schoeps A, Rudolph A, Seibold P, Dunning A, Milne R, Bojesen S, Swerdlow A, Andrulis I, Brenner H, Behrens S, Orr N, Jones M, Ashworth A, Li J, Cramp H, Connley D, Czene K, Darabi H, Chanock S, Lissowska J, Figueroa J, Knight J, Glendon G, Mulligan A, Dumont M, Severi G, Baglietto L, Olson J, Vachon C, Purrington K, Moisse M, Neven P, Wildiers H, Spurdle A, Kosma V, Kataja V, Hartikainen J, Hamann U, Ko Y, Dieffenbach A, Arndt V, Stegmaier C, Malats N, Arias Perez J, Benítez J, Flyger H, Nordestgaard B, Truong T, Cordina-Duverger E, Menegaux F, dos Santos Silva I, Fletcher O, Johnson N, Häberle L, Beckmann M, Ekici A, Braaf L, Atsma F, van den Broek A, Makalic E, Schmidt D, Southey M, Cox A, Simard J, Giles G, Lambrechts D, Mannermaa A, Brauch H, Guénel P, Peto J, Fasching P, Hopper J, Flesch-Janys D, Couch F, Chenevix-Trench G, Pharoah P, Garcia-Closas M, Schmidt M, Hall P, Easton D, Chang-Claude J
GENET EPIDEMIOL. 2014;38(1):84-93.

Collection of vaccination data in the German National Cohort: Findings of a feasibility study in three study centers
Schultze A, Akmatov M, Castell S, Karch A, Ahrens W, Günther K, Schlenz H, Flesch-Janys D, Obi N, Pessler F, Krause G
BUNDESGESUNDHEITSBLA. 2014;57(11):1292-9.

Mast cell sarcoma mimicking metastatic colon carcinoma
Schwaab J, Horny H, Jonescheit J, Metzgeroth G, Schafhausen P, Gaiser T, Marx A, Kienle P, Hofmann W, Reiter A
ANN HEMATOL. 2014;93(6):1067-9.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko A, Westermann A, Friccius-Quecke H, Lordick F
MED ONCOL. 2014;31(8):76.

Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake
Seibold P, Vrieling A, Heinz J, Obi-Osius N, Sinn H, Flesch-Janys D, Chang-Claude J
CANCER EPIDEMIOL. 2014;38(4):419-26.

Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis
Seibold P, Vrieling A, Johnson T, Buck K, Behrens S, Kaaks R, Linseisen J, Obi-Osius N, Heinz J, Flesch-Janys D, Chang-Claude J
INT J CANCER. 2014;135(4):923-33.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Shah N, Guilhot F, Cortes J, Schiffer C, le Coutre P, Brümmendorf T, Kantarjian H, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G
BLOOD. 2014;123(15):2317-24.

Evaluation of a questionnaire to assess selected infectious diseases and their risk factors: findings of a multicenter study
Sievers C, Akmatov M, Kreienbrock L, Hille K, Ahrens W, Günther K, Flesch-Janys D, Obi-Osius N, Michels K, Fricke J, Greiser K, Kaaks R, Peter H, Pessler F, Nieters A, Krause G
BUNDESGESUNDHEITSBLA. 2014;57(11):1283-91.

A novel mouse model for inhibition of DOHH mediated hypusine modification reveals crucial function for embryonic development, proliferation and oncogenic transformation
Sievert H, Pällmann N, Miller K, Hermans-Borgmeyer I, Venz S, Sendoel A, Preukschas M, Schweizer M, Böttcher S, Janiesch P, Streichert T, Walther R, Hengartner M, Manz M, Brümmendorf T, Bokemeyer C, Balabanov M, Hauber J, Duncan K, Balabanov S
DIS MODEL MECH. 2014.

High-flow nasal cannula oxygen versus non-invasive ventilation in patients with acute hypoxaemic respiratory failure undergoing flexible bronchoscopy - a prospective randomised trial
Simon M, Braune S, Frings D, Wiontzek A, Klose H, Kluge S
CRIT CARE. 2014;18(6):712.

Spiroketals from marine isolates of the fungi Penicillium thomii KMM 4645 and P. lividum KMM 4663
Sobolevskaya M, Zhuravleva O, Leshchenko E, Afiyatullov S, Khudyakova Y, Kim N, Kirichuk N, Dyshlovoy S
CHEM NAT COMPD+. 2014;50(6):1122-1124.

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
Spurdle A, Couch F, Parsons M, McGuffog L, Barrowdale D, Bolla M, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans D, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson K, Domchek S, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen U, Rantala J, Borg Å, Andrulis I, Miron A, Hansen T, Caldes T, Neuhausen S, Toland A, Nevanlinna H, Montagna M, Garber J, Godwin A, Osorio A, Factor R, Terry M, Rebbeck T, Karlan B, Southey M, Rashid M, Tung N, Pharoah P, Blows F, Dunning A, Provenzano E, Hall P, Czene K, Schmidt M, Broeks A, Cornelissen S, Verhoef S, Fasching P, Beckmann M, Ekici A, Slamon D, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen T, Heikkilä P, Blomqvist C, Figueroa J, Chanock S, Brinton L, Lissowska J, Olson J, Pankratz V, John E, Whittemore A, West D, Hamann U, Torres D, Ulmer H, Rüdiger T, Devilee P, Tollenaar R, Seynaeve C, Van Asperen C, Eccles D, Tapper W, Durcan L, Jones L, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane A, Glendon G, Mulligan A, Giles G, Milne R, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko Y, Cox A, Cross S, Reed M, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon T, Hillemanns P, Haiman C, Henderson B, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning M, Collée J, Martens J, Tilanus-Linthorst M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias J, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo S, Easton D, Antoniou A, Chenevix-Trench G, Goldgar D
BREAST CANCER RES. 2014;16(6):3419.

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study
Stein A, Arnold D, Thuss-Patience P, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz R, Schmoll H
ACTA ONCOL. 2014;53(3):392-8.

How to select the optimal treatment for first line metastatic colorectal cancer
Stein A, Bokemeyer C
WORLD J GASTROENTERO. 2014;20(4):899-907.

Neue Substanzen für die Therapie solider Tumoren
Stein A, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:300-4.

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis
Stelljes M, Krug U, Beelen D, Braess J, Sauerland M, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen G, Berning B, Kolb H, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann B, Hiddemann W, Berdel W, Büchner T
J CLIN ONCOL. 2014;32(4):288-96.

Moderne Systemtherapie des fortgeschrittenen Prostatakarzinoms
Steuber T, Stroeilin P, Amsberg G
Onkologie heute. 2014;(04):22-25.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893)
Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki J, Yekebas E
BMC CANCER. 2014;14(1):411.

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma
Thiele B, Kloster M, Alawi M, Indenbirken D, Trepel M, Grundhoff A, Binder M
BLOOD. 2014;123(23):3618-21.

55-jährige Patientin, Raucherin, mit deutlicher Abgeschlagenheit, Fieber und Hämoptysen
Thoennissen N, Clauditz T, Ittrich H, Stahl R, Bokemeyer C, Klose H
DEUT MED WOCHENSCHR. 2014;139(41):2073-4.

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M
HAEMATOLOGICA. 2014.

Neue Peptide mit Spezifität für die Lunge
Trepel M, Körbelin J, Michelfelder S
2014.

A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies
Vehreschild M, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal M, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild J, Cornely O, Seifert H
J ANTIMICROB CHEMOTH. 2014;69(12):3387-92.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
Vermorken J, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler T, Keilholz U, Delord J, Schafhausen P, Erfán J, Brümmendorf T, Iglesias L, Bethe U, Hicking C, Clement P
ANN ONCOL. 2014;25(3):682-8.

Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?
Vrieling A, Seibold P, Johnson T, Heinz J, Obi-Osius N, Kaaks R, Flesch-Janys D, Chang-Claude J
INT J CANCER. 2014;134(12):2972-83.

Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
Wellbrock J, Sheikhzadeh S, Oliveira Ferrer L, Stamm H, Hillebrand M, Keyser B, Klokow M, Vohwinkel G, Bonk V, Otto B, Streichert T, Balabanov S, Hagel C, Rybczynski M, Bentzien F, Bokemeyer C, Kodolitsch Y, Fiedler W
PLOS ONE. 2014;9(8):e104742.

Standard-pO2 zur Unterscheidung von primärer und sekundärer Hypoxämie. Erwiderung
Wichmann D, Baumann H, Kluge S
MED KLIN-INTENSIVMED. 2014;109(1):64-5.

Oxirapentyns F-K from the marine-sediment-derived fungus Isaria felina KMM 4639
Yurchenko A, Smetanina O, Kalinovsky A, Pushilin M, Glazunov V, Khudyakova Y, Kirichuk N, Ermakova S, Dyshlovoy S, Yurchenko E, Afiyatullov S
J NAT PROD. 2014;77(6):1321-8.

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs: Highlights des ASCO-Meetings 2014
Zeller N, Busch C, Schafhausen P, Knecht R, Möckelmann N
HNO. 2014;62(11):787-92.

Sargassopenillines A-G, 6,6-spiroketals from the alga-derived fungi Penicillium thomii and Penicillium lividum
Zhuravleva O, Sobolevskaya M, Afiyatullov S, Kirichuk N, Denisenko V, Dmitrenok P, Yurchenko E, Dyshlovoy S
MAR DRUGS. 2014;12(12):5930-43.

Meroterpenoids from the alga-derived fungi Penicillium thomii Maire and Penicillium lividum Westling
Zhuravleva O, Sobolevskaya M, Leshchenko E, Kirichuk N, Denisenko V, Dmitrenok P, Dyshlovoy S, Zakharenko A, Kim N, Afiyatullov S
J NAT PROD. 2014;77(6):1390-5.

Seltene Gerinnungsstörung oder ein Fall für den Psychiater
Zinser M, Holstein K, Langer F, Voigt P, Holzhüter J
Hamb Ärztebl. 2014;2014(11):30-31.

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

NAT GENET. 2013;45(4):392-8, 398e1-2.

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study
Abraham I, MacDonald K, Tharmarajah S, Bokemeyer C, Ludwig H, Soubeyran P, Battistel V, Aapro M
J GERIATR ONCOL. 2013;4(2):196-201.

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Al-Batran S, Pauligk C, Homann N, Hartmann J, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz R, Luley K, Kullmann F, Jäger E
EUR J CANCER. 2013;49(4):835-842.

Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses
Amirkhosravi A, Bigsby G, Desai H, Rivera-Amaya M, Coll E, Robles-Carrillo L, Faust P, Waters A, Meyer T, Reyes E, Langer F, Francis J
BLOOD COAGUL FIBRIN. 2013;24(5):510-7.

Bosutinib in the management of chronic myelogenous leukemia
Amsberg G, Schafhausen P
BIOL-TARGETS THER. 2013;7:115-22.

Antiangiogenese-Therapie beim kolorektalen Karzinom
Arnold D, Stein A
Onkologie heute. 2013;32-35.

New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy
Arnold D, Stein A
DRUGS. 2013;73(9):883-91.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders
Atanackovic D, Nowottne U, Freier E, Weber C, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl M, Bokemeyer C, Deter H
STRESS. 2013;16(4):421-8.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer C
HUM VACC IMMUNOTHER. 2013;9(12):2533-42.

Second autologous transplant as salvage therapy in multiple myeloma
Atanackovic D, Schilling G
BRIT J HAEMATOL. 2013;163(5):565-72.

Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors
Balabanov S, Wilhelm T, Venz S, Amsberg G, Scharf C, Pospisil H, Balabanov M, Barett C, Bokemeyer C, Walther R, Brümmendorf T, Schuppert A
PLOS ONE. 2013;8(1):e53668.

Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease
Becker-Grünig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, Gorenflo M, Tiede H, Schranz D, Hager A, Kaemmerer H, Miera O, Ulrich S, Speich R, Uiker S, Grünig E
INT J CARDIOL. 2013;168(1):375-81.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy
Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B
HUM VACC IMMUNOTHER. 2013;9(6):1205-16.

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives
Berger L, Riesenberg H, Bokemeyer C, Atanackovic D
LUNG CANCER. 2013;80(3):242-8.

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke N, Claßen J, Cohn-Cedermark G, Dahl A, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann K, Fenner M, Fizazi K, Flechon A, Fossa S, Germá Lluch J, Gietema J, Gillessen S, Giwercman A, Hartmann J, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart R, Kliesch S, Kollmannsberger C, Krege S, Laguna M, Looijenga L, Lorch A, Lotz J, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis J, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C
ANN ONCOL. 2013;24(4):878-888.

Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke L, Murga Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G
BRIT J HAEMATOL. 2013;161(1):87-94.

CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL.
Binder M, Müller F, Frick M, Wehr C, Simon F, Leistler B, Veelken H, Mertelsmann R, Trepel M
BLOOD. 2013;121(1):239-241.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Bojesen S, Pooley K, Johnatty S, Beesley J, Michailidou K, Tyrer J, Edwards S, Pickett H, Shen H, Smart C, Hillman K, Mai P, Lawrenson K, Stutz M, Lu Y, Karevan R, Woods N, Johnston R, French J, Chen X, Weischer M, Nielsen S, Maranian M, Ghoussaini M, Ahmed S, Baynes C, Bolla M, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier D, Vincent D, Bacot F, Vergote I, Lambrechts S, Despierre E, Risch H, González-Neira A, Rossing M, Pita G, Doherty J, Alvarez N, Larson M, Fridley B, Schoof N, Chang-Claude J, Cicek M, Peto J, Kalli K, Broeks A, Armasu S, Schmidt M, Braaf L, Winterhoff B, Nevanlinna H, Konecny G, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne R, Garcia J, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer E, Haiman C, Wang-Gohrke S, Andrulis I, Moysich K, Hopper J, Odunsi K, Lindblom A, Giles G, Brenner H, Simard J, Lurie G, Fasching P, Carney M, Radice P, Wilkens L, Swerdlow A, Goodman M, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova N, Dörk T, Pelttari L, Zheng W, Leminen A, Anton-Culver H, Bunker C, Kristensen V, Ness R, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu A, Harter P, Teo S, Schwaab I, Shu X, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan B, Sangrajrang S, Kjaer S, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen C, Brown J, Woo Y, Shah M, Azmi M, Luben R, Omar S, Czene K, Vierkant R, Nordestgaard B, Flyger H, Vachon C, Olson J, Wang X, Levine D, Rudolph A, Weber R, Flesch-Janys D, Iversen E, Nickels S, Schildkraut J, Silva I, Cramer D, Gibson L, Terry K, Fletcher O, Vitonis A, van der Schoot C, Poole E, Hogervorst F, Tworoger S, Liu J, Bandera E, Li J, Olson S, Humphreys K, Orlow I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen H, Muranen T, Wik E, Brouwers B, Krakstad C, Wauters E, Halle M, Wildiers H, Kiemeney L, Mulot C, Aben K, Laurent-Puig P, Altena A, Truong T, Massuger L, Benitez J, Pejovic T, Perez J, Hoatlin M, Zamora M, Cook L, Balasubramanian S, Kelemen L, Schneeweiss A, Le N, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin M, Miller N, Cybulski C, Henderson B, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang H, Mulligan A, Glendon G, Engelholm S, Knight J, Høgdall C, Apicella C, Gore M, Tsimiklis H, Song H, Southey M, Jager A, den Ouweland A, Brown R, Martens J, Flanagan J, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore A, Baglietto L, McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao Y, Goldberg M, Yang G, Dumont M, McLaughlin J, Hartmann A, Ekici A, Beckmann M, Phelan C, Lux M, Permuth-Wey J, Peissel B, Sellers T, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus S, Orr N, Menon U, Pearce C, Brüning T, Pike M, Ko Y, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock S, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka I, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar R, Durda K, Jaworska K, Hartikainen J, Kosma V, Kataja V, Antonenkova N, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsan P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler R, Ito H, Iwata H, Tajima K, Tseng C, Stram D, van den Berg D, Yip C, Ikram M, Teh Y, Cai H, Lu W, Signorello L, Cai Q, Noh D, Yoo K, Miao H, Iau P, Teo Y, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung C, Yu J, Hou M, Healey C, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck T, Piedmonte M, Singer C, Friedman E, Thomassen M, Offit K, Hansen T, Neuhausen S, Szabo C, Blanco I, Garber J, Narod S, Weitzel J, Montagna M, Olah E, Godwin A, Yannoukakos D, Goldgar D, Caldes T, Imyanitov E, Tihomirova L, Arun B, Campbell I, Mensenkamp A, van Asperen C, van Roozendaal K, Meijers-Heijboer H, Collée J, Oosterwijk J, Hooning M, Rookus M, van der Luijt R, Os T, Evans D, Frost D, Fineberg E, Barwell J, Walker L, Kennedy M, Platte R, Davidson R, Ellis S, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova O, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle A, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson K, Domchek S, Rodriguez G, Salani R, Kaulich D, Tea M, Paluch S, Laitman Y, Skytte A, Kruse T, Jensen U, Robson M, Gerdes A, Ejlertsen B, Foretova L, Savage S, Lester J, Soucy P, Kuchenbaecker K, Olswold C, Cunningham J, Slager S, Pankratz V, Dicks E, Lakhani S, Couch F, Hall P, Monteiro A, Gayther S, Pharoah P, Reddel R, Goode E, Greene M, Easton D, Berchuck A, Antoniou A, Chenevix-Trench G, Dunning A
NAT GENET. 2013;45(4):371-84, 384e1-2.

Tumore des Urogenitaltrakts
Bokemeyer C, Oechsle K, Oing C
2013. OnkoUpDate. Wiesbaden: med publico GmbH, .

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf T, Bug G, Ottmann O, Giagounidis A, Stadler M, Hofmann W, Schafhausen P, Lübbert M, Schlenk R, Blau I, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D
LEUKEMIA RES. 2013;37(8):900-6.

CD24 polymorphisms in breast cancer: impact on prognosis and risk
Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jäger D, Flesch-Janys D, Chang-Claude J, Marmé F
BREAST CANCER RES TR. 2013;137(3):927-37.

Tumor shrinkage during VEGF inhibitor therapy as an independent predictor of PFS and OS in renal cell carcinoma (RCC)
Busch J, Weikert S, Seidel C
J CLIN ONCOL. 2013;31(6_suppl):423.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?
Clauditz T, Gontarewicz A, Bokemeyer C, Sauter G, Knecht R, Münscher A, Wilczak W
J ORAL PATHOL MED. 2013;42(10):769-73.

Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a meta-analysis of adjusted observational results
D'Ascenzo F, Conrotto F, Giordana F, Moretti C, D'Amico M, Salizzoni S, Omedè P, La Torre M, Thomas M, Khawaja Z, Hildick-Smith D, Ussia G, Barbanti M, Tamburino C, Webb J, Schnabel R, Seiffert M, Wilde S, Treede H, Gasparetto V, Napodano M, Tarantini G, Presbitero P, Mennuni M, Rossi M, Gasparini M, Biondi Zoccai G, Lupo M, Rinaldi M, Gaita F, Marra S
INT J CARDIOL. 2013;168(3):2528-2532.

Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment
de Wit M, Ortner P, Lipp H, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K
ONKOLOGIE. 2013;36(3):127-35.

Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT
Dicke C, Kertész A, Henke R, Hasenkamp J, Jung W, Trümper L, Wulf G
BONE MARROW TRANSPL. 2013;48(3):467-8.

Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder
Eggers H, Seidel C, Schrader A, Lehmann R, Wegener G, Kuczyk M, Steffens S
MED ONCOL. 2013;30(4):705.

Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression
Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H
CLIN CHEM. 2013;59(10):1489-96.

Axl Represents a Therapeutic Target In T315I-Mutated and WT Myeloid Leukemia
Erdmann R
2013. Hematology 2013. .

The extracts of some marine invertebrates and algae collected off the coast waters of vietnam induce the inhibitory effects on the activator protein-1 transcriptional activity in JB6 Cl41 cells
Fedorov S, Krasokhin V, Shubina L, Dyshlovoy S, Nam N, Minh C
J CHEM-NY. 2013.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Fernández de Larrea C, Kyle R, Durie B, Ludwig H, Usmani S, Vesole D, Hajek R, San Miguel J, Sezer O, Sonneveld P, Kumar S, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson K, Richardson P, Badros A, Caers J, Cavo M, LeLeu X, Dimopoulos M, Chim C, Schots R, Noeul A, Fantl D, Mellqvist U, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta J, Bladé J, Orlowski R, Shah J
LEUKEMIA. 2013;27(4):780-91.

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
EUR J CANCER. 2013;49(6):1273-9.

40-jähriger Patient mit Dyspnoe ein Jahr nach Lungentransplantation
Fuchs A, Klose H, Harbaum L, Kreuz J, Wilhelm K, Nickenig G, Skowasch D
DEUT MED WOCHENSCHR. 2013;138(21):1107-8.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension
Ghofrani H, D'Armini A, Grimminger F, Hoeper M, Jansa P, Kim N, Mayer E, Simonneau G, Wilkins M, Fritsch A, Neuser D, Weimann G, Wang C
NEW ENGL J MED. 2013;369(4):319-29.

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
Ghoussaini M, Edwards S, Meyer K, Michailidou K, Ahmed S, Khan S, Maranian M, O'Reilly M, Hillman K, Betts J, Carroll T, Bailey P, Dicks E, Beesley J, Tyrer J, Maia A, Beck A, Knoblauch N, Chen C, Kraft P, Barnes D, González-Neira A, Alonso M, Herrero D, Tessier D, Vincent D, Bacot F, Luccarini C, Baynes C, Conroy D, Dennis J, Bolla M, Wang Q, Hopper J, Southey M, Schmidt M, Broeks A, Verhoef S, Cornelissen S, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching P, Loehberg C, Ekici A, Beckmann M, Peto J, dos Santos Silva I, Johnson N, Aitken Z, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Milne R, Zamora M, Arias Perez J, Benitez J, Anton-Culver H, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler R, Engel C, Brauch H, Hamann U, Justenhoven C, Aaltonen K, Heikkilä P, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Sueta A, Bogdanova N, Antonenkova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Wu A, Tseng C, Van Den Berg D, Stram D, Lambrechts D, Peeters S, Smeets A, Floris G, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Sardella D, Couch F, Wang X, Pankratz V, Lee A, Giles G, Severi G, Baglietto L, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Goldberg M, Labrèche F, Dumont M, Teo S, Yip C, Ng C, Vithana E, Kristensen V, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight J, Glendon G, Mulligan A, Devilee P, Seynaeve C, García-Closas M, Figueroa J, Chanock S, Lissowska J, Czene K, Klevebring D, Schoof N, Hooning M, Martens J, Collée J, Tilanus-Linthorst M, Hall P, Li J, Liu J, Humphreys K, Shu X, Lu W, Gao Y, Cai H, Cox A, Balasubramanian S, Blot W, Signorello L, Cai Q, Pharoah P, Healey C, Shah M, Pooley K, Kang D, Yoo K, Noh D, Hartman M, Miao H, Sng J, Sim X, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, McKay J, Toland A, Ambrosone C, Yannoukakos D, Godwin A, Shen C, Hsiung C, Wu P, Chen S, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ponder B, Nevanlinna H, Brown M, Chenevix-Trench G, Easton D, Dunning A
AM J HUM GENET. 2013;92(4):489-503.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer
Grob T, Hoenig T, Clauditz T, Atanackovic D, Koenig A, Vashist Y, Klose H, Simon R, Pantel K, Izbicki J, Bokemeyer C, Sauter G, Wilczak W
LUNG CANCER. 2013;79(3):221-7.

The expression of podocyte-specific proteins in parietal epithelial cells is regulated by protein degradation
Guhr S, Sachs M, Wegner A, Becker J, Meyer T, Kietzmann L, Schlossarek S, Carrier L, Balabanov M, Jat P, Stahl R, Meyer-Schwesinger C
KIDNEY INT. 2013;84(3):532-44.

Hamburger Netzwerk Pulmonale Hypertonie
Harbaum L, Hennigs J, Baumann H, Lüneburg N, Kluge S, Weil J, Sydow K, Klose H
Hamb Ärztebl. 2013;(10):26-28.

A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas
Hartmann J, Horger M, Kluba T, Königsrainer A, de Zwart P, von Weyhern C, Eckert F, Budach W, Bokemeyer C
INVEST NEW DRUG. 2013;31(6):1592-601.

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C
INVEST NEW DRUG. 2013;31(3):661-668.

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Harzheim D, Klose H, Pinado F, Ehlken N, Nagel C, Fischer C, Ghofrani A, Rosenkranz S, Seyfarth H, Halank M, Mayer E, Grünig E, Guth S
RESP RES. 2013;14:104.

Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A, Scholz H, Rogenhofer S, Arsov C, Retz M, Müller S, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D
EUR UROL. 2013;63(6):977-982.

A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication
Hein R, Flesch-Janys D, Dahmen N, Beckmann L, Lindström S, Schoof N, Czene K, Mittelstraß K, Illig T, Seibold P, Behrens S, Humphreys K, Li J, Liu J, Olson J, Wang X, Hankinson S, Truong T, Menegaux F, Dos Santos Silva I, Johnson N, Chen S, Yu J, Ziogas A, Kataja V, Kosma V, Mannermaa A, Anton-Culver H, Shen C, Brauch H, Peto J, Guénel P, Kraft P, Couch F, Easton D, Hall P, Chang-Claude J
BREAST CANCER RES TR. 2013;138(2):529-42.

Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013
Hezel M, Kurzweg T, Münscher A, Schafhausen P, Knecht R
HNO. 2013;61(11):911-3.

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry
Hoeper M, Huscher D, Ghofrani H, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohé C, Lange T, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth H, Olsson K, Opitz C, Gaine S, Vizza C, Vonk-Noordegraaf A, Kaemmerer H, Gibbs J, Pittrow D
INT J CARDIOL. 2013;168(2):871-80.

44-jährige Patientin mit hereditärem nichtpolypösem Kolonkarzinom: Vorsorgeuntersuchungen nichtkolonischer Tumoren
Holzhüter J, Rösch T, Block A, Lohse A, Lüth S
INTERNIST. 2013;54(3):353-8.

A 44-year-old woman with hereditary nonpolyposis colon carcinoma: screening examinations for non-colonic tumors.
Holzhüter J, Rösch T, Block A, Lohse A, Lüth S
INTERNIST. 2013;54:353-358.

Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy
Honecker F, Koychev D, Lühmann A, Langer F, Dieckmann K, Bokemeyer C, Oechsle K
ONKOLOGIE. 2013;36(11):663-8.

Cancer patients and advance directives: a survey of patients in a hematology and oncology outpatient clinic
Hubert E, Schulte N, Belle S, Gerhardt A, Merx K, Hofmann W, Stein A, Burkholder I, Hofheinz R, Kripp M
ONKOLOGIE. 2013;36(7-8):398-402.

Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2013;129(2):121-125.

Late recurrence of a pineal germinoma 14 years after radiation and chemotherapy: a case report and review of the literature
Janjetovic S, Bokemeyer C, Fiedler W, Frenzel T, Calaminus G, Honecker F
ONKOLOGIE. 2013;36(6):371-3.

Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature
Janjetovic S, Janning M, Daukeva L, Bokemeyer C, Fiedler W
TUMORI J. 2013;99(3):e96-9.

Relevant bleeding diathesis due to acquired factor XIII deficiency
Janning M, Holstein K, Spath B, Schnabel C, Bannas P, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2013;33 Suppl 1:S50-4.

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling
Kaiser M, Heider U, Mieth M, Zang C, von Metzler I, Sezer O
EUR J HAEMATOL. 2013;90(4):263-72.

A new antimicrobial and anticancer peptide producing by the marine deep sediment strain "Paenibacillus profundus" sp. nov. Sl 79
Kalinovskaya N, Romanenko L, Kalinovsky A, Dmitrenok P, Dyshlovoy S
NAT PROD COMMUN. 2013;8(3):381-4.

Isolation, structures, and biological activities of triterpenoids from a Penares sp. marine sponge
Kolesnikova S, Lyakhova E, Kalinovsky A, Pushilin M, Afiyatullov S, Yurchenko E, Dyshlovoy S, Minh C, Stonik V
J NAT PROD. 2013;76(9):1746-52.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Molecular targeting agents in the context of primary chemoradiation strategies.
Laban S, Busch C, Münscher A, Tribius S, Schafhausen P, Knecht R
HEAD NECK-J SCI SPEC. 2013;35(5):738-746.

Perioperative thromboprophylaxis
Langer F
VISZERALMEDIZIN. 2013;29(5):297-302.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension.
Ley S, Fink C, Risse F, Ehlken N, Fischer C, Ley-Zaporozhan J, Kauczor H, Klose H, Gruenig E
EUR RADIOL. 2013;23(2):324-331.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih H, Cazzola M, Melillo L, Carella A, Brandts C, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp M, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk R, Platzbecker U
NEW ENGL J MED. 2013;369(2):111-21.

Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Martens T, Matschke J, Müller C, Riethdorf S, Balabanov S, Westphal M, Heese O
CLIN NEUROL NEUROSUR. 2013;115(3):323-328.

A survey of chinese medicinal herbal treatment for chemotherapy-induced oral mucositis
Meyer-Hamme G, Beckmann K, Radtke J, Efferth T, Greten H, Rostock M, Schröder S
EVID-BASED COMPL ALT. 2013;2013:284959.

Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R, Sauter G, Schlomm T, Wilczak W
MODERN PATHOL. 2013;26(1):106-116.

Die wichtigsten Studienergebnisse der primären Radio-Chemo-Therapie von Kopf-Hals-Tumoren: Highlights des ASCO-Meetings 2013
Münscher A, Busch C, Schafhausen P, Tribius S, Knecht R
HNO. 2013;61(11):905-10.

Analysis of TET expression/activity and 5mC oxidation during normal and malignant germ cell development
Nettersheim D, Heukamp L, Fronhoffs F, Grewe M, Haas N, Waha A, Honecker F, Waha A, Kristiansen G, Schorle H
PLOS ONE. 2013;8(12):e82881.

Active surveillance is the preferred approach to clinical stage I testicular cancer
Nichols C, Roth B, Albers P, Einhorn L, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney C, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C
J CLIN ONCOL. 2013;31(28):3490-3.

Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors
Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, Eilber U, Schmidt M, Häberle L, Vrieling A, Gaudet M, Figueroa J, Schoof N, Spurdle A, Rudolph A, Fasching P, Hopper J, Makalic E, Schmidt D, Southey M, Beckmann M, Ekici A, Fletcher O, Gibson L, Silva I, Peto J, Humphreys M, Wang J, Cordina-Duverger E, Menegaux F, Nordestgaard B, Bojesen S, Lanng C, Anton-Culver H, Ziogas A, Bernstein L, Clarke C, Brenner H, Müller H, Arndt V, Stegmaier C, Brauch H, Brüning T, Harth V, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Lambrechts D, Smeets D, Neven P, Paridaens R, Flesch-Janys D, Obi-Osius N, Wang-Gohrke S, Couch F, Olson J, Vachon C, Giles G, Severi G, Baglietto L, Offit K, John E, Miron A, Andrulis I, Knight J, Glendon G, Mulligan A, Chanock S, Lissowska J, Liu J, Cox A, Cramp H, Connley D, Balasubramanian S, Dunning A, Shah M, Trentham-Dietz A, Newcomb P, Titus L, Egan K, Cahoon E, Rajaraman P, Sigurdson A, Doody M, Guénel P, Pharoah P, Schmidt M, Hall P, Easton D, Garcia-Closas M, Milne R, Chang-Claude J
PLOS GENET. 2013;9(3):e1003284.

Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt.
Nistal M, Pace A, Klose H, Benten D, Lohse A
THORAX. 2013;68(9):889-890.

MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients
Nuber N, Curioni-Fontecedro A, Dannenmann S, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M
LEUKEMIA. 2013;27(8):1767-9.

Anxiety and depression in caregivers of terminally ill cancer patients: impact on their perspective of the patients' symptom burden
Oechsle K, Goerth K, Bokemeyer C, Mehnert A
J PALLIAT MED. 2013;16(9):1095-101.

Symptom burden in palliative care patients: perspectives of patients, their family caregivers, and their attending physicians
Oechsle K, Görth K, Bokemeyer C, Mehnert A
SUPPORT CARE CANCER. 2013;21(7):1955-62.

Spättoxizität und Survivorship bei Keimzelltumoren
Oechsle K, Schilling G, Oing C, Bokemeyer C
ONKOLOGE. 2013;19(7):573-581.

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Oldenburg J, Fosså S, Nuver J, Heidenreich A, Schmoll H, Bokemeyer C, Horwich A, Beyer J, Kataja V
ANN ONCOL. 2013;24 Suppl 6:vi125-32.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
Oliveira Ferrer L, Wellbrock J, Bartsch U, Penas E, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G
MOL CANCER. 2013;12(1):144.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo T, Laack H, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann A, Visseren-Grul C, Gridelli C
J CLIN ONCOL. 2013;31(23):2895-902.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab
Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S
J CLIN ONCOL. 2013;31(30):3764-75.

Germline variants of base excision repair genes and breast cancer: A polymorphism in DNA polymerase gamma modifies gene expression and breast cancer risk.
Popanda O, Seibold P, Nikolov I, Oakes C, Burwinkel B, Hausmann S, Flesch-Janys D, Plass C, Chang-Claude J, Schmezer P
INT J CANCER. 2013;132(1):55-62.

Macitentan and morbidity and mortality in pulmonary arterial hypertension
Pulido T, Adzerikho I, Channick R, Delcroix M, Galiè N, Ghofrani H, Jansa P, Jing Z, Le Brun F, Mehta S, Mittelholzer C, Perchenet L, Sastry B, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin L, Simonneau G
NEW ENGL J MED. 2013;369(9):809-18.

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study
Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, Aschard H, Bolla M, Wang J, Truong T, Cordina-Duverger E, Menegaux F, Brüning T, Harth V, Severi G, Baglietto L, Southey M, Chanock S, Lissowska J, Figueroa J, Eriksson M, Humpreys K, Darabi H, Olson J, Stevens K, Vachon C, Knight J, Glendon G, Mulligan A, Ashworth A, Orr N, Schoemaker M, Webb P, Guénel P, Brauch H, Giles G, García-Closas M, Czene K, Chenevix-Trench G, Couch F, Andrulis I, Swerdlow A, Hunter D, Flesch-Janys D, Easton D, Hall P, Nevanlinna H, Kraft P, Chang-Claude J
ENDOCR-RELAT CANCER. 2013;20(6):875-87.

Schulbasierte Tabakprävention: Profitieren Risikogruppen ebenfalls? Ergebnisse aus "Nichtrauchen ist cool!"
Sack P, Bröning S, Andritzky B, Laack H, Thomasius R
Päd Praxis. 2013;81(2):291-300.

Was limitiert schulische Tabakprävention? Ergebnisse aus "Nichtrauchen ist cool!" für 5. und 6. Klassen.
Sack P, Hampel J, Bröning S, Petersen K, Andritzky B, Laack H, Thomasius R
PRAVENT GESUNDHEIT. 2013;8(4):246-251.

Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus.
Schilling G, Murga-Penas E, Janjetovic S, Oliveira Ferrer L, Balabanov M, Behrmann P, Bokemeyer C, Dierlamm J
LEUKEMIA RES. 2013;37(3):280-286.

Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J
BREAST. 2013;22(5):817-23.

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V
BRIT J CANCER. 2013;109(12):2998-3004.

Value of Computed Tomography of the Chest in Subjects With ARDS: A Retrospective Observational Study
Simon M, Braune S, Laqmani A, Metschke M, Berliner C, Kalsow M, Klose H, Kluge S
RESP CARE. 2013.

Prolonging Survival Through a Personalized Approach in Metastatic Colorectal Cancer
Stein A, Bokemeyer C
J OncoPathol. 2013;1(3):31-41.

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Stein A, Kretzschmar A, Behringer D, Wolff T, Zimber J, Hegewisch-Becker S, Kettner E, Pflüger K, Kirsch A, Arnold D
BMC CANCER. 2013;13:454.

Oxaliplatin for colorectal cancer: recent evidence from clinical trials
Stein A, Quidde J, Arnold D
COLORECTAL CANCER. 2013;135-44.

Optimum Duration of Metastatic Colorectal Cancer Treatment
Stein A, Schmoll H
CURR COLORECT CANC R. 2013;9(3):223-29.

Systemic treatment of liver metastases from colorectal cancer
Stein A, Schmoll H
THER ADV MED ONCOL. 2013;5(3):193-203.

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
Stein B, Schrader A, Wegener G, Seidel C, Kuczyk M, Steffens S
BMC CANCER. 2013;13:101.

Monanchomycalin C, a new pentacyclic guanidine alkaloid from the far-eastern marine sponge Monanchora pulchra
Tabakmakher K, Denisenko V, Guzii A, Dmitrenok P, Dyshlovoy S, Lee H, Makarieva T
NAT PROD COMMUN. 2013;8(10):1399-402.

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease
Terpos E, Morgan G, Dimopoulos M, Drake M, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar S, Durie B, Roodman G
J CLIN ONCOL. 2013;31(18):2347-57.

Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Thol F, Winschel C, Sonntag A, Damm F, Wagner K, Chaturvedi A, Göhring G, Schlegelberger B, Lübbert M, Fiedler W, Kirchner H, Krauter J, Ganser A, Heuser M
ANN HEMATOL. 2013;92(3):315-323.

Meningeosis neoplastica
Trepel M, Müller F
2013. Das Rote Buch: Hämatologie und Internistische Onkologie. EcoMed, 1067-1071.

Receiving palliative treatment moderates the effect of age and gender on demoralization in patients with cancer
Vehling S, Oechsle K, Koch-Gromus U, Mehnert A
PLOS ONE. 2013;8(3):e59417.

Reducing the burden of bone metastases: current concepts and treatment options
von Moos R, Sternberg C, Body J, Bokemeyer C
SUPPORT CARE CANCER. 2013;21(6):1773-83.

Dietary patterns and survival in German postmenopausal breast cancer survivors.
Vrieling A, Buck K, Seibold P, Heinz J, Obi N, Flesch-Janys D, Chang-Claude J
BRIT J CANCER. 2013;108(1):188-192.

Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.
Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller L, Christopeit M, Bacher U
ACTA HAEMATOL-BASEL. 2013;129(3):135-136.

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti J, Loges S, Dimmeler S, Carmeliet P
J CLIN INVEST. 2013;123(8):3190-200.

Langzeitadaptation an chronische Hypoxämie. Klinische Präsentation
Wichmann D, Baumann H, Kluge S
MED KLIN-INTENSIVMED. 2013;108(4):323-4.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

Guía clínica sobre el cáncer de testículo de la EAU: actualización de 2011
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M
ACTAS UROL ESP. 2012;36(3):127-45.

[EAU guidelines on testicular cancer: 2011 update].
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Urology E
ACTAS UROL ESP. 2012;36(3):127-145.

Current challenges in personalized treatment for colorectal cancer
Arnold D, Stein A
COLORECTAL CANCER. 2012;1(3):185-188.

Personalized treatment of colorectal cancer.
Arnold D, Stein A
ONKOLOGIE. 2012;35 Suppl 1:42-48.

Role of interleukin 16 in multiple myeloma.
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander A, Marx A, Uhlig R, Zustin J, Bokemeyer C, Kröger N
JNCI-J NATL CANCER I. 2012;104(13):1005-1020.

Identification of genetic parameters associated with disease progression in plasma cell myeloma.
Bacher U, Binder M
LEUKEMIA RES. 2012;36(1):23-24.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
Bachner M, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M
ANN ONCOL. 2012;23(1):59-64.

Low intensity, long-term outpatient rehabilitation in COPD: a randomised controlled trial.
Baumann H, Kluge S, Rummel K, Klose H, Hennigs J, Schmoller T, Meyer A
RESP RES. 2012;13:86.

The international factor IX treatment network survey
Berntorp E, Shapiro A, Waters J, Astermark J, , Holstein K
HAEMOPHILIA. 2012;18(3):e60-2.

Acceleration of collateral development by carcinoembryonic antigen-related cell adhesion molecule 1 expression on CD11b/⁺Gr-1⁺ myeloid cells--brief report
Bickert T, Marshall R, Zhang Z, Ludewig P, Binder M, Klinke A, Rottbauer W, Amling M, Wagener C, Ito W, Horst A
ARTERIOSCL THROM VAS. 2012;32(11):2566-8.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Billecke L, Murga-Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G
ANTICANCER RES. 2012;32(5):2031-2034.

Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis
Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass J, Walker U, Peter H, Warnatz K
ANN RHEUM DIS. 2012;71(2):311-2.

Kolorektales Karzinom: den Wirkmechanismen auf der Spur
Block A, Arnold D
Onkologie heute. 2012;10(5):12.

Palliative und supportive Therapie beim Karzinom des ösophagogastralen Übergangs
Block A, Arnold D
VISZERALMEDIZIN. 2012;28(2):121-127.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
Bokemeyer C, Eric V, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C
EUR J CANCER. 2012;48(10):1466-1475.

The role of regulatory T cells and TH17 cells in multiple myeloma.
Braga W, Atanackovic D, Colleoni G
Clin Dev Immunol. 2012;2012:293479.

The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn L, Horwich A, Krege S, Schmoll H, Sternberg C, Daugaard G
EUR UROL. 2012;61(6):1212-1221.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of: an exploratory analysis of a phase 3 trial
Canon J, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K
MED ONCOL. 2012;29(3):2291-9.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon J, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K
MED ONCOL. 2012;29(3):2291-2299.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target.
Clauditz T, Gontarewicz A, Lebok P, Tsourlakis M, Grob T, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W
ORAL ONCOL. 2012;48(10):991-996.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes J, Kim D, Kantarjian H, Brümmendorf T, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis A, Gambacorti-Passerini C
J CLIN ONCOL. 2012;30(28):3486-3492.

Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors
Dyshlovoy S, Fedorov S, Kalinovsky A, Shubina L, Bokemeyer C, Stonik V, Honecker F
MAR DRUGS. 2012;10(6):1212-24.

Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity.
Dyshlovoy S, Naeth I, Venz S, Preukschas M, Sievert H, Jacobsen C, Shubina L, Manuela G, Scharf C, Walther R, Krepstakies M, Priyadarshini P, Hauber J, Fedorov S, Bokemeyer C, Stonik V, Balabanov S, Honecker F
J PROTEOME RES. 2012;11(4):2316-2330.

Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
Fenske A, Glaesener S, Bokemeyer C, Thomale J, Dahm-Daphi J, Honecker F, Dartsch D
CANCER LETT. 2012;324(2):171-178.

Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
APMIS. 2012;120(11):901-8.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K, Schrader J, Ittrich H, von Amsberg G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse A, Hörsch D, Brümmendorf T, Benten D
CLIN CANCER RES. 2012;18(17):4621-4632.

Tumorerfassung
Frenzel T, Honecker F, Krüll A, Petersen C, Yekebas E
2012. Tumorerfassung: mit Erfassungsbögen und Leitlinien für die interdiszipl. Diagnostik und Therapie. Thieme-Verlag Stuttgart: 1-328.

Reversible phosphocholination of Rab proteins by Legionella pneumophila effector proteins
Goody P, Heller K, Oesterlin L, Itzen A, Goody R
EMBO J. 2012;31(7):1774-84.

Hypoxic cardiac arrest in pregnancy due to pulmonary haemorrhage.
Grimme I, Winter R, Kluge S, Petzoldt M
BMJ CASE REP. 2012;2012:6741.

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob T, Kannengiesser I, Tsourlakis M, Atanackovic D, König A, Vashist Y, Klose H, Marx A, Koops S, Simon R, Izbicki J, Bokemeyer C, Sauter G, Wilczak W
MODERN PATHOL. 2012;25(12):1566-1573.

Safety and efficacy of exercise training in various forms of pulmonary hypertension.
Grünig E, Lichtblau M, Ehlken N, Ghofrani H, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth H, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C
EUR RESPIR J. 2012;40(1):84-92.

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Hein R, Abbas S, Seibold P, Salazar R, Flesch-Janys D, Chang-Claude J
BREAST CANCER RES TR. 2012;131(2):653-661.

Pain management in patients with haemophilia: a European survey.
Holstein K, Klamroth R, Richards M, Carvalho M, Pérez-Garrido R, Gringeri A, Board E
HAEMOPHILIA. 2012;18(5):743-752.

Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2012;32 Suppl 1:48-51.

Integrative Aspekte der Thoraxonkologie
Horneber M, Mehnert A, Roser T, Rostock M
ONKOLOGIE. 2012;35 Suppl 3:2-5.

Umsetzung integrativer Konzepte - eine Bestandsaufnahme
Horneber M, Overkamp F, Rostock M
ONKOLOGIE. 2012;35 Suppl 5:3-11.

Erfahrungen der Hafeninspektoren an Bord: Sichere Anwendung von Schädlingsbekämpfungsmitteln auf Schiffen (MSC.1/Circ. 1358 und 1264) gemäß SOLAS-Regel VI/4
Hüsing U
ZENTRALBLATT ARB ARB. 2012;62(6):338.

Gastrointestinale Tumore
Jensen W, Oechsle K
2012. Sport und körperliche Aktivität in der Onkologie. Springer Verlag Berlin Heidelberg: 155-166.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury H, Cortes J, Kantarjian H, Gambacorti-Passerini C, Baccarani M, Kim D, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf T
BLOOD. 2012;119(15):3403-3412.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2012;2012:134081.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Kumar S, Lee J, Lahuerta J, Morgan G, Richardson P, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein S, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel J, Orlowski R, Palumbo A, Sezer O, Rajkumar S, Durie B, Group I
LEUKEMIA. 2012;26(1):149-157.

Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren: Highlights vom ASCO-Meeting 2012
Laban S, Zielinski V, Busch C, Münscher A, Schafhausen P, Tribius S, Knecht R
HNO. 2012;60(11):962-967.

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, Jensen M, Sterz J, von Metzler I, Sezer O
EUR J HAEMATOL. 2012;88(5):406-415.

Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor.
Langer F, Bokemeyer C
HAMOSTASEOLOGIE. 2012;32(2):95-104.

Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
Lorch A, Kleinhans A, Kramar A, Kollmannsberger C, Hartmann J, Bokemeyer C, Rick O, Beyer J
J CLIN ONCOL. 2012;30(8):800-805.

[New aspects of current therapeutic strategies in oropharyngeal carcinoma: highlights of the 2012 ASCO meeting].
Löwenthal M, Vitez E, Laban S, Münscher A, Güldenzoph B, Knecht R, Busch C
HNO. 2012;60(11):951-956.

Bromine-containing alkaloids from the marine sponge Penares sp.
Lyakhova E, Kolesnikova S, Kalinovsky A, Afiyatullov S, Dyshlovoy S, Krasokhin V, Minh C, Stonik V
TETRAHEDRON LETT. 2012;53(45):6119-6122.

The impact of a specific aqua-training for adult haemophilic patients--results of the WATERCISE study (WAT-QoL).
Mackensen von S, Eifrig B, Zäch D, Kalnins J, Wieloch A, Zeller W
HAEMOPHILIA. 2012;18(5):714-721.

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.
Marsh J, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano A, Passweg J, Killick S, Warren A, Foukaneli T, Aljurf M, Al-Zahrani H, Schafhausen P, Roth A, Franzke A, Brummendorf T, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute M, Mufti G, Socie G, Blood E, Party M
BLOOD. 2012;119(23):5391-5396.

Preliminary data of a HAMD-17 validated symptom scale derived from the ICD-10 to diagnose depression in outpatients
Melzer J, Rostock M, Brignoli R, Keck M, Saller R
FORSCH KOMPLEMENTMED. 2012;19(4):191-6.

PTEN deletion is rare but often homogeneous in gastric cancer.
Mina S, Bohn B, Simon R, Krohn A, Reeh M, Arnold D, Bokemeyer C, Sauter G, Izbicki J, Marx A, Stahl P
J CLIN PATHOL. 2012;65(8):693-698.

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer
Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2012;44(5):448-452.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S, Lübke A, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W
HISTOPATHOLOGY. 2012;61(3):445-453.

Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma.
Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C
CANCER-AM CANCER SOC. 2012;118(5):1268-1275.

Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia.
Müller-Schmah C, Solari L, Weis R, Pfeifer D, Scheibenbogen C, Trepel M, May A, Engelhardt R, Lübbert M
ANN HEMATOL. 2012;91(1):27-32.

Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions
Naumer M, Ying Y, Michelfelder S, Reuter A, Trepel M, Müller O, Kleinschmidt J
HUM GENE THER. 2012;23(5):492-507.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
Neoptolemos J, Moore M, Cox T, Valle J, Palmer D, McDonald A, Carter R, Tebbutt N, Dervenis C, Smith D, Glimelius B, Charnley R, Lacaine F, Scarfe A, Middleton M, Anthoney A, Ghaneh P, Halloran C, Lerch M, Oláh A, Rawcliffe C, Verbeke C, Campbell F, Büchler M, , Schafhausen P
JAMA-J AM MED ASSOC. 2012;308(2):147-56.

Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4+ T cells via retinoic acid
Neumann K, Kruse N, Szilagyi B, Erben U, Rudolph C, Flach A, Zeitz M, Hamann A, Klugewitz K
HEPATOLOGY. 2012;55(6):1976-84.

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M
BRIT J CANCER. 2012;107(11):1853-1863.

Bone metastases in germ cell tumor patients.
Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger L, Oing C, Honecker F
J CANCER RES CLIN. 2012;138(6):947-952.

Integrierte onkologische und palliativmedizinische Patientenbetreuung
Oechsle K, Schilling G
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2012;27(5):354.

The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature.
Oliveira-Ferrer L, Wellbrock J, Balabanov M, Klockow M, Hauschild J, Bokemeyer C, Fiedler W, Ergun S, Schuch G
CANCER LETT. 2012;326(2):161-167.

How to manage neutropenia in multiple myeloma.
Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, Jesus S
CL LYMPH MYELOM LEUK. 2012;12(1):5-11.

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Preukschas M, Hagel C, Schulte A, Riecken K, Lamszus K, Sievert H, Pällmann N, Bokemeyer C, Hauber J, Balabanov M, Balabanov S
PLOS ONE. 2012;7(8):43468.

Clinical management of localized colon cancer with capecitabine.
Quidde J, Arnold D, Stein A
CLIN MED INSIGHTS-ON. 2012;6:363-373.

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.
Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M
CANCER IMMUNOL IMMUN. 2012;61(10):1639-1651.

Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Richardson P, Delforge M, Beksac M, Wen P, Jongen J, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar S, Harousseau J, Moreau P, Avet-Loiseau H, Lee J, Cavo M, Merlini G, Voorhees P, Chng W, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta J, Niesvizky R, Siegel D, Mateos M, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel J, Morgan G, Anderson K, Durie B, Sonneveld P
LEUKEMIA. 2012;26(4):595-608.

[Tracheal metastasis of a cutaneous malignant melanoma].
Ritzel R, Klose H, Habermann C
ROFO-FORTSCHR RONTG. 2012;184(8):742-743.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo J, Lopez-Vivanco G, Adler G, Canon J, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld D, Garcia Giron C, Rodriguez R, Schoffski P, Misset J
BRIT J CANCER. 2012;107(3):435-441.

[Long-term sequelae of cancer survivors].
Schilling G, Arnold D
BUNDESGESUNDHEITSBLA. 2012;55(4):493-500.

Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.
Schmidt T, Ben-Batalla I, Schultze A, Loges S
CELL MOL LIFE SCI. 2012;69(9):1391-1414.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, , Bokemeyer C
LANCET ONCOL. 2012;13(12):1250-9.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-Tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A
ANN ONCOL. 2012;23(10):2479-2516.

[New aspects in the therapy of recurrence and metastasis of head and neck cancer: highlights from the 2012 ASCO meeting].
Schöpper S, Laban S, Güldenzoph B, Münscher A, Knecht R, Kurzweg T
HNO. 2012;60(11):957-961.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Schultze A, Ben-Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Harms-Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-887.

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V
EUR J CANCER. 2012;48(7):1023-1030.

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).
Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V
BMC CANCER. 2012;12:186.

Characterization of enzymes from Legionella pneumophila involved in reversible adenylylation of Rab1 protein
Shkumatov A, Oesterlin L, Schoebel S, Goody P, Goody R, Itzen A
J BIOL CHEM. 2012;287(42):35036-46.

New meroterpenoids from the marine sponge Aka coralliphaga
Shubina L, Kalinovsky A, Makarieva T, Fedorov S, Dyshlovoy S, Dmitrenok P, Kapustina I, Mollo E, Utkina N, Krasokhin V, Denisenko V, Stonik V
NAT PROD COMMUN. 2012;7(4):487-90.

Protein-protein-interaction network organization of the hypusine modification system.
Sievert H, Venz S, Platas-Barradas O, Dhople V, Schaletzky M, Nagel C, Balabanov M, Preukschas M, Pällmann N, Bokemeyer C, Brümmendorf T, Pörtner R, Walther R, Duncan K, Hauber J, Balabanov S
MOL CELL PROTEOMICS. 2012;11(11):1289-1305.

Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B, Hansen A, Bokemeyer C, Langer F
PLATELETS. 2012;23(1):60-68.

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
Steffens S, Janssen M, Roos F, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff J, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk M, Junker K, Schrader A
EUR J CANCER. 2012;48(15):2347-2352.

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.
Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk M, Schrader A
BMC CANCER. 2012;12:399.

Oxaliplatin: a review of approved uses.
Stein A, Arnold D
EXPERT OPIN PHARMACO. 2012;13(1):125-137.

Kolorektale Tumoren: Individualisierte Therapiestrategien
Stein A, Bokemeyer C
Der Allgemeinarzt. 2012;34(20):38-41.

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt H, Schmoll H
BMC CANCER. 2012;12:356.

Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access.
Stein A, Hiemer S, Jordan K, Arnold D, Schmoll H
ONKOLOGIE. 2012;35(7-8):440-442.

Targeting Epithelial Growth Factor Receptor (EGFR) With Cetuximab in Combination With Irinotecan as Salvage Treatment in Refractory Gastric Cancer Patients: A Retrospective Analysis and Review of the Literature
Stein A, Peinert S, Al-Batran S, Arnold D
Eur J Clin Med Oncol. 2012;4(1):11-17.

How to Achieve Long-Term Survival in Patients with Metastatic Rectal Cancer?
Stein A, Schmoll H
2012. Multidisciplinary Management of Rectal Cancer. Springer Berlin Heidelberg: 205-216.

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Eric V
J CLIN ONCOL. 2012;30(29):3570-3577.

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry
Tengborn L, Baudo F, Huth-Kühne A, Knoebl P, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P, , Holstein K
BJOG-INT J OBSTET GY. 2012;119(12):1529-37.

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.
Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M
PLOS ONE. 2012;7(2):31998.

Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger H, Brase J, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf T, Balabanov S
J PROTEOME RES. 2012;11(4):2452-2466.

Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.
Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus H, Kleinschmidt J, Müller O
GENE THER. 2012;19(8):800-809.

Is advanced cancer associated with demoralization and lower global meaning? The role of tumor stage and physical problems in explaining existential distress in cancer patients.
Vehling S, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Koch-Gromus U, Mehnert A
PSYCHO-ONCOLOGY. 2012;21(1):54-63.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M, Braig F, Goethel M, Schulte A, Lamszus K, Bokemeyer C, Binder M
NEOPLASIA. 2012;14(11):1023-1031.

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
von Amsberg G, Brümmendorf T
EXPERT REV ANTICANC. 2012;12(9):1121-1127.

Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study.
Vrieling A, Buck K, Heinz J, Obi N, Benner A, Flesch-Janys D, Chang-Claude J
BREAST CANCER RES TR. 2012;136(1):195-207.

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.
Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig H, Mertelsmann R, Trepel M
INT J CANCER. 2012;131(2):10-20.

CD146: a new partner for VEGFR2.
Wellbrock J, Fiedler W
BLOOD. 2012;120(11):2164-2165.

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Ziegler P, Chahoud T, Wilhelm T, Pällmann N, Balabanov M, Wiehle V, Ziegler S, Schröder M, Meier C, Kolodzik A, Rarey M, Panse J, Hauber J, Balabanov S, Brümmendorf T
INVEST NEW DRUG. 2012;30(6):2274-2283.

Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.
Ziegler P, Schrezenmeier H, Akkad J, Brassat U, Vankann L, Panse J, Wilop S, Balabanov S, Schwarz K, Martens U, Brümmendorf T
ANN HEMATOL. 2012;91(7):1115-1120.

EAU guidelines on testicular cancer: 2011 update
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M
EUR UROL. 2011;60(2):304-319.

[Gastrointestinal tumors--interdisciplinary discussion over new data].
Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel W, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll H, Vanhoefer U
ONKOLOGIE. 2011;34 Suppl 3:1-31.

Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastasis: What is the Evidence?
Arnold D, Stein A
CURR COLORECT CANC R. 2011;7(2):180-186.

Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.
Arraras J, Greimel E, Chie W, Sezer O, Bergenmar M, Costantini A, Young T, Kuljanic K, Velikova G, Research E, Group T
EXPERT REV PHARM OUT. 2011;11(3):281-286.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N
AM J HEMATOL. 2011;86(11):918-922.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander A, Marx A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2011;96(10):1512-1520.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S, Gontarewicz A, von Amsberg G, Raddrizzani L, Balabanov M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake T, Brümmendorf T
PLOS ONE. 2011;6(4):19164.

Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors.
Barnes B, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J
CANCER DETECT PREV. 2011;35(4):345-352.

Fiber optic bronchoscopy in patients with acute hypoxemic respiratory failure requiring noninvasive ventilation--a feasibility study.
Baumann H, Klose H, Simon M, Ghadban T, Braune S, Hennigs J, Kluge S
CRIT CARE. 2011;15(4):179.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel D, Staehler M, Strauss U, Mersmann S, Burock K, Escudier B
ANN ONCOL. 2011;22(8):1812-1823.

B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
Binder M, Müller F, Jackst A, Lechenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M
CANCER-AM CANCER SOC. 2011;117(9):1891-1900.

Kastrationsrefraktäres Prostatakarzinom - Second-line-Chemotherapie bietet Option auf Überlebensvorteil - Patientenselektion und Nebenwirkungsmanagement - Palliation tumorbedingter Beschwerden
Bokemeyer C
ONKOLOGE. 2011;17(7):1-8.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C, Bondarenko I, Hartmann J, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P
ANN ONCOL. 2011;22(7):1535-1546.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf T
EXP HEMATOL. 2011;39(1):62-66.

Dietary patterns and the risk of postmenopausal breast cancer in a German case-control study.
Buck K, Vrieling A, Flesch-Janys D, Chang-Claude J
CANCER CAUSE CONTROL. 2011;22(2):273-282.

Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K, Vrieling A, Zaineddin A, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J
J CLIN ONCOL. 2011;29(28):3730-3738.

Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer.
Buck K, Zaineddin A, Vrieling A, Heinz J, Linseisen J, Flesch-Janys D, Chang-Claude J
BRIT J CANCER. 2011;105(8):1151-1157.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors
Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S
EUR UROL. 2011;60(6):1163-70.

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V
BMC CANCER. 2011;11:295.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M, Rajkumar S, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos M, Attal M, Sonneveld P, Boccadoro M, Anderson K, Richardson P, Bensinger W, Johnsen H, Kröger N, Gahrton G, Bergsagel P, Vesole D, Einsele H, Jagannath S, Niesvizky R, Durie B, Jesus S, Lonial S, Group I
BLOOD. 2011;117(23):6063-6073.

Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz T, Reiff M, Gravert L, Gnoss A, Tsourlakis M, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W
PATHOLOGY. 2011;43(5):459-464.

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk P, Krauter J, Ganser A
BLOOD. 2011;117(17):4561-4568.

Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, Morgan M, Bomm K, Göhring G, Lübbert M, Kanz L, Fiedler W, Schlegelberger B, Heil G, Schlenk R, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M
J CLIN ONCOL. 2011;29(6):682-689.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch J, Bokemeyer C, Schmoll H
ANN ONCOL. 2011;22:1054-1061.

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F, Costa E, Camargo A, Gregorio J, Masotti C, Andrade V, Strauss B, Caballero O, Atanackovic D, Colleoni G
PLOS ONE. 2011;6(11):27707.

Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar [, Ingrid M, Herpen v, Carla M, Asten v, Jack J, Fiedler W, Walter [, Marreaud [, Sandrine [, Timmer-Bonte [, Johanna N, Ter V, Edwin G, Lambiase [, Antonio [, Bordignon [, Claudio [, Heerschap [, Arend [, Laarhoven v, Hanneke W
EUR J RADIOL. 2011;80(3):655-661.

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S, Nahar R, Balabanov M, Park E, Kim Y, Hofmann W, Herzog S, Jumaa H, Koeffler H, Yu J, Heisterkamp N, Graeber T, Wu H, Ye B, Melnick A, Müschen M
NATURE. 2011;473(7347):384-388.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis
Eichhorst B, Fischer K, Fink A, Elter T, Wendtner C, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M, , Bokemeyer C
BLOOD. 2011;117(6):1817-21.

Supportivtherapie
Feyer P, Bokemeyer C, Panse J, Link H, Piso P
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 187-194.

Phase I trial of SU14813 in patients with advanced solid malignancies.
Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky D, Bokemeyer C, Boven E
ANN ONCOL. 2011;22(1):195-201.

Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21.
Friend E, Yadegarfar G, Byrne C, Johnson C, Sezer O, Pucciarelli S, Pereira S, Chie W, Banfield A, Ramage J, Group E
BRIT J CANCER. 2011;104(4):587-592.

Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011.
Ghofrani H, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli W, Held M, Hoeper M, Kähler C, Kaemmerer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H
INT J CARDIOL. 2011;154 Suppl 1:20-33.

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M, Diedrich H, Güldenzoph B, Hartung G, Horst H, Hüttmann A, Kobbe G, Naumann R, Ratei R, Reichle A, Serve H, Stelljes M, Viardot A, Wattad M, Hoelzer D
BLOOD. 2011;118(13):3504-3511.

The versatile Legionella effector protein DrrA
Goody R, Schoebel S, Oesterlin L, Blümer J, Peters H, Blankenfeldt W, Itzen A
Commun Integr Biol. 2011;4(1):72-4.

Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension.
Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer F, Juenger J, Opitz C, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M
RESPIRATION. 2011;81(5):394-401.

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V, Desar I, Haanen J, Fiedler W, Mouritzen U, Olsen M, Herpen v, Carla M
ACTA ONCOL. 2011;50(1):121-126.

Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC
Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M
ONKOLOGIE. 2011;34(6):310-4.

Prostatakarzinom
Hautmann R, Küfer R, Bokemeyer C, Panse J, Belka C, Hinkelbein W
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 148-152.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller M, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause S, Nerl C, Pralle H, Gratwohl A, Hossfeld D, Hasford J, Hochhaus A, Saussele S
J CLIN ONCOL. 2011;29(12):1634-1642.

Klassifikation und Differentialdiagnose der pulmonalen Hypertonie
Hennigs J, Baumann H, Lüneburg N, Kluge S, Sydow K, Klose H
Atemwegs LungenKh. 2011;37:443-448.

Characterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis.
Hennigs J, Baumann H, Schmiedel S, Tennstedt P, Sobottka I, Bokemeyer C, Kluge S, Klose H
LUNG. 2011;189(6):475-483.

Molecular basis of P2-receptor-mediated calcium signaling in activated pancreatic stellate cells.
Hennigs J, Seiz O, Spiro J, Berna M, Baumann H, Klose H, Pace A
PANCREAS. 2011;40(5):740-746.

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Hennigs J, von Amsberg G, Baumann H, Honecker F, Kluge S, Bokemeyer C, Brümmendorf T, Klose H
BMC PULM MED. 2011;11:30.

Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.
Hermans C, De Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, Lavigne-Lissalde G, Perez R, Richards M, Dolan G, Board E
HAEMOPHILIA. 2011;17(3):383-392.

Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score.
Hessler C, Vettorazzi E, Madert J, Bokemeyer C, Panse J
SPINE. 2011;36(12):983-989.

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K, Lipp H, Beijnen J, Bokemeyer C, Hartmann J
CANCER CHEMOTH PHARM. 2011;68(3):693-701.

Modern imaging techniques during therapy in patients with multiple myeloma
Horger M, Weisel K, Bares R, Ernemann U, Claussen C, Lichy M, Fenchel M
ACTA RADIOL. 2011;52(8):881-8.

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe D, Chen E, Zhang L, Watson K, Mancuso P, Lappin P, Wickman G, Chen J, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson T, Simmons B, Lippincott J, Casperson G, Levin W, Stampino C, Shalinsky D, Ferrara K, Fiedler W, Bertolini F
CANCER RES. 2011;71(4):1362-1373.

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
Hurtz C, Hatzi K, Cerchietti L, Balabanov M, Park E, Kim Y, Herzog S, Ramezani-Rad P, Jumaa H, Müller M, Hofmann W, Hochhaus A, Ye B, Agarwal A, Druker B, Shah N, Melnick A, Müschen M
J EXP MED. 2011;208(11):2163-2174.

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll H
BONE MARROW TRANSPL. 2011;46(6):784-789.

Chondrogenic differentiation of human mesenchymal stem cells in micro-masses is impaired by high doses of the chemokine CXCL7.
Kalwitz G, Neumann K, Ringe J, Sezer O, Sittinger M, Endres M, Kaps C
J TISSUE ENG REGEN M. 2011;5(1):50-59.

Brachyury expression predicts poor prognosis at early stages of colorectal cancer.
Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, Viebahn C, Kreipe H, Schumacher U
EUR J CANCER. 2011;47(7):1080-1085.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Knudsen L, Schurawlew A, Nickel N, Tiede H, Ghofrani H, Wilkens H, Ewert R, Halank M, Klose H, Bäzner C, Behr J, Hoeper M
BMC PULM MED. 2011;11:56.

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W
BONE MARROW TRANSPL. 2011;46(8):1053-1056.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2011;2011:302145.

Treatment of patients with stage II A/B and advanced nonseminomatous germ cell tumors
Kollmannsberger C, Bokemeyer C
2011. Cancer of the Testis. Springer Berlin Heidelberg: 185-196.

Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
Koychev D, Oechsle K, Bokemeyer C, Honecker F
INT J ANDROL. 2011;34(4 Pt 2):266-273.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.
Laack E, Simon R, Regier M, Andritzky B, Tennstedt P, Habermann C, Verth C, Thoem I, Grob T, Sauter G, Bokemeyer C
J THORAC ONCOL. 2011;6(1):199-202.

Akute Blutungen ohne Trauma - Gerinnung checken mit System
Langer F, Holstein K, Bokemeyer C
Der Allgemeinarzt. 2011;33(15):37-40.

Physical activity and endogenous sex hormones in postmenopausal women: to what extent are observed associations confounded or modified by BMI?
Liedtke S, Schmidt M, Becker S, Kaaks R, Zaineddin A, Buck K, Flesch-Janys D, Wahrendorf J, Chang-Claude J, Steindorf K
CANCER CAUSE CONTROL. 2011;22(1):81-89.

Coffee consumption modifies risk of estrogen-receptor negative breast cancer.
Li J, Seibold P, Chang-Claude J, Flesch-Janys D, Liu J, Czene K, Humphreys K, Hall P
BREAST CANCER RES. 2011;13(3):49.

Management of Late Relapse
Maroni P, Honecker F, Foster R
2011. Cancer of the testis. Springer London: 263-274.

Histopathological and molecular features of late relapses in non-seminomas.
Mayer F, Wermann H, Albers P, Stoop H, Gillis A, Hartmann J, Bokemeyer C, Oosterhuis J, Looijenga L, Honecker F
BJU INT. 2011;107(6):936-943.

Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis.
Meyer-Schwesinger C, Dehde S, Klug P, Becker J, Mathey S, Arefi K, Balabanov S, Venz S, Endlich K, Pekna M, Gessner J, Thaiss F, Meyer T
J IMMUNOL. 2011;187(6):3218-3229.

Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.
Meyer-Schwesinger C, Meyer T, Sievert H, Hoxha E, Sachs M, Klupp E, Münster S, Balabanov S, Carrier L, Helmchen U, Thaiss F, Stahl R
AM J PATHOL. 2011;178(5):2044-2057.

Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo.
Michelfelder S, Varadi K, Raupp C, Hunger A, Körbelin J, Pahrmann C, Schrepfer S, Müller O, Kleinschmidt J, Trepel M
PLOS ONE. 2011;6(8):23101.

Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Milne R, Goode E, García-Closas M, Couch F, Severi G, Hein R, Fredericksen Z, Malats N, Zamora M, Pérez A, Ignacio J, Benítez J, Dörk T, Schürmann P, Karstens J, Hillemanns P, Cox A, Brock I, Elliot G, Cross S, Seal S, Turnbull C, Renwick A, Rahman N, Shen C, Yu J, Huang C, Hou M, Nordestgaard B, Bojesen S, Lanng C, Grethe G, Kristensen V, Børrensen-Dale A, Hopper J, Dite G, Apicella C, Southey M, Lambrechts D, Yesilyurt B, Floris G, Leunen K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Chang-Claude J, Wang-Gohrke S, Radice P, Peterlongo P, Manoukian S, Barile M, Giles G, Baglietto L, John E, Miron A, Chanock S, Lissowska J, Sherman M, Figueroa J, Bogdanova N, Antonenkova N, Zalutsky I, Rogov Y, Fasching P, Bayer C, Ekici A, Beckmann M, Brenner H, Müller H, Arndt V, Stegmaier C, Andrulis I, Knight J, Glendon G, Mulligan A, Mannermaa A, Kataja V, Kosma V, Hartikainen J, Meindl A, Heil J, Bartram C, Schmutzler R, Thomas G, Hoover R, Fletcher O, Gibson L, Isabel D, Peto J, Flesch-Janys D, Flesch-Janys D, Anton-Culver H, Ziogas A, Sawyer E, Tomlinson I, Kerin M, Miller N, Schmidt M, Broeks A, Tollenaar R, Pharoah P, Dunning A, Pooley K, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Jakubowska A, Lubinski J, Jaworska K, Durda K, Kang D, Yoo K, Noh D, Ahn S, Hunter D, Hankinson S, Kraft P, Lindstrom S, Chen X, Beesley J, Hamann U, Harth V, Justenhoven C, Network G, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Hooning M, Hollestelle A, Oldenburg R, Tilanus-Linthorst M, Khusnutdinova E, Bermisheva M, Prokofieva D, Farahtdinova A, Olson J, Wang X, Humphreys M, Wang Q, Chenevix-Trench G, Group A, Easton D
CANCER EPIDEM BIOMAR. 2011;20(10):2222-2231.

7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium.
Milne R, Lorenzo-Bermejo J, Burwinkel B, Malats N, Arias J, Zamora M, Benítez J, Humphreys M, García-Closas M, Chanock S, Lissowska J, Sherman M, Mannermaa A, Kataja V, Kosma V, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Anton-Culver H, Ziogas A, Devilee P, Asperen v, Christie J, Tollenaar R, Seynaeve C, Hall P, Czene K, Liu J, Irwanto A, Kang D, Yoo K, Noh D, Couch F, Olson J, Wang X, Fredericksen Z, Nordestgaard B, Bojesen S, Flyger H, Margolin S, Lindblom A, Fasching P, Schulz-Wendtland R, Ekici A, Beckmann M, Wang-Gohrke S, Shen C, Yu J, Hsu H, Wu P, Giles G, Severi G, Baglietto L, English D, Cox A, Brock I, Elliott G, Reed M, Beesley J, Chen X, Investigators K, Group A, Fletcher O, Gibson L, Isabel D, Peto J, Frank B, Heil J, Meindl A, Chang-Claude J, Hein R, Flesch-Janys D, Flesch-Janys D, Southey M, Smith L, Apicella C, Hopper J, Dunning A, Pooley K, Pharoah P, Hamann U, Pesch B, Ko Y, Network G, Easton D, Chenevix-Trench G
J MED GENET. 2011;48(10):698-702.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Lübke A, Krohn A, Mayer P, Simon R, Tennstedt P, Müller J, Scholz L, Brase J, Liu A, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
CLIN CANCER RES. 2011;17(18):5878-5888.

Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, Bokemeyer C, Huland H, Sauter G, Schlomm T
HUM PATHOL. 2011;42(12):1946-1952.

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T
PROSTATE. 2011;71(3):281-288.

S3-Leitlinie „Magenkarzinom”: Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032-009-OL)
Moehler M, Al-Batran S, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer W, Dietrich C, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert H, Galle P, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann J, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz R, Höfler H, Höhler T, Hölscher A, Horneber M, Hübner J, Izbicki J, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause B, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer H, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag P, Schmid R, Schmidberger H, Schmiegel W, Schmoll H, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C, AWMF [
Z GASTROENTEROL. 2011;49(4):461-531.

[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
Müller F, Riesenberg H, Hirnle P, Gehl H, Düwel P, Görner M
STRAHLENTHER ONKOL. 2011;187(12):826-830.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Munshi N, Anderson K, Bergsagel P, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart A, Harousseau J, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar S, Jesus S, Crowley J, Avet-Loiseau H
BLOOD. 2011;117(18):4696-4700.

Interventional lung assist enables lung protective mechanical ventilation in acute respiratory distress syndrome.
Nierhaus A, Frings D, Braune S, Baumann H, Schneider C, Wittenburg B, Kluge S
MINERVA ANESTESIOL. 2011;77(8):797-801.

Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells
Nilsson S, Huelsenbeck J, Fritz G
CANCER LETT. 2011;304(1):60-9.

Treatment of brain metastases from germ cell tumors.
Oechsle K, Bokemeyer C
HEMATOL ONCOL CLIN N. 2011;25(3):605-613.

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann J, Chi K, Bokemeyer C, Kollmannsberger C
ANN ONCOL. 2011;22(12):2654-60.

Physical activity, quality of life, and the interest in physical exercise programs in patients undergoing palliative chemotherapy.
Oechsle K, Jensen W, Schmidt T, Reer R, Braumann K, De Wit M, Bokemeyer C
SUPPORT CARE CANCER. 2011;19(5):613-619.

Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller C, Hartmann J, Boehlke I, Bokemeyer C, Group G
EUR UROL. 2011;60(4):850-855.

Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
Otten J, Schmitz L, Vettorazzi E, Schultze A, Marx A, Simon R, Krauter J, Loges S, Sauter G, Bokemeyer C, Fiedler W
LEUKEMIA. 2011;25(2):375-9.

[Venous thrombembolism in tumour patients].
Pabinger I, Alt-Epping B, Demarmels Biasutti F, Langer F, Wörmann B, Riess H
HAMOSTASEOLOGIE. 2011;31(4):281-282.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
Palumbo A, Bringhen S, Ludwig H, Dimopoulos M, Bladé J, Mateos M, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen H, Fernando L, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, Miguel S, Jesus F, Sonneveld P
BLOOD. 2011;118(17):4519-4529.

Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
Port M, Gläsener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M
MOL CANCER. 2011;10:52.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Rajkumar S, Harousseau J, Durie B, Anderson K, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi N, Jesus S
BLOOD. 2011;117(18):4691-4695.

Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Rawnaq T, Kunkel M, Bachmann K, Simon R, Zander H, Brandl S, Sauter G, Izbicki J, Kaifi J
ANN SURG ONCOL. 2011;18(2):559-565.

Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence.
Rawnaq T, Schwarzenbach H, Schurr P, Freise K, Brandl S, Izbicki J, Kaifi J
J SURG RES. 2011;169(1):31-35.

Classical homeopathy in the treatment of cancer patients - a prospective observational study of two independent cohorts
Rostock M, Naumann J, Guethlin C, Guenther L, Bartsch H, Walach H
BMC CANCER. 2011;11:19.

Komplementärmedizinische Beratung in der Onkologie
Rostock M, Saller R
FORSCH KOMPLEMENTMED. 2011;18(4):174-5.

Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab.
Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll H, Arnold D
J CLIN ONCOL. 2011;29(22):644-646.

Antiinflammatorisch wirksame Phytotherapeutika und ihr mögliches Potential bei tumorkranken Menschen
Saller R, Melzer J, Rostock M
FORSCH KOMPLEMENTMED. 2011;18(4):203-12.

Primary tumor dependent inhibition of tumor growth, Angio-Genesis, and perfusion of secondary breast cancer in bone.
Schäfer C, Schröder M, Fuhrhop I, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2011;29(8):1251-1258.

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
Schimmer A, Herr W, Hänel M, Borthakur G, Frankel A, Horst H, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman M, Koschmieder S
CL LYMPH MYELOM LEUK. 2011;11(5):433-438.

Rektumkarzinom
Schlag P, Panse J, Bokemeyer C, Budach W
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 98-101.

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
Schlemmer M, Bauer S, Schütte R, Hartmann J, Bokemeyer C, Hosius C, Reichardt P
EUR J MED RES. 2011;16(5):206-212.

Success and Failure of Primary Medical, Nonoperative Management In Breast Cancer.
Schmid S, Modlasiak A, Myrick M, Kilic N, Viehl C, Schötzau A, Güth U
ANN SURG ONCOL. 2011;18(8):2166-2172.

Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Schultze A, Fiedler W
ANTI-CANCER AGENT ME. 2011;11(7):593-599.

Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk.
Seibold P, Hein R, Schmezer P, Hall P, Liu J, Dahmen N, Flesch-Janys D, Popanda O, Chang-Claude J
INT J CANCER. 2011;129(6):1467-1476.

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients
Seidel C, Fenner M, Merseburger A, Reuter C, Ivanyi P, Länger F, Ganser A, Grünwald V
WORLD J UROL. 2011;29(3):355-60.

Retrospective analyses of patient characteristics having predictive impact on survival under everolimus
Seidel C, Fenner M, Reuter C, Merseburger A, Ganser A, Grünwald V
ONKOLOGIE. 2011;34(3):111-4.

Einsatz von mTOR-Inhibitoren bei soliden Tumoren
Seidel C, Grünwald V
Med Monatsschr Pharm. 2011;34(4):116-26; quiz 127-8.

Supportivtherapie und Behandlung von Komplikationen
Sezer O
2011. Multiples Myelom: Moderne Diagnoseverfahren, aktuelle Behandlungsoptionen und Supportivtherapie. Deutscher Ärzte-Verlag: 129-148.

Efficient synthesis and applications of peptides containing adenylylated tyrosine residues
Smit C, Blümer J, Eerland M, Albers M, Goody R, Itzen A, Hedberg C
ANGEW CHEM INT EDIT. 2011;50(39):9200-4.

Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.
Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner V, Rabkin S, Demestre M
PLOS ONE. 2011;6(6):21099.

Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
Steffens S, Grünwald V, Ringe K, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk M, Schrader A
ONCOLOGIST. 2011;16(11):1565-71.

Kolorektales Karzinom: Innovationen bei den multimodalen Therapien
Stein A, Arnold D
Deutsches Ärzteblatt. 2011;111(6 / Suppl. Perspektiven der Onkologie):.

Multimodale Therapiestrategien bei Lebermetastasen kolorektaler Karzinome
Stein A, Arnold D
VISZERALMEDIZIN. 2011;27(6):437-444.

Current standards and new trends in the primary treatment of colorectal cancer.
Stein A, Atanackovic D, Bokemeyer C
EUR J CANCER. 2011;47 Suppl 3:312-314.

Adjuvant Therapy for Early Colon Cancer: Current Status.
Stein A, Hiemer S, Schmoll H
DRUGS. 2011;71(17):2257-2275.

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.
Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B
BLOOD. 2011;117(7):2121-2128.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M
J CLIN ONCOL. 2011;29(21):2889-2896.

Phytodolor® in musculoskeletal disorders: re-analysis and meta-analysis
Uehleke B, Brignoli R, Rostock M, Saller R, Melzer J
FORSCH KOMPLEMENTMED. 2011;18(5):249-56.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R, Jost E, Balabanov M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf T, Balabanov S
MOL CANCER. 2011;10:129.

Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform.
Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf T, Balabanov S
PLOS ONE. 2011;6(2):16833.

Global meaning and meaning-related life attitudes: exploring their role in predicting depression, anxiety, and demoralization in cancer patients.
Vehling S, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Koch-Gromus U, Mehnert A
SUPPORT CARE CANCER. 2011;19(4):513-520.

Structural brain changes related to disease duration in patients with asthma.
Von Leupoldt A, Brassen S, Baumann H, Klose H, Büchel C
PLOS ONE. 2011;6(8):23739.

Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study.
Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, Chang-Claude J
BREAST CANCER RES. 2011;13(4):74.

Forced activation of β-catenin signaling supports the transformation of hTERT-immortalized human fetal hepatocytes.
Wege H, Heim D, Lütgehetmann M, Dierlamm J, Lohse A, Brümmendorf T
MOL CANCER RES. 2011;9(9):1222-1231.

Clinical experience with antiangiogenic therapy in leukemia.
Wellbrock J, Fiedler W
CURR CANCER DRUG TAR. 2011;11(9):1053-1068.

Inhibitor-immunology-study. Evaluation of inhibitor development in haemophilia B.
Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Eberl W, Kemkes-Matthes B, Bidlingmaier C, Kurnik K, Lischetzki G, Nimtz-Talaska A, Eisert R, Bogdanova N, Doerk T, Sykora K
HAMOSTASEOLOGIE. 2011;31 Suppl 1:57-60.

Hodenkarzinom
Winter C, Rabenalt R, Albers P, Bokemeyer C, Panse J, Schmidberger H
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 152-158.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuketang Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang G, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic S, Greinix H, Holler E
BIOL BLOOD MARROW TR. 2011;17(1):1-17.

Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z, Doondeea J, Gholami A, Janning M, Lemeer S, Kramer K, Eccles S, Gollin S, Grenman R, Walch A, Feller S, Kuster B
MOL CELL PROTEOMICS. 2011;10(12):11635.

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy
Abbas S, Beckmann L, Chang-Claude J, Hein R, Kropp S, Parthimos M, Dünnebier T, Hamann U, Brors B, Eils R, Zapatka M, Brauch H, Justenhoven C, Flesch-Janys D, Braendle L, Brüning T, Pesch B, Spickenheuer A, Baisch C, Ko Y, Dahmen N
INT J CANCER. 2010;126(12):2935-2946.

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women
Abbas S, Beckmann L, Chang-Claude J, Hein R, Kropp S, Parthimos M, Dünnebier T, Hamann U, Brors B, Eils R, Zapatka M, Brauch H, Justenhoven C, Flesch-Janys D, Brüning T, Pesch B, Spickenheuer A, Baisch C, Ko Y, Dahmen N, Salazar R
BREAST CANCER RES TR. 2010;120(3):727-736.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2010;45(9):1404-1407.

Studien und personalisierte Medizin in der Onkologie?
Arnold D, Bokemeyer C
ONKOLOGIE. 2010;33(7):25-29.

An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.
Arraras J, Greimel E, Sezer O, Chie W, Bergenmar M, Costantini A, Young T, Vlasic K, Velikova G
EUR J CANCER. 2010;46(15):2726-2738.

LINE-1 retrotransposition events affect endothelial proliferation and migration
Banaz-Yaşar F, Steffen G, Hauschild J, Bongartz B, Schumann G, Ergün S
HISTOCHEM CELL BIOL. 2010;134(6):581-9.

[Tracheostomy in the intensive care unit].
Baumann H, Kemei C, Kluge S
PNEUMOLOGIE. 2010;64(12):769-776.

[Utility of invasive diagnostics in acute lung injury].
Baumann H, Meyer A, Klose H, Kluge S
PNEUMOLOGIE. 2010;64(8):488-495.

Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells
Binder M, Léchenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, Schlüter H, Braren I, Spillner E, Trepel M
PLOS ONE. 2010;5(12):e15992.

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Bokemeyer C
EXPERT OPIN BIOL TH. 2010;10(8):1259-1269.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.
Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff A, Kröger N, Bokemeyer C, Atanackovic D
J IMMUNOL METHODS. 2010;358(1-2):56-65.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic D
EXP HEMATOL. 2010;38(10):860-867.

S2-Leitlinie zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien
Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G
KLIN PADIATR. 2010;222(6):399-406.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Cavattoni I, Zabelina T, Ayuketang Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2010;51(1):146-148.

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women
Chang-Claude J, Beckmann L, Corson C, Hein R, Kropp S, Parthimos M, Dünnebier T, Hamann U, Brors B, Eils R, Brauch H, Justenhoven C, Flesch-Janys D, Braendle L, Brüning T, Pesch B, Spickenheuer A, Krankenhaus J, Ko Y, Baisch C, Dahmen N, Zapatka M
BREAST CANCER RES TR. 2010;119(2):463-474.

Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome.
Choschzick M, Lassen P, Lebeau A, Marx A, Terracciano L, Heilenkötter U, Jänicke F, Bokemeyer C, Izbicki J, Sauter G, Simon R
MODERN PATHOL. 2010;23(4):603-610.

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Dimopoulos M, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J, Bladé J, Comenzo R, Sezer O, Palumbo A, Harousseau J, Richardson P, Barlogie B, Anderson K, Sonneveld P, Tosi P, Cavo M, Rajkumar S, Durie B, Jésus S
J CLIN ONCOL. 2010;28(33):4976-4984.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal A, Brüchmann M, Zustin J, Isbarn H, Hellwinkel O, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf T, Izbicki J, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T
CLIN CANCER RES. 2010;16(1):56-64.

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
Engelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A
LEUKEMIA LYMPHOMA. 2010;51(8):1424-1443.

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón J, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen H, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A
LEUKEMIA LYMPHOMA. 2010;51(11):2006-2011.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A, Plütschow A, Eich H, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn K, Wilhelm M, Debus J, Eble M, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink H, Müller R, Diehl V
NEW ENGL J MED. 2010;363(7):640-652.

The anticancer effects of actinoporin RTX-A from the sea anemone Heteractis crispa (=Radianthus macrodactylus)
Fedorov S, Dyshlovoy S, Monastyrnaya M, Shubina L, Leychenko E, Kozlovskaya E, Jin J, Kwak J, Bode A, Dong Z, Stonik V
TOXICON. 2010;55(4):811-817.

Chemotherapie und systemische Therapie bei Lebermetastasen - Kolorektales Karzinom
Folprecht G, Bokemeyer C
2010. Hepatobiliäre und Pankreastumoren. Springer-Verlag GmbH: 387-395.

Mobilization of hematopoietic progenitor cells in patients with liver cirrhosis.
Gehling U, Willems M, Schlagner K, Benndorf R, Dandri-Petersen M, Petersen J, Sterneck M, Pollok J, Hossfeld D, Rogiers X
WORLD J GASTROENTERO. 2010;16(2):217-224.

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Gontarewicz A, Brümmendorf T
Recent Results Cancer Res. 2010;184:199-214.

[The concept of chronic disease in the palliative treatment of oncologic patients: current Swiss data and insights in the context of breast and ovarian cancer].
Güth U, Kilic N, Schmid S
Praxis (Bern 1994). 2010;99(23):1413-1421.

Monanchocidin: a new apoptosis-inducing polycyclic guanidine alkaloid from the marine sponge Monanchora pulchra
Guzii A, Makarieva T, Denisenko V, Dmitrenok P, Kuzmich A, Dyshlovoy S, Krasokhin V, Stonik V
ORG LETT. 2010;12(19):4292-5.

Genetische Veränderungen beim Multiplen Myelom: Einfluss von Chromosomenaberrationen auf die Prognose nach allogener Stammzelltransplantation bei Patienten mit Multiplem Myelom
Hansen T
2010. Genetische Veränderungen beim Multiplen Myelom: Einfluss von Chromosomenaberrationen auf die Prognose nach allogener Stammzelltransplantation bei Patienten mit Multiplem Myelom. Suedwestdeutscher Verlag fuer Hochschulschriften: 1-120.

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Heider U, Rademacher J, Kaiser M, Kleeberg L, von Metzler I, Sezer O
CL LYMPH MYELOM LEUK. 2010;10(2):134-137.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Ivanchenko V, Dudnichenko A, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons S
INT J CANCER. 2010;127(9):2209-2221.

Der Stellenwert von aktiviertem Protein C und Immunglobulinen in der Sepsistherapie
Hennigs J, Baumann H, Klose H, Kluge S
Atemwegs LungenKh. 2010;36:405-412.

Patients with advanced non-seminomatous germ-cell tumour: the art of the start.
Honecker F, Bokemeyer C
ANN ONCOL. 2010;21(8):1569-1571.

[A multi-disciplinary approach to the treatment of germ cell tumors].
Honecker F, Souchon R, Krege S, Bokemeyer C
INTERNIST. 2010;51(11):1382-1387.

Multimodale Therapiekonzepte von Keimzelltumoren
Honecker F, Souchon R, Krege S, Bokemeyer C
INTERNIST. 2010;51(11):1382-7.

Therapie von Hodentumoren: Stadienspezifisch und leitliniengerecht behandeln
Honecker F, Souchon R, Krege S, Bokemeyer C
best practice onkologie. 2010;5(1):4-13.

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski G, Lee D, En-Gal S, Doan N, Castor B, Vogt M, Toh M, Bokemeyer C, Said J, Thoennissen N, Koeffler H
BRIT J PHARMACOL. 2010;160(4):998-1007.

Comparative expressed sequence hybridization detects recurrent patterns of altered sequence expression in oral squamous cell carcinoma
Janjetovic S, Sticht C, Knoepfle K, Joos S, Hofele C, Lichter P, Freier K
ONCOL REP. 2010;24(2):369-74.

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M, Lamottke B, Mieth M, Jensen M, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O
EUR J HAEMATOL. 2010;84(4):337-344.

Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.
Kalinina T, Güngör C, Thieltges S, Möller-Krull M, Murga-Penas E, Wicklein D, Streichert T, Schumacher U, Kalinin V, Simon R, Otto B, Dierlamm J, Schwarzenbach H, Harms-Effenberger K, Bockhorn M, Izbicki J, Yekebas E
BMC CANCER. 2010;10:295.

Bosutinib
Keller G, Schafhausen P, Brümmendorf T
Recent Results Cancer Res. 2010;184:119-27.

Two new asterosaponins, archasterosides A and B, from the Vietnamese starfish Archaster typicus and their anticancer properties
Kicha A, Ivanchina N, Huong T, Kalinovsky A, Dmitrenok P, Fedorov S, Dyshlovoy S, Long P, Stonik V
BIOORG MED CHEM LETT. 2010;20(12):3826-3830.

Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
Kilic N, Tilki D, Ergün B, Seitz M, Stief C, Reich O, Ergün S
ANTICANCER RES. 2010;30(7):2651-2657.

Pulmonary hypertension after ventriculoatrial shunt implantation.
Kluge S, Baumann H, Regelsberger J, Kehler U, Gliemroth J, Koziej B, Klose H, Meyer A
J NEUROSURG. 2010;113(6):1279-1283.

Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type.
Kobold S, Kilic N, Luetkens T, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2010;123(3):179-181.

Autoantibodies against tumor-related antigens: incidence and biologic significance.
Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D
HUM IMMUNOL. 2010;71(7):643-651.

Prognostic and diagnostic value of spontaneous tumor-related antibodies.
Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D
Clin Dev Immunol. 2010;2010:721531.

Novel cytotoxic vectors based on adeno-associated virus
Kohlschütter J, Michelfelder S, Trepel M
Toxins. 2010;2(12):2754-68.

Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.
Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A
BLOOD. 2010;115(16):3413-3415.

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, Zander A, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T
BRIT J HAEMATOL. 2010;148(2):323-331.

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Laack H, Sauter G, Bokemeyer C
LUNG CANCER. 2010;69(3):259-264.

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
Laarhoven v, Fiedler W, Fiedler W, Desar I, Asten v, Jack J, Marréaud S, Lacombe D, Govaerts A, Bogaerts J, Lasch P, Timmer-Bonte J, Lambiase A, Bordignon C, Punt C, Heerschap A, Herpen v, Carla M
CLIN CANCER RES. 2010;16(4):1315-1323.

High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
Lorch A, Rick O, Wündisch T, Hartmann J, Bokemeyer C, Beyer J
J UROLOGY. 2010;184(1):168-173.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx A, Burandt E, Choschzick M, Simon R, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki J
HUM PATHOL. 2010;41(11):1577-1585.

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.
Marx A, Zielinski M, Kowitz C, Dancau A, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Brümmendorf T, Fiedler W, Bokemeyer C, Izbicki J, Sauter G
HISTOPATHOLOGY. 2010;57(3):418-426.

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
Mautner V, Nguyen R, Knecht R, Bokemeyer C
ANN ONCOL. 2010;21(11):2294-2295.

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
Mautner V, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich R, Panse J
NEURO-ONCOLOGY. 2010;12(1):14-8.

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord J, Bokemeyer C, Curran D, Gross A, Vermorken J
ANN ONCOL. 2010;21(10):1967-1973.

Bewegungstherapie bei obstruktiven Atemwegserkrankungen
Meyer A, Baumann H
2010. Bewegungstherapie bei internistischen Erkrankungen. Springer Berlin Heidelberg: 153-166.

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf T, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T
CLIN CANCER RES. 2010;16(5):1553-1560.

Y chromosome loss is a frequent early event in urothelial bladder cancer.
Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2010;42(4):356-359.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia.
Ocheni S, Oyekunle A, Kröger N, Ayuketang Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjalle R, Wolschke C, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2010;125(3):175-178.

Keimzelltumore des Hodens
Oechsle K
2010. Therapiealgorithmen Onkologie. rs media GmbH: .

Organprotektion in der Tumortherapie - mit Medikamenten vor unerwünschten Wirkungen schützen
Oechsle K, Bokemeyer C
Im Fokus Onkologie. 2010;12:43-47.

Unterschätztes Risiko - Kardiotoxizität onkologischer Therapien
Oechsle K, Bokemeyer C
Im Fokus Onkologie. 2010;7(8):49-53.

Erratum to: Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Oechsle K, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2010;136(1):169.

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Oechsle K, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2010;136(1):165-167.

Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
Oechsle K, Lange-Brock V, Krüll A, Bokemeyer C, De Wit M
J CANCER RES CLIN. 2010;136(11):1729-1735.

Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.
Oechsle K, Lorch A, Honecker F, Kollmannsberger C, Hartmann J, Boehlke I, Beyer J, Bokemeyer C
ONCOLOGY-BASEL. 2010;78(1):47-53.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A
EXP MOL PATHOL. 2010;89(2):175-181.

Quantitative MR imaging of targeted SPIO particles on the cell surface and comparison to flow cytometry.
Peldschus K, Schultze A, Nollau P, Kaul M, Schumacher U, Wagener C, Adam G, Ittrich H
MAGN RESON IMAGING. 2010;28(4):599-606.

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.
Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, Amaya M, Garber E, Francis J, Hsu Y, Amirkhosravi A
J IMMUNOL. 2010;185(3):1577-1583.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark R, Hochhaus A, Hughes T, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson R, Kantarjian H, , Schafhausen P
NEW ENGL J MED. 2010;362(24):2251-9.

Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.
Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz M, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris M, Solé F
BLOOD. 2010;116(9):1479-1488.

Microcirculation of secondary bone tumors in vivo: the impact of minor surgery at a distal site.
Schäfer C, Fuhrhop I, Schröder M, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2010;28(11):1515-1521.

Lapatinib.
Schneider-Merck T, Trepel M
Recent Results Cancer Res. 2010;184:45-59.

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Schultze A, Fiedler W
EXPERT OPIN INV DRUG. 2010;19(6):777-788.

Recall pneumonitis during systemic treatment with sunitinib
Seidel C, Janssen S, Karstens J, Welte T, Morgan M, Ganser A, Grünwald V
ANN ONCOL. 2010;21(10):2119-20.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D, Lindhofer H, Bokemeyer C
CANCER TREAT REV. 2010;36(6):458-467.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander A, Kröger N, Nagler A
CANCER-AM CANCER SOC. 2010;116(15):3621-3630.

Three new aaptamines from the marine sponge Aaptos sp. and their proapoptotic properties
Shubina L, Makarieva T, Dyshlovoy S, Fedorov S, Dmitrenok P, Stonik V
NAT PROD COMMUN. 2010;5(12):1881-4.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Sterz J, Jakob C, Kuckelkorn U, Heider U, Mieth M, Kleeberg L, Kaiser M, Kloetzel P, Sezer O, von Metzler I
EUR J HAEMATOL. 2010;85(2):99-107.

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
Terpos E, Dimopoulos M, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake M, Harousseau J, Anderson K, Durie B, Group I
LEUKEMIA. 2010;24(10):1700-1712.

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thoem I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen J, Bokemeyer C, Schumacher U, Laack H
CANCER-AM CANCER SOC. 2010;116(17):4114-4121.

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
Thoennissen N, Krug U, Lee D, Kawamata N, Iwanski G, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih L, Nagler A, Raynaud S, Muller-Tidow C, Mesa R, Haferlach T, Gilliland D, Tefferi A, Ogawa S, Koeffler H
BLOOD. 2010;115(14):2882-2890.

Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Thoennissen N, O'Kelly J, Lu D, Iwanski G, La D, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler H
ONCOGENE. 2010;29(2):285-296.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A
BLOOD. 2010;116(4):614-616.

Bosutinib.
von Amsberg G, Schafhausen P, Brümmendorf T
Recent Results Cancer Res. 2010;184:119-127.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J
J CLIN ONCOL. 2010;28(14):2356-2364.

Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Wellbrock J, Bokemeyer C, Fiedler W
J ONCOL. 2010;2010:317068.

Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H, Stoop H, Gillis A, Honecker F, Gurp v, Ruud J, Ammerpohl O, Richter J, Bokemeyer C, Bokemeyer C, Looijenga L
J PATHOL. 2010;221(4):433-442.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

[28-year old female patient with respiratory insufficiency, elevated liver enzymes, pancytopenia and fever].
Wolschke C, Fiedler W, Habermann C, Janka-Schaub G, Kluge S
INTERNIST. 2010;51(11):1434-1438.

Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library
Ying Y, Müller O, Goehringer C, Leuchs B, Trepel M, Katus H, Kleinschmidt J
GENE THER. 2010;17(8):980-90.